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The renin-angiotensin-aldosteron system (RAAS) is an important regulator of the hemodynamic 
stability in the human body by controlling circulating volume and electrolyte balances. The 
RAAS accomplishes this function by regulating extracellular fluid volume, sodium balance and 
cardiovascular function through direct and indirect effects on several organ systems and it 
interacts with the autonomic nervous system and several vasoactive hormones (1). The RAAS 
is activated in response to threats which compromise blood pressure stability and extracellular 
fluid volume homeostasis. A decrease in the perfusion of the juxtaglomerular apparatus raises 
the production of renin from the kidney. A cascade of hormones is initially triggered by the 
release of renin (2, 3). Renin is a proteolytic enzyme that has a local action on angiotensinogen 
in the kidney as well as in the circulation. Angiotensinogen is a protein precursor produced in 
the liver and is cleaved by renin to form an inactive peptide angiotensin I (AT-I), which is finally 
converted to the active octapeptide angiotensin II (AT-II) by the angiotensin-converting enzyme 
(ACE). ACE is a largely tissue-based zinc metalloprotease, mainly generated by the lungs, the 
cell membranes of the kidneys and the endothelial cells of the vasculature (1-3). Therefore, the 
serum concentrations of ACE determine the levels of AT-II, which is the active metabolite of the 
system through which the RAAS mediates its main unfavorable effects (pro-atherosclerotic) in 
the human body. Angiotensin II mediates its effects through the AT-1 receptor which results in 
arteriolar vasoconstriction and water and salt retention. Excessive or maladaptive stimulation 
of this hormonal cascade causes pathologic changes in a wide variety of organ systems. For 
example, an overactive RAAS is associated with hypertension, renal injury, atherosclerosis and 
left ventricular dysfunction (4). These conditions have been associated with high levels of tissue 
ACE (4). Likewise, the blockade of an activated RAAS has become a key therapeutic target in a 
wide variety of patients, such as patients with hypertension, heart failure, renal disease, and ath-
erosclerotic (cardio-)vascular disease. The clinically most important examples of pharmacologic 
agents that block the RAAS currently are the ACE-inhibitors, and AT1 receptor blockers (ARBs). 
TrEATmEnT EffECT of ACE-inhiBiTors 
The clinical efficacy of ACE-inhibitors has been clearly demonstrated in a wide variety of patient 
groups (5-11), such as the EUROPA trial which studied 12.218 patients with stable coronary artery 
disease (CAD) randomized to the ACE-inhibitor perindopril versus placebo (11). Perindopril 
was associated with a 20% reduction in the event rate of cardiovascular mortality, myocardial 
infarction and resuscitated cardiac arrest during 4 years of follow-up (HR 0.80; 95% CI 0.71-0.91) 
P-value 0.0003). As a results, the European Society of Cardiology (ESC) clinical treatment guide-
lines recommend the use of ACE inhibitors as routine secondary prevention for the broad group 
of patients with known CAD with, respectively, a class I (level of evidence A) recommendation 
for ACE-inhibitor therapy in CAD patients with hypertension, heart failure, left ventricular 
dysfunction, previous myocardial infarction with left ventricular dysfunction or diabetes and a 
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class IIa recommendation in all patients with angina pectoris and confirmed coronary disease 
(level of evidence B) (12). Currently, the ACE-inhibitors, as antihypertensive and cardioprotective 
drug class, compromise one of the most frequently prescribed drugs in cardiovascular patients.
Still, in a patient population of stable CAD, several considerations need to be made, as these 
patients compromise a relatively low-risk group. In the EUROPA trial, the absolute risk reduc-
tion of the primary endpoint (cardiovascular mortality, myocardial infarction and resuscitated 
cardiac arrest) by perindopril was 2 % during 4 years of treatment, which means that 50 patients 
needed to be treated for 4 years to prevent one cardiovascular event in EUROPA (12). Therefore, 
it is important to study whether the treatment benefit of ACE-inhibitors in stable CAD is equal 
to all patients studied, in other words a high consistency in treatment benefit across clinical 
subgroups of patients, or whether specific subgroups of patients can be identified that do not 
experience the full treatment benefit. By elucidating heterogeneity in the treatment effect of 
ACE-inhibitors, doctors could target prescription of ACE-inhibitors only to those patients most 
likely to benefit and by doing so reduce the number of patients treated with such prolonged 
prophylactic treatment (13,14). In recent years, the consistency of the treatment effect of ACE-
inhibitors has been tested according to clinical characteristics, risk factors and concomitant 
medication use (14-18). A risk model based on clinical characteristics related to the incidence 
of the primary endpoint in EUROPA further showed no modification of treatment effect of 
perindopril (figure 1) (16). Prior attempts to identify responding or non-responding patients to 
ACE-inhibitor therapy appeared not feasible based on clinical characteristics (14-18). Therefore, 
Chapter 1 
Introduction 
 
Figure 1.  
The consistency of treatment benefit of perindopril according to a risk model based on clinical 
characteristics. 
 
 
  
 
 
figure 1 The consistency of treatment benefit of perindopril according to a risk model based on clinical 
characteristics. Tertiles of baseline risk based upon clinical characteristics related to the incidence of the 
primary endpoint in the EUROPA-trial. Adapted from Deckers J, et al. Eur Heart J. 2006;27:796-801 with 
permission.
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at current, all patients fitting the indication of stable CAD (as complete group) are treated 
with ACE-inhibitors for secondary prevention of recurrent cardiovascular events according to 
international treatment guidelines (12). 
TAilorED-ThErAPy of ACE-inhiBiTors
To optimally treat patients, and to develop ways to guide ACE-inhibitor treatment, it remains 
essential to identify those patients most likely to benefit from therapy. New research to elu-
cidate such heterogeneity is necessary. If feasible, guided-therapy of ACE-inhibitors will have 
a large impact on clinical practice by increasing patient’s benefit of drug prescriptions and 
reducing healthcare costs: to get the right drug to the right patient.
“The quest for the Holy Grail: tailoring drug therapies to individual patients”
The purpose of this thesis was to investigate a new approach to guide ACE-inhibitor therapy 
using patient specific genetic characteristics (19). We studied the feasibility of pharmacogenetic 
profiling of the treatment benefit of ACE-inhibitor therapy. We focused on the common genetic 
variation in the candidate genes of the direct pharmacodynamic pathway of ACE-inhibitors: 
the renin-angiotensin-system and kallikrein-bradykinin system. These studies were conducted 
within the randomized placebo-controlled EUROPA-trial studying the ACE-inhibitor perindopril 
versus placebo in ten thousand patients with stable coronary artery disease. 
The main research questions we examined were as follows:
- Is the treatment benefit (reduction of cardiovascular events) of ACE-inhibitor therapy modi-
fied by genetic variation between patients?
- Is the level of blood pressure and blood pressure reduction by ACE-inhibitor therapy modi-
fied by genetic variation between patients?
- Can we develop a pharmacogenetic profile to individualize ACE-inhibitor therapy and 
optimize patients’ benefit in stable coronary artery disease?
ouTlinE of ThE ThEsis 
In the following chapters, several issues are discussed. Part I focuses on the clinical efficacy 
of ACE-inhibitors, especially perindopril (chapter 2), as demonstrated in various clinical trials 
in different patient groups. Also, the lessons learned from previous clinical trials with ACE-
inhibitors are discussed (chapter 3). Part II focuses on the search for the heterogeneity in treat-
ment benefit of ACE-inhibitors by clinical subgroup analyses. In particular, we focus on the risk 
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marker – renal insufficiency – which we investigated with regard to the incidence of cardiovas-
cular events in relatively healthy subjects (chapter 4), as well as in patients with coronary artery 
disease (chapter 5). As renal insufficiency proved to be an important marker of cardiovascular 
risk and considering the effect of ACE-inhibitors in renal insufficiency, we further investigated 
whether renal insufficiency was a modifier of treatment benefit of ACE-inhibitors which could 
be used to guide ACE-inhibitor therapy (chapter 6). Part III focuses on the consistency of the 
treatment effect of ACE-inhibitor therapy in a combined analysis of several ACE-inhibitor trials 
with in-depth subgroup analyses using clinical characteristics as well as blood pressure and 
blood pressure response to ACE-inhibitor therapy as potential mediators of treatment effect 
(chapter 7). Part IV summarizes all prior attempts to target ACE-inhibitor therapy by our group 
and other research groups (chapter 8) and advocates a new approach of targeting therapy to 
those patients most likely to benefit of treatment using (pharmaco-) genetic factors (chapter 
9). In part V, the study design and rationale of the PERindopril GENEtic association (PERGENE) 
study is presented (chapter 10) and the results of this large-scale pharmacogenetic analysis 
are revealed (chapter 11 and 12). In part VI, the feasibility of pharmacogenetic profiling is 
discussed with respect to the findings of the PERGENE study (chapter 13) and other suc-
cesses in pharmacogenetic research of cardiovascular drugs. As the current pharmacogenetic 
approach can be applied for other cardiovascular drugs as well, and should be integrated in 
future randomized clinical trials, we advocate the use of pharmacogenetics in statins, one of the 
worlds most frequently prescribed drugs, to optimize drug response. In Part VII, we study the 
treatment benefit of statins and the consistency according to clinical characteristics. Due to the 
strong consistency as observed, the same pharmacogenetic concept of optimizing treatment 
benefit of statins should be proposed in future pharmacogenetic analyses in similarity with 
the ACE-inhibitors (chapter 14). Finally, in the general discussion (chapter 15), methodological 
considerations are addressed and the main findings of this thesis are placed in a broader con-
text, and the potential clinical implications (number needed to treat) and directions for future 
pharmacogenetic research of ACE-inhibitors are discussed. 
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ABsTrACT
The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl®) is a long-acting lipo-
philic drug with a high-tissue affinity for the angiotensin-converting enzyme. ACE-inhibition 
by perindopril has two main effects: it inhibits the angiotensin II formation and potentiates 
bradykinin. Perindopril is one of the ACE-inhibitors, which has been extensively studied in 
randomized clinical trials within various patient populations. The clinical efficacy has been 
demonstrated in patients with hypertension, diabetes mellitus, cerebrovascular disease, stable 
coronary artery disease (CAD), and heart failure. Also, perindopril has a positive safety and toler-
ability profile. Therefore, perindopril, as ACE-inhibitor, has an established place in the clinical 
treatment guidelines of the European Society of Cardiology, European Society of Hyperten-
sion, European Association for the Study of Diabetes and the American Heart Association and 
American College of Cardiology. The Action in Diabetes and Vascular disease: preterAx and 
diamicroN Controlled Evaluation (ADVANCE) trial, the Anglo-Scandinavian Cardiac Outcomes 
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), the European trial on Reduction Of cardiac 
events with Perindopril among patients with stable coronary Artery disease study (EUROPA), 
and the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that 
an antihypertensive treatment with perindopril reduces and prevents cardiovascular events 
in a large range of patients with established vascular disease or high-risk of vascular disease. 
The observed cardioprotective benefits of perindopril were independent of blood pressure. 
The outcome of these and other trials support the concept of specific cardioprotective proper-
ties of ACE-inhibition by perindopril in addition to the blood-pressure lowering effects, such 
as anti-atherosclerotic, anti-inflammatory and anti-thrombotic properties. In addition, the 
observed consistency of the treatment benefit across subgroups indicates that the absolute 
benefits conferred by treatment are established mainly by each patient’s future risk of vascular 
complications, rather than their initial blood pressure level or other risk factors. This review 
describes these issues according to the main studies with perindopril or perindopril based-
regimens, concluding that the blood pressure dependent and independent cardioprotective 
effects extend to all patients with vascular disease. This concept supports the provision of ACE-
inhibitor based treatment, not on the basis of arbitrary cut-off points for blood pressure but 
rather on assessment of vascular risk, which is raised in patients with stable CAD, diabetes and 
stroke. Therefore, perindopril should be considered as first line agent in patients with height-
ened (cardio-)vascular risk considering its properties and the clinical evidence on efficacy, 
safety profile and tolerability.
Drug profile of perindopril 23
inTroDuCTion
The renin-angiotensin aldosteron system (RAAS) is an important regulator of the hemodynamic 
stability in the human body by controlling circulating volume and electrolyte balances (Figure 
1). The RAAS accomplishes this function by regulating extracellular fluid volume, sodium bal-
ance and cardiovascular function through direct and indirect effects on several organ systems 
and interaction with the autonomic nervous system and several vasoactive hormones(1). The 
RAAS is activated in response to signals of compromises in the blood pressure stability or extra-
cellular fluid volume homeostasis. A decrease in pressure of the juxtaglomerular apparatus, 
raises the production of renin from the kidney(2,3). Renin is a proteolytic enzyme that has a 
local action on angiotensinogen in the kidney as well as in the circulation. Angiotensinogen is 
a protein precursor produced in the liver and is cleaved by renin to form an inactive peptide 
angiotensin I (AT-I), which is subsequently converted to the active octapeptide angiotensin II 
(AT-II) by the angiotensin-converting enzyme (ACE). ACE is a largely tissue-based zinc metal-
loprotease, mainly generated by the lungs, the cell membranes of the kidneys and endothelial 
cells of the vasculature(1-3). Therefore, the concentrations of ACE influence the levels of AT-II, 
which is the active metabolite of the system through which the RAAS mediates the majority of 
unfavorable effects (pro-atherosclerotic) in the human body (Table 1). Renin production is the 
rate limiting step in the system(4). Excessive or maladaptive stimulation of this hormonal cas-
cade causes pathologic changes in a wide variety of organ systems. For example, an overactive 
RAAS results in excessive vasoconstriction, which is associated with hypertension, renal injury, 
atherosclerosis and left ventricular dysfunction(4). These conditions have been associated with 
high levels of tissue ACE(4). Likewise, the blockade of an activated RAAS has become a key 
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figure 1 Renin-angiotensin-aldosteron system
ACE = angiotensin-converting enzyme
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therapeutic target in a wide variety of patients, such as patients with hypertension, diabetes 
mellitus, renal disease, atherosclerotic cardiovascular disease and heart failure. The clinically 
most important examples of pharmacologic agents that block the RAAS are currently the ACE-
inhibitors, and AT1 receptor blockers (ARBs). 
The ACE-inhibitors were introduced almost three decades ago for the treatment of hyper-
tension. From that moment onwards, ACE-inhibitors have been associated with significant 
advances in the secondary prevention of a wide range of cardiovascular diseases. This impor-
tant role of ACE inhibitors has been established by several large clinical trials that demonstrated 
the efficacy of this drug class in patients at high risk of cardiovascular disease, including those 
with post-myocardial infarction left ventricular ejection fraction of less than 40%, heart failure 
or a history of cerebrovascular disease [the Survival and Ventricular Enlargement (SAVE) study, 
Studies of Left Ventricular Dysfunction (SOLVD), the Acute Infarction Ramipril Efficacy (AIRE) 
study and the Trandolapril Cardiac Evaluation (TRACE) study], and those with a lower risk of 
cardiovascular events, in particular patients with stable coronary artery disease (CAD) without 
overt heart failure [the Heart Outcomes Prevention Evaluation (HOPE) study, and the EUROPA-
trial (while the PEACE-trial was neutral) (Figure 2) (5-11). 
The use of ACE-inhibitors is now recognized and recommended in the European Society of 
Cardiology/American Heart Association/American College of Cardiology/European Society of 
Hypertension/European Association for the Study of Diabetes guidelines on the management 
of hypertension, stable CAD, myocardial infarction, heart failure, and in the prevention of the 
progression of renal insufficiency in diabetes mellitus-related kidney disease (specific indica-
tion see Table 2) (12-17). For example, the European Society of Cardiology 2006 clinical treatment 
guidelines recommend the use of ACE-inhibitors in secondary prevention for the broad group 
of patients with known CAD with, respectively, a class I (level of evidence A) recommendation 
Table 1. Main effects of angiotensin-II in the human body
Effect of AT1 receptor stimulation
Arteriolar vasoconstriction
Increased Na+ and Cl- reabsorption and K+ excretion 
Aldosteron synthesis
Increased plasminogen activator inhibitor 1 activity (thrombogenic)
Increased sympathetic activity
ADH secretion: H2O absorption by collecting duct 
Vascular smooth muscle growth 
Endothelial dysfunction by:
- Increased connective tissue and low-density lipoprotein accumulation in vascular media 
- Increased uptake and oxidation of LDL by macrophages and endothelial cells
- Oxidative stress 
- Activation of adhesion molecules; monocyte chemo-attractants
- Matrix degradation (increased matrix-metalloproteinases)
- Activation of inflammatory cytokines (Il-6, TNFa)
- Enhanced expression of MMP and oxyradical production (NADH/NADH oxidase activity, cNOS)
Reference: Ferrari et al. Exp Rev Cardiovasc Ther. 2005 (ref 38).
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 figure 2 Efficacy of ACE-inhibitors in patients at high risk of cardiovascular disease (post-MI, LVEF,40%, 
history of CVA) or relatively lower risk of cardiovascular disease (stable CAD without overt heart failure). 
Adapted from Dagenais et al. Lancet 2006; 368:581–8 with permission (reference 49) 
Table 2. ESC guidelines on administration of ACE-inhibitors in specific patient categories.
Indication Specifics Recommendation
level
Hypertension -  Patients with heart failure, systolic LVD, diabetes mellitus, previous 
MI or CVA, high coronary artery disease risk
- Control based on blood pressure levels in hypertensives
I-A
I-A
Heart failure - Symptomatic heart failure and reduced LVEF
- LVSD after AMI
- Asymptomatic reduced LVEF (40-45%), no previous MI
- Diastolic heart failure
I-A
I-A
I-A
IIa-C
Acute MI, after 
stabilization
- High-risk patients (heart failure, LVD, no perfusion, large infarct)
- All patients
I-A
IIa-A
Evolving AMI 
(>24h), post-MI
- Clinical heart failure or asymptomatic LVD (LVEF <45%)
- Diabetes Mellitus or other high risk patients 
I-A
I-A
Secondary 
Prevention
-  Patients with evidence of cardiovascular disease (independent of 
LVEF) or diabetes and 1 other risk factor.
-  All patients with LVEF<40% and in patients with diabetes mellitus, 
hypertension or chronic kidney disease.
I-A
I-A
Class I: evidence or general agreement that a given treatment is beneficial, useful and effective. Class II: 
conflicting evidence and/or divergence of opinion about the efficacy of the treatment. Class IIa: weight 
of evidence is in favor of efficacy. Level of evidence A: data derived from multiple randomized clinical 
trials or meta-analyses. Level of evidence B: data derived from a single randomized clinical trial or non 
randomized studies. Level of evidence C: consensus of opinion of the experts and/or small studies, or 
standard of care. Modified from ESC treatment guideline statements (ref 12-15). LVEF= left ventricular 
ejection fraction; LVSD left ventricular systolic dysfunction; AMI= acute myocardial infarction; LVD= left 
ventricular dysfunction; MI= myocardial infarction.
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for ACE-inhibitor therapy in CAD patients with hypertension, heart failure, left ventricular 
dysfunction, previous myocardial infarction with left ventricular dysfunction or diabetes and a 
class IIa recommendation in all patients with angina pectoris and confirmed coronary disease 
(level of evidence B). In angina pectoris without co-existing indications for ACE-inhibitor treat-
ment, the anticipated benefit should be weighted against the costs and risks of side effects, and 
the dose and agent used should be of confirmed efficacy for this indication(12). 
Although there are other agents modulating the renin–angiotensin system which have 
some overlapping pharmacological and clinical effects, ACE-inhibitors remain a unique drug 
class because of the broad range of their confirmed benefits and tolerability, forming a solid 
basis for the treatment of cardiovascular disease, including potential combinations with other 
established drugs, such as statins and antiplatelet agents. At current, ACE-inhibitors are the 
gold standard in secondary prevention guidelines for blockade of the RAAS, other agents such 
as ARBs can be considered in cases of intolerance to ACE-inhibitors. Results of ARB trials have 
been inconsistent until now. The ACE-inhibitors are considered as a homogenous drug class. 
Among the available ACE-inhibitors important differences exist in their chemical structure 
and pharmacokinetic aspects, of which the most important is the affinity for tissue-bound and 
circulating ACE(18). 
short overview of perindopril
The ACE-inhibitor perindopril has been extensively studied in several large randomized clinical 
trials such as the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Perindopril Protec-
tion Against Recurrent Stroke Study (PROGRESS), the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study, and the EUROPA-trial of 
which each has made its own contribution to the expansion of treatment strategies in cardio-
vascular disease(11,19-21). A lot of data has been gathered on the safety profile and tolerability 
of perindopril(22,23). In a 12 month post marketing study of perindopril, no unexpected hazards 
were observed in a large cohort of patients treated with perindopril (n=47351 patients) (22). 
Research with perindopril has extended our knowledge of the maladaptive responses and 
pathophysiological processes in the renin–angiotensin–aldosteron system. Several sub studies 
of EUROPA, have established that perindopril has additional effects beyond blood pressure 
reduction alone, such as the improvement of endothelial function, improvement of the neuro-
humoral balance and reduction of unfavorable remodeling of the coronary arteries(24-26). Per-
indopril has several unique properties above other ACE-inhibitors in its class, such as a higher 
affinity for tissue and circulating ACE, which is thought to be related to the penetration capacity 
in atherosclerotic plaques(18) and 24 h duration of action with once daily administration. 
The above mentioned studies and aspects of perindopril will be discussed in the current 
review focusing at the pharmacokinetics, pharmacodynamics, safety profile and clinical efficacy 
of the ACE-inhibitor perindopril in the management of cardiovascular disease. 
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Chemical structure of perindopril
All ACE inhibitors are 2-methylpropionyl- L - proline analogues, but they differ from each other 
by their individual chemical structure(28) by which they are currently classified. Some contain 
a sulfydryl group (captopril), a phosphinyl group (fosinopril) but most have a carboxyl moiety 
(ie. ramipril and perindopril). ACE-inhibitors exert their effect on ACE by chelating Zn 2+ in the 
active centre. The functional (Zn 2+ -chelating) group binding to ACE is the primary structural 
difference among these agents. Some of the specific characteristics of these agents may be 
linked to these different binding groups(29).
Perindopril was discovered in 1982 by Laboratoires Servier (30). Perindopril ((2S,3aS,7aS)-1-
[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-
2-carboxylic acid) is a potent long-acting lipophilic ACE-inhibitor(28-30) (Figure 3). It is a prodrug 
ester that, after oral administration, is converted to the active diacid perindoprilat by hydrolysis 
in the liver and plasma. Perindopril is orally administered in the form of tablets containing its 
salts (1:1) with erbumine (tert-butylamine) and l-arginine (perindopril erbumine and perindopril 
l-arginine). The new formulation of the ACE inhibitor perindopril as an arginine salt improves 
the stability of the product and increases its shelf life. Pharmacokinetic studies indicate that 
perindopril-arginine can be expected to have equivalent antihypertensive efficacy to the 
previous formulation, with a revised dosage due to the difference in molecular weight of the 
two salts: perindopril-arginine 5–10 mg replaces perindopril tert-butylamine 4–8 mg (31). In 
general, it is expected that with the pharmacokinetic results of perindopril-arginine the phar-
macodynamic effect are at least equivalent with the prior formulation. Therefore, the benefits 
demonstrated in large-scale trials performed with the perindopril-tert-butylamine formulation 
are likely to apply to perindopril-arginine formulation. Figure 3. 
Chemical structure of perindopril (C19H32N2O5). 
  
   
 
Figure 4. 
Tissue potency of different ACE-inhibitors 
  
 
figure 3 Chemical structure of perindopril (C19H32N2O5).
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PhArmACoDynAmiCs
The biological effects of angiotensin II are 1) vasoconstriction, which increases blood pressure, 
2) constriction of the efferent renal arterioles, which increases glomerular perfusion pressure 
of the glomeruli, 3) stimulation of the adrenal cortex to release aldosteron, which acts on 
renal tubules to retain sodium and chloride ions and excrete potassium (this leads to water 
retention which increases blood volume and hence blood pressure), also angiotensin acts on 
the proximal tubule causing sodium retention, 4) stimulation of the posterior pituitary gland 
into releasing vasopressin (also known as anti-diuretic hormone (ADH)) which also acts on the 
kidneys to increase water retention, 5) ventricular remodelling processes in the heart leading 
to ventricular hypertrophy and heart failure as presented in Table 1 (1-4, 32-34). The ACE-inhibitors 
competitively block the conversion of A-I into A-II. This blockade results in a decrease in circulat-
ing and local levels of A-II, thus inhibiting the effects of A-II (Table 3). 
It is important to realize that ACE-inhibitors do not antagonize the AT1 receptor and thus 
do not inhibit the unfavorable effects of A-II completely. In addition, it needs to be appreciated 
Table 3. Pharmacodynamic effects of ACE-inhibitors
ACE-inhibitors
Inhibit ACE in plasma and tissue and blood vessels
 - Reduce ATII (inhibits conversion of AT-I in AT-II)
 - Increase Bradykinin
Reduce plasma aldosteron levels
 - SBP and DBP ↓
 - Systemic vascular disease ↓ 
Arterial diameter ↑ (reduces vasoconstrictive effects of AT-II)
Arterial compliance ↑ 
Arterial blood flow ↑ 
Pulse wave velocity ↓
 - Aortic, carotid, femoral 
Lower albuminuria in HT or diabetic nephropathy 
Lower plasma uric acid levels in hypertensives
Reduce thrombogenesis and improves fibrolysis
Reverse endothelial damage
Prevent endothelial cell apoptosis
Reduced monocyte adhesion
Reduced ECM degradation
Increase NO availability
Reduce remodeling
 - Less SMC growth, proliferation and migration
Anti-oxidative function
 - Reduced free radical production
Anti-atherosclerotic effects
No adverse effect on plasma glucose or plasma lipid profiles. 
References 1-4, 32-34
Drug profile of perindopril 29
that when ACE is inhibited, the formation of A-II is restored, at least in part, due to the reac-
tive renin rise that occurs when blocking the A-II-induced negative feedback on renin release. 
Still, an additional beneficial effect of ACE-inhibitors, in contrast to ARBs, is the increase in 
bradykinin levels by a decrease in degradation of bradykinin in inactive peptides (Table 4) 
(34). The increase in bradykinin levels induced by ACE-inhibitors leads to the release of nitric 
oxide and prostaglandins, resulting in additional vasodilatation (35). The bradykinin-mediated 
effect is linked to at least some extent of the beneficial effect of ACE-inhibitors (35) such as 
the anti-atherosclerotic, anti-thrombotic and anti-inflammatory effects which have not been 
demonstrated by ARBs. Yet, in the comparison of ACE-inhibitors to ARBs a unsolved dilemma 
remains since in clinical trials ARBs do have a similar effect as compared to ACE-inhibitors, but 
when compared to placebo there is a greater inconsistency (as compared to ACE-inhibitors) 
in convincingly reducing cardiovascular events. These observations have not been explained 
momentarily. 
ACE-inhibitors versus ARBs
As ACE inhibitors have been shown to reduce mortality and cardiovascular morbidity among 
a wide variety of patient groups at different level of risk, these agents are being compared to 
ARBs for their clinical effect. The VALIANT trial compared the effect of the ACE inhibitor captopril 
versus the ARB valsartan in this population of patients and showed that valsartan is as effective 
as captopril in patients who are at high risk for cardiovascular events after myocardial infarction 
(36). In patients with vascular disease or diabetes without heart failure, ACE inhibitors reduce 
mortality and morbidity from cardiovascular causes, but the role of ARBs in such patients is 
unknown. The ONTARGET investigators studied the ACE inhibitor ramipril, the ARB telmisartan 
and the combination of the two drug combinations (37). The investigators concluded that 
telmisartan was equivalent to ramipril in patients with vascular disease or diabetes. Telmisartan 
was as effective as captopril in reducing the rates of death and other cardiovascular outcomes 
(including the prevention of myocardial infarction). The combination of the two drugs was 
associated with more adverse events without an increase in benefit. There is currently no 
Table 4. Bradykinin effect of ACE-inhibitors.
increased bradykinin levels:
- counteracts the negative effects of AT-II 
- increased nitric oxide levels (NO)
- preserves endothelial function
- cardiovascular anti-remodelling activities
- exerts an indirect anti-oxidant effect
- increases tPA and fibrinolysis
- results in monocyte anti-adhesion
- increases eNOS expression
References 34,35.
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clinical data on either agent being superior to the other. At the moment, the ACE-inhibitor 
perindopril has not been compared to ARBs in a comparative trial. 
The mechanism through which perindoprilat lowers blood pressure is believed to be primar-
ily inhibition of ACE-activity(18). ACE is a peptidyl dipeptidase that catalyzes conversion of the 
inactive decapeptide, angiotensin I, to the vasoconstrictor, angiotensin II. The concentration 
of an ACE-inhibitor in a particular tissue depends on the physicochemical characteristics of 
its molecule, e.g. molecular size, dissociation constant, lipophilicity, as well as the presence of 
blood–tissue barriers and the ability of the tissue to transform inactive prodrugs into active 
form(18). Perindopril also affects endothelial function and has been shown to reverse endothelial 
damage, increase NO availability, and improve fibrinolytic balance which may all underlie the 
anti-atherosclerotic actions of perindopril(18,24-27,38,39), which will be discussed in more detail 
elsewhere below. 
PhArmACokinETiCs AnD mETABolism
Following oral administration, perindopril is rapidly absorbed with peak plasma concentrations 
being reached within 1 hour with a mean bio-availability of 95% (40,41). Approximately 20-50% 
of the perindopril absorbed is rapidly converted during its first pass of the liver into the biologi-
cally active metabolite perindoprilat (elimination half-life mean 1-2 hours). Peak plasma con-
centrations of perindoprilat occur after 3-7 hours but perindoprilat is already detectable within 
30 minutes of administration. Approximately 60% of circulating perindopril is bound to plasma 
proteins, and only 10 to 20% of perindoprilat is bound, which reduces the amount of potential 
drug interactions through effects on protein binding (40,41). During repeated once-daily oral 
dosing with perindopril, perindoprilat accumulates about 1.5 to 2 fold and attains steady state 
plasma levels in 3 to 6 days. Perindopril does not accumulate with a once-a-day multiple dosing 
regimen. Mean total body clearance of perindopril is 219 to 362 mL/min and its mean renal 
clearance is 23.3 to 28.6 mL/min (40,41). Perindopril has a long half-life and 24 hour persistence of 
action allowing 24 hour BP-control, especially during the sleeping and awakening hours (40,41).  
Perindoprilat has a strong affinity for ACE. In patients with CAD, perindopril has been shown 
to reduce both plasma and vascular levels of ACE, such as endothelial and adventitial ACE and 
to increase the expression of eNOS in the endothelium and in vascular smooth muscle cells 
(18,42). The relative tissue affinity of perindoprilat compares favourably with other ACE-inhibitors 
(18,38,43) (Figure 4). The exact meaning of these difference is still unclear. 
The bioavailability of perindopril is influenced when taking the drug during meals. Co-
administration with food did not affect the pharmacokinetics of perindopril, but did reduce 
the conversion of perindopril to perindoprilat and hence its bioavailability(44,45). Therefore, per-
indopril should be taken before food (see section 6) (45). In patients with severe liver failure or 
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compensated liver cirrhosis, the metabolic clearance of perindopril is reduced (46). The AUC of a 
single-dose perindopril 8 mg in patients with mild to severe hepatic cirrhosis was 2-fold higher 
than that in healthy volunteers, but the AUC of perindoprilat was similar to that in healthy vol-
unteers. Therefore, no dosage adjustment is required in patients with hepatic impairment (45,46). 
ACE inhibitors, including perindopril, may increase serum lithium concentrations and increase 
the risk of lithium toxicity when administered concomitantly with lithium (45,47). Since the clear-
ance of perindoprilat and its metabolites is almost exclusively renal, also elderly in whom renal 
function is impaired and renal impaired hypertensive patients should have an adjusted dosage 
of the drug in these circumstances (45,48). 
CliniCAl EffiCACy
The introduction of ACE-inhibitors has had a wide impact on cardiovascular medicine since 
it has been associated with a reduction of cardiovascular risk a wide variety of patients with 
hypertension, heart failure, left ventricular dysfunction, post myocardial infarction, diabetic 
nephropathy, peripheral vascular disease, diabetes mellitus and stroke. A brief overview of 
the effect of the ACE-inhibitor perindopril within the some of these specific patient groups 
(hypertension, diabetes mellitus, cerebrovascular disease and stable coronary artery disease) 
is summarized below:
Figure 3. 
Chemical structure of perindopril (C19H32N2O5). 
  
   
 
Figure 4. 
Tissue potency of different ACE-inhibitors 
  
 
figure 4 Tissue potency of different ACE-inhibitors. Modified from (38) Ferrari R. Angiotensin-converting 
enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther. 
2005;3(1):15–29 with permission.
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hypertension
The ASCOT-BPLA trial investigated the long term effects on cardiac outcomes of a conventional 
antihypertensive regimen (beta-blocker -diuretic) with a newer regimen (calcium channel antag-
onist -ACE-inhibitor) in patients with hypertension at moderate risk of developing cardiovascular 
events (19). In ASCOT, 19.257 patients with hypertension and at least three other cardiovascular 
risk factors were randomized to stepwise regimens of amlodipine 5–10 mg/day adding perindo-
pril 4 or 8 mg/day as required, or atenolol 50–100 mg/day adding bendroflumethiazide 1.25–2.5 
mg/day plus potassium as required. Patients were aged 47–79 (mean 63) years and mean BP at 
baseline was 164/95 mm Hg. The primary endpoint was the combined endpoint of non fatal 
MI and fatal coronary heart disease. The trial was stopped prematurely (median follow-up of 
5.5 years) because the amlodipine-perindopril regimen, compared with atenolol-bendroflume-
thiazide recipients, reduced all-cause mortality by 11% (738 vs 820 events; p = 0.025). The risk 
of the primary endpoint (nonfatal MI and fatal CHD) was not significantly lowered by 10% with 
the amlodipine-perindopril compared with the atenolol-based regimen, but the amlodipine-
perindopril regimen did show a significant reduction in total coronary events (by 13%; 753 vs 852 
events), total cardiovascular events and procedures (by 16%; 1362 vs. 1602 events), cardiovascular 
mortality (by 24%; 263 vs 342 events), fatal and non fatal stroke (by 23%; 327 vs 422 events) and 
new-onset diabetes (by 30%; 567 vs 799 events; p < 0.0001). During the trial, the mean difference 
in systolic and diastolic blood pressure measurements in the amlodipine-perindopril compared 
with the atenolol-thiazide regimen was 2.7/1.9 mm Hg. The findings demonstrate that an antihy-
pertensive drug regimen starting with amlodipine adding perindopril is better than one starting 
with atenolol adding thiazide in terms of reducing death and cardiovascular risk. 
Diabetes mellitus
In type 2 diabetes mellitus, controlling blood pressure levels is important to further prevent 
the risk of macrovascular and microvascular complications of type 2 diabetes. This concept 
was studied in the ADVANCE study which is a randomized controlled trial performed in 11.140 
patients from 215 collaborating centres in 20 countries from Asia, Europe, and North America 
(20). Patients were eligible if they had been diagnosed with type 2 diabetes mellitus at the age of 
30 years or older and were aged 55 years or older at study entry. Eligible patients also needed to 
have at least one of the following: a history of major cardiovascular disease (stroke, myocardial 
infarction, hospital admission for transient ischaemic attack, hospital admission for unstable 
angina, coronary revascularization, peripheral revascularization, or amputation secondary to 
vascular disease), or at least one other risk factor for cardiovascular disease. Detailed descrip-
tions of in- and exclusion criteria can be found elsewhere (20). There were no blood pressure 
criteria for inclusion. The primary study outcomes were composites of major macrovascular 
(cardiovascular mortality, MI, and non-fatal stroke) and microvascular events (new or wors-
ening nephropathy or retinopathy). In ADVANCE, 11.140 patients with type 2 diabetes were 
randomized to treatment with a fixed combination of perindopril and indapamide or matching 
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placebo, in addition to current therapy (20). Compared with patients assigned placebo, those 
assigned active therapy had a mean reduction in systolic and diastolic blood pressure of 5.6/2.2 
mm Hg. After a mean of 4.3 years of follow-up, the perindopril-based regimen reduced the risk 
of major macrovascular or microvascular events by 9% (HR 0.91, 95% CI 0.83–1.00, 15.5% vs 
16.8%; p=0·04) (Figure 5). The separate reductions in macrovascular and microvascular events 
were similar, but were not independently significant (macrovascular HR 0.92; 95% CI 0.81–1.04, 
microvascular HR 0.91; 95% CI 0.80–1.04). The relative risk of cardiovascular mortality was 
reduced by 18% (HR 0.82, 95% CI 0.68–0.98; 3.8% vs 4.6%) and all-cause mortality was reduced 
by 14% (HR 0.86, 95% CI 0.75–0.98; 7.3% vs. 8.5%) (20). There was no evidence that the effects 
of the study treatment differed by initial blood pressure level or concomitant medication use. 
The results suggest that over 5 years, 79 patients needed to be treated to prevent one death 
(all-cause) (20). The administration of a fixed combination of perindopril and indapamide was 
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with equal numbers allocated to active blood pressure 
treatment and placebo. Half-way through follow-up, the 
overall event rates (in active and placebo groups 
combined) were lower than expected. To enhance the 
statistical power of the trial to detect plausible treatment 
eff ects, two amendments dated Nov 30, 2005, were made 
to the study protocol: fi rst, analyses of the primary 
outcomes were extended to include consideration of 
major macrovascular and microvascular events jointly 
as well as separately; and second, treatment and 
follow-up in the blood pressure arm was extended by 
12 months.
Thus, the protocol pre-specifi ed that the composite of 
major mascrovascular and microvasular outcomes would 
be included in the analyses of the primary outcomes. All 
analyses would also be by intention to treat. The eff ects of 
treatment on the primary and secondary endpoints were 
estimated from unadjusted Cox proportional hazard 
models. For participants with more than one outcome 
event during follow-up, survival time to the fi rst relevant 
endpoint was used in each analysis. Participants were 
censored at their date of death or, for those still alive at the 
end of follow-up, the date of their last visit. Patients with 
an unknown vital status were censored when they were 
last known to be alive. Relative risk reductions are 
described in the text and fi gures as percentage reductions 
([1–hazard ratio]×100). Diff erences between randomised 
groups during follow-up, in blood pressure and other 
continuous variables, were estimated from linear mixed 
models. Numbers needed to treat were calculated as 
reciprocals of the absolute risk diff erences with their 
normally-approximated 95% CIs.14 All p values were 
calculated from two-tailed tests of statistical signifi cance 
with a Type I error rate of 5%. As is common practice in 
the analysis of data from large scale trials in which all 
major outcomes are reported (many of which are 
correlated), no adjustment for multiple statistical testing 
was done.15 
Separate estimates for treatment eff ects were obtained 
among subgroups of participants defi ned by age, sex, 
history of vascular disease, ancillary treatments, blood 
pressure, and HbA1c at study entry. No subgroup 
analyses were pre-specifi ed. Homogeneity of treatment 
eff ects for both categorical and continuous variables 
was tested by adding interaction terms to the relevant 
Cox models. All analyses were done using SAS 
version 9.1.
Role of the funding source
ADVANCE was funded by grants from Servier and the 
National Health and Medical Research Council of 
Australia. The sponsor of the study had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all data in the study. The Management 
Committee had fi nal responsibility for the decision to 
submit for publication.
Results
12 877 potentially eligible participants were registered, 
1737 (13·5%) were subsequently withdrawn during the 
6-week active run-in period, and 11 140 (86·5%) were 
randomised (fi gure 1). As would be expected in a 
population of this size, there was good balance between 
randomised groups across a range of characteristics at 
entry (tables 1 and 2). Around a third of patients had a 
history of major macrovascular disease and about 10% 
had a history of major microvascular disease at baseline 
(table 1). The mean entry blood pressure of randomised 
patients was 145/81 mm Hg and 41% had a blood pressure 
less than 140 mm Hg systolic and 90 mm Hg diastolic. At 
randomisation, 47% of patients were receiving treatment 
with open-label perindopril (2–4 mg a day). Additionally, 
47% of patients were receiving anti-platelet therapy, 35% 
were receiving cholesterol lowering drugs, and 91% were 
receiving oral hypoglycaemic agents at baseline (table 2).
The mean duration of follow-up was 4·3 years 
(24 005 patient-years in the active treatment group and 
Combined macro+micro
 Macrovascular
 Microvascular
All deaths
 Cardiovascular death
 Non–cardiovascular disease death
Total coronary events
 Major coronary events
 Other coronary events*
Total cerebrovascular events
 Major cerebrovascular events
 Other cerebrovascular events†
Total renal events
 New or worsening nephropathy
 New microalbuminuria
Total eye events
 New or worsening retinopathy
 Visual deterioration
Hazard ratio
0·5 1·0 2·0
 9% (0 to 17)
 8% (–4 to 19)
 9% (–4 to 20)
 14% (2 to 25)
 18% (2 to 32)
 8% (–12 to 24)
 14% (2 to 24)
 11% (–6 to 24)
 14% (–1 to 27)
 6% (–10 to 20)
 2% (–18 to 19)
 21% (–6 to 41)
 21% (15 to 27)
 18% (–1 to 32)
 21% (14 to 27)
 5% (–1 to 10)
 –1% (–18 to 15)
 5% (–1 to 10)
(15·5%)
(8·6%)
(7·9%)
(7·3%)
(3·8%)
(3·5%)
(8·4%)
(4·8%)
(5·1%)
(5·1%)
(3·9%)
(1·4%)
(22·3%)
(3·3%)
(19·6%)
(45·4%)
(5·2%)
(43·9%)
(16·8%)
(9·3%)
(8·6%)
(8·5%)
(4·6%)
(3·8%)
(9·6%)
(5·3%)
(5·8%)
(5·4%)
(3·9%)
(1·8%)
(26·9%)
(3·9%)
(23·6%)
(46·9%)
(5·1%)
(45·1%)
938
520
477
471
257
212
535
294
324
303
218
99
1500
216
1317
2611
286
2514
861
480
439
408
211
197
468
265
283
286
215
79
1243
181
1094
2531
289
2446
Number (%) of patients
with event
Placebo
(n=5571)
Perindopril–
indapamide
(n=5569)
Favours
perindopril–
indapamide
Favours
placebo
Relative risk
reduction 
(95% CI)
Figure 4: Eff ects of study treatment on deaths, coronary events, cerebrovascular events, renal events, and eye 
events
*Other coronary events=unstable angina requiring hospitalisation, coronary revascularisation or silent myocardial 
infarction. †Other cerebrovascular events=transient ischaemic attack (including amaurosis fugax) or subarachnoid 
haemorrhage. Black squares=point estimates (with area proportional to number of events); horizontal 
lines=95% CI. Diamonds=point estimate and 95% CI for overall eff ects. Vertical broken lines=point estimates for 
overall eff ect, within categories.
figure 5 ADVANCE-trial: result of a perindopril-bas d regimen in pati ts with typ  II diabetes mellitus.
Adapted from (20) Patel A; ADVANCE Collaborative Group, et al. Effects of a fixed combination of 
perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 
diabetes mellitus (the ADVANCE trial):  r ndomised controlled trial. Lance . 2007 Sep 8;370(9590):829-40 
with permission.
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safe and well-tolerated. Treatment guidelines now recommend intensive lowering of blood 
pressure for diabetic patients with hypertension.
Cerebrovascular disease
The PROGRESS study was designed to determine the effects of a perindopril-based antihyper-
tensive regimen in patients with a history of stroke or transient ischaemic attack (21). In PROG-
RESS, 6105 individuals from 172 centres in Asia, Australasia, and Europe were randomly assigned 
active treatment (n=3051) or placebo (n=3054). Active treatment comprised a flexible regimen 
based on perindopril (4 mg daily), with the addition of the diuretic indapamide at the discretion 
of treating physicians. The primary outcome was total stroke (fatal or non-fatal). Over 4 years 
of follow up, active treatment reduced blood pressure by 9/4 mm Hg and reduced the primary 
For personal use. Only reproduce with permission from The Lancet Publishing Group.
There were only small differences between the
standardised blood pressure reductions seen among
participants classified as hypertensive (9·5/3·9 mm Hg
[0·6/0·3]) and those classified as non-hypertensive at
entry (8·8/4·2 mm Hg [0·5/0·3]).
Effects on stroke
727 participants had a stroke during follow-up: 307
(10%) in the active group and 420 (14%) in the placebo
group (relative risk reduction 28% [95% CI 17–38%];
p<0·0001). The cumulative stroke curves diverged early
and continued to separate throughout follow-up (figure
3). The annual rate of new cases of stroke was 2·7% in
the treatment group and 3·8% in the control group.
There was no clear evidence of heterogeneity in the size of
the hazard ratios between subgroups of participants
defined by type of qualifying cerebrovascular event
(haemorrhagic or ischaemic), time between the qualifying
event and enrolment (<6 months or 6 months–5 years),
or geographic region of residence (Asia or elsewhere; p for
homogeneity all >0·1).
Overall, 92 (13%) strokes were fatal and a further 212
(29%) were non-fatal but disabling. Fewer patients in the
active group than the placebo group had strokes that were
fatal or disabling, and fewer in the active group had less
severe strokes (figure 4). Overall, 565 participants were
judged to have had an ischaemic stroke during follow-up,
111 a cerebral haemorrhage and 93 a stroke of unknown
pathological type. Again, fewer patients in the active
group than the placebo group had either ischaemic stroke
or cerebral haemorrhage (figure 4).
Effects on major vascular events
During follow-up, 1062 participants had a major vascular
event (379 fatal events and 683 major non-fatal events):
458 (15%) in the active treatment group and 604 (20%)
in the placebo group (figure 4). The annual rate of new
cases was 4·1% in the treatment group and 5·5% in the
control group. Fewer patients in the active group than the
placebo group had non-fatal stroke or non-fatal
myocardial infarction; however, there was no difference
between the groups in terms of vascular death (figure 4).
There were fewer total major coronary events (non-fatal
myocardial infarction or death from coronary heart
disease) among participants assigned active treatment
(115) than among those on placebo (154; relative risk
reduction 26% [95% CI 6–42]).
Effects on deaths and hospital admissions
Data on vital status at the scheduled end of follow-up
were available for all but three (0·05%) randomised
participants. 625 individuals died during the study (379
from vascular causes and 246 from non-vascular causes).
There were no significant differences between
randomised groups in total deaths or deaths from
vascular or non-vascular causes (figure 4). 2601
participants were admitted to hospital on 5085 occasions
during follow-up. Among those assigned active
treatment, there was a reduction in the proportion of
participants admitted to hospital during the scheduled
follow-up period (1252 [41%] vs 1349 [44%], relative
risk reduction 9% [95% CI 1–15]), with a median
reduction of 2·5 days in the time spent in hospital during
follow-up.
Effects of combination and single-drug therapy 
Among participants treated with the combination of
perindopril plus indapamide (in whom blood pressure
was lowered by a mean of 12/5 mm Hg), stroke risk was
significantly lower than that among participants who
received double placebo (figure 5). Among participants
treated with perindopril alone (in whom blood pressure
was lowered by a mean of 5/3 mm Hg), stroke risk was
not discernibly different from that among participants
who received single placebo (figure 5). There was
significant heterogeneity in the sizes of these treatment
effects (p for homogeneity <0·001). Neither the strength
of this evidence of heterogeneity nor the individual
hazard ratios were materially affected by statistical
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Figure 3: Cumulative incidence of stroke among participants
assigned active treatment and those assigned placebo
Stroke subtypes
Fatal or disabling 123
Number of events
Active
(n=3051)
Placebo
(n=3054)
Favours
active
Favours
placebo
Relative risk
reduction (95% CI)
181 33% (15 to 46)
Not fatal or disabling 201 262 24% (9 to 37)
Ischaemic stroke 246 319 24% (10 to 35)
Cerebral haemorrhage 37 74 50% (26 to 67)
Stroke type unknown 42 51 18% (–24 to 45)
Total stroke 307 420 28% (17 to 38)
Major vascular events
Vascular death 181 198 9% (–12 to 25)
Non-fatal MI 60 96 38% (14 to 15)
Non-fatal stroke 275 380 29% (17 to 39)
Total events 458 604 26% (16 to 34)
Mortality
Stroke 42 50 16% (–27 to 44)
Coronary 58 62 7% (–34 to 39)
Other vascular 81 86 6% (–28 to 30)
Cancer 64 65 2% (–39 to 30)
Other non-vascular 61 56
0·5 1·0
Hazard ratio
2·0
–9% (–57 to 24)
Total deaths 306 319 4% (–12 to 18)
Figure 4: Effects of study treatment on stroke subtypes, major
vascular events, and deaths
Black squares=point estimates (with area proportional to number of
events); horizontal lines=95% CIs. Diamonds=point estimate and 95% CI
for overall effects. Vertical broken line=point estimate for overall effect.
MI=myocardial infarction.
figure 6 PROGRESS trial: treatment benefit of perindopril-based regimen in patients with cerebrovascular 
disease. Adapted with permission from: (21) PROGRESS Collaborative Group. Randomised trial of a 
perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or 
transient ischaemic attack. Lancet. 2001;29;358(9287):1033-41.
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endpoint of fatal and non-fatal stroke by 28% (HR 0.72, 95% CI 0.62-0.83; 307 vs 420 events) 
and total major vascular events by 26% (HR 0.74;95% CI 0.66-0.84; 458 vs 604 events) (Figure 
6). There were similar reductions in the risk of stroke in hypertensive and non-hypertensive 
subgroups (all p<0·01). Combination therapy with perindopril plus indapamide reduced blood 
pressure even more by 12/5 mm Hg and increased the treatment benefit on stroke risk to 43%. 
This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and 
non hypertensive individuals with a history of stroke or transient ischaemic attack (21). Only the 
combination of the two drugs, perindopril and indapamide was associated with the beneficial 
effects as single therapy was not associated with significant treatment benefits. 
stable coronary artery disease 
The EUROPA trial studied the ACE-inhibitor perindopril in a relatively low-risk population with 
stable coronary artery disease and no apparent heart failure (11). In EUROPA, 12.218 patients 
were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). 
The primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Mean 
age of patients was 60 years and 85% were male, 92% were taking platelet inhibitors, 62% beta-
blockers, and 58% statins. During a mean follow-up of 4.2 years, perindopril was associated with 
a 20 % relative reduction in the primary endpoint (HR 0.80; 95% CI 0.71-0.91; 8% vs 10%) (Figure 
7). These benefits were consistent in clinical subgroups and secondary endpoints. Results were 
independent of baseline blood pressure and on top op concomitant medication use. Perindopril 
was safe and well tolerated. Among patients with stable coronary heart disease without apparent 
heart failure, perindopril significantly improves outcome. To prevent one major cardiovascular 
event, about 50 patients with stable CAD need to be treated for a period of 4 years (11). 
An analysis of three trials of ACE inhibitors in stable vascular disease without left ventricular 
systolic dysfunction (LVSD) or heart failure, which involved 29 805 patients, demonstrated that, 
when the findings of HOPE, EUROPA and PEACE were combined (49), ACE-inhibitors significantly 
reduced all-cause mortality (7.8% versus 8.9%, P = 0.0004), cardiovascular mortality (4.3% versus 
5.2%, P = 0.0002), non-fatal myocardial infarction (5.3% versus 6.4%, P = 0.0001), stroke (2.2% 
versus 2.8%, P = 0.0004), heart failure (2.1% versus 2.7%, P = 0.0007), coronary artery bypass 
graft surgery (6.0% versus 6.9%, P = 0.0036) but not percutaneous coronary intervention (PCI) 
(7.4% versus 7.6%, P = 0.48). The ACE-inhibitors used in these three trials (HOPE ramipril, EUROPA 
perindopril, PEACE trandolapril) share several pharmacological characteristics and have been 
shown to reduce cardiovascular events in patients with heart failure and myocardial infarction 
or stroke (18,49). However, in stable CAD trandolapril showed no significant benefit in the PEACE 
trial, which is possibly related to the reduced power caused by greater crossover and inefficacy 
of the dosage used. However, the combined analysis confirms that ACE-inhibitors consistently 
reduce major vascular events in patients with atherosclerosis with preserved LV function. The 
benefits of ACE inhibitors were independent of baseline blood pressure and apparent in patients 
taking ß-blockers, lipid-lowering agents and antiplatelet therapy individually or together (49).
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Elderly
In patients 80 years of age or older, the benefit of a perindopril-indapamide regimen has been 
demonstrated in the HYVET trial (50). The HYVET study randomly assigned 3845 elderly patients 
with a sustained systolic blood pressure of 160 mmHg or more to receive the diuretic indap-
amide or matching placebo, the ACE-inhibitor perindopril was added if necessary to achieve the 
target blood pressure of 150/80 mmHg. In the active treatment group, at 2 years, 25.8% were 
receiving indapamide only, 23.9% indapamide and perindopril 2 mg, and 49,5% indapamide 
and perindopril 4 mg. The active treatment group was associated with a 30% reduction in the 
rate of fatal or nonfatal stroke (95% CI -1 to 51, P 0.06) and 21 reduction in the rate of death 
(95% CI 4-35, P 0.02) and 64% in the rate of heart failure (95% CI 42-78; P <0.001). The HYVET 
study provides evidence that antihypertensive treatment with indapamide or a combination 
of indapamide with perindopril is beneficial in persons aged 80 years or older (50). Additionally, 
ACE-inhibitors have demonstrated beneficial effects in improving outcome in patients with 
(diabetic) nephropathy, however, perindopril has not been studies in this patient category and 
not incorporated in this review.
For personal use. Only reproduce with permission from The  Lancet publishing Group.
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and lipid-lowering drugs. At a mean follow-up of 4·5 years,
HOPE reported a placebo mortality of 12%, cardiovascular
mortality of 8%, and Q-wave myocardial infarction of 
3%, compared with 7%, 4%, and 2%, respectively, in our
study at 4·2 years of follow-up. Thus, the major annual
event rates in HOPE were 40% to 80% higher than those in
EUROPA. The frequency of clinical myocardial infarction
and cardiovascular death was reduced by 21% with 
ACE inhibition in HOPE. We saw a similar 20% reduction,
from 10% o % at 4·2 years. At 3 years of follow-up,
concomitant medication was recorded in 11547 (95%)
patients—platel t inhibitors (91%), lipid-lowering agents
(69%), and  blockers (63%). Thus, the benefits of ACE
inhibition were still evident on top of current comm nded
secondary preventive measures. 
The 8 mg dose of perindopril, nce daily, used in our
study was well tolerated. Around 10% of patients did not
continue after the open-label dose-titration phase for
various reasons. Specific adverse effects, such as cough,
hypotension, or abnor al creatinine rise were infrequent.
After randomisation, withdrawals from treatment were
similar to those for placebo; cough was a reason for
withdrawals in 2·7% of perindopril treated patients
compared with 0·5% on placebo. 
We recruited patients without heart failure. Although
65% of patients had had previous myocardial infarction,
only 1·4% developed heart failure during the study period.
This proportion contrasts with about 25% of new-onset
heart failure among patients who have pre-existing left-
ventricular dysfunction in the Studies of Left Ventricular
Dysfunction prevention study,7 and provides some support
that our patients did not have left-ventricular dysfunction. 
The effects of perindopril on the primary outcome 
seem to begin after 1 year of treatment, after which the
event curves continued to separate throughout the
remaining study period. Differences between the event
curves were significant at 3 years of follow-up and beyond.
The gradual onset of effect and progressive benefit ov r
time is consistent with the antiatherosclerotic and
antih pertensive properties of ACE inhibition.
In several studies ACE inhibitors have modulated various
co ponents of the atheros l rotic process by inhibiting
angiotensin II formation and by reducing bradykinin
breakdown.14–18,27–29 Angiote sin II increases lipid
peroxidation and oxyradical formation, and stimulates the
expression of proinflammatory genes, such as
chemoattractant protein and leucocyte adhesion molecules,
resulting in endothelial dysfunction. In addition,
angiotensin II improves vascular smooth-muscle
proliferation and stimulates the production of PAI-I.
Conversely, bradykinin counteracts the negative action of
angiotensin II and improves endothelial function by
increasing expression and activity of the constitutive nitric-
oxide synthase, the enzyme that produces nitric oxide.
Bradykinin also inhibits the expression of monocytes 
and adhesion molecules, has an antiproliferative effect, 
Perindopril Placebo
(n=6110) (n=6108)
Cardiovascular mortality, MI, cardiac arrest 488 (8·0%) 603 (9·9%)
Total mortality, MI, UA, cardiac arrest 904 (14·8%) 1043 (17·1%)
Cardiovascular mortality, MI 484 (7·9%) 596 (9·8%)
Cardiovascular mortality, MI, UA 753 (12·3%) 885 (14·5%)
Total mortality 375 (6·1%) 420 (6·9%)
Cardiovascular mortality 215 (3·5%) 249 (4·1%)
MI, fatal and non-fatal 320 (5·2%) 418 (6·8%)
Unstable angina 342 (5·6%) 367 (6·0%)
Cardiac arrest 6 (0·1%) 11 (0·2%)
Stroke 98 (1·6%) 102 (1·7%)
Revascularisation 577 (9·4%) 601 (9·8%)
Heart failure requiring hospital admission 63 (1·0%) 103 (1·7%)
0·5
Favours
perindopril
Favours
placebo
1·0 2·0
Figure 4: Beneficial effect of treatment with perindopril on primary endpoint and selected secondary endpoints
MI=myocardial infarction. UA=unstable angina. Size of squares proportional to number of patients in that group. Dashed line indicates overall relative risk.figure 7 Treatment benefit of perindopril on primary endpoint and selected secondary endpoints in the 
EUROPA-trial. MI=myocardial infarction. UA=unstable angina. Size of squares proportional to number of 
patients in that group. Dashed line indicates overall relative risk. Adapted with permission (ref 11) (Lancet 
2003; 362: 782–88).
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ConsisTEnCy of CliniCAl EffECTs
To ascertain whether or not there is a threshold above which ACE inhibitors have no effect, data 
from the control group on this composite outcome from HOPE and EUROPA were divided in 
tertiles of low, medium and high risk according to a risk model for baseline characteristics (51): 
for HOPE, the annual rates in the placebo were 2.2% for low risk, 3.6% for medium risk and 6.0% 
for high risk, and for EUROPA the annual placebo rates according to the tertiles were 1.4% for 
low risk, 2.4% for medium risk and 4.0% for high risk. Even for low annual rates, below or equal 
to the 2.1% rate in PEACE, the percentage reductions in odds were between 18% and 28%. 
Results showing these benefits in lower and intermediate-risk patients complement existing 
evidence of similar benefit in higher-risk patients with LVSD or heart failure. There was no clear 
indication for a threshold of ACE inhibitor therapy according to baseline risk. A second analysis 
on the consistency of the treatment benefit of perindopril was performed in relation to renal 
insufficiency with similar results (52). 
meta-analysis of EuroPA, ADVAnCE, and ProgrEss
A recent meta-analysis using non-patient level data of the three largest perindopril trials, 
EUROPA, ADVANCE and PROGRESS, which combines patients with a variety of cardiovascular 
disease risk states, coronary artery disease, diabetes mellitus, and stroke but all have in com-
mon that the vascular bed is diseased (53). So, the combined population is one of vascular 
disease or heightened risk of vascular disease. Figure 8 shows a combined analysis of three 
perindopril trials (EUROPA, PROGRESS and ADVANCE). When these findings were combined, 
perindopril significantly reduced all-cause mortality (OR 0.89; 95% CI 0.82–0.97), and cardiovas-
cular mortality, myocardial infarction (OR 0.82; 95% CI 0.74–0.90) (53). This meta-analysis shows 
that perindopril reduced cardiovascular events irrespective of the type of patients and level 
of risk, which is in line with previous meta-analyses and risk models (49,51). This consistency of 
the treatment benefit by perindopril in patients with stable CAD, type 2 diabetes mellitus, or a 
history of stroke indicate that the absolute benefits conferred by treatment will be established 
mainly by each patient’s future risk of vascular complications. It becomes more important to 
base decisions on the treatment of individual patients, on assessment of total cardiovascular 
risk, rather than on arbitrary cut-off points for single risk factors (53). 
ADDiTionAl EffECTs BEyonD BlooD PrEssurE lowEring
Among ACE inhibitors, perindopril has been extensively studied with regard to the blood 
pressure-independent effects. This was first suggested by the ASCOT–BPLA investigators, 
because the observed risk reduction by amlodipine/perindopril was larger than might be 
expected by the reduction in blood pressure which was 3/2 mmHg greater as compared to a 
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ß-blocker/ diuretic regimen in hypertensive patients. This concept that the observed benefits of 
ACE-inhibitors, such as perindopril, in reducing cardiovascular outcomes is greater than might 
be expected from the mere blood pressure reductions alone is observed in the other clinical tri-
als as well (11,19-21), including the HOPE trial with ramipril (9). The observed benefits in ADVANCE, 
EUROPA and PROGRESS were independent of the level of baseline blood pressure. This sug-
gests that, in addition to blood pressure dependent effects, other factors also contribute to the 
benefits of ACE inhibition in patients with CAD. 
The Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTCC) evaluated the 
blood pressure-dependent and independent effects of ACE-inhibitors and ARBs on major 
cardiovascular events using data from 26 large-scale trials comparing ACE-inhibitors or an 
ARBs with placebo or another drug class (54,55). From a total of 146.838 individuals with high 
blood pressure or an elevated risk of cardiovascular disease, 22.666 major cardiovascular 
events were documented during follow-up. The analyses showed comparable blood pressure-
dependent reductions in risk with ACE-inhibitors and ARBs (54,55). However, the analyses also 
showed that ACE-inhibitors produced an additional blood pressure-independent reduction 
in the relative risk of CHD of approximately 9% (95% confidence interval 3–14%) (54,55). This 
blood-pressure independent effects have not been observed for ARBs, and there was evidence 
of a significant heterogeneity between ACE-inhibitors and ARB in this regard (p = 0.002). The 
Figure 8.  
Meta-analysis of EUROPA, ADVANCE* and PROGRESS trials using perindopril-based 
regimens versus placebo in patients with vascular disease or high-risk of vascular disease.  
 
  figure 8 Meta-analysis of EUROPA, ADVANCE* and PROGRESS trials using perindopril-based regimens 
versus placebo in patients with vascular disease or high-risk of vascular disease.
Adapted from Brugts JJ, Simoons ML with permission. Meta-analysis of ACE-inhibitors in CAD: lessons 
from trials in stable coronary artery disease. In: Perindopril. A major contribution to the prevention and 
treatment of cardiovascular disease. Ferrari R, Fox KM (editors). Paris: Wolters Kluwer Health - Servier; 2008.
pp 107-115. Reference 53
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authors concluded that there are similar blood pressure-dependent effects of ACE-inhibitors 
and ARBs, but only for ACE-inhibitors there is evidence of blood pressure-independent effects 
on the risk of major coronary disease events (54,55). Also the ON-Target study is relevant in this 
regard, however the BP reduction of the treatment regimen of either ramipril or telmarsitan in 
On-Target were comparable, with a slightly higher BP reduction by telmarsitan (0.9/0.6 mmHg), 
with equivalence in risk reduction. Also, no difference in the treatment effect was observed 
with combination therapy which was related to an additional 2.4/1.4 mmHg BP lowering as 
compared to ramipril alone (37). 
A recent analysis of EUROPA-investigators focused on this particular issue of effects beyond 
BP lowering of perindopril (56). The authors discussed the potential alternative mechanisms to 
explain the beneficial effects of perindopril in EUROPA. A special feature was that the slight 
differences between ACE-inhibitors may depend on the degree of tissue affinity of specific 
ACE-inhibitors (lipophilicity), but also different effects on bradykinin (57,58) Perindopril has 
high tissue affinity for ACE (59) and, compared with a non-lipid-soluble ACE-inhibitor such 
as enalapril, markedly increases local tissue bradykinin production (60). Perindopril has the 
highest selectivity for the bradykinin binding sites and significantly reduces endothelial cell 
apoptosis compared to other ACE-inhibitors (61,62). Bradykinin, by increasing cNOS expression, 
improves endothelial dysfunction, has anti-oxidant effects, enhances fibrinolysis (tPA release), 
and reduces cardiovascular remodeling, as such counteracting the effects of angiotensin II (63). 
The bradykinin mediated effects could also be an explanation for the observed blood pressure 
independent effects which absent with ARBs in the BPLTCC analyses. Unfortunately, ACE-
inhibitors have not been compared prospectively, and therefore the exact clinical meaning of 
these specific properties is still unknown. 
Several sub studies of EUROPA have been performed to explain the additional beneficial 
effects observed with perindopril: [the Perindopril – Function of the Endothelium in Coronary 
Artery Disease Trial (PERFECT), Perindopril’s Prospective Effect on Coronary Atherosclerosis 
by Angiography and Intravascular Ultrasound Evaluation (PERSPECTIVE) and the Perindopril 
– Thrombosis, Inflammation, Endothelial Dysfunction and Neurohumoral Activation Trial (PERTI-
NENT) (24-27, 39). The PERSPECTIVE study evaluated the effect of perindopril on coronary plaque 
progression as assessed by quantitative coronary angiography and intravascular ultrasound (27). 
The initial analysis revealed no progression of CAD by quantitative angiography and intravascular 
ultrasound with long term administration of either perindopril or placebo (median follow-up 3 
years), possibly because most patients were on concomitant treatment with a statin. A further 
analysis showed an association of long-term administration with perindopril and constrictive 
remodeling patterns without affecting the lumen, suggesting that this treatment is associated 
with plaque stabilization. The PERTINENT study examined the effects of perindopril on endothe-
lial function and concluded that abnormal endothelial function occurs in patients with CAD (up 
regulated ACE) and this can be reversed by perindopril (26). Perindopril significantly increased bra-
dykinin and eNOS levels after one year of treatment and decreased von Willebrand factor (26). The 
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PERFECT study also concluded that the beneficial effects of perindopril on cardiovascular morbid-
ity and mortality in the EUROPA study might be at least partly explained by an improvement in 
endothelial function (24). In the PREAMI study investigated 1252 elderly post-myocardial infarction 
patients with preserved left ventricular function in which perindopril reduced the progressive 
left ventricular deterioration and remodeling (39). These studies with perindopril demonstrates 
its additional effects beyond blood pressure lowering by improving endothelial function, throm-
bolysis and neurohumoral balance and reducing atherosclerosis, and inflammation. 
sAfETy AnD TolErABiliTy
At initiation of an ACE-inhibitor, the physician has to check renal function parameters and 
serum electrolyte. After initiation, up-titration is possible after 2-4 weeks of treatment when 
necessary. Renal function and serum electrolytes should be monitored after initiation. Usually, 
up-titration is done slowly but more rapid titration is possible in closely monitored patients. An 
ARB is recommended as an alternative in patients intolerant of ACE-inhibitor. 
Adverse effects
Common adverse drug reactions (≥1% of patients) include: hypotension, cough, hyperkali-
emia, headache, dizziness, fatigue, nausea, renal impairment (12-17,64). A persistent dry cough is 
a relatively common adverse effect (10%) and is believed to be associated with the increases 
in bradykinin levels produced by ACE-inhibitors, although the role of bradykinin in producing 
these symptoms remains disputed. Recent safety data from EUROPA (n=12218) and PROGRESS 
(n=6105) reported relatively low withdrawal rates (11,21). In EUROPA, 13655 patients were 
registered, and during run-in period 290 patients did not proceed to randomization due to 
hypotension (2.1%), 149 due to raised potassium or creatinine concentrations (1.1%) and 332 
due to other intolerance (2.4%). After randomization, withdrawal associated with dry cough 
was 2.7 and 2.2% in EUROPA and PROGRESS respectively (11,21). “However, patients in these 
studies were selected and the cough rate could be under-estimated”. Since this is one of the 
main arguments for general practitioners to switch to ARBs (ARBs do not influence bradykinin 
levels), these withdrawal rates seem rather low and the persistent dry cough discomfort, when 
apparent, must be evaluated for the individual patient. The potential benefit of the bradykinin 
mediated effects, as described in this review, is also important to when assessing the demon-
strated anti-atherosclerotic, anti-inflammatory and anti-thrombotic effects of ACE-inhibitors by 
bradykinin. The second common side effect of ACE-inhibitors first dose hypotension, but with 
perindopril because of its slow onset has a very low incidence of this side-effect as compared 
to other in its class. Again, safety data from EUROPA and PROGRESS show only 1.0 and 2.1% of 
the patients withdrew from treatment as a result of hypotension (11,21). 
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Renal impairment is a significant adverse effect of all ACE-inhibitors (12-17,64). The reason 
for this is still unknown. Some suggest that it is associated with their effect on angiotensin II-
mediated homeostatic functions such as renal blood flow. In hypertensive patients, renal blood 
flow may be affected by angiotensin II because it vasoconstricts the efferent arterioles of the 
glomeruli of the kidney, thereby decreasing glomerular filtration rate (GFR) and a rise in serum 
creatinin. Hence, by reducing angiotensin II levels, ACE-inhibitors may reduce GFR, a marker 
of renal function. The afferent arteriole is not under the influence of AT-II and when blood 
pressure is reduced there is a fall in glomerular capillary pressure, which prevents progression 
of glomerular damage (64). In some cases, fe. renal artery stenosis, ACE-inhibitors can induce 
or exacerbate renal impairment. ACE-inhibitors may further cause hyperkalemia, because 
angiotensin II increases aldosteron release. Since aldosteron is responsible for increasing the 
excretion of potassium, ACE inhibitors ultimately cause retention of potassium. Some patients 
develop angioedema due to increased bradykinin levels (64). 
Contraindications and precautions
The ACE-inhibitors are contraindicated in patients with bilateral renal artery stenosis ( or 
unilateral stenosis with a solitary functioning kidney) and patients with previous angioedema 
associated with ACE-inhibitor therapy (12-17,64). Additional caution with the prescription of ACE 
inhibitors is needed in patient with renal insufficiency, cardiac outflow obstruction (aortic valve 
stenosis), hypovolemia, dehydration, and patients with haemodialysis. Potassium supplemen-
tation should be used with caution and under medical supervision owing to the hyperkalaemic 
effect of ACE inhibitors.
ACE-inhibitors in pregnancy (ADEC category D)
ACE-inhibitors should be avoided in women who are likely to become pregnant or are pregnant 
(12-17,64). There is a risk of birth defects when taking during the second and third trimester. When 
pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. 
rEgulATory AffAirs
In Europe, perindopril is approved by the EMEA for the treatment of hypertension, heart failure, 
and more recently, based on the EUROPA trial results, for the reduction of cardiac events in 
patients with a history of myocardial infarction and / or revascularization. In the USA, perindo-
pril is approved by FDA for the use in patients with hypertension and in patients with stable 
coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial 
infarction.  Perindopril is available in a fixed combination with indapamide for the treatment of 
hypertension, and more recently, in combination with amlodipine for the treatment of hyper-
tension and/or stable coronary artery disease. 
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EXPErT oPinion & fiVE-yEAr ViEw
The ACE-inhibitors have influenced cardiovascular medicine in a wide variety of patient groups 
as no other. Especially, perindopril has been studied extensively from basic research into 
mechanisms of action and tissue penetrance to clinical efficacy in large randomized trials in 
various patient groups. The great consistency of the treatment benefit across several clinical 
subgroups, on top of concomitant medication, have established that ACE-inhibitors, perindo-
pril, are first-line choice in the cardioprotective treatment of heart failure, hypertension, diabet-
ics, stroke and stable CAD. In patients at high-risk of events, ACE-inhibitors therapy is indicated 
since benefit is expected in all cases. However, in patients at relatively low risk, for example 
stable CAD, one would like to target ACE-inhibitors to those patients most likely to benefit of 
such prolonged prophylactic treatment. Research focused at the consistency of the treatment 
effects is important, since it may elucidate heterogeneity in the treatment effect. It is likely that 
the treatment benefit differs between patients, some will benefit, other will not. Also, many 
patients need to be treated against modest benefits (NNT in EUROPA was 50). Several prior 
approaches to target therapy to those patients most likely to benefit have not been successful. 
These prior approaches have mainly focused at simple clinical patient characteristics (65). One 
option to tailored therapy might be to look into pharmacogenetic aspects of ACE-inhibitors 
therapy in stable CAD. Until now, cardiovascular pharmacogenetic research is in a formative 
stage, but it has the potential to guide ACE-inhibitor therapy in patients with stable CAD. Cur-
rently, the PERindopril GENEtic Association study is being performed focused at this particular 
issue of elucidating a heterogeneity in the treatment effect of perindopril which can be used to 
target therapy to those patients most likely to benefit of treatment (66). The PERGENE study will 
investigate the feasibility of pharmacogenetic profiling of ACE-inhibitors. If proven successful, 
this would revolutionize CVD practice at many other levels but will also lead to an increased 
clinical efficacy and cost-effectiveness of ACE-inhibitors in patients with stable CAD. 
kEy issuEs
•	 Perindopril has a good safety and tolerability profile.
•	 Several differences between ACE-inhibitors exist and perindopril has been shown to have 
unique properties such as:
 - a higher tissue ACE-affinity as compared to other ACE-inhibitors.
 -  the highest selectivity for the bradykinin binding sites and higher effect on   bradykinin 
levels as  compared to other ACE-inhibitors.
 - the clinical meaning of these differences between ACE-inhibitors is yet unknown
•	 Perindopril has a long half-life and 24 hour persistence of action allowing BP to be con-
trolled during sleep and the awakening hours.
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•	 ACE-inhibition by perindopril has additional effects beyond BP reduction such anti-
inflammatory, anti-atherosclerotic and antithrombotic properties.
•	 Perindopril has been demonstrated to be effective in reducing cardiovascular events in a 
wide range of patient populations. ACE-inhibitors are first-line choice in treatment guide-
lines of ESC/AHA/ACC of stable CAD, hypertension, cardiovascular disease and heart failure. 
•	 Perindopril reduced cardiovascular events irrespective of the type of patients and level of 
baseline risk of events. 
•	 The consistency of the treatment benefit by perindopril in patients with stable CAD, type 
2 diabetes mellitus, or a history of stroke indicate that the absolute benefits conferred by 
treatment will be established mainly by each patient’s future risk of vascular complications 
rather than on arbitrary cut-off points for single risk factors such as blood pressure.
•	 Treatment decisions on the treatment of individual patients could therefore be based on 
the assessment of total cardiovascular risk.
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ABsTrACT
Angiotensin converting enzyme (ACE) inhibitors have consistently demonstrated a reduction 
in cardiovascular endpoints, independently of blood pressure reductions, in patients with coro-
nary artery disease (CAD). The persistent effects of perindopril across different populations sug-
gest that it reduces cardiovascular risk via mechanisms in addition to blood pressure reduction.
These effects were demonstrated in the EUROPA study, in which patients with stable CAD 
receiving perindopril experienced reductions in the risk of cardiovascular mortality, myocardial 
infarction, cardiac arrest and non-fatal myocardial infarction. The results of these studies sup-
port the initiation of ACE inhibitors in patients with stable CAD to reduce the risk of future 
cardiovascular events based on the individual’s cardiovascular risk rather than initial blood 
pressure.
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inTroDuCTion
The angiotensin-converting enzyme (ACE) inhibitors were introduced almost three decades ago 
for the treatment of hypertension. Since that time, ACE-inhibitors have been associated with 
significant advances in the secondary prevention of a wide range of cardiovascular diseases. 
This important role of ACE-inhibitors has been established by several large clinical trials that 
demonstrated the efficacy of this drug class (Figure 1) in patients at high risk of cardiovascular 
disease, including those with post-myocardial infarction left ventricular ejection fraction of less 
than 40%, heart failure or a history of cerebrovascular accidents [the Survival and Ventricular 
Enlargement (SAVE) study, Studies of Left Ventricular Dysfunction (SOLVD), the Acute Infarction 
Ramipril Efficacy (AIRE) study and the Trandolapril Cardiac Evaluation (TRACE) study], and those 
with a lower risk of cardiovascular events, in particular patients with stable coronary artery 
disease (CAD) without overt heart failure [the Heart Outcomes Prevention Evaluation (HOPE) 
study, the Prevention of Events with ACE inhibition (PEACE) study and the European Trial on 
Reduction of Cardiac Events with Perindopril among Patients with Stable Coronary Artery 
Disease (EUROPA)] (1-7).
The use of ACE-inhibitors is now recognized and recommended in the European Society 
of Cardiology / American Heart Association / American College of Cardiology / European 
Society of Hypertension / European Association for the Study of Diabetes guidelines on the 
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Figure 2 
Combined analysis angiotensin-converting enzyme inhibitor trials. 
  
  
 
 
 
 
 
figure 1 Benefit of angiotensin-converting enzyme inhibition. ACE = Angiotensin-converting enzyme; 
CAD = coronary artery disease; EF = ejection fraction; HF = heart failure; MI = myocardial infarction.
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management of hypertension, stable CAD, myocardial infarction (MI), heart failure, and in the 
prevention of the progression of renal insufficiency in diabetes mellitus-related kidney disease 
(8-10) For example, the European Society of Cardiology 2006 clinical treatment guidelines rec-
ommend the use of ACE-inhibitors as routine secondary prevention for the broad group of 
patients with known CAD with, respectively, a class I (level of evidence A) recommendation for 
ACE-inhibitor therapy in CAD patients with hypertension, heart failure, left ventricular dysfunc-
tion, previous myocardial infarction with left ventricular dysfunction or diabetes and a class IIa 
recommendation in all patients with angina pectoris and confirmed coronary disease (level of 
evidence B). In angina pectoris without co-existing indications for ACE-inhibitor treatment, the 
anticipated benefit should be weighted against the costs and risks of side effects, and the dose 
and agent used should be of confirmed efficacy for this indication (8) Although other agents 
modulating the renin–angiotensin system can provide some overlapping pharmacological and 
clinical effects, ACE-inhibitors remain unique in the range of their confirmed benefits, forming 
a solid basis for the prevention and treatment of cardiovascular disease, including potential 
combinations with other established drugs, such as statins and anti-platelet agents. 
The ACE-inhibitor perindopril has been extensively studied in several large clinical trials such 
as EUROPA, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Perindopril Protection 
Against Recurrent Stroke Study (PROGRESS), the Perindopril and Remodeling in the Elderly with 
Acute Myocardial Infarction (PREAMI) study and the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study, of which each has con-
tributed to the extension of treatment strategies in cardiovascular disease (7,11-14). Furthermore, 
ACE-inhibitor research has led to a better understanding of pathophysiological processes and 
maladaptive responses in the renin–angiotensin–aldosterone system. In particular, several sub-
studies of EUROPA, [the Perindopril – Function of the Endothelium in Coronary Artery Disease 
Trial (PERFECT), Perindopril’s Prospective Effect on Coronary Atherosclerosis by Angiography 
and Intravascular Ultrasound Evaluation (PERSPECTIVE) and the Perindopril – Thrombosis, 
Inflammation, Endothelial Dysfunction and Neurohumoral Activation Trial (PERTINENT)], have 
established that ACE-inhibitors have additional effects beyond blood pressure reduction alone, 
such as the improvement of endothelial function, improvement of the neurohumoral balance 
and reduction of unfavourable remodeling of the coronary arteries(15-17). 
In this chapter, we will discuss and compare different ACE-inhibitor trials with respect to 
their confirmed efficacy in stable CAD (HOPE, EUROPA, PEACE). We will analyze the relationship 
between the effect on blood pressure by perindopril and the reduction in cardiovascular risk in 
different types of patients in three large trials with this agent (EUROPA, PROGRESS, ADVANCE), 
and we will summarize the lessons learned from over three decades of research with ACE-
inhibitors in cardiovascular disease. 
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AngioTEnsin-ConVErTing EnZymE inhiBiTor TriAls in sTABlE 
CoronAry ArTEry DisEAsE 
Three large clinical trials have examined the beneficial effect of ACE inhibition on the incidence 
of cardiovascular  events in high-risk patients who had evidence of vascular disease or diabetes 
plus one other cardiovascular risk factor (HOPE) or in relatively low-risk patients with stable CAD 
(EUROPA, PEACE). HOPE demonstrated that the ACE-inhibitor ramipril reduced the incidence of 
cardiovascular events during long-term follow-up in high-risk patients(5). EUROPA revealed a sig-
nificant reduction in the incidence of cardiovascular events during long-term follow-up in low-
risk patients with stable CAD without overt heart failure receiving the ACE-inhibitor perindopril(7). 
In a comparable patient population, however, PEACE did not show a reduction in cardiovascular 
events and all-cause mortality with the ACE inhibitor trandolapril(6). The PEACE investigators 
claimed that the absence of any treatment benefits in the trial might have been related to a lower 
baseline risk of cardiovascular events compared with the HOPE and EUROPA trials, and referred 
to the high proportion of patients who had previously undergone revascularization and were 
using more concomitant medication. A comparison of the baseline characteristics of EUROPA, 
PEACE and HOPE is shown in Table 1. In contrast with the assumption by the PEACE investigators, 
Table 1. Baseline characteristics HOPE, EUROPA, PEACE-trials
HOPE
(n=9297)
EUROPA 
(n=12218)
PEACE 
(n=8290)
Characteristics (%)
Age (years) 66 (7) 60 (9) 64 (8)
Female 26.8 14.6 17.5
Previous myocardial infarction 52.7 64.8 55.0
PCI 17.9 29.3 41.5
CABG 25.8 29.4 39.0
Previous stroke or TIA 10.9 3.4 6.5
Peripheral artery disease 43.6 7.3 NA
Current smokers 14.2 15.2 14.5
Diabetes mellitus 38.5 12.3 17.0
Hypertension 46.8 27.1 45.5
Serum cholesterol (mg/L)* 65.9 63.3  192 (40)
Systolic blood pressure (mm Hg) 139 (20) 137 (15) 134 (17)
Diastolic blood pressure (mm Hg) 79 (11) 82 (8) 78 (10)
Medication use
 Antiplatelet agents 76.1 92.3 90.5
 β-blockers 39.5 61.7 60.0
 Lipid-lowering agents 28.6 57.6 70.0
 Diuretics 15.3 9.2 13.0
 Calcium channel blockers 47.1 31.4 35.5
PCI=percutaneous coronary intervention. CABG=coronary-artery bypass graft. * Percentage of patients 
with serum cholesterol ≥201 mg/L for HOPE; or >250 mg/L or on a lipid-lowering treatment for EUROPA; 
for PEACE, serum cholesterol data are mean (± SD). Data are mean (± SD) unless otherwise indicated.
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subgroup analyses in EUROPA showed a remarkable consistency in the beneficial treatment 
effect of ACE inhibition by perindopril, independent of concomitant therapy (ß-blockers, statins 
and antiplatelet drugs), previous revascularization or the level of baseline risk(7,18). Notably, the 
mortality rates in the placebo group were even lower in EUROPA than in the PEACE trial. 
Until recently, the PEACE investigators did not present subgroup analyses to support their 
remarks on the possibilities on the difference in risk or concomitant therapy, which could 
have explained the neutral results. A recent subgroup analysis by the PEACE investigators did 
note renal insufficiency defined as an estimated glomerular filtration rate of less than 60 ml/
min per 1.73 m2 as a target subgroup of patients with a beneficial effect of trandolapril (19). 
The relatively low presence of renal insufficiency in the main study population, in line with 
the presumed lower risk level, might explain the absence of an overall treatment benefit with 
trandolapril in PEACE. As the treatment effect of trandolapril in the entire PEACE study was 
neutral, retrospective analyses to define patient subgroups with positive effects should be 
regarded cautiously and verified in comparable patients. Therefore, the EUROPA investigators 
performed a subgroup analysis to examine a possible interaction between renal function and 
the treatment benefit of perindopril(20). The authors concluded that the treatment effect of 
perindopril remained consistent and was not modified by renal insufficiency (with a compa-
rable estimated glomerular filtration rate distribution in both studies). This indicates that the 
apparent neutral results of PEACE are not explained by the level of risk or the background 
therapies used, but are possibly related to the reduced power caused by greater crossover and 
shorter follow-up than in the other studies. PEACE may have been inadequately powered to 
detect moderate differences in spontaneously occurring clinical outcomes that are unaffected 
by clinical judgement or variations in practice patterns. In support of this possibility are the 
results for all-cause mortality, as well as the composite outcome of cardiovascular mortality, 
non-fatal myocardial infarction and stroke in PEACE, which tended to be favourable [odds ratio 
(OR) 0.93; 95% confidence interval (CI) 0.81–1.08] with confidence intervals overlapping with 
those of HOPE and EUROPA. In EUROPA, patients were assigned to receive a relatively high 
dose of perindopril (8 mg), which was achieved rapidly and in a high proportion of patients, 
whereas in PEACE, trandolapril was up-titrated to the target dose (4 mg) only 6 months after 
random selection. At 3 years, the target dose was achieved in 57.8% of patients in PEACE and 
93.0% of patients in EUROPA(6,7). Both agents are in a broadly similar ACE-inhibitor subgroup, 
share chemical moieties, are lipophilic, and were used in doses that showed important phar-
macological effects. Still, without head-to head trials the possibility cannot be excluded that 
there are pharmacological differences between perindopril and trandolapril that are important 
for their clinical efficacy to reduce cardiovascular endpoints. The absence of a treatment effect 
in PEACE may also be a mere chance finding. Among ACE inhibitors, perindopril at the dose of 
8 mg and ramipril at the dose of 10 mg have been proved to be effective in the prevention of 
cardiovascular events in stable CAD patients without overt heart failure, in contrast to other 
agents studied(5,7).
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ComBinED AnAlysis of hoPE, EuroPA, PEACE 
An analysis of three trials of ACE-inhibitors in stable vascular disease without left ventricular sys-
tolic dysfunction (LVSD) or heart failure, which involved 29.805 patients, demonstrated that, when 
the findings of HOPE, EUROPA and PEACE were combined, ACE inhibitors significantly reduced 
all-cause mortality (7.8% versus 8.9%, P = 0.0004), cardiovascular mortality (4.3% versus 5.2%, P = 
0.0002), non-fatal myocardial infarction (5.3% versus 6.4%, P = 0.0001), stroke (2.2% versus 2.8%, P 
= 0.0004), heart failure (2.1% versus 2.7%, P = 0.0007), coronary artery bypass graft surgery (6.0% 
versus 6.9%, P = 0.0036) but not percutaneous coronary intervention (PCI) (7.4% versus 7.6%, P = 
0.48). Except for stroke and revascularization, these results were similar to those of the five trials 
in patients with heart failure or LVSD(21). For the pooled participants, the composite outcomes of 
cardiovascular mortality, myocardial infarction and stroke occurred in 10.3% of patients of the 
ACE inhibitor group and in 12.4% of patients of the placebo group (OR 0.81; 95% CI 0.75–0.87; P < 
0.0001) as presented in Figure 2 (21). There was no evidence of heterogeneity across the trials (het-
erogeneity P = 0.083). The 2.1% absolute risk reduction implies that to prevent one cardiovascular 
death, myocardial infarction or stroke, 48 patients needed to be treated for 4.5 years (21). The same 
composite outcome, except that cardiovascular death is replaced by total mortality, in the SAVE, 
AIRE, TRACE, SOLVD trials, occurred in 29.2% of the patients receiving an ACE inhibitor and in 
34.1% of the patients who received placebo (OR 0.79; 95% CI 0.73–0.85; P < 0.0001; heterogeneity 
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Figure 1 
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figure 2 Combined analysis angiotensin-converting enzyme inhibitor trials. ACE-I = Angiotensin-
converting enzyme inhibitor; MI = myocardial infarction. Reproduced from Dagenais et al. Lancet 
2006;368:581-8 with permission.
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P = 0.835). The 4.9% absolute risk reduction implies that to prevent one event, 20 patients needed 
to be treated for approximately 3 years. There was no apparent heterogeneity in effects between 
the two categories of trials (P = 0.455). Overall, there was a highly significant reduction in the 
composite of these outcomes: 16.0% versus 18.9% (OR 0.80; 95% CI 0.76–0.84; P < 0.0001) (21).
Table 2 shows the percentage reduction in odds for the composite outcome of cardiovas-
cular death, myocardial infarction and stroke in the different trials of ACE inhibitors(21). The 
reduction varies between 15% and 30% for the different trials irrespective of their annual rates 
of events in the placebo groups of each trial except for PEACE, which had a 7% OR reduction. 
To ascertain whether or not there is a threshold above which ACE inhibitors have no effect, 
data from the control group on this composite outcome from HOPE and EUROPA were divided 
in tertiles of low, medium and high-risk according to a risk model for baseline characteristics, 
and are presented as annual rates: for HOPE, the annual rates in the placebo were 2.2% for low 
risk, 3.6% for medium risk and 6.0% for high risk, and for EUROPA the annual placebo rates 
according to the tertiles were 1.4% for low risk, 2.4% for medium risk and 4.0% for high risk. 
Even for low annual rates, below or similar to the 2.1% rate in PEACE, the percentage reductions 
in odds were between 18% and 28% (21). 
The ACE inhibitors used in these three trials (HOPE ramipril, EUROPA perindopril, PEACE 
trandolapril) share several pharmacological characteristics and have been shown to reduce 
cardiovascular events in patients with heart failure and myocardial infarction or stroke. Analysis 
of the combined results of the HOPE, EUROPA and PEACE studies shows significant reductions in 
Table 2. Reduction in odds (percentage) of cardiovascular death, non-fatal MI, or stroke for PEACE, HOPE, 
and EUROPA, and for trials of patients with heart failure or LVSD
Trials Number of
patients
Annual rates
in placebo group
OR (95% CI) P-value
PEACE 8290 2.13 7 (–8 - 19) 0.328
HOPE total 9297 3.95 25 (16 - 32) 0.0001
- HOPE lower-risk 3083 2.17 18 (–4 - 35)
- HOPE medium-risk 3100 3.58 20 ( 3 - 33)
- HOPE high-risk 3114 5.98 24 (12 - 34)
EUROPA total 12 218 2.60 19 (8 - 28) 0.0007
- EUROPA lower-risk 3976 1.40 19 (–5 - 38)
- EUROPA medium-risk 3975 2.41 28 (11 - 41)
- EUROPA high-risk 3975 4.00 10 (–4 - 22)
AIRE 1986 22.6 24 (7 - 38) 0.0068
TRACE 1749 17.0 25 (9 - 33) 0.0028
SOLVD-P 4228 7.4 15 (2 - 27) 0.0252
SOLVD-T 2569 13.1 23 (10 - 33) 0.0009
SAVE 2231 9.8 20 (4 - 33) 0.0168
LVSD= left ventricular systolic dysfunction. In trials of patients with heart failure or LVSD, total mortality 
was used instead of cardiovascular mortality. P for heterogeneity 0.083 for HOPE, EUROPA and PEACE. 
P-value for heterogeneity 0.835 for the trials of patients with heart failure or LVSD (Dagenais et al. Lancet 
2006; 368: 581–88)
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a broad range of cardiovascular outcomes with no significant differences between the studies. 
There was, however, little overall effect on reducing PCI, which could be caused by indications 
for PCI having varying thresholds in different countries. This combined analysis confirms that 
ACE inhibitors consistently reduce serious vascular events in patients with atherosclerosis either 
with or without known evidence of heart failure or LVSD. Results showing these benefits in lower 
and intermediate-risk patients complement existing evidence of similar benefit in higher-risk 
patients with LVSD or heart failure. At least in these patients with vascular disease, there was no 
clear indication for a threshold of ACE inhibitor therapy according to baseline risk. Therefore, the 
use of ACE inhibitors should be considered in all patients with atherosclerosis. The benefits of 
ACE inhibitors were apparent in patients taking ß-blockers, lipid-lowering agents and antiplatelet 
therapy individually or together. Furthermore, ACE inhibitors benefited patients who underwent 
coronary revascularization and were additionally taking all three drugs. This analysis confirms the 
consistency with which ACE inhibitors reduce the risk of fatal and non-fatal cardiovascular events.
BlooD PrEssurE rEDuCTion AnD imProVED ouTComE wiTh ACE-
inhiBiTors
The mean blood pressure reductions in the three trials were 3/2 mmHg in HOPE, 5/2 mmHg 
in EUROPA, and 5/3 mmHg in PEACE. At 3-year follow-up, adherence to the ACE inhibitor was 
82.2% in HOPE, 81.0% in EUROPA, and 74.5% in PEACE. The number of patients who were 
receiving the target dose of ACE inhibitors at 3-years’ follow up were 93.0% in EUROPA, 70.9% 
in HOPE and 68.6% in PEACE (5-7).
With a comparable blood pressure reduction by ramipril and perindopril, the risk reduc-
tion in cardiovascular death, myocardial infarction or stroke was similar in HOPE and EUROPA 
(Table 3). In PEACE, with a similar population of relatively low-risk patients with stable CAD, 
the same reduction in blood pressure by trandolapril occurred but a weaker risk reduction in 
cardiovascular death, non-fatal myocardial infarction and stroke. This suggests that, in addi-
tion to blood pressure-lowering effects, other factors also contribute to the benefits of ACE 
inhibition in patients with CAD. This was also suggested by the ASCOT–BPLA investigators, 
because the event reduction by amlodipine/perindopril was larger than might be expected by 
the reduction in blood pressure with this treatment regimen in comparison with a ß-blocker/
diuretic regimen.
Further support for the benefit of the ACE inhibition by perindopril is provided in studies in 
patients with cerebrovascular disease and diabetes: The PROGRESS study investigated whether 
a perindopril 4 mg (with or without indapamide) or placebo-based regimen in 6105 patients 
with cerebrovascular disease reduced the incidence of recurrent stroke/cerebrovascular 
accidents(12) After 4 years of treatment, a mean blood pressure reduction of 9/4 mmHg was 
observed with active treatment compared with placebo. For the total group, a 28% reduction 
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in the risk of stroke was observed, which was as expected from the observed blood pressure 
reduction. The perindopril/indapamide regimen reduced the incidence of major coronary 
events by 26% and non-fatal myocardial infarction by 38%, which is in line with the results of 
the ACE inhibitor trials (HOPE, EUROPA) with coronary events as study endpoint. These results 
were independent of the baseline blood pressure levels at study entry.
The ADVANCE trial studied 11.140 patients with type 2 diabetes who were randomly assigned 
to a perindopril 4 mg/ indapamide-based regimen or placebo. Blood pressure was reduced 
by 6/2 mmHg with perindopril/indapamide compared with placebo. Perindopril/indapamide 
lowered the incidence of major macro- and microvascular events, cardiovascular deaths, total 
coronary events and renal events [hazard ratio (HR) 0.91; 95% CI 0.83–1.00; P = 0.04] during 4.3 
years of follow-up. There was no evidence that the effects of the study treatment differed by 
initial blood pressure or the concomitant use of other treatments at baseline. Interestingly, the 
reduction in cardiovascular mortality was greater than expected from the blood pressure effect 
alone (HR 0.82; 95% CI 0.68–0.98), which is comparable with other trials using perindopril.
Figure 3 shows a combined analysis of three perindopril trials (EUROPA, PROGRESS and 
ADVANCE). When these findings were combined, perindopril significantly reduced all-cause 
mortality (OR 0.89; 95% CI 0.82–0.97), cardiovascular mortality (OR 0.85; 95% CI 0.75–0.96) 
and cardiovascular mortality, myocardial infarction (OR 0.82; 95% CI 0.74–0.90). This combined 
analysis shows that perindopril reduced cardiovascular events by approximately 20% irrespec-
tive of the type of patients and level of risk, which is in line with previous meta-analyses and risk 
models (18,21). This consistency of the treatment benefit by perindopril in patients with stable 
CAD, type 2 diabetes mellitus, or a history of stroke is important. Interestingly, in patients with 
a history of stroke (PROGRESS), the addition of indapamide resulted in a higher blood pressure 
reduction (12/5 mmHg) and particularly attenuated the reduction in risk of recurrent stroke. 
With regard to patients with cerebrovascular disease, the effect of blood pressure reduction 
seems to be more directly related to the reduction in the risk of recurrent stroke than to cardio-
vascular risk reduction.
Table 3 Summary of effects of ACE-inhibitors on BP and clinical outcomes in clinical trials of CAD patients.
Compliance 
at 3 years 
Target dose
at 3 years
Mean BP 
reduction
RRD in CV death, 
MI, Stroke (95% CI) 
hoPE (ramipril 10 mg) 82.2 % 70.9 % -3/2 mmHg 0.78 (0.70-0.86)
EuroPA (perindopril 8 mg) 81.0 % 93.0 % -5/2 mmHg 0.81 (0.72-0.92)
PEACE (trandolapril 4 mg) 74.5 % 68.6 % -5/3 mmHg 0.93 (0.81-1.07)
Abbreviations: CV = cardiovascular, MI = myocardial infarction, RRD = relative risk reduction, CI = 
confidence interval. Mean follow-up (yrs) HOPE (4.5), EUROPA (4.2), PEACE (4.8).
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Figure 3. 
Meta-analysis of combined data from EUROPA, ADVANCE and PROGRESS.  
 
  
 
 
 
 
figure 3. Meta-analysis of combined data from EUROPA, ADVANCE and PROGRESS.
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ADDiTionAl EffECTs BEyonD BlooD PrEssurE rEDuCTion
Among ACE inhibitors, perindopril has been extensively studied with regard to the blood 
pressure-independent effects: The PERFECT study concluded that the beneficial effects of per-
indopril on cardiovascular morbidity and mortality in the EUROPA study might be at least partly 
explained by an improvement in endothelial function (15). The PERSPECTIVE study evaluated 
the effect of perindopril on coronary plaque progression as assessed by quantitative coronary 
angiography and intravascular ultrasound. The initial analysis revealed no progression of CAD 
by quantitative angiography and intravascular ultrasound with long term administration of 
either perindopril or placebo (median follow-up 3 years), possibly because most patients were 
on concomitant treatment with a statin (16). A further analysis showed an association of long-
term administration with perindopril and constrictive remodeling patterns without affecting 
the lumen, suggesting that this treatment is associated with plaque stabilization(22). The PER-
TINENT study examined the effects of perindopril on endothelial function and concluded that 
abnormal endothelial function occurs in patients with CAD (up-regulated ACE) and this can be 
reversed by perindopril(17). The PREAMI study investigated 1252 elderly post-myocardial infarc-
tion patients with preserved left ventricular function randomly assigned to receive perindopril 
8 mg or placebo. Perindopril significantly reduced the combined primary endpoint (death, 
hospitalization for heart failure and remodelling) and reduced the progressive left ventricular 
deterioration and remodelling occurring in the presence of small infarct size(13).
lEssons lEArnED from ACE-inhiBiTors TriAlsin sTABlE CoronAry 
ArTEry DisEAsE 
In the clinical trials in patients with CAD or vascular disease, as discussed in this chapter, the 
use of an ACE inhibitor showed a consistent reduction in cardiovascular endpoints (except for 
the PEACE trial). This reduction in the risk of cardiovascular disease seems larger than can be 
expected from the modest reduction in blood pressure reported in these trials (approximately 
6/2 mmHg). The consistency across different risk populations (CAD, diabetes, stroke) by perin-
dopril and the additional effects shown in several substudies make it likely that perindopril also 
has important blood pressure-independent effects related to the reduction in cardiovascular 
risk across the continuum of (cardio-)vascular disease (Figure 4).
The benefit of perindopril was most evident in stable CAD patients with a risk reduction of 
20% for cardiovascular mortality, myocardial infarction and cardiac arrest to 22% for nonfatal 
myocardial infarction(7). This may be related to the dose of the ACE inhibitor because in EUROPA 
perindopril was used at a dose of 8 mg. The dose of an ACE inhibitor may be important, if the 
assumed additional effects are involved in their protective effects. The additional effects are 
probably more likely to occur at higher dosages of ACE inhibition.
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The consistency of the relative effects across subgroups indicates that the absolute benefits 
conferred by treatment will be established mainly by each patient’s future risk of vascular 
complication, rather than their initial level of blood pressure alone. These results support the 
provision of treatment, not on the basis of arbitrary cut-off points for blood pressure (ADVANCE 
and EUROPA showed a treatment benefit in normotensive patients), but rather on assessment 
of vascular risk, which is raised in patients with stable CAD, diabetes and stroke as shown in 
EUROPA, ADVANCE and PROGRESS. Figure 4 
Treatment effect of perindopril in the continuum of cardiovascular disease. 
 
  
 
figure 4 Treatment effect of perindopril in the continuum of cardiovascular disease.
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ABsTrACT
Background: Renal insufficiency is a risk factor for cardiovascular disease in patients with 
renal disease or coronary heart disease; however, it is unknown whether renal function is an 
independent predictor of cardiovascular disease in the general population.
methods: We investigated whether the level of renal function, estimated by glomerular filtra-
tion rate, was associated with the risk of incident myocardial infarction among 4484 apparently 
healthy subjects in the Rotterdam Study (mean age, 69.6 years). We estimated the glomerular 
filtration rate by Cockcroft-Gault and abbreviated modification of diet in renal disease equa-
tions and used Cox regression analysis to estimate hazard ratios adjusted for cardiovascular risk 
factors, atherosclerosis, and medication use.
results: During the follow-up period (mean, 8.6 years), 218 subjects (4.9%) had a myocardial 
infarction. A 10 mL/min per 1.73m2 decrease in glomerular filtration rate was associated with 
a 32% increased risk of myocardial infarction (P<0.001). Compared with subjects in the fourth 
quartile, the multivariate-adjusted hazard ratios for the risk of myocardial infarction increased 
from 1.64 (95% confidence interval [CI], 1.03-2.59) in the third quartile to 1.94 (95% CI, 1.21-3.10) 
in the second quartile and 3.06 (95% CI, 1.80-5.19) in the quartile with the lowest glomerular 
filtration rate estimated by the Cockcroft-Gault equation. Using the abbreviated modification 
of diet in renal disease equation, the risk estimates for the third to first quartiles were 1.34 (95% 
CI, 0.89-2.01), 1.66 (95% CI, 1.14-2.49), and 1.90 (95% CI, 1.25-2.90), respectively.
Conclusions: The present study shows that renal function is a graded and independent predic-
tor of the development of myocardial infarction in an elderly population. Early detection of 
decreased renal function may identify subjects who are at heightened risk of coronary heart 
disease.
Renal insufficiency in healthy subjects 69
inTroDuCTion
Recent studies have shown that renal failure is an independent risk factor for cardiovascular 
mortality and morbidity in high-risk populations such as patients with chronic kidney or cardio-
vascular disease and patients with cardiovascular risk factors (1-7). It remains uncertain whether 
the level of renal function within asymptomatic ranges predicts the risk of cardiovascular disease 
in the general population. Until now, population-based studies (8-12) on renal insufficiency and 
cardiovascular disease gave conflicting results. Most prospective studies have been conducted 
with middle-aged populations. In some of these studies (8.9), renal insufficiency has been associ-
ated with increased risk of cardiovascular disease. In others (10,11), renal insufficiency was not 
an independent predictor after adjustment for cardiovascular risk factors. The Cardiovascular 
Health Study (CHS), a prospective population-based study of subjects 65 years or older, is the 
only study that has investigated the association between renal insufficiency and cardiovascular 
disease in elderly individuals (12,13). In this study, an increased risk of cardiovascular disease 
was found in subjects with elevated serum cystatin C, whereas a much weaker association 
was found between serum creatinine level and risk of cardiovascular disease. No significant 
association between glomerular filtration rate (GFR) and risk of myocardial infarction was 
found (12,13). The elderly population is growing and, because renal function decreases with age, 
renal insufficiency will become an increasingly important problem. Therefore, we examined 
the association between renal function, estimated by glomerular filtration rate (eGFR), and risk 
of myocardial infarction in the Rotterdam Study, a large population-based study in men and 
women 55 years and older.
mEThoDs
study population
The Rotterdam Study is an on-going prospective population based cohort study aimed at 
assessing the incidence and determinants of chronic diseases in the elderly population(14). In 
short, all inhabitants 55 years or older of Ommoord, a suburb of Rotterdam, the Netherlands, 
were invited to participate in the study. A total of 7983 men and women (response rate, 78%) 
agreed to participate, and 6950 participants visited the research center for the required physical 
examination. The main reason for not visiting the research center was that an individual lived 
in a nursing home. Baseline data were collected from March 1990 to July 1993. The medical 
ethics committee of the Erasmus Medical Center, Rotterdam, approved the study, and written 
informed consent was obtained from all participants.
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Baseline examination
At baseline, a trained research assistant obtained information on smoking habits and medica-
tion use from each subject during a home interview. Individuals were classified as never having 
smoked, a past smoker, or a current smoker. Clinical measurements were obtained during the 
visit to the research center. Height and weight were measured, and body mass index was cal-
culated as weight in kilograms divided by the square of height in meters(2) Blood pressure was 
calculated as the average of 2 consecutive measurements at the right brachial artery with a ran-
dom zero sphygmomanometer. Serum total cholesterol was measured by an automated enzy-
matic procedure in a non fasting blood sample. Serum high-density lipoprotein cholesterol was 
measured similarly after precipitation of the non-high-density lipoprotein fraction. Diabetes 
mellitus was defined as the use of antidiabetic medication and/or a random or postload serum 
glucose level above 198.2 mg/dL (11.0 mmol/L). C-reactive protein levels were measured by 
enzyme-linked high-sensitivity immunoassays. Carotid intima media thickness, as a measure-
ment of generalized atherosclerosis, was assessed by ultrasonography. We computed values 
of intima media thickness by averaging the anterior and posterior walls of the left and right 
common carotid arteries (distal)(15). Prevalent myocardial infarction at baseline was considered 
present in the case of a self-report, verified by a general practitioner or hospital discharge data, 
or confirmed by electrocardiogram measurements (16).
Assessment of renal function
Serum creatinine was assessed by a nonkinetic alkaline picrate (Jaffe) method (17). Creatinine 
clearance was computed with the Cockcroft-Gault equation and standardized for body surface 
area using the Dubois formula (18,19). Creatinine clearance generally exceeds GFR by 10% to 15% 
due to urinary creatinine derived from tubular secretion (20). The eGFR was therefore calculated 
using a correction factor of 0.90. In an additional analysis, we used the abbreviated Modifica-
tion of Diet in Renal Disease (MDRD) equation (21).
Assessment of incident myocardial infarction
After all baseline examinations were performed, general practitioners in the research area 
(Ommoord) reported incident cardiovascular events to the study center. An incident myo-
cardial infarction was considered to have occurred when the event led to hospitalization 
and the hospital discharge records indicated a diagnosis of myocardial infarction based on 
symptoms, electrocardiographic recordings, and repeated laboratory investigations during 
the patient’s hospital stay. Research assistants collected all information by checking medical 
records at the general practitioners’ offices, including discharge reports from medical special-
ists. Subsequently, two research physicians independently coded all reported events according 
to the International Classification of Diseases, 10th Revision. If research physicians disagreed on 
diagnoses, these were discussed to reach consensus. Finally, an expert in the field of cardiology 
reviewed all events. In case of disagreement between the medical expert and the research 
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physicians, the expert’s judgment was considered final. Information on the vital status of the 
participants was obtained at regular intervals from the municipal authorities in Rotterdam.
Population for analysis
Of the 6950 subjects who visited the research center, 808 (12%) were excluded because of 
prevalent myocardial infarction. Blood samples for measurement of serum creatinine level 
were available for 4568 (74.4%) of the remaining 6142 subjects. Data were available on eGFRs 
for 4484 (73.0%) of 6142 subjects. Baseline data on cardiovascular risk factors were missing 
for 212 subjects (<5%). For missing data on cardiovascular risk factors, the mean of the study 
population was imputed. Of the study population, 8 individuals (0.1%) were lost to follow-up. 
For these subjects, the follow-up time was computed until the last date of contact. Follow-up 
data on incident myocardial infarction were completed until January 1, 2002.
statistical analysis
Cox proportional hazard regression analysis was used to estimate hazard ratios for incident 
myocardial infarction with corresponding 95% confidence intervals (CIs). Analyses were con-
ducted with eGFRs divided into sex-specific quartiles. The quartile with the highest eGFR was 
used as the reference quartile. Analyses were conducted for crude values (model 1), adjusted for 
age, sex, body mass index, systolic and diastolic blood pressure, smoking habits, total and high-
density lipoprotein cholesterol, and diabetes mellitus (model 2) and further adjusted for use 
of cardiac medication (angiotensin-converting enzyme inhibitors, diuretics, and beta-blocking 
agents) and non steroidal anti-inflammatory drugs, C-reactive protein, and carotid intima media 
thickness (full model). The association between the eGFR and the risk of myocardial infarction 
was also assessed with the eGFR as a continuous variable. Tests for trend were performed, using 
the quartiles of the eGFR as a categorical measurement. In an additional analysis, the eGFR was 
estimated using the abbreviated MDRD equation rather than the Cockcroft-Gault equation. 
Kaplan-Meier survival plots of quartiles of the eGFR in relation to the risk of myocardial infarc-
tion were examined with log-rank test. The attributable risk and population-attributable risk 
percentage of renal insufficiency associated with myocardial infarction were calculated using 
an eGFR below 60 mL/min per 1.73 m2 as the cut-off point(22). For purposes of comparison, we 
calculated the attributable risk and population-attributable risk of the 4 major, classical cardio-
vascular risk factors. All measurements of association are presented with 95% CIs. A P value of 
less than 0.05 was considered statistically significant. All analyses were performed using SPSS 
statistical software (version 12.0; SPSS Inc, Chicago, Ill) for Windows.
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rEsulTs
Baseline characteristics of the study population are shown in Table 1. The mean ± SD age was 
69.6 ± 8.8 years, and 63.7% of the population were women. The eGFRs (mean ± SD, 61.9 ± 14.7) 
ranged from 6.1 to 142.6 mL /min per 1.73 m2. A mild degree of renal insufficiency, with an eGFR 
between 60 and 89, was present in 2317 subjects (51.7%). The mean/SD follow-up time was 8.6 
± 2.8 years. During follow-up, 38479 person-years were collected. Incident myocardial infarc-
tion occurred in 218 subjects (4.9%; 125 men and 93 women). The risk of myocardial infarction 
is significantly increased in the lower 3 quartiles compared with the highest quartile of eGFR (P 
value for trend, 0.001) (Table 2). Risk estimates using quartiles of eGFRs based on the abbrevi-
ated MDRD equation were somewhat smaller, but a similar trend was seen (Table 3). In the 
following analyses, the eGFR is based on the Cockcroft-Gault equation. The survival curves for 
quartiles of eGFRs are shown in Figure 1. The log-rank test gave P values of 0.056, 0.002, and less 
than 0.001, respectively, corresponding to descending quartiles of eGFRs. The attributable and 
population-attributable risks of renal insufficiency associated with myocardial infarction were 
32.8% and 14.7%, respectively (Table 4). If renal insufficiency is assumed to be causally related 
to myocardial infarction, our findings suggest that it contributed to 32.8% of the cases affected 
by renal insufficiency and that it was involved in the pathogenesis of 14.7% of all myocardial 
infarctions in the study sample. 
Table 1. Baseline Characteristics of the Study Population
Characteristic All subjects
(n=4484)
Males 
(n=1628)
Females
(n=2856)
Age, yrs. 69.6 ± 8.8 68.8 ± 8.1 70.1 ± 9.1
Body mass index, kg/m2 26,2 ± 3.7 25.6 ± 3.0 26.6 ± 4.1
Systolic blood pressure, mmHg 139.6 ± 22.3 139.4 ± 21.9 139.7 ± 22.5
Diastolic blood pressure, mmHg 73.8 ± 11.7 74.9 ± 12.1 73.2 ± 11.4
Current smokers, % 23.3 31.0 (505) 18.9 (539)
Former smoker, % 38.8 59.2 (963) 27.1 (775)
Total cholesterol, mmol/l 6.6 ± 1.2 6.3 ± 1.2 6.8 ± 1.2
HDL-cholesterol, mmol/l 1.3 ± 0.4 1.2 ± 0.3 1.4 ± 0.4
Diabetes mellitus, % 10.0 9.3 (152) 10.3 (295)
C-reactive protein, mg/l 3.1 ± 5.7 3.4 ± 5.5 2.9 ± 5.8
Cardiac Medication, % 29.8 23.8 (387) 33.2 (948)
 - ACE-inhibitors, % 4.5 5.4 (88) 4.0 (114)
 - Diuretics use, % 14.7 8.4 (137) 18.3 (524)
 - β-blockers use, % 13.3 12.0 (196) 14.0 (401)
NSAID use, % 8.2 5.6 (91) 9.6 (275)
Body surface area (m2)* 1.8 ± 0.2 1.9 ± 0.1 1.7 ± 0.1
Carotid intima media thickness, mm 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
Data are percentages for dichotomous variables and mean ± SD for continuous variables. 
* Body surface area is computed by (0.007184 * weight0.425 * height0.725).
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Table 2. Hazard Ratios for Incident Myocardial Infarction associated with GFR-levels (based on adjusted 
Cockcroft and Gault equation)
unadjusted     Traditional 
hazard ratios CVD-risk factors†  full model‡
GFR* Total/events HR   95% CI HR   95% CI HR   95% CI
Males
Reference 81.4  407/19 1.00  1.00 1.00
Third quartile 68.2  407/29 1.56  (0.88-2.78) 1.60  (0.87-2.89) 1.60  (0.89-2.89)
Second quartile 59.4  407/35 1.97  (1.13-3.45) 2.10  (1.14-3.85) 2.06  (1.12-3.79)
First quartile 45.9  407/42 3.04  (1.77-5.24) 3.17  (1.58-6.34) 2.96  (1.48-5.95)
Females
Reference 79.8  714/13 1.00 1.00 1.00
Third quartile 65.2  714/19 1.51  (0.74-3.05) 1.71  (0.82-3.54) 1.64  (0.78-3.42)
Second quartile 55.9  714/23 1.88  (0.95-3.71) 1.87  (0.88-3.96) 1.74  (0.81-3.70)
First quartile 42.2  714/38 4.02  (2.14-7.56) 3.43  (1.50-7.87) 3.34  (1.45-7.66)
Total
Reference 80.4 1121/32 1.00 1.00 1.00
Third quartile 66.4 1121/48 1.54  (0.98-2.41) 1.64  (1.04-2.60) 1.64  (1.03-2.59)
Second quartile 57.2 1121/58 1.92  (1.25-2.96) 1.98  (1.24-3.17) 1.94  (1.21-3.10)
First quartile 43.0 1121/80 3.42  (2.27-5.16) 3.22  (1.90-5.47) 3.06  (1.80-5.19)
Upper (fourth) quartile was used as reference category. * GFR: mean glomerular filtration rate (ml/
min/1.73 m2). CVD: cardiovascular disease. † adjusted for age, gender, body mass index, systolic and 
diastolic blood pressure, smoking-habits, total and HDL-cholesterol, and diabetes mellitus. ‡ further 
adjusted for, cardiac medication (ACE-inhibitors, diuretics and beta-blocking agents), NSAID-use, 
C-reactive protein (hs-CRP) and carotid IMT. GFR as continuous variable (for every 10 ml/min per 1.73 m2: 
HR 1.32 (1.18-1.47), HR 1.30 (1.11-1.50) in males, HR 1.37 (1.16-1.59) in females 
Table 3. Hazard Ratios for Incident MI associated with GFR-levels (based on  MDRD equation)
Mean 
eGFR
 Total/events     Unadjusted 
   Hazard Ratios
   Adjusted for 
 CVD risk factors†   Full Model‡
  HR     95% CI  HR     95% CI HR     95% CI
Reference 94.2 1121/44 1.00 1.00 1.00
Third quartile 78.4 1121/50 1.12 (0.74-1.67) 1.35 (0.90-2.03) 1.34 (0.89-2.01)
Second quartile 69.5 1121/58 1.34 (0.90-1.98) 1.70 (1.14-2.55) 1.66 (1.14-2.49)
Lowest quartile 55.9 1121/66 1.68 (1.15-2.46) 1.99 (1.31-3.03) 1.90 (1.25-2.90)
Upper (fourth) quartile was used as reference category .Abbreviations: BMI, body mass index; CI, confidence 
interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MDRD, modification of 
diet in renal disease. † adjusted for age, gender, body mass index, systolic and diastolic blood pressure, 
smoking-habits, total and HDL-cholesterol, and diabetes mellitus. ‡ further adjusted for cardiac medication 
(ACE-inhibitors, diuretics and beta-blocking agents), NSAID-use, hs-CRP and carotid IMT.
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CHAPTER 4 
 
Figure 1 
Event-free survival curves for quartiles of estimated glomerular filtration rate 
(eGFR) (Cockcroft-Gault equation). 
 
  figure 1 Event-free survival curves for quartiles of estimated glomerular filtration rate (eGFR) (Cockcroft-Gault equation). Kaplan-Meier survival curves were used to calculate the event-free survival curves in 
the descending quartiles of eGFR. The lines correspond to the survival curves of the fourth quartile 
as reference group, third quartile (q3), second quartile (q2), and the lowest quartile of the eGFR (q1), 
respectively.
Table 4. Attributable risk and population attributable risk percentages associated with incident MI. 
Risk Factor Prevalence Age-Adjusted  
Hazard Ratio 1
Attributable
Risk
Population
Attributable Risk
% %
Diabetes Mellitus 10.0 1.6 38.1 3.8
Hypertension 25.6 1.5 34.5 8.8
Smoking 23.3†/38.8‡ 1.9/1.6 48.2/38.8 11.2/15.0
Hypercholesterolemia 60.9 1.4 26.8 16.3
Renal Insufficiency2 44.9 1.5 32.8 14.7 
1  Determined by Cox proportional hazards regression analysis. 2  Renal insufficiency with eGFR below 
60 ml/min per 1.73 m2 as cut-off point. † Current compared to never smokers. ‡ Past compared to never 
smokers.
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DisCussion
In this population-based cohort study of adults 55 years or older, we found that impaired renal 
function was common and associated with an increased risk of myocardial infarction. Even 
the earlier stages of renal function loss, before there are any symptoms of renal disease, are 
associated with an increased risk of myocardial infarction. This association is independent of 
cardiovascular risk factors and atherosclerosis. The population attributable risk is substantial 
and within range of traditional cardiovascular risk factors. 
A previous study (7) demonstrated the association between renal insufficiency and adverse 
outcomes in patients after a myocardial infarction. Relatively few studies (8-12) have evaluated 
the relationship between renal function and risk of incident coronary heart disease in the 
general population. The results of these studies were inconsistent. Most studies (8-11) reported 
on the association between renal function and cardiovascular disease in middle-aged subjects. 
The Framingham Heart Study (10) and the National Health and Nutrition Examination Survey (11) 
(NHANES I) found no association between elevated serum creatinine level and cardiovascular 
events after adjustment for cardiovascular risk factors. The Atherosclerotic Risk in Communities 
study (9) in subjects aged 45 to 64 years (mean age, 54.2 years) showed an association between 
renal insufficiency and atherosclerotic cardiovascular disease as a composite outcome. 
Although the investigators in that study found an increased risk of 1.38 (95% CI, 1.02-1.87) for 
subjects with an eGFR below 60 mL/min per 1.73 m2 and a risk of 1.16 (95% CI, 1.00-1.34) for 
subjects with an eGFR above 60 mL/min per 1.73 m2 compared with subjects with an eGFR 
above 90 mL/min per 1.73 m2, these risks are relatively small compared with those found in the 
present study and were not adjusted for C-reactive protein and a measurement of atheroscle-
rosis. No separate analysis of myocardial infarction was performed. 
A recent study (8) in a middle-aged population of 1.120.295 insured adults 20 years or older 
(mean age, 52 years) reported an increased risk of cardiovascular events (heart failure, stroke, 
coronary heart disease, and peripheral artery disease) in subjects with chronic kidney disease, 
defined as an eGFR below 60 mL/min per 1.73 m2. This risk8 increased substantially at an eGFR 
below 45 mL/min per 1.73 m2. Although we support their results, our study differs in several 
important aspects. First, we found an increased risk at higher levels of renal function, namely, 
in asymptomatic subjects with an eGFR well above the level of patients with chronic kidney 
disease. Second, the authors of the California study9 were not able to adjust for smoking, cho-
lesterol and C-reactive protein levels, blood pressure, use of cardiac medication, and measure-
ments of atherosclerosis. In addition, we excluded subjects with a history of myocardial infarc-
tion at baseline. Our study is the first to show a graded and independent association between 
renal function and the risk of myocardial infarction in an elderly population. The only previous 
study that evaluated the association between renal function and cardiovascular disease in an 
elderly population was the CHS. The CHS (mean age of subjects, 72.9 years) found an associa-
tion between elevated serum creatinine level and total cardiovascular disease as a combined 
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outcome. In that study(12), a 1.5 times increased risk was found for subjects with elevated serum 
creatinine level, defined as 1.5 mg/dL (132.6 μmol/L) or higher in men or 1.3 mg/dL (114.9 
μmol/L) or higher in women, compared with subjects with creatinine levels in the reference 
range. In contrast with our study, however, no association of elevated serum creatinine level 
with incident myocardial infarction was found after adjusting for cardiovascular risk factors.(12) 
A recent report of the CHS concluded that serum cystatin C level is a stronger predictor of the 
risk of cardiovascular outcomes than serum creatinine level and eGFR(13). The study showed a 
relationship between serum cystatin C level and the risk of death from cardiovascular disease; 
the association of cystatin C level with incident myocardial infarction was less strong than was 
the case for association with mortality outcomes. In multivariate analysis, only a subgroup of 
the highest quintile (quintile subgroup 5c) was at significantly increased risk of myocardial 
infarction. Creatinine level and eGFR estimated by MDRD equation had no significant associa-
tion with myocardial infarction in either unadjusted or adjusted analyses. Risk estimates were 
not adjusted for measurements of atherosclerosis, low-density lipoprotein cholesterol, or his-
tory of smoking (13). We have no explanation for the discrepancy with our findings. However, 
there are important differences between the two studies in population (the CHS population is 
somewhat older), ascertainment methods, and analysis.
The reason why mild renal insufficiency is associated with an increased risk of cardiovascular 
disease in our study is not clear. It has been suggested the increased risk can be explained 
by co-occurrence of a high prevalence of cardiovascular risk factors at baseline.(5,10) In that 
case, renal insufficiency would be a marker for cardiovascular risk factors and their severity 
rather than an independent risk factor. However, we still observed an independent association 
after adjusting for cardiovascular risk factors. Another possible explanation is the presence of 
atherosclerosis, commonly thought to pre-exist in individuals with mild renal insufficiency. 
However, after adjustment for carotid intima media thickness, as a measurement of general-
ized atherosclerosis, an increased risk remained associated with lower levels of renal function. 
Therefore, pre-existing atherosclerotic vascular disease cannot fully explain the relationship, 
although the possibility exists that it is mediated by small vessel disease rather than large vessel 
disease. Finally, renal insufficiency itself might initiate and accelerate cardiovascular disease.
The US National Kidney Foundation has provided guidelines for the assessment of renal 
function. Definitions of stages 1 to 5 of renal function correspond to eGFR levels of 90 or higher 
(reference range), 60 to 89, 30 to 59, 15 to 29, and less than 15 mL/min per 1.73 m2. Stage 3 is 
the first stage at which a patient shows symptoms of renal insufficiency, and it is considered 
the cut-off point for chronic kidney disease(2). The results of our study show an increased risk of 
myocardial infarction starting at earlier stages of renal function loss than commonly thought, 
namely, well above the levels of chronic kidney disease. Using the Cockcroft-Gault equation, 
the third quartile with a mean eGFR of 66.3 mL / min per 1.73 m2 was associated with a 64% 
increased risk of myocardial infarction. An additional analysis with the MDRD equation in 
the second quartile with a mean eGFR of 69.5 mL/min per 1.73 m2. Both equations show a 
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significantly increased risk at these mildly decreased eGFR levels, with the difference in size 
of risk estimates related to the difference in mean eGFR levels of the quartiles. These mildly 
decreased eGFR levels, corresponding to stage 2, represent subjects at an early stage of renal 
insufficiency, without symptoms or signs of renal function loss. With descending quartiles of 
eGFR, the risk of myocardial infarction increased gradually to a 2-fold (MDRD equation; mean 
eGFR, 54 mL/min per 1.73 m2) to a 3-fold (Cockcroft-Gault equation; mean eGFR 44 mL/min per 
1.73 m2) increased risk. 
A mild degree of renal insufficiency with an eGFR of 60 to 89 mL/min per 1.73 m2 (based on 
the Cockcroft-Gault equation) was present in 51% of the study population. In aging popula-
tions, such as that of Western Europe, mild degrees of renal insufficiency will be progressively 
more important because renal function declines rapidly with age but life expectancy is increas-
ing. Early detection of decreased renal function, using eGFR measurements as a relatively 
simple screening method, may identify subjects at high risk of coronary heart disease. Because 
renal insufficiency is associated with a high prevalence of traditional risk factors, early risk factor 
reduction measures may be of benefit in these subjects. Therefore, the early stages of renal 
insufficiency may be a key target to prevent worsening renal function as well as to reduce the 
risk of cardiovascular disease. Some of the factors detrimental to kidney function, such as smok-
ing, dyslipidemia, and elevated blood pressure, can be modified. Recent studies (3,23) report 
that angiotensin converting enzyme inhibitors may have renoprotective effects and delay the 
progression of renal insufficiency. Because the subjects in our study were predominantly white, 
the generalizability of the study to other racial groups is limited. Moreover, data on proteinuria 
were unavailable in this database because urinalyses were not performed in the Rotterdam 
Study(14). Microalbuminuria is an early marker of diabetic nephropathy and cardiovascular 
disease; however, a recent study (24) showed that the GFR is a predictor of cardiovascular events 
independent of the presence of microalbuminuria in patients with asymptomatic diabetes 
mellitus. The CHS study found that cystatin C was a stronger predictor of cardiovascular events 
than serum creatinine level and eGFR. Cystatin C levels were not available in our study, but the 
use of an eGFR in our study provided risk estimates for myocardial infarction stronger than 
those based on cystatin C levels in the CHS study(13). A study on the diagnostic accuracy of eGFR 
formulas and cystatin C concluded that cystatin C is superior to serum creatinine in estimat-
ing renal function but similar to estimates of GFR by Cockcroft-Gault or MDRD equations(25). 
Whether serum cystatin C has potential clinical value and could be a useful prognostic tool 
in the evaluation of elderly patients needs to be confirmed in future studies(13,25). The use of 
serum creatinine alone may lead to some underrecognition of renal insufficiency, particularly 
in elderly subjects, because muscle mass tends to decline with age(26,27). We used the Cockcroft-
Gault equation corrected for body surface area and tubular secretion to estimate eGFR more 
accurately in elderly individuals(18,20,26,27). The new MDRD equation has not yet been validated 
in elderly individuals and in healthy subjects, and the accuracy of this formula in these popu-
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lations is still being discussed(21,28,29). Using the MDRD equation in our study yielded similar 
results.
In this prospective, population-based study of older individuals, we found that renal insuf-
ficiency was highly prevalent and predicted the onset of myocardial infarction even in subjects 
without symptoms or signs of renal disease. The population-attributable risk was substantial 
and within the range of that of traditional cardiovascular risk factors. Therefore, the impact of 
renal insufficiency on the development of coronary heart disease may be larger than commonly 
thought. This suggests that assessment and treatment of decreased renal function at an early 
stage may help in the prevention of coronary heart disease. 
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ABsTrACT
Background: Proteinuria was associated with cardiovascular events and mortality in commu-
nity-based cohorts. The association of proteinuria with mortality and cardiovascular events in 
patients undergoing percutaneous coronary intervention (PCI) was unknown. The association 
of urinary dipstick proteinuria with mortality and cardiovascular events (composite of death, 
myocardial infarction, or non-hemorrhagic stroke) in 5,835 subjects of the EXCITE trial was 
evaluated. 
methods: Dipstick urinalysis was performed before PCI, and proteinuria was defined as trace 
or greater. Subjects were followed up for 210 days/7 months after enrolment for the occur-
rence of events. Multivariate Cox regression analysis evaluated the independent association of 
proteinuria with each outcome. 
results: Mean age was 59 years, 21% were women, 18% had diabetes mellitus, and mean 
estimated glomerular filtration rate was 90 ml/min/ 1.73 m2. Proteinuria was present in 750 
patients (13%). During follow-up, 22 subjects (2.9%) with proteinuria and 54 subjects (1.1%) 
without proteinuria died (adjusted hazard ratio 2.83, 95% confidence interval [CI] 1.65 to 4.84, 
p <0.001). The severity of proteinuria attenuated the strength of the association with mortality 
after PCI (low-grade proteinuria, hazard ratio 2.67, 95% CI 1.50 to 4.75; high-grade proteinuria, 
hazard ratio 3.76, 95% CI 1.24 to 11.37). No significant association was present for cardiovas-
cular events during the relatively short follow-up, but high-grade proteinuria tended toward 
increased risk of cardiovascular events (hazard ratio 1.45, 95% CI 0.81 to 2.61).
Conclusion: Proteinuria was strongly and independently associated with mortality in patients 
undergoing PCI. These data suggest that such a relatively simple and clinically easy to use tool 
as urinary dipstick may be useful to identify and treat patients at high risk of mortality at the 
time of PCI. 
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inTroDuCTion
We evaluated the predictive value of proteinuria, determined using standard urinary dipstick, 
in patients with coronary artery disease (CAD) at the time of percutaneous coronary interven-
tion (PCI). We conducted a post hoc analysis  of the Evaluation of Oral xemilofiban in Controlling 
Thrombotic Events (EXCITE) trial, a randomized placebo controlled trial designed to evaluate 
whether long-term administration of an oral glycoprotein IIb/IIIa receptor inhibitor would be 
associated with lower cardiovascular events and death rates. We hypothesized that the pres-
ence of proteinuria would be associated with higher mortality and cardiovascular event rates 
independent of traditional cardiovascular risk factors, diabetes mellitus, and renal function 
(estimated glomerular filtration rate [eGFR]) in patients with CAD undergoing PCI. Urinary 
dipstick, as a relatively simple and clinically easy-to-use tool to detect proteinuria, may identify 
and treat patients at high risk of mortality at the time of PCI.
mEThoDs
The EXCITE trial was a double-blind randomized placebo controlled study conducted at 412 
centers in North and South America, Europe, Israel, Australia, New Zealand, and South Africa. 
The protocol and main results of the trial have been described elsewhere(1). In brief, 7,232 
patients with angiographic evidence of clinically significant CAD were randomly assigned to 
receive 20 mg of an oral glycoprotein IIb/IIIa inhibitor (xemilofiban) or placebo 30 to 90 minutes 
before PCI, with maintenance doses of 10 or 20 mg of xemilofiban or placebo administered 3 
times/day for up to 182 days. Patients with high-risk features, including unstable angina, acute 
myocardial infarction (MI), diabetes mellitus, left ventricular ejection fraction <30%, anticipated 
need for placement of >1 stent, and multivessel CAD, were specifically sought according to 
the study protocol. Exclusion criteria included serum creatinine >1.5 mg/dl, history of bleeding 
disorders or active bleeding, thrombocytopenia (platelet count >120,000 cells/mm3), coagula-
tion factor deficiency, uncontrolled hypertension, major trauma or surgery within the previ-
ous three months, thrombolytic treatment within 6 hours before PCI, inability to discontinue 
oral anticoagulant therapy, non hemorrhagic stroke within the previous two months, history 
of hemorrhagic stroke, or inability to provide informed consent. The primary results of this 
study showed no significant effect of xemilofiban for prevention of mortality or cardiovascular 
events(1). Nineteen percent (n = 1,397) of EXCITE study subjects had missing data regarding 
proteinuria at baseline and were excluded from analyses. However, there were complete 
follow-up data for the remaining 5,835 subjects. Subjects with missing proteinuria data were of 
similar age (59 years) and gender (23% women) and had a similar eGFR (96 ml/min/1.73 m2) and 
prevalence of diabetes mellitus (20%). Additionally, clinical outcomes of these subjects were 
compared, and no relevant differences were observed. 
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A urine sample was collected during a 7-day period before PCI. The presence of proteinuria 
was determined using a standard urinary dipstick that measured albumin through a colorimet-
ric reaction between albumin and tetrabromophenol blue, producing different shades of green 
according to the concentration of albumin in the sample(2). Each color was semiquantified by 
central laboratory personnel as negative, trace (protein 15 to 30 mg/dl), 1+ (30 to 100), 2+ (100 
to 300), 3+ (300 to 1,000), or 4+ (>1,000) proteinuria. eGFR was determined using the abbrevi-
ated (4-variable) Modification of Diet in Renal Disease Study equation(3). Patients with eGFR 
<60 ml/min/1.73 m2 were considered to have moderate chronic kidney disease, consistent with 
stage 3 or higher chronic kidney disease using the National Kidney Foundation classification(4). 
Subjects were evaluated within 24 hours from 10 to 21 days after PCI and again 60 days after PCI. 
Subsequent monitoring for cardiac events, safety, laboratory values, concurrent medications, 
and compliance was performed monthly using telephone or site visits. For patients who did 
not have a diagnosis of acute MI at the time of enrolment, the criterion for a new MI occurring 
within 24 hours after PCI was creatine kinase-MB ≥3 times the upper limit of normal range. For 
patients undergoing PCI within 24 hours after the onset of acute MI, criteria for the diagnosis 
of reinfarction within 24 hours after the procedure was defined as CK≥MB twice as high as the 
lowest increased value before PCI. For all patients, MI ≥24 hours after PCI was defined as CK ≥2 
times the upper limit of the normal range or electrocardiographic appearance of new Q waves 
of 0.04 seconds in duration with a depth >1/4 of the corresponding R wave amplitude in ≥2 
contiguous leads. When CK-MB was not available, total CK was used. Serum samples for cardiac 
enzymes were collected at baseline and 8, 16, and 24 hours after PCI. An independent Clinical 
Endpoints Committee reviewed and adjudicated all cardiac clinical events. In addition, a central 
electrocardiographic laboratory reviewed the screening and final electrocardiograms for each 
patient to determine whether a Q-wave MI occurred during the study. Non hemorrhagic stroke 
was defined as the onset of a new neurologic deficit that occurred any time after PCI, persisted 
≥24 hours, and was confirmed using computed tomography or magnetic resonance imaging 
studies. Subjects who died for any reason during follow-up were censored for the all-cause 
mortality outcome. Subjects were censored for a cardiovascular event if they experienced ≥1 of 
the outcomes during follow-up of MI, non-hemorrhagic stroke, or all-cause mortality. 
Subjects were categorized into 2 groups on the basis of the presence or absence of pro-
teinuria (trace or greater vs none). Baseline characteristics were compared across proteinuria 
groups using Student’s t test or Kruskal-Wallis test for continuous variables or chi-square test or 
Fisher’s exact test for dichotomous variables, as appropriate. Univariate and multivariable Cox 
proportional hazard regression analysis evaluated the association of proteinuria with mortality 
and cardiovascular events. We developed 3 models. The first was unadjusted. The second model, 
termed demographic adjusted, was adjusted for age, gender, race, diabetes, and eGFR. The final 
model, termed fully adjusted, was adjusted for any additionally important potential confound-
ing variables selected on the basis of previous published research (age, gender, race, diabetes, 
eGFR, left ventricular ejection fraction, number of diseased vessels on coronary angiography, 
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systolic and diastolic blood pressure, body mass index, and use of ACE inhibitors or angiotensin 
receptor blocking medications, beta-blockers, statins, or anti-platelet inhibitors and allocated 
treatment [xemilofiban or placebo]). The primary analysis evaluated proteinuria as a dichoto-
mous predictor variable. In a companion analysis, indicator variables were created for severity 
of proteinuria (none, low-grade [trace (protein 15 to 30 mg/dl) to 1+ (20 to 100)], and high-grade 
[2+ (100 to 300) or greater (>300)]), and tests for trend were evaluated to determine whether 
severity of proteinuria was associated with each outcome. In addition, we evaluated for effect 
modification on the basis of eGFR (<60 vs >60 ml/min/1.73 m2) and presence of diabetes mel-
litus. For all tests, p <0.05 (two-sided) was considered statistically significant. Statistical analyses 
were performed using SAS, version 8.0 software package (SAS Institute, Cary, North Carolina). 
rEsulTs
Mean age of the study population (n = 5,835) was 59 years, 79% were men, 88% were Cauca-
sian, and 19% had diabetes mellitus. Coronary stents were placed at the time of PCI in 71% 
subjects. Mean eGFR was 90 ml/min/1.73 m2. Three hundred ninety-two subjects (5.4%) had an 
eGFR <60 ml/min/1.73 m2. There was no loss to follow-up during the observation period. Seven 
hundred fifty subjects (13%) had trace or greater proteinuria. Subjects with proteinuria had a 
higher prevalence of diabetes, hypertension, and eGFR <60 ml/min/1.73 m2; were more likely 
to be using renin-angiotensin system inhibitors; and had higher blood pressure and body mass 
index. Randomized allocation to xemilofiban by study protocol did not differ by proteinuria 
status (P-value 0.10; Table 1).
During the 210-day follow-up, 22 subjects (2.9%) with proteinuria and 54 subjects (1.1%) 
without proteinuria died (Figure 1). Of 76 all-cause deaths, 69 (91%) were cardiac deaths with 
similar distribution in the proteinuria and nonproteinuria groups. Subjects with proteinuria had 
a nearly 3-fold odds of death compared with those without proteinuria, an association that was 
essentially unaltered after extensive statistical adjustment for potential confounding variables, 
including allocated treatment (Table 2). Moreover, the association was similar between per-
sons with eGFR <60 or >60 ml/min/1.73 m2 and between subjects with and without diabetes 
mellitus (p for interaction = 0.72 and 0.88, respectively). Additionally, increasing severity of 
proteinuria was associated with increased risk of all-cause mortality in both unadjusted and 
adjusted analyses (Table 2). 
During follow-up, there were 558 cardiovascular events (454 MIs, 28 strokes, and 76 deaths). 
Sixty-six subjects (8.8%) with proteinuria and 456 subjects (9%) without proteinuria reached 
the composite secondary outcome. In adjusted analysis, there was no association of proteinuria 
with this outcome, with 95% confidence intervals (CIs) excluding an odds ratio >30% in either 
direction. We found no evidence of effect modification on the basis of eGFR <60 ml/min/1.73 
m2 or diabetes mellitus (p for interaction = 0.23 and 0.78, respectively). Severity of proteinuria 
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showed a trend toward increased risk of incident cardiovascular events with more severe 
proteinuria status (low-grade proteinuria hazard ratio 0.89, 95% CI 0.66 to 1.21; high grade 
proteinuria hazard ratio 1.45, 95% CI 0.81 to 2.61; Table 2). 
DisCussion 
This study showed that proteinuria, measured using standard urinary dipstick, was associated 
with a nearly 3-fold increased odds of all-cause mortality in patients with established CAD at the 
Table 1. Baseline characteristics of patients with or without proteinuria. 
Proteinuria
Variable No Yes P-value
N 5085 750
Age(years) 59 (8) 58 (8) 0.20
Men 78.1 % 80.5 % 0.13
Race 0.02
 Caucasian 88.4 % 88.0 %
 Black 1.5 % 1.9 %
 Other 10.1 % 10.0 %
Diabetes 17.1 % 28.0 % <0.01
Hypertension 45.7 % 50.0 % 0.026
Prior percutaneous coronary intervention 13.6 % 13.9 % 0.86
Prior coronary artery bypass graft 17.6 % 18.4 % 0.59
Prior myocardial infarction 25.1 % 24.1 % 0.59
Prior Stroke 2.0 % 2.0 % 0.98
ACE-inhibitor use 32 % 39 % <0.01
Beta-blocker use 68 % 70 % 0.40
Statin use 54 % 51 % 0.13
Glomerular filtration rate <60 ml/min/1.73m2 5.2 % 8.3 % <0.01
Systolic blood pressure, mmHg* 130 (11) 130 (10) 0.021
Diastolic blood pressure, mmHg* 76 (6) 78 (8) 0.006
Body mass index (kg/m2)* 27.5 (2.4) 28.3 (2.2) <0.01
Left ventricular ejection fraction ≤30% 2.0 % 2.2 % 0.71
Diseased Coronary Vessel
 Right coronary artery 22.4 % 24.5 % 0.18
 Left anterior descendens 42.8 % 42.8 % 1.0
 Left circumflex artery 35.0 % 35.2 % 0.89
 Left main 1.0 % 1.6 % 0.14
Multivessel Disease 45.5 % 47.9 % 0.21
Allocated to Xemilofiban 66.0 % 69.1 % 0.10
Values are n (%) unless marked otherwise. PCI= percutaneous coronary-intervention. CABG= coronary 
bypass surgery, ACE=angiotensin-converting enzyme, GFR= glomerular filtration rate, RCA= right 
coronary artery, LAD= left anterior descendens, LCX= left circumflex artery, LM= left main. * Median (Inter-
Quartile Range).
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Figure 1 
Kaplan-Meier curve of mortality by the presence or absence of proteinuria. 
 
 
 figure 1 Kaplan-Meier curve of mortality by the presence or absence of proteinuria. Bold black line, 
patients with proteinuria; thin black line, patients without proteinuria.
Table 2.
All-cause Mortality
Variable Events / N at risk Unadjusted Demographic 
Adjusted†
Fully 
Adjusted‡
No proteinuria 54/5085 (1.1%) 1.00 1.00 1.00
Proteinuria   22/750 (2.9%) 2.81 (1.70 – 4.65) 2.64 (1.57 – 4.44) 2.83 (1.65 – 4.84)
     - low-grade   18/643 (2.8%) 2.68 (1.56 – 4.60) 2.53 (1.44 – 4.43) 2.67 (1.50 – 4.75)
     - high-grade     4/107 (3.7%) 3.61 (1.28 – 10.17) 3.03 (1.04 – 8.86) 3.76 (1.24 – 11.37)
P-value for trend <0.001 <0.001 <0.001
Cardiovascular events
No proteinuria 456/5085 (9%) 1.00 1.00 1.00
Proteinuria  66/750 (8.8%) 0.98 (0.74 – 1.28) 0.95 (0.72 – 1.26) 0.97 (0.74 – 1.28)
     - low-grade  52/643 (8.0%) 0.89 (0.66 – 1.20) 0.87 (0.64 – 1.18) 0.89 (0.66 – 1.21)
     - high-grade  14/107 (13%) 1.52 (0.86 – 2.70) 1.46 (0.82 – 2.60) 1.45 (0.81 – 2.61)
P-value for trend 0.70 0.83 0.76
Association of Proteinuria* and the severity of proteinuria with mortality and cardiovascular events 
among patients undergoing PCI.
*Dipstick urinalysis with proteinuria defined as trace or greater. Low-grade proteinuria defined as trace to 
1+ and high-grade as 2+ or greater. § Composite outcome of mortality, myocardial infarction, and stroke. 
† Adjusted for age, gender, race, diabetes, and eGFR. ‡ Adjusted for demographic adjusted variables and 
ejection fraction, number of diseased vessels, systolic and diastolic blood pressure, body mass index, and 
use of ACE/ARB, beta-blockers, statins, anti-platelet inhibitors and allocated treatement (xemilofiban).
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time of PCI. This association was essentially unaltered despite extensive statistical adjustment 
for traditional cardiac risk factors, chronic kidney disease, or diabetes mellitus. Surprisingly, 
despite the independent association of proteinuria with mortality, we observed no strong 
associations of proteinuria with cardiovascular events in the EXCITE cohort, although the risk of 
cardiovascular events increased with more severe proteinuria. 
Proteinuria is the earliest manifestation of kidney dysfunction in patients with several forms 
of kidney disease (5) because it is a marker of loss of the normal selective barrier at the glomerular 
filtration slits. It also strongly correlated with markers of endothelial dysfunction (6-11) Previous 
epidemiologic studies consistently showed that proteinuria predicted mortality in populations 
with and without diabetes or cardiovascular disease (1,11-14) However, the predictive value of 
proteinuria at the time of PCI has not been extensively studied. Marso et al (15) showed that 
proteinuria at the time of PCI was strongly associated with mortality in patients with diabetes 
mellitus in a large single-center study. However, Reeder et al (16) refuted this finding, show-
ing that serum creatinine was a stronger predictor of death than proteinuria in persons with 
diabetes undergoing PCI. Therefore, debate existed regarding the prognostic significance of 
proteinuria in diabetic subjects undergoing PCI, and to our knowledge, no previous study has 
evaluated the prognostic significance of proteinuria in persons without diabetes in this clinical 
setting. Thus, the observations presented here contributed to existing reports in several ways. 
First, the large sample size, multinational nature of the study cohort, and use of coronary stents 
in most subjects made our results generalizable to diverse populations and to practices that 
closely resemble those used in current clinical practice. Second, we showed that the association 
of proteinuria with mortality was similar between diabetic and nondiabetic subjects and per-
sons with or without moderate chronic kidney disease. Because urinary dipstick was routinely 
available and inexpensive, it may be clinically useful to identify and treat subjects at high risk 
of mortality after PCI irrespective of diabetes status or kidney function. Ibsen et al (17) showed 
that treatments that decreased proteinuria translated into decreased cardiovascular events 
during follow-up in persons with hypertension. Third, the increase in risk of all-cause mortal-
ity and cardiovascular events observed with an increase in severity of proteinuria in patients 
undergoing PCI was a new and clinically relevant finding. Whether medications that decrease 
proteinuria might also be associated with a decrease in mortality in persons undergoing PCI, 
or alternatively, whether proteinuria is simply a marker of early kidney disease or endothelial 
dysfunction is an important question to be addressed in future studies. 
Mild to moderate kidney disease was also associated with cardiac structural abnormalities 
(18) and conduction system disease (19). Therefore, we hypothesized that proteinuria may be 
associated with an increased risk of sudden cardiac death, which could explain the stronger 
relation to mortality. This outcome was not specifically adjudicated in EXCITE and can therefore 
not be evaluated in the context of the present study. However, regardless of cause, because 
we observed the association of proteinuria with mortality during a relatively short 7-month 
follow-up, persons undergoing PCI who have proteinuria may benefit from closer surveillance 
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during this time frame. Future studies are required to evaluate the cause of death in this setting 
and determine whether proteinuria is associated with mortality or cardiovascular events dur-
ing longer periods of observation after PCI. 
This study had several limitations. The present analysis mainly addressed patients with mild 
to moderate renal insufficiency according to the National Kidney Foundation kidney disease 
outcomes quality initiative (KDOQI) guidelines (4) because patients with a serum creatinine 
>1.5 mg/dl were excluded in the trial. We used standard urinary dipstick evaluation for assess-
ment of proteinuria, a relatively insensitive marker of urinary protein excretion compared with 
microalbuminuria. Whether microalbuminuria may represent a more sensitive test to identify 
persons at increased risk of death after PCI requires evaluation in future studies. Additionally, 
random urine dipstick assessment of proteinuria may vary by the concentration of the urine 
sample. However, such variation should have biased the results toward the null hypothesis. 
We emphasize that urinary dipstick is an inexpensive, easy-to-use, and simple tool to identify 
the presence of proteinuria. The majority of EXCITE study subjects were men and Caucasian, 
and results may not generalize to other patient populations. Nineteen percent of EXCITE study 
subjects did not have urinary dipstick proteinuria measurement and were excluded from the 
present study. However, clinical characteristics and event rates were similar in persons with 
and without proteinuria data. Last, the observation period in EXCITE was relatively short at 7 
months, which could be inadequate to answer this question adequately for incident cardio-
vascular events. Still, it is important to emphasize that more sensitive tests of proteinuria are 
warranted, regardless of whether it is less convenient, because proteinuria was convincingly 
shown to be an important risk factor. Whether the association of proteinuria with mortality 
remains or the association with cardiovascular events develops at longer follow-up should be 
evaluated in future studies.
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ABsTrACT
objectives: This study sought to examine whether the cardioprotective effects of angiotensin-
converting enzyme (ACE) inhibitor therapy by perindopril are modified by renal function in 
patients with stable coronary artery disease. 
Background: A recent study reported that an impaired renal function identified a subgroup 
of patients with stable coronary artery disease more likely to benefit from ACE inhibition 
therapy. In light of the growing interest in tailored therapy for targeting medications to specific 
subgroups, remarks on the consistency of the treatment effect by ACE inhibitors are highly 
important. 
methods: The present study involved 12.056 patients with stable coronary artery disease 
without heart failure randomized to perindopril or placebo. Estimated glomerular filtration rate 
(eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease equation. 
Cox regression analysis was used to estimate multivariable-adjusted hazard ratios.
results: The mean eGFR was 76.2 (18.1) ml/min/1.73 m2. During follow-up, the primary end 
point (cardiovascular death, nonfatal myocardial infarction, or resuscitated cardiac arrest) 
occurred in 454 of 5,761 patients (7.9%) with eGFR ≥75 and in 631 of 6.295 patients (10.0%) with 
eGFR <75. Treatment benefits of perindopril were apparent in both patient groups either with 
eGFR ≥75 (hazard ratio 0.77; 95% CI 0.64 to 0.93) or eGFR <75 (hazard ratio 0.84; 95% CI 0.72 to 
0.98). We observed no significant interaction between renal function and treatment benefit (p 
= 0.47). Using different cutoff points of eGFR at the level of 60 or 90 resulted in similar trends. 
Conclusions: The treatment benefit of perindopril is consistent and not modified by mild to 
moderate renal insufficiency.
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inTroDuCTion
Several clinical trials in patients with stable coronary artery disease (CAD) have shown that 
inhibitors of the angiotensin-converting enzyme (ACE) reduce the incidence of cardiovascular 
events during long-term follow-up (1–4). Because these effects are apparent in both low- and 
high-risk populations, as well as in those with and without preserved left ventricular function, 
clinical treatment guidelines argue that ACE inhibitors should be used as routine secondary 
prevention for the broad group of patients with known CAD (5). Still, it should be realized that 
absolute treatment effects in low-risk patients are modest. Because the cost effectiveness of 
medications is of increasing importance, there is a rapidly growing interest in tailored therapy. 
In cardiovascular disease, targeting ACE inhibitor therapy to specific patient groups that are 
most likely to benefit is of high clinical relevance. Patients with impaired renal function are 
a potential target because renal function is independently associated with adverse clinical 
outcome in cardiovascular disease (6,7).
In a recent substudy of the PEACE (Prevention of Events With ACE Inhibition) trial, a significant 
heterogeneity in treatment effect with trandolapril was observed in relation to renal function 
(8). In patients with poor renal function, defined as an estimated glomerular filtration rate (eGFR) 
below 60 ml/min/1.73 m2, trandolapril was associated with a significant reduction in all-cause 
mortality (27% relative risk reduction) as compared with placebo. In contrast, no risk reduction 
was observed in patients with higher eGFR levels. The PEACE Investigators concluded that, in 
a stable CAD population, ACE inhibition offered the best cardiovascular protection in patients 
with poor renal function, which could be used as a subgroup to target therapy (8,9). As the treat-
ment effect of trandolapril in the entire PEACE study was neutral (10), retrospective analyses to 
define patient populations with positive ACE inhibitor effects should be regarded cautiously 
and verified in comparable patient populations.
The EUROPA (European Trial on Reduction of Cardiac Events With Perindopril) study exam-
ined the preventive effects of ACE inhibition in a large population of patients with stable CAD 
and preserved left ventricular function. In light of the growing interest in tailored therapy and 
the recent results of the PEACE trial, we examined whether renal function modified the cardio-
protective benefits of ACE inhibition therapy by perindopril in the EUROPA study. 
mEThoDs
study population
The design and principal results of the EUROPA study have been reported elsewhere (2,11). In 
short, the EUROPA study was a randomized, double-blind, multicenter study of 12,218 patients 
with stable CAD without overt heart failure designed to assess the effect of 8 mg perindopril 
(n = 6,110) versus placebo (n = 6,108) on the combined end point of cardiovascular death, non 
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fatal myocardial infarction (MI), and resuscitated cardiac arrest. After a mean follow-up of 4.2 
years, 8.0% of patients randomized to perindopril and 9.9% of those randomized to placebo 
reached the primary end point, which yields a 20% relative risk reduction with perindopril 
(hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.71 to 0.91). In the EUROPA study, a serum 
creatinine level >1.7 mg/dl was an exclusion criteria; however, 30 patients (0.02%) enrolled with 
serum creatinine between 1.7 and 2.2 mg/dl. Baseline blood samples with standardized mea-
surements of serum creatinine levels according to protocol were available in 12.056 patients. 
Written informed consent was obtained from all patients. 
Assessment of renal function 
Renal function was assessed by eGFR using the abbreviated 4-variable Modification of Diet in 
Renal Disease equation (12). The dimension of all mentioned eGFR levels is in ml/min/1.73 m2. 
outcome measures 
The primary end point was a composite of cardiovascular death, non fatal MI, and resuscitated 
cardiac arrest. Secondary end points were the composite of total mortality, non fatal MI, hospital 
admission for unstable angina, and cardiac arrest with successful resuscitation; cardiovascular 
mortality, non fatal MI, and stroke or unstable angina; fatal and non fatal MI and unstable 
angina; stroke; and admission for heart failure. In addition, we assessed total mortality and 
cardiovascular mortality as individual end points. The diagnosis of MI was based on the recom-
mendations of the European Society of Cardiology and the American College of Cardiology (13).
statistical analysis
Summary statistics for continuous variables are presented as mean ± standard deviation. Cat-
egorical data are summarized as frequencies and percentages. One-way analysis of variance and 
Pearson chi square tests were used to calculate p values. We examined eGFR as a categorical vari-
able for the association of renal function and clinical outcome (<45, 45 to 59.9, 60 to 74.9, 75 to 
89.9, and ≥90 ml/min/1.73 m2). In our initial analyses for the relation between renal function and 
clinical outcome, we confined ourselves to this clinically relevant classification. Still, we realize that 
dichotomization of a continuous measure may result in loss of information. Therefore, all analy-
ses were repeated with eGFR as a continuous variable. Because both approaches showed similar 
results (we found no evidence of heterogeneity in treatment effect in relation to renal function), 
we present our findings of the analysis of renal function and treatment benefit by perindopril 
according to a binary classification. To systematically test the consistency of perindopril in rela-
tion to renal function, we have chosen 2 approaches. First, because there is a continuous relation 
between eGFR and cardiovascular risk, we divided the study population according to the median 
eGFR in our study. This resulted in 2 groups of comparable size, which we defined as relatively 
preserved (eGFR ≥75) versus impaired (eGFR <75) renal function. Second, from a clinical point of 
view, we have chosen a cutoff (also dichotomous) at an eGFR ≥60 or an eGFR <60 and at an eGFR 
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≥90 or an eGFR <90, corresponding to the presence of chronic kidney disease or a normal renal 
function at baseline, respectively. In the literature, there is an ongoing debate regarding which 
cutoff point to use. For completeness and comparability, we present all treatment effects on all 
cardiovascular end points at different cutoff points of eGFR, namely 60, 75, and 90 ml/min/1.73 
m2. Because of numerous studies reporting that the increased risk of cardiovascular events is 
already apparent at the earliest stages of renal insufficiency, well above 60 ml/min/1.73 m2, we 
confined ourselves to the cutoff at 75 ml/min/1.73 m2 for our main analyses (14–16).
The incidence of the primary and secondary end points over time was studied using the 
Kaplan-Meier method. Differences in incidence according to renal function were evaluated by 
log-rank tests. Absolute risk differences were calculated until 4 years of follow-up; after that 
Kaplan-Meier estimates became increasingly unstable because of the small number of patients 
at risk. 
Univariable and multivariable Cox proportional hazards regression analyses were applied 
to examine the association between renal function and study end points. In multivariable 
analysis, we adjusted for the following (potentially) confounding baseline characteristics: 
age, gender, systolic blood pressure, diastolic blood pressure, presence of diabetes mellitus, 
hypercholesterolemia, current smoking, history of CAD (MI, percutaneous coronary interven-
tion, coronary artery bypass graft surgery). Interaction between renal function and treatment 
effect was analyzed in a continuous as well as a categorical model for eGFR. Each model was 
tested for interaction and included an [renal function * treatment group] interaction term. The 
assumption of proportional hazards was assessed by visual judgment of the log-minus-log 
survival plots. All measures of association are presented as multivariable-adjusted HRs together 
with 95% CIs. All analyses were based on intention to treat. Statistical tests were 2-sided, and a 
value of p < 0.05 was considered significant. We used SPSS statistical software (version 12.01 for 
Windows, SPSS Inc., Chicago, Illinois) for our calculations. 
rEsulTs
Patients
The distribution of eGFR in the EUROPA trial is presented in Figure 1. The mean eGFR in our study 
population was 76.2 ± 18.1 (median 74.2, interquartile range 64.6 to 85.2) ml/min/1.73 m2, cor-
responding to a mean serum creatinine of 1.1 ± 0.2 mg/dl. A total of 6,295 (52.1%) patients had 
impaired renal function (eGFR <75). Baseline characteristics are shown in Table 1. Patients with 
lower eGFR were older and more often were female. Furthermore, patients with impaired renal 
function were more likely to have a higher frequency of comorbidities including hypertension 
and diabetes mellitus, but less often reported current smoking. Baseline characteristics for 
patients randomized for treatment with perindopril or placebo were in balance in the subjects 
considered in the analysis of treatment benefits and yielded no clinically relevant differences.
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renal function and clinical outcome
Regardless of allocated treatment, renal function was significantly associated with clinical out-
come. In patients allocated to perindopril, each 10 ml/min/1.73 m2 decrease in eGFR was related 
to an 8.7% (HR 1.09, 95% CI 1.03 to 1.15, p = 0.005) increased risk in the primary end point. A 
similar increased risk was found in those allocated to placebo: 6.5% (HR 1.06, 95% CI 1.02 to 
1.12, p = 0.015). With worsening eGFR categories, the associated HRs increased considerably 
for all end points in both treatment groups (Table 2). Kaplan-Meier estimates of the primary 
end point with perindopril and placebo for the 2 different categories of eGFR are presented in 
Figure 2. Log-rank tests were performed for perindopril versus placebo in patients with  eGFR 
≥75 and <75, which resulted in p values of 0.005 and 0.023, respectively.
renal function and treatment effects by perindopril 
In patients with a relatively preserved renal function, perindopril was associated with a 23% 
(HR 0.77, 95% CI 0.64 to 0.93) relative reduction in the incidence of the primary end point as 
compared with placebo. For patients with impaired renal function, perindopril was associated 
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Figure 1 
Distribution of estimated glomerular filtration rate (eGFR) in the EUROPA trial (n = 
12,056). 
 
 
  
 figure 1 Distribution of estimated glomerular filtration rate (eGFR) in the EUROPA trial (n = 12,056). MDRD 
= Modification of Diet in Renal Disease equation.
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with a 16% reduction (HR 0.84, 95% CI 0.72 to 0.98). There was no evidence of heterogeneity 
in the cardioprotective effect of perindopril in relation to eGFR, when assessed as a categorical 
(p = 0.47) or as a continuous variable (p = 0.37). Similar consistencies were found for all other 
end points considered. The treatment effects of perindopril at the other cutoff levels of 60 
and 90 ml/min/1.73 m2 are presented in Table 3. The results were similar, and no significant 
heterogeneity in treatment effect of perindopril was observed over the whole range of eGFR 
on all cardiovascular end points.
Absolute risks during follow-up
The absolute risk of the primary end point was highest in patients with impaired renal function 
using placebo (10.3%). The absolute risk reduction of the primary end point by perindopril at 4 
years of follow-up was 1.90% in patients with an eGFR ≥75 and 1.77% in patients with eGFR <75 
(Table 4). For comparability, we present the number of events of total mortality, cardiovascular 
mortality, and nonfatal MI in the PEACE and EUROPA trials in Table 5.
Table 1. Baseline characteristics of study population (n=12,056).
Characteristic
Estimated gfr (ml/min per 1.73 m2)
≥90 75-89.9 60 - 74.9 45.0 - 59.9 <45 Pv
(n=2131) (n=3630) (n=4378) (n=1756) (n=161)
Mean (Sd) age (years) 55.2 (9.3) 58.3 (9.1) 61.5 (8.5) 65.1 (7.9) 69.1 (6.7) <0.01
Gender, female 155 (7.3) 322 (8.9) 678 (15.5) 516 (29.4) 94 (58.4) <0.01
Hypertension * 472 (22.1) 926 (25.5) 1218 (27.8) 610 (34.7) 64 (39.8) <0.01
Hypercholesterolemia † 1288 (60.4) 2312 (63.6) 2815 (64.2) 1134 (64.5) 94 (58.4) 0.02
Diabetes Mellitus 232 (10.9) 411 (11.3) 529 (12.1) 277 (15.8) 31 (19.3) <0.01
Current smoking 469 (22.0) 626 (17.2) 538 (12.3) 180 (10.2) 17 (10.6) <0.01
Peripheral vessel disease 130 (6.1) 236 (6.5) 328 (7.5) 161 (9.2) 18 (11.2) <0.01
Previous stroke/TIA 47 (2.2) 91 (2.5) 165 (3.8) 96 (5.5) 10 (6.2) <0.01
History of CAD
      MI
      PCI
      CABG
1444 (67.8)
637 (29.9)
514 (24.1)
2359 (64.9)
1107 (30.5)
1011 (27.8)
2771 (63.3)
1259 (28.8)
1408 (32.2)
1130 (64.3)
475 (27.0)
556 (31.6)
113 (70.2)
37 (23.0)
55 (34.2)
0.01
0.03
<0.01
Medication
      Platelet inhibitors
      Statins 
      β-blockers
      Calcium-antagonists
      Nitrates
      Diuretics
1965 (92.2)
1134 (53.2)
1299 (60.9)
624 (29.3)
960 (45.0)
139  (6.5)
3386 (93.2)
2040 (56.2)
2269 (62.5)
1130 (31.1)
1553 (42.8)
237  (6.5)
4039 (92.3)
2492 (56.9)
2781 (63.5)
1428 (32.6)
1917 (43.8)
467 (10.6)
1589 (90.4)
1002 (57.0)
1128 (64.2)
647 (36.8)
846 (48.1)
325 (18.5)
140 (87.0)
79 (49.1)
96 (59.6)
73 (45.3)
82 (50.9)
49 (30.4)
<0.01
0.02
0.18
<0.01
<0.01
<0.01
Mean (Sd) SBP, mmHg 134.5(14.2) 136.3(15.2) 138.0(15.8) 139.5(15.8) 143.5(17.5) <0.01
Mean (Sd) DBP, mmHg 82.0 (8.1) 81.8 (8.2) 81.8 (8.1) 81.4 (8.4) 80.5 (9.0) 0.08
Mean (Sd) eGFR 104.1(18.3) 81.7 (4.2) 68.0 (4.2) 54.5 (3.9) 40.9 (4.4) <0.01
Randomized,perindopril 1060 (49.7) 1809 (49.8) 2189 (50.0) 906 (51.6) 72 (44.7) 0.46
Values are n (%) unless marked otherwise. MI= myocardial infarction. PCI= percutaneous coronary-
intervention. CABG= coronary bypass surgery. TIA= transient ischemic attack. * Blood pressure > 160/95 
mm Hg or receiving antihypertensive treatment. † Cholesterol > 6.5 mmol/L or receiving lipid-lowering 
treatment. 
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Table 2. Multivariable-adjusted hazard ratios for baseline renal function and clinical outcome (n=12,056)
Placebo 
(n=6,027)
Perindopril 
(n=6,029)
Endpoints  eGFR  Events 
/total
HR   95% CI Events
/total
HR   95% CI
Primary endpoint 
(cardiovascular death, non-fatal 
MI, resuscitated CA)
Reference
75-89.9
60-74.9
45-59.9
<45
 8.6
 9.1
10.1
12.3
15.7
1.00
1.03 (0.80-1.33)
1.13 (0.88-1.46)
1.31 (0.97-1.76)
1.59 (0.88-2.86)
 6.7
 6.9
 8.0
11.4
15.3
1.00
1.00 (0.74-1.34)
1.10 (0.83-1.46)
1.53 (1.10-2.11)
1.86 (0.96-3.60)
Total mortality, Ami, uAP or 
cardiac arrest
Reference
75-89.9
60-74.9
45-59.9
<45
16.0
15.4
17.3
20.7
29.2
1.00 
0.92 (0.76-1.11)
1.00 (0.83-1.20)
1.15 (0.92-1.43)
1.57 (1.01-2.42)
12.5
13.1
15.1
18.8
29.2
1.00
1.00 (0.80-1.23)
1.09 (0.88-1.34)
1.31 (1.03-1.66)
1.86 (1.15-3.01)
Cardiovascular mortality, Ami 
and stroke
Reference
75-89.9
60-74.9
45-59.9
<45
 9.2
10.0
11.4
13.3
19.1
1.00
1.04 (0.82-1.33)
1.18 (0.93-1.50)
1.30 (0.98-1.73)
1.77 (1.03-3.04)
 7.1
 8.0
 9.1
12.9
18.1
1.00
1.08 (0.81-1.43)
1.16 (0.89-1.53)
1.61 (1.18-2.19)
1.99 (1.08-3.69)
Cardiovascular mortality, Ami Reference
75-89.9
60-74.9
45-59.9
<45
 8.4
 9.0
10.0
12.1
15.7
1.00
1.05 (0.81-1.35)
1.15 (0.89-1.48)
1.31 (0.97-1.77)
1.62 (0.90-2.93)
 6.7
 6.9
 8.0
11.2
15.3
1.00
0.99 (0.74-1.33)
1.10 (0.82-1.46)
1.50 (1.09-2.08)
1.86 (0.96-3.60)
Cardiovascular mortality, Ami 
and uAP
Reference
75-89.9
60-74.9
45-59.9
<45
13.4
12.9
14.8
18.1
23.6
1.00
0.93 (0.76-1.15)
1.06 (0.86-1.30)
1.26 (0.99-1.60)
1.58 (0.98-2.56)
10.5
11.2
12.6
15.5
23.6
1.00
1.04 (0.83-1.32)
1.13 (0.90-1.42)
1.38 (1.06-1.80)
2.00 (1.18-3.41)
fatal and non fatal Ami Reference
75-89.9
60-74.9
45-59.9
<45
 4.9
 7.2
 7.3
 7.1
 9.0
1.00 
1.47 (1.07-2.03)
1.54 (1.12-2.12)
1.46 (0.99-2.16)
1.82 (0.84-3.94)
 4.4
 5.4
 4.7
 7.3
 6.9
1.00
1.20 (0.84-1.70)
1.03 (0.72-1.47)
1.65 (1.11-2.45)
1.56 (0.60-4.03)
Total mortality Reference
75-89.9
60-74.9
45-59.9
<45
6.6
5.5
6.7
9.5
14.6
1.00
0.74 (0.54-0.99)
0.80 (0.59-1.05)
0.94 (0.67-1.31)
1.28 (0.69-2.40)
 4.8
 4.8
 6.5
 8.8
16,7
1.00 
0.86 (0.61-1.22)
1.04 (0.75-1.45)
1.23 (0.85-1.78)
1.72 (0.88-2.33)
Cardiovascular mortality Reference
75-89.9
60-74.9
45-59.9
<45
4.0
2.8
4.2
6.2
9.0
1.00
0.64 (0.43-0.96)
0.86 (0.59-1.24)
1.06 (0.69-1.62)
1.32 (0.60-2.94)
 2.6
 2.7
 3.8
 5.3
 9.7
1.00
0.93 (0.58-1.47)
1.22 (0.78-1.89)
1.49 (0.91-2.45)
2.11 (0.88-5.05)
stroke Reference
75-89.9
60-74.9
45-59.9
<45
 1.3
 1.2
 2.1
 1.9
 5.6
1.00 
0.79 (0.40-1.54)
1.16 (0.63-2.14)
0.87 (0.41-1.85)
2.13 (0.71-6.36)
 0.7
 1.4
 1.7
 2.8
 2.8
1.00
1.74 (0.75-4.03)
1.88 (0.83-4.26)
2.45 (1.02-5.87)
1.84 (0.36-9.29)
heart failure Reference
75-89.9
60-74.9
45-59.9
<45
1.2
1.1
1.9
2.8
4.5
1.00
0.80 (0.40-1.62)
1.20 (0.63-2.28)
1.43 (0.70-2.91)
1.75 (0.53-5.74)
 0.6
 0.9
 1.1
1.3
 6.9
1.00
1.28 (0.50-3.29)
1.41 (0.57-3.50)
1.29 (0.46-3.57)
5.39 (1.52-19.1)
Cox regression multivariable-adjusted hazard ratios adjusted for age, gender, systolic blood pressure, 
diastolic blood pressure, presence of diabetes mellitus, hypercholesterolemia, current smoking, history 
of coronary artery disease (MI, PCI, CABG). CA= cardiac arrest, AMI= acute myocardial infarction, UAP= 
unstable angina pectoris.
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DisCussion
This analysis confirms that perindopril is effective in reducing cardiovascular events in patients 
with stable CAD irrespective of renal function. Treatment benefit by perindopril is substantial 
and consistent in patients with and without impaired renal function. Hence, renal function, as 
measured by eGFR, cannot be used to select a target population that will benefit most from 
ACE inhibition. 
Regarding clinical outcome, we showed a significant relationship with renal function. With 
worsening eGFR, patients showed higher comorbidity and the associated HRs increased con-
siderably for all end points. On a continuous scale, each 10 ml/min/1.73 m2 decrease in eGFR 
was related to a 6.5% increase in risk of the primary end point in the placebo group. The relation 
between renal function and risk of cardiovascular events has been intensively investigated for 
Figure 2.  
Kaplan-Meier Estimates of Primary End Point With Perindopril and Placebo 
According to Baseline eGFR. 
 
figure 2. Kaplan-Meier Estimates of Primary End Point With Perindopril and Placebo According to 
Baseline eGFR. The black line corresponds to patients with an eGFR <75 using placebo, and the dotted 
black line corresponds to patients with an eGFR <75 using perindopril. The red line corresponds to 
patients with an eGFR ≥75 using placebo, and the dotted red line corresponds to patients with an eGFR 
≥75 using perindopril. The X-axis represents the follow-up time in days. The Y-axis represents the risk of 
the primary end point. AMI = acute myocardial infarction.
Ch
ap
te
r 6
102
Table 3. Treatment benefit of perindopril at different levels of renal function (n=12,056)
egfr 60 egfr 75 egfr 90
HR   95% CI Pint HR   95% CI Pint HR   95% CI Pint
Primary endpoint 0.77 (0.68-0.89)
0.96 (0.74-1.24)
0.19 0.77 (0.64-0.93)
0.84 (0.72-0.98)
0.47 0.76 (0.56-1.04)
0.82 (0.72-0.93)
0.71
Total mortality, AMI, UAP 
or cardiac arrest
0.84 (0.76-0.93)
0.92 (0.76-1.13)
0.48 0.83 (0.72-0.95)
0.89 (0.79-1.00)
0.44 0.76 (0.61-0.96)
0.88 (0.80-0.97)
0.30 
CV mortality, AMI and 
stroke
0.79 (0.69-0.90)
1.00 (0.78-1.27)
0.12 0.79 (0.66-0.94)
0.86 (0.74-0.99)
0.48 0.75 (0.55-1.01)
0.84 0.74-0.95)
0.51 
CV mortality, AMI 0.78 (0.68-0.89) 
0.96 (0.74-1.24)
0.20 0.77 (0.64-0.93)
0.84 (0.72-0.99)
0.50 0.78 (0.57-1.07)
0.82 (0.72-0.93)
0.81 
CV mortality, AMI and 
UAP
0.84 (0.75-0.93)
0.88 (0.71-1.09)
0.76 0.83 (0.72-0.97)
0.86 (0.75-0.97)
0.81 0.76 (0.59-0.97)
0.86 (0.77-0.95)
0.41 
Fatal and non fatal AMI, 
UAP
0.82 (0.73-0.93)
0.89 (0.69-1.14)
0.65 0.86 (0.73-1.01)
0.82 (0.70-0.94)
0.62 0.80 (0.60-1.06)
0.84 (0.74-0.94)
0.85 
Fatal and non fatal AMI 0.71 (0.61-0.84)
1.04 (0.75-1.46)
0.06 0.79 (0.63-0.98)
0.75 (0.62-0.92)
0.74 0.88 (0.59-1.30)
0.75 (0.64-0.88)
0.45 
Total mortality 0.87 (0.74-1.03)
0.97 (0.72-1.29) 
0.72 0.80 (0.64-1.00)
0.97 (0.81-1.16)
0.25 0.71 (0.49-1.02)
0.93 (0.80-1.08)
0.24 
CV mortality 0.86 (0.69-1.06)
0.90 (0.62-1.30)
0.94 0.81 (0.60-1.09)
0.91 (0.72-1.14)
0.70 0.65 (0.59-0.94)
0.91 (0.74-1.11)
0.32 
Stroke 0.86 (0.62-1.18)
1.24 (0.70-2.20)
0.28 0.89 (0.55-1.44)
0.96 (0.68-1.35)
0.79 0.50 (0.20-1.25)
1.00 (0.75-1.35)
0.51 
Heart failure 0.64 (0.44-0.92)
0.59 (0.32-1.08)
0.84 0.65 (0.38-1.12)
0.61 (0.42-0.90)
0.80 0.46 (0.17-1.21)
0.65 (0.47-0.91)
0.16 
Cox regression multivariable-adjusted hazard ratios adjusted for age, gender, systolic and diastolic BP, 
diabetes mellitus, hypercholesterolemia, current smoking, history of CAD (MI, PCI, CABG). Analysis of 
treatment effect by perindopril at different cut-off levels of eGFR: upper line corresponds to patients with 
an eGFR above the cut-off level and the lower line with an eGFR below the mentioned cut-off level for 
each endpoint (dichotomous ≥ or <60; ≥ or <75; ≥ or <90). CV = cardiovascular, AMI = acute myocardial 
infarction, UAP = unstable angina pectoris. Pint = p-value for testing interaction.
Table 4. Absolute risk reduction by perindopril for the primary endpoint (n=12,056).
egfr 
above 75
egfr 
below 75
Follow-up Placebo Perindopril Risk
Difference
Placebo Perindopril Risk
Difference
1 yr.
2 yrs.
3 yrs.
4 yrs.
2.01 %
3.95 %
6.08 %
8.54 %
1.96 %
3.54 %
5.12 %
6.64 %
-0.05 %
-0.41 %
-0.96 %
-1.90 %
3.01 %
5.41 %
7.51 %
10.29 %
2.44 %
4.72 %
6.49 %
8.52 %
-0.57 %
-0.69 %
-1.02 %
-1.77 %
Absolute risks during follow-up were calculated using Kaplan-Meier analysis.
Table 5. Comparing data from the EUROPA and PEACE-trials.
no. of events / no. of controls (%)
EUROPA PEACE
Total mortality 420/6108 (6.9) 334/4132 (8.1)
Cardiovascular mortality 249/6108 (4.1) 152/4132 (3.7)
Non-fatal MI 378/6108 (6.2) 220/4132 (5.3)
Mean follow-up EUROPA 4.2 years, PEACE 4.8 years.
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several years. It has been suggested that the increased risk can be explained by the co-occur-
rence of a high prevalence of baseline risk factors (17,18). However, in our study, the observed 
relationships remained significant after multivariable analysis including these factors. Another 
explanation may be that renal function is a marker of ongoing or pre-existing atherosclerosis 
starting in the smallest vessels at the glomerulus, explaining the increased risk of subjects 
with only mildly decreased renal function (16–18). Regarding the observed treatment effect, we 
showed that perindopril reduced events in all patients with stable CAD regardless of the level of 
renal function. The relative reduction in the incidence of the primary end point by perindopril 
was somewhat better for patients with relatively preserved renal function. However, CIs were 
overlapping and we observed no significant interaction between treatment and renal function.
A recent substudy of the PEACE trial investigated the relationship between renal function 
and the effectiveness of ACE inhibition therapy in stable CAD (8). In that study, patients with an 
eGFR <60 showed a significant treatment effect of trandolapril on total mortality, but not on 
the other studied end points nor in patients with better levels of renal function. The investiga-
tors observed a significant heterogeneity in treatment effect in relation to renal function. The 
inconsistency of the treatment effect of trandolapril was mainly related to the lack of benefit in 
patients with an eGFR >60. Therefore, they concluded that an impaired renal function defined 
a subset of CAD patients more likely to benefit from ACE inhibitor therapy for cardiovascular 
protection (8,9).
The results of the PEACE trial could not be confirmed by our analysis. Both trials studied a 
population of stable CAD patients with a similar cardiovascular risk profile and a similar eGFR 
and gender distribution. In contrast to the PEACE trial, we have shown considerable treatment 
benefits at different levels of renal function and no heterogeneity in the treatment effect of 
perindopril. In particular, no heterogeneity in the treatment effect was observed on total 
mortality and cardiovascular mortality in contrast to the PEACE trial analysis. The direction of 
the treatment benefit by ACE inhibition is different because point estimates were somewhat 
better at higher eGFR levels, implying that the treatment effect is also present in patients with 
relatively preserved renal function. The difference in direction must be considered against the 
background of the overall neutral results of the main PEACE trial. Our analysis confirms that the 
treatment benefit of ACE inhibition with perindopril is consistent within subgroups, which is 
in line with our prior subgroup analyses and risk models (2,19). The HOPE (Heart Outcome and 
Prevention Evaluation) and SAVE (Survival and Ventricular Enlargement) trials studied the rela-
tionship between renal function and treatment effect of ACE inhibition, respectivelyramipril 
and captopril, in a high-risk population (20,21). In these patients, no heterogeneity in treatment 
effect in relation to renal function was shown. 
In the main study of the PEACE trial, the overall treatment effect of trandolapril was neutral 
(10). The investigators performed subgroup analyses for possible explanations for this neutral 
finding. They stated that their study consisted of relatively few patients with poor renal function 
(16.3% eGFR <60). Trandolapril reduced the incidence of total mortality only in patients with 
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poor renal function. Because of this low prevalence in the PEACE trial, the investigators stated 
that this could potentially explain the overall neutral results. However, the distribution of eGFR 
in the EUROPA trial was similar (15.9% eGFR <60). Still, the overall effect of the main EUROPA 
study was in favor of ACE inhibition therapy (2). The different result in the PEACE trial may be 
explained by the fact that the PEACE study potentially had the lowest-risk population.
Renal insufficiency could identify a higher risk subgroup and hence explain why the PEACE 
trial shows a benefit only in this subgroup in an otherwise low-risk population. However, 
subgroup analyses of the HOPE and EUROPA studies in low-risk groups showed similar event 
rates compared with those of the PEACE study, and in low-risk groups of the EUROPA study, 
perindopril reduced the risk of cardiovascular mortality and non fatal MI by 17%, contrasting 
with 3% in the PEACE trial. These analyses indicate that the apparent neutral results of the 
PEACE trial may not be attributable to the lower risk of these patients nor to the background 
therapies used, but rather are related to the reduced power of the PEACE trial caused by greater 
crossover and shorter follow-up than in the other studies (1,2,4,10,19). In addition, the different 
results may be related to substance-specific or (target) dose-dependent differences between 
ACE inhibitors potentially in relation to the level of renal function, which may have resulted in 
suboptimal dosages (22). In the EUROPA trial, patients were assigned to receive a relatively high 
dose of perindopril (8 mg), which was achieved rapidly and in a high proportion of patients, 
whereas in the PEACE trial, trandolapril was up-titrated to the target dose (4 mg) only 6 months 
after randomization. At 3 years, target dose was achieved in 57.8% of patients in the PEACE trial 
and 93.0% of patients in the EUROPA trial. Both agents are in a broadly similar ACE inhibitor 
subgroup, share chemical moieties, are lipophilic, and are mainly excreted from the kidney and 
were used in doses that showed important pharmacologic effects. Still, without head-to-head 
trials it cannot be excluded that there are pharmacologic differences between the agents, 
possibly in relation to renal insufficiency, that are important to their clinical efficacy to reduce 
cardiovascular end points (22).
In an additional analysis, we investigated whether the treatment effect of perindopril 
showed any differences between the renal groups in absolute risks during follow-up. Impaired 
renal function was associated with higher comorbidity, such as hypertension, and worse clini-
cal outcome in our study. This may explain the small difference in absolute risk reduction in the 
beginning of follow-up, in which this group shows a direct benefit presumably from the blood 
pressure lowering effects. Still, at longer follow-up the absolute benefits of perindopril were 
the same in both groups, which may further be related to the additional effects of ACE inhibi-
tors (beyond lowering blood pressure). The ACE inhibitors with high tissue affinity especially 
improve the angiotensin II– bradykinin balance, reduce remodeling, improve endothelial func-
tion, and may have antiatherosclerotic effects (23,24). 
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Clinical perspective
Remarks on the consistency of thetreatment effect of ACE inhibition in patients with stable CAD 
are clinically relevant. In our study, in contrast to the PEACE trial, also patients with an eGFR 
>60 ml/min/ 1.73 m2 benefited from ACE inhibition by perindopril (eGFR >60: 83.4% in the 
PEACE trial, 84.1% in the EUROPA trial). In patients with mild renal insufficiency, an increased 
risk of cardiovascular events was already apparent and perindopril significantly reduced car-
diovascular events. Therefore, the earliest stages of renal insufficiency can be considered a key 
target for preventing the progression of renal disease and to decrease the risk of cardiovascular 
disease, especially when we also take into account the recent remarks on potential renopro-
tective effects of ACE inhibitors. We question the conclusion of the PEACE trial to specifically 
target therapy to patients with an eGFR <60 as the subgroup more likely to benefit from ACE 
inhibition.
Some limitations of this study can be noted. The generalizability of these findings to patients 
with severe renal insufficiency is limited because numbers in the lowest eGFR category were 
relatively small, which limits our statistical power to detect differences in treatment benefit 
in these patients. The current analysis mainly addresses patients with mild to moderate renal 
insufficiency according to the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative guidelines (25). Furthermore, the eGFR levels calculated with the Modification of Diet 
in Renal Diseaseequation remain an estimate of the true GFR; however, it is superior to using 
the serum creatinine level or the Cockcroft-Gault equation (12). Unfortunately, we did not have 
data on microalbuminuria (26).
Conclusions
The treatment benefit of perindopril is consistent and not modified by the level of renal func-
tion in patients with stable CAD. We observed no heterogeneity in the treatment effect of 
perindopril in relation to mild or moderate renal insufficiency. 
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ABsTrACT
Aims: Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce cardiovas-
cular risk in different groups of patients. Whether these effects can be generalized to the broad 
group of patients with vascular disease is unknown. Therefore, we undertook a combined 
analysis using individual data from ADVANCE, EUROPA, and PROGRESS to determine the con-
sistency of the treatment effect of perindopril-based regimen in patients with vascular disease 
or at high risk of vascular disease. 
methods: We studied all-cause mortality and major cardiovascular outcomes during a follow-
up of about 4 years in the 29.463 patients randomly assigned a perindopril-based treatment 
regimen or placebo. 
results: The perindopril-based regimens were associated with a significant reduction in 
all-cause mortality [hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.82–0.96; P = 0.006], 
cardiovascular mortality (HR 0.85; 95% CI 0.76–0.95; P = 0.004), non-fatal myocardial infarction 
(HR 0.80; 95% CI 0.71–0.90; P < 0.001), stroke (HR 0.82; 95% CI 0.74–0.92; P = 0.002), and heart 
failure (HR 0.84; 95% CI 0.72–0.96; P = 0.015). Results were consistent in subgroups with differ-
ent clinical characteristics, concomitant medication use, and across all strata of baseline blood 
pressure. 
Conclusion: This study provides strong evidence for a consistent cardiovascular protection 
with an ACE-inhibitor treatment regimen (perindopril–indapamide) by improving survival 
and reducing the risk of major cardiovascular events across a broad spectrum of patients with 
vascular disease. 
The consistency of treatment benefit 113
inTroDuCTion
Clinical trials have demonstrated the efficacy of angiotensin-converting enzyme (ACE)-
inhibitors in specific groups of patients at risk of cardiovascular events(1–9). Nowadays, the use 
of ACE-inhibitors is recommended in guidelines on the management of hypertension, stable 
coronary artery disease (CAD), myocardial infarction (MI), and heart failure(10-15). The beneficial 
effect of ACE-inhibitors is related, at least in part, to the blood pressure (BP)-lowering effects. 
However, ACE-inhibitors may have many valuable protective properties quite apart from BP 
lowering. Especially, perindopril has been extensively investigated in this regard and has been 
shown to improve endothelial function and neurohumoral balance, and inhibit remodelling of 
the coronary arteries(16-19). Since, the BPLTTC has demonstrated that BP-independent effects 
of ACE-inhibitor-based regimens do contribute to the reduction in CAD(20,21), it becomes more 
important to base decisions on the treatment of individual patients, on the assessment of total 
cardiovascular risk, rather than on arbitrary cut-off points for single risk factors such as BP. Most 
of the evidence currently available has been obtained from studies conducted in patient popu-
lations with vascular disease in a single vascular territory or with a metabolic disorder such as 
diabetes. There is, therefore, a need for a broadly based study pooling individual patient data 
from patient populations with a wider spectrum of vascular disease. 
For this purpose, we undertook a combined analysis of the individual data from trials of 
perindopril-based regimens in patients with diabetes, CAD, and cerebrovascular disease(7–9). 
We investigated the treatment effect on clinical endpoints and their consistency in patient 
subgroups. 
mEThoDs
The methodological principles that lie behind a combined analysis of randomized clinical trials 
based on data from individual patients have been described in detail. (22) We therefore only 
briefly describe the applied methods of trial selection, data-management, endpoint definitions, 
and statistical analysis. 
Trial selection 
We obtained data from the ADVANCE, EUROPA, and PROGRESS studies that are the three main 
large trials with a regimen based primarily on the ACE-inhibitor perindopril. The ASCOT-BPLA 
was not selected because the combined treatment regimen was based on amlodipine with the 
addition of perindopril so that it was impossible to make unbiased estimates for the treatment 
effect of perindopril(23). Since all trials studied a regimen based on the same agent, perindopril, 
we had the opportunity to include individual data in this combined analysis, which made 
important subgroup analyses possible at the patient level. The types of patients included in 
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these studies were different in their primary diagnoses, but since atherosclerosis and vascu-
lar disease is not restricted to a single vascular bed, we conclude that these patients are at 
least homogenous in having vascular disease or being at a high risk of vascular disease. The 
combined data set consisted of 29.463 patients, who were followed for on average 4 years. We 
had full access to all individual data of the trials. After data merging, data were tested carefully 
for completeness, internal consistency of patients’ records, and consistency with the published 
reports. Table 1 shows the main inclusion and exclusion criteria, outcomes, recruitment, and 
follow-up of the three trials. 
outcomes 
In this analysis, we assessed all-cause mortality, cardiovascular mortality, fatal and non-fatal 
stroke, revascularization, non-fatal MI, hospital admission for heart failure, and major cardio-
vascular endpoints as a composite of cardiovascular mortality, MI, and stroke. The definitions 
of endpoints in these trials were carefully checked and were not essentially different across the 
trials. Where there were slight differences in endpoints or thresholds, we did not try to match 
everything, since that this is often impossible retrospectively. Moreover, this is not necessary 
Table 1 Characteristics of clinical trials
ADVAnCE 
(N=11.140)
EuroPA
(n=12.218)
ProgrEss
(n=6.105)
main inclusion criteria
Age at entry (years) ≥ 55 ≥ 18 Not specified
Type of patients (entry) Diabetes Mellitus Stable CAD Stroke or TIA
main exclusion criteria
Known CHF No No No
Patients with LVEF <40% Not assessed 18 / 7096 assessed Not assessed
Myocardial Infarction --- Within 3 months ---
Stroke --- --- Within 5 years
PCI --- Within 6 months ---
CABG --- Within 6 months ---
ACE-inhibitor and 
target daily dose
Perindopril 4 mg / 
Indapamide 1.25 mg
Perindopril 8 mg Perindopril 4 mg / 
Indapamide 2.5 mg 
main outcomes
Primary (composite) Major macro- or 
microvascular events
Cardiac death, MI, 
or cardiac arrest.
Fatal or non-fatal stroke.
recruitment
Recruitment period June 2001, 
to March 2003
October 1997, 
to June 2000
May 1995, 
to November 1997
Mean follow-up duration 4.3 years 4.2 years 3.9 years
MI= myocardial infarction, UAP= unstable angina pectoris, CHF = congestive heart failure, LVEF = left 
ventricular ejection fraction, TIA= transient ischaemic attack, Sd =standard deviation, HF = heart failure, 
ACE= angiotensin-converting enzyme.
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since in each study the treatment effects were compared within rigorously randomized and 
well-balanced treatment groups. Since we know that heterogeneity in an endpoint definition 
will not lead to invalid results, we applied the trial-specific definition of MI for practical rea-
sons(24). Several endpoints were not presented in the main papers of the ADVANCE and PROG-
RESS trials, for example, the data for revascularization. For a comprehensive and comparable 
analysis, these endpoints were included. 
subgroups 
We tested the consistency of the treatment effect of perindopril-based regimens in relation to 
baseline clinical characteristics [gender, age categories (<60; 60–70; >70 years), mean age (<63; 
>63 years) hypertension, diabetes, cerebrovascular accident (CVA) / transient ischaemic attack 
(TIA), and revascularization] and in relation to concomitant medication (anti-platelet agents, 
lipid-lowering agents, b-blockers, diuretics, and calcium antagonists). We investigated the treat-
ment effect of perindopril-based regimen on the outcomes according to BP levels at baseline 
(first screening visit). Ordinal categories of systolic BP and diastolic BP were defined as follows: 
systolic BP ,120, 120–139, 140–159, and ≥160 mmHg; diastolic BP <80, 80–90, 90–100, and ≥100 
mmHg. Further, we investigated whether the treatment effect was independent of the level of 
BP-reduction by active treatment. All patients were treated during run-in period of 4 weeks. Blood 
pressure reduction was calculated as the difference between the baseline measurement and the 
end of the run-in period. We accounted for the difference in dosage of perindopril (EUROPA 
4–8 mg, ADVANCE and PROGRESS 2–4 mg) and combination with indapamide (ADVANCE and 
PROGRESS 2.5 mg) in all analyses. We emphasize that for analyses of BP reduction during run-in, 
baseline BP was added as continuous variable in the model to adjust for the starting level of BP 
before initiation of ACE-inhibitor treatment (avoids regression to the mean). 
statistical analysis
The statistical principles used in these analyses have been described previously in the main 
papers of the trials for the assessment of reduction in outcomes. Although baseline char-
acteristics are well balanced between the randomized groups for each trial, we choose to 
perform a multivariate Cox regression analysis because of the difference between the studies 
themselves and because adjustment for baseline characteristics, even when randomized, is 
recommended in clinical trials(25). By multivariate analysis, confidence intervals (CIs) will widen 
slightly (although compensated by the large number of patients) but the validity will increase 
which is most important. In multivariate Cox regression analysis, we adjusted for age, gender, 
hypertension, diabetes, smoking, prior MI, prior percutaneous coronary intervention / coronary 
artery bypass grafting, prior CVA/TIA, medication use (anti-platelet agents, b-blockers, diuret-
ics, calcium-antagonists, and lipid-lowering agents), indapamide use, and active treatment 
(perindopril) dosage. We further adjusted for differences in baseline risk across trials by adding 
dummy study variables to the model. Tests for heterogeneity in the treatment effects were 
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performed by including interaction terms [treatment * characteristic] in the multivariate model 
for each covariate separately. Test for heterogeneity among trials was by including interaction 
terms of dummy study variables with treatment, and we calculated the difference in -2 log 
likelihood of two models. The difference chi-square (Q-test) between the two -2 log likelihoods 
follows chi-square distribution. If P <0.05, then there is evidence of heterogeneity between 
trials. Survival analysis was performed by the Kaplan–Meier analysis. Hazard ratios (HR) and 
95% CIs are presented with corresponding two-sided P-values. A p-value <0.05 was considered 
significant. In all trials, analysis was by intention-to-treat principle.
rEsulTs
The baseline characteristics of the total study population (n = 29.463) are summarized in Table 
2. The mean (SD) age was 63.0 (8.8) years, 28.4% were female, 54.1% hypertensives, 45.5% 
diabetics, and 32.8% experienced a previous MI. Mean BP was 142/82 mmHg, 70.8% were 
Table 2. Baseline characteristics patients in the ADVANCE, EUROPA and PROGRESS trials.
ADVAnCE 
(n=11.140)
EuroPA 
(n=12.218)
ProgrEss 
(n=6.105)
Combined 
(n=29.463)
Characteristics
Age (years), mean (Sd) 66 (6) 60 (9) 64 (10) 63 (9)
Female (%) 42.5 14.6 30.3 28.4
Previous MI (%) 12.0 64.8 7.0 32.8
Previous PCI/CABG (%) 8.5 54.9 2.7 26.6
Previous CVA/TIA (%) 12.9 3.4 99.9* 27.0
Previous PAD (%) 2.4 7.3 4.1 4.8
Current smokers (%) 15.1 15.2 20.0 16.2
Diabetes (%) 100.0 12.3 12.5 45.5
Hypertension (%) 68.7 27.1 47.8 54.1
Hypercholesterolemia (%) 58.9 63.3 --- 61.2**
Systolic blood pressure (mmHg) 145 (21) 137 (15) 147 (9) 142 (19)
Diastolic blood pressure (mmHg) 81 (11) 82 (8) 86 (11) 82 (10)
Medications
Antiplatelet agents (%) 46.7 92.3 72.3 70.8
β-blockers (%) 24.5 61.7 17.0 38.8
Lipid-lowering agents (%) 35.3 55.9 14.1 39.5
Calcium antagonists (%) 30.8 31.4 39.9 33.3
Diuretics use (%) †   9.2 23.7 11.5 15.1
 Summary statistics for continuous variables are presented as mean (standard deviation (SD).) Categorical 
data are summarized as percentages. * Protocol violation for 7/6105 patients. ** Hypercholesterolemia 
data was not present in PROGRESS, percentage was 61.2% (14294) based on 23358 patients (advance and 
europa). † diuretics use, not indapamide study medication. MI= myocardial infarction, PCI= percutaneous 
coronary intervention, CABG = coronary artery bypass grafting, CVA = cerebrovascular disease, TIA = 
transient ischemic attack, PAD = peripheral arterial disease.
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taking anti-platelet agents, 38.8% beta-blockers, 39.5% lipid-lowering agents, and 33.3% cal-
cium antagonists. Of the 29463 patients, 14730 (50.0%) were randomized to active treatment 
(perindopril-based regimen) and 14733 (50.0%) received matched placebo. Indapamide was 
used in 14684 patients (49.8%), and other diuretics in 15.1%. 
Clinical endpoints 
The perindopril-based regimen was associated with a significantly lower cumulative incidence 
of all-cause mortality as well as major cardiovascular events when compared with placebo 
in the Kaplan–Meier analysis (both log ranks P-value <0.001) as presented in Figure 1a and 
1b. During a mean follow-up of 4.0 years (SD 0.8), there were 1089 deaths (7.4%) in the active 
treatment group and 1210 (8.2%) in the placebo group (HR 0.89; 95% CI 0.82–0.96; P-value = 
0.006). No heterogeneity between the studies was observed (P for interaction 0.56). Results for 
the other endpoints were comparable and are presented in Table 3. Significant heterogene-
ity in the treatment effect between the studies was observed for heart failure admission (no 
effect in ADVANCE) and for fatal and non-fatal stroke (no effect in ADVANCE or EUROPA). The 
perindopril-based regimen did not significantly affect subsequent revascularizations (HR 0.92; 
95% CI 0.84–1.01; P-value = 0.092), with 852 revascularizations (5.8%) in treatment group and 
920 revascularizations (6.2%) in placebo group. 
Blood pressure 
The perindopril-based treatment regimen was associated with lower major cardiovascular 
event rates across all strata of systolic BP as well as diastolic BP, although in the lower systolic 
BP categories, the treatment effect estimates did not reach significance. Also, the relative 
treatment benefit was somewhat larger at higher diastolic BP levels (P for interaction <0.001) 
(Figure 2a). During the run-in period of four weeks, all patients were treated with perindopril 
(n = 29463) and BP decreased from 142/82 to 134/78 mmHg. The average BP reduction dur-
ing run-in was 8.3/3.8 mmHg and during follow-up 5.4/2.3 mmHg. The BP reduction during 
run-in was comparable in each of the three trials (ADVANCE: 8/3 mmHg; EUROPA 9/4 mmHg; 
and PROGRESS 9/5 mmHg). The perindopril-based regimen reduced the incidence of major 
cardiovascular events in all categories of BP reduction during run-in (Figure 2b). However, the 
relative treatment benefit was somewhat larger in patients with a higher diastolic BP reduction 
during run-in (P for interaction 0.05). 
subgroups
The treatment effect of the perindopril-based regimen was independent of baseline clinical 
characteristics and concomitant medication (Figure 3). In subgroups of age and diabetes mel-
litus, P for interaction was, respectively, 0.07 and 0.06, but the perindopril-based regimen was 
associated with a significant positive treatment effect in patients with or without diabetes, and 
in patients aged <60, 60–70, or >70 years. A dichotomized age variable, at the median age of the 
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Figure 1a and b   
Kaplan Meier analysis of cumulative incidence of all-cause mortality (A) and major 
cardiovascular events (cardiovascular mortality, MI and stroke) (B) in 29.463 
patients.  
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figure 1a and b Kaplan Meier analysis of cumulative incidence of all-cause mortality (A) and major 
cardiovascular events (cardiovascular mortality, MI and stroke) (B) in 29.463 patients. The x-axis 
corresponds to the duration of follow-up in years. The y-axis to the cumulative incidence of all-cause 
mortality (A) and major cardiovascular events in percentages (%) (B). The percentages along the lines 
correspond to the Kaplan–Meier estimates at 1, 2, 3, and 4 years of follow-up in patients allocated the 
perindopril-based regimen (red line) or placebo (black line). Below the graph, the number of events and 
the number of patients at risk during follow-up (per year) are presented.
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Table 3. Data for total mortality and cardiovascular events.
Active treatment
Events/total (%)
Placebo
Events/total (%)
hr 95% Ci P Pint
All-cause mortality
ADVANCE (n=11.140) 408/5569 (7.3) 471/5571 (8.5) 0.86 (0.75-0.98) 0.026 0.56
EUROPA (n=12.218) 375/6110 (6.1) 420/6108  (6.9) 0.89 (0.77-1.02) 0.098
PROGRESS (n=6105) 306/3051 (10.0) 319/3054  (10.4) 0.96 (0.82-1.12) 0.596
Total (n= 29.463) 1089/14730 (7.4) 1210/14733 (8.2) 0.89 (0.82-0.96) 0.006
Cardiovascular mortality
ADVANCE (n=11.140) 211/5569  (3.8) 257/5571 (4.6) 0.82 (0.68-0.98) 0.028 0.58
EUROPA (n=12.218) 215/6110 (3.5) 249/6108  (4.1) 0.86 (0.72-1.03) 0.001
PROGRESS (n=6105) 181/3051 (5.9) 198/3054  (6.5) 0.91 (0.75-1.12) 0.380
Total (n= 29.463) 607/14730 (4.1) 704/14733 (4.8) 0.85 (0.76-0.95) 0.004
Cardiovascular mortality, mi
ADVANCE (n=11.140) 320/5569 (5.7) 370/5571 (6.6) 0.86 (0.74-1.00) 0.045 0.82
EUROPA (n=12.218) 484/6110 (7.9) 596/6108  (9.8) 0.80 (0.71-0.91) <0.001
PROGRESS (n=6105) 230/3051 (7.5) 279/3054   (9.1) 0.82 (0.69-0.96) 0.025
Total (n= 29.463) 1034/14730 (7.0) 1245/14733 (8.5) 0.82 (0.76-0.88) <0.001
Cardiovascular mortality, 
mi, stroke
ADVANCE (n=11.140) 480/5569 (8.6) 520/5571 (9.3) 0.91 (0.80-1.03) 0.135 0.10
EUROPA (n=12.218) 552/6110 (9.0) 664/6108  (10.9) 0.83 (0.74-0.92) 0.001
PROGRESS (n=6105) 458/3051 (15.0) 604/3054  (19.8) 0.74 (0.66-0.84) <0.001
Total (n= 29.463) 1490/14730(10.1) 1788/14733(12.1) 0.82 (0.76-0.87) <0.001
fatal and non-fatal 
stroke
ADVANCE (n=11.140) 215/5569 (3.9) 218/5571 (3.9) 0.98 (0.82-1.19) 0.755 0.02*
EUROPA (n=12.218) 98/6110 (1.6) 102/6108 (1.7) 0.96 (0.73-1.27) 0.774
PROGRESS (n=6105) 307/3051 (10.1) 420/3054 (13.8) 0.72 (0.62-0.83) <0.001
Total (n= 29.463) 620/14730 (4.2) 740/14733 (5.0) 0.82 (0.74-0.92) 0.002
non-fatal mi
ADVANCE (n=11.140) 136/5569 (2.4) 135/5571 (2.4) 1.01 (0.80-1.29) 0.913 0.06
EUROPA (n=12.218) 295/6110 (4.8) 378/6108 (6.2) 0.77 (0.66-0.90) 0.001
PROGRESS (n=6105) 60/3051 (2.0) 96/3054 (3.1) 0.62 (0.44-0.86) 0.003
Total (n= 29.463) 491/14730 (3.3) 609/14733 (4.1) 0.80 (0.71-0.90) <0.001
hospitalization for 
heart failure 
ADVANCE (n=11.140) 197/5569 (3.5) 199/5571 (3.6) 0.98 (0.81-1.20) 0.856 0.04
EUROPA (n=12.218) 63/6110 (1.0) 103/6108 (1.7) 0.61 (0.44-0.83) 0.002
PROGRESS (n=6105) 75/3051 (2.5) 93/3054 (3.1) 0.80 (0.59-1.09) 0.159
Total (n= 29.463) 335/14730 (2.3) 395/14733 (2.7) 0.84 (0.72-0.96) 0.015
Cox regression multivariate analysis was used to calculate hazard ratio’s and 95% CI adjusted for age, 
gender, hypertension, diabetes mellitus, smoking, history of MI, prior revascularization, prior CVA/TIA, use 
of beta-blockers, lipid-lowering agents, anti-platelet agents, diuretics, calcium antagonists, indapamide, 
and perindopril dosage. HR=hazard ratio; CI=confidence interval. MI= myocardial infarction, HF= heart 
failure, Pint = p-value for testing interaction. * In single therapy analysis, P for heterogeneity >0.10.
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study population (63.0 years), resulted in similar treatment effect estimates (age <63: HR 0.78; 
95% CI 0.69–0.87 and age >63: HR 0.85; 95% CI 0.78–0.93). For combinations of concomitant 
medication use compromising platelet-inhibitors, lipid-lowering agents, calcium antagonists, 
 
Figure 2a.  
Treatment effect of perindopril-based regimen in relation to major cardiovascular disease 
(Cardiovascular mortality, MI, stroke) according to baseline blood pressure strata.  
 
 
 
 
figure 2a. Treatment effect of perindopril-based regimen in relation to major cardiovascular disease 
(Cardiovascular mortality, MI, stroke) according to baseline blood pressure strata. (A) Cox regression 
multivariate analysis was used to calculate HRs and 95% CI adjusted the full model. Additionally, P-values 
for interaction were calculated by including an interaction term in the model using systolic and diastolic 
BP levels as continuous variable * treatment. HR, hazard ratio; CI, confidence interval.
Figure 2b. 
Treatment effect of perindopril-based regimen in relation to major cardiovascular disease 
(Cardiovascular mortality, MI, stroke) according to blood pressure reduction levels.  
 
 
figure 2b. Treatment effect of perindopril-based regimen in relation to major cardiovascular disease 
(Cardiovascular mortality, MI, stroke) according to blood pressure reduction levels. (B) Cox regression 
multivariate analysis was used to calculate HRs and 95% CI. These analyses were also corrected for the 
starting systolic and diastolic BP values before application of treatment in all patients. Additionally, 
P-values for interaction were calculated by including an interaction term in the model using systolic and 
diastolic BP reduction levels as continuous variable * treatment. MI, myocardial infarction; HR, hazard 
ratio; CI, confidence interval.
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Treatment effect of perindopril-based regimen in reducing cardiovascular mortality, MI and 
stroke according to baseline characteristics.  
  
figure 3. Treatment effect of perindopril-based regimen in reducing cardiovascular mortality, MI and 
stroke according to baseline characteristics. For combinations of concomitant medication use (none, one, 
two , three, four, all) results were similar (data not shown)
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b-blockers, and diuretics use (none, one, two, three, four, or all of the mentioned medication 
use), HRs were similar as shown for the individual medications and no heterogeneity in the 
treatment effect was observed (Figure 3, data not shown). Results for other study endpoints 
were similar and no heterogeneity was observed. Significant heterogeneity between the stud-
ies was observed for fatal and non-fatal stroke, non-fatal MI, and hospital admission for heart 
failure (Table 3). In a separate analysis of single therapy by perindopril (n = 14.779), by excluding 
all indapamide use, heterogeneity vanished (P = 0.10). Single therapy was no longer associated 
with a significant treatment benefit on fatal and non-fatal stroke (HR 0.96; 95% CI 0.82–1.12). In 
contrast, the effect on non-fatal MI and heart failure admissions increased to, respectively, HR 
0.76 (95% CI 0.66–0.89) and HR 0.71 (95% CI 0.55–0.92).
DisCussion
The present analysis, based on individual data from 29.463 patients, demonstrates that a per-
indopril-based regimen reduces the risk of mortality and major cardiovascular events among 
patients with various levels of cardiovascular risk. Furthermore, the benefit was observed 
across a wide spectrum of baseline BP levels. Therefore, the use of ACE-inhibitors should be 
considered in all patients with established vascular disease or at high-risk of vascular disease 
even in patients with normal BP levels. 
A prior study, a meta-analysis, which studied three trials with similar type of patients with 
CAD (HOPE, EUROPA, and PEACE) showed a consistent treatment effect of ACE-inhibitors in 
reducing cardiovascular events(26). The current analysis demonstrates clear evidence for a con-
sistent cardiovascular protection in a broader range of patients with vascular disease including 
clear benefits in reducing death. These results confirm the generalizability of prior studies in 
separate patients’ groups and support the provision of treatment, not on the basis of arbitrary 
cut-off points for BP, but rather on the assessment of absolute or total vascular risk, which is 
raised in patients with stable CAD, diabetes, and stroke as shown in EUROPA, ADVANCE, and 
PROGRESS. These results are consistent with the findings of the HOPE trial which studied the 
ACE-inhibitor ramipril(5). Significant interaction was observed for fatal and non-fatal stroke as 
a separate outcome (Table 3). Such heterogeneity can be related to differences across trials in 
the study medication, patient selection, or concomitant medication (Table 2). While ADVANCE 
and EUROPA showed low stroke rates and no treatment benefit for stroke, PROGRESS showed 
a significant reduction of 28% in stroke in patients with cerebrovascular disease. Therefore, 
the ACE-inhibitor-based treatment regimen was more effective in reducing recurrent stroke 
(PROGRESS) than in reducing incident stroke in patients without a history of cerebrovascular 
disease (EUROPA and ADVANCE). These benefits were contingent on the BP-lowering effect 
with additional indapamide use. Single therapy with perindopril was not associated with a 
significant reduction in the risk of stroke. Additional interaction was observed on the separate 
outcome of non fatal MI and hospitalization for heart failure (Table 3), mainly caused by the 
lack of benefit in ADVANCE conducted in patients with DM but most without a history of 
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macrovascular disease. In both cases, interaction was observed for cause-specific outcomes; 
however, there was no heterogeneity in reducing the over-arching endpoints of all cause 
mortality or the composite endpoint of cardiovascular mortality, MI, and stroke. In the analysis 
of single perindopril therapy, heterogeneity vanished and the risk reduction by single therapy 
improved for both outcomes. 
Regarding BP, the findings from the BPLTTC already suggested some BP-dependent and 
some BP-independent effects of ACE-inhibitors on the risk of major coronary disease events by 
using tabular data(20,21,27,28). Now, we can confirm these findings in a large combined patient-
level data analysis with access to individual BP measurements. We showed a lower major 
cardiovascular event rate across all strata of systolic and diastolic BPs, although not statistically 
significant for lower systolic BP strata, as well as across the tertiles of BP reduction during run-in. 
Patients with the highest diastolic BP or highest diastolic BP reduction experienced a somewhat 
larger relative treatment effect. Also the patients with the highest BP reduction remained on 
average also at lower BP during follow-up. 
The current study is unique and important because it studies the individual data of large 
trials across a broad range of vascular risk and is focused on one ACE-inhibitor. The use of 
individual data makes the results robust and provides a unique opportunity to detect the sub-
groups of patients who might (or might not) benefit the most from treatment. Furthermore, the 
ACE-inhibitor perindopril has several properties different from other agents in its class, being a 
long-acting (24 h), once-daily lipophilic ACE-inhibitor with high affinity for both tissue and cir-
culating ACE. Tissue ACE affinity is related to specific anti-atherosclerotic and anti-thrombotic 
effects, as well as improvements in endothelial function(29). However, we acknowledge that the 
exact clinical meaning of these properties remains unknown, since ACE-inhibitors have not 
been prospectively compared with each other in studies. 
Several limitations of this analysis can be noted. The trials differed in the patient selection, 
adjunctive therapy, and drug dosage. Therefore, we adjusted for perindopril dosage and inda-
pamide use in all analyses and checked for interaction or heterogeneity among trials. This is 
unlikely to have affected our conclusions as discussed above. Furthermore, we acknowledge 
that the accuracy of the BP measurements in large trials and different hospital settings may be 
questioned. However, any inaccuracy would be equally distributed among randomized treat-
ment groups and unlikely to affect our conclusions. Although, the patient populations in the 
three trials studied were different, it is well established that atherosclerotic vascular disease 
is a generalized process not restricted to a single vascular bed. Therefore, we believe that our 
pooled patient sample is broadly representative of patients with established vascular disease 
at high risk of vascular disease across the world. Despite the differences between the trials, the 
outcomes are consistent with findings from other different meta-analyses on patients without 
heart failure(26,28,30,31) and patients with heart failure(32). 
The currents study demonstrates that perindopril-based regimens (perindopril in part 
of the patients combined with indapamide) reduce death in patients with vascular disease. 
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The consistency of the relative effects across subgroups indicates that the absolute benefits 
conferred by treatment will be determined mainly by each patient’s future risk of vascular 
complications, rather than their initial level of BP alone or other risk factors.
These results support the provision of ACE-inhibitor-based treatment, not on the basis of 
arbitrary cut-off points for BP, but rather on the assessment of vascular risk, which is raised in 
patients with stable CAD, diabetes, and stroke. This approach, based on total cardiovascular 
risk, should form the basis for the recommendations for treatment in the revision of the major 
national and international guidelines. 
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ABsTrACT
Drugs that modulate the renin-angiotensin-aldosterone system (RAAS) play an important 
role in modern cardiovascular prevention strategies. Inhibitors of the RAAS, in particular 
angiotensin-converting enzyme (ACE) inhibitors, have been proven to be beneficial in specific 
patient groups, including patients with hypertension, heart failure, diabetes mellitus and stable 
coronary artery disease. Although clinical trials demonstrated a rather consistent beneficial 
effect of ACE inhibitors across groups of patients based on clinical characteristics, the variability 
in treatment response on the individual patient level is extensive. Recent publications suggest 
that genetic polymorphisms in the RAAS are related to cardiovascular risk. Genetic variability 
also seems associated with the response to ACE inhibitor therapy, and can probably be used 
to tailor treatment. This review discusses several approaches to guide ACE inhibitor therapy in 
patients with coronary artery disease. In addition, the potential impact of pharmacogenetics 
regarding this particular topic is highlighted.
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inTroDuCTion
The renin-angiotensin-aldosterone system (RAAS) plays an integral role in the preservation 
of hemodynamic stability in humans. The RAAS accomplishes this action by regulation of 
extracellular fluid volume, sodium balance and cardiovascular function through direct and 
indirect effects on multiple organ systems(1). The RAAS complements and interacts with other 
vasomotor systems, such as the autonomic nervous system and several vasoactive hormones. 
The RAAS is stimulated in response to threats that compromise blood pressure stability and 
extracellular fluid volume homeostasis.
Components of the rAAs
The RAAS is composed of a cascade of hormones initially triggered by the release of renin from 
the kidney (figure 1) (2,3). The production of renin is raised by a decrease in perfusion of the 
juxtaglomerular apparatus. Renin is a proteolytic enzyme that has a local action in the kidney 
as well as in the circulation upon the substrate angiotensinogen, which is a protein precursor 
that is produced in and secreted by the liver. Angiotensinogen is cleaved by renin to form the 
biologically inactive peptide angiotensin I (A-I). This circulating decapeptide is then efficiently 
converted to the active octapeptide angiotensin II (A-II) by angiotensin-converting enzyme 
(ACE). ACE is a largely tissue-based zinc metalloprotease, mainly generated by the lungs, the 
cell membranes of the kidneys and the endothelial cells of the vasculature. A-II is produced 
in a number of organs, largely locally from locally generated A-I. This local production of A-I 
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Figure 1 
The RAAS cascade. 
 
 
figure 1 The RAAS cascade. 
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involves renal renin taken up at tissue sites, possibly involving a renin receptor (4). This allows 
the tissue renin levels to be higher than expected on the basis of simple diffusion from blood. 
Consequently, A-II levels are often much higher in tissues than in the circulation. Two well-char-
acterized subtypes of A-II receptors mediate the major physiologic actions of A-II in humans: 
these have been termed angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors. Both 
receptors are G-coupled polypeptides, containing approximately 360 amino acids, and have 7 
cell membrane-spanning regions (5,6). In the human body, the AT1 receptor is more widely dis-
tributed and thus more important than the AT2 receptor. Genetically, both receptor subtypes 
share a sequence homology of only 30%. Their genes reside on different chromosomes: the AT1 
receptor on chromosome 3 and the AT2 receptor on the X chromosome (7,9). Stimulating either 
the AT1 or the AT2 receptor results in activation of different signal transduction pathways, 
which results in antagonizing effects (table 1 ). For example, A-II, stimulating the AT1 receptor, 
is a potent vasoconstrictor, whereas AT2 receptor stimulation by A-II results in vasodilation. In 
addition to its vasoconstricting and other effects, A-II can activate AT1 receptors in the adrenal 
gland, which results in synthesis of the steroid hormone aldosterone (10). It is generally accepted 
that excessive stimulation of the AT1 receptor by A-II results in unfavourable effects, whereas 
stimulation of the AT2 receptor is responsible for the beneficial, however in humans less impor-
tant, effects of A-II. The overall effect of activation of the RAAS is an increase in effective circulat-
ing volume, resulting in an increase in perfusion of the juxtaglomerular apparatus. Through this 
phenomenon, the release of renin by the kidney is inhibited: a feedback mechanism. 
Table 1. Effects of stimulation of the most important angiotensin II receptor subtypes: AT1 and AT2
receptor subtypes Effects of receptor stimulation
AT1 receptor Arteriolar vasoconstriction
Aldosterone synthesis
Increased tubular Na+ and Cl- re-absorption and K+ excretion
Increased plasminogen activator inhibitor 1 activity 
Increased sympathetic activity
ADH secretion ® H2O absorption by collecting duct 
Vascular smooth muscle growth
Endothelial dysfunction
Increased connective tissue and LDL accumulation in vascular media
Activation of adhesion molecules and monocyte chemo-attractants
Activation of inflammatory cytokines
Oxidative stress
Enhanced expression of matrix metalloproteinases
AT2 receptor Vasodilation
Anti-proliferation
Decreased renal sodium re-absorption
Decreased myocyte hypertrophy
Decreased cardiac fibrosis
ADH, antidiuretic hormone
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The rAAs: an important drug target 
As mentioned above, the RAAS has an important function in maintaining normal hemodynam-
ics and electrolyte balances. However, excessive or maladaptive stimulation of this hormonal 
cascade can cause pathologic changes in a wide variety of organ systems. For example, 
A-II-induced vasoconstriction of renal efferent arterioles increases glomerular filtration rate, 
which is a protective response to maintain glomerular filtration rate in states of renal hypo-
perfusion. However, an overactive RAAS and thus overproduction of A-II results in extravagant 
vasoconstriction, which is associated with hypertension, renal injury, atherosclerosis and left 
ventricular dysfunction. Understandably, an activated RAAS has become a key therapeutic 
target in patients with cardiovascular disease. The clinically most important examples of phar-
macologic agents that block the RAAS include ACE inhibitors, AT1 receptor blockers (ARBs) and 
aldosterone antagonists. This review focuses on ACE inhibitors. 
ACE inhibitors – Chemical structure 
Although all ACE inhibitors are 2-methylpropionyl- L - proline analogues, they differ from each 
other by their individual chemical structure (11). ACE inhibitors exert their effect on ACE by 
chelating Zn 2+ in the active center. The functional (Zn 2+ -chelating) group binding to ACE 
is the primary structural difference among these agents. Most ACE inhibitors have a carboxyl 
functional group. On the other hand, captopril contains a sulfhydryl group and fosinopril has 
a phosphinyl group (12). Some of the characteristics of these agents may be linked to these 
different binding groups.
ACE inhibitors – Pharmacokinetic Profile
The absorption of ACE inhibitors varies from 25 to 75%, depending on lipophilicity and molecu-
lar size of the specific agent. Food either has no effect or reduces the rate of absorption. Several 
ACE inhibitors are prodrugs: they remain inactive until they are converted into active metabo-
lites in the liver or in the gastrointestinal tissue (12). The peak plasma drug concentrations are 
reached 1 – 4 h after ingestion. Most ACE inhibitors and their metabolites are excreted by the 
renal route, whereas fosinopril, zofenopril, trandolapril and spirapril are eliminated through 
hepatic and renal routes (13). Captopril is eliminated rapidly from the body, which accounts for 
its brief duration of action: less than 6 h. Ramiprilat, which is the active metabolite of ramipril, 
and especially trandolaprilat are eliminated more slowly than other ACE inhibitors. For most 
ACE inhibitors, dose reductions are required in the presence of impaired renal function (13). 
Dose reductions are not necessary in case of use of the aforementioned ACE inhibitors that are 
excreted in both the urine and the bile. 
ACE inhibitors – Pharmacodynamics
ACE inhibitors competitively block the conversion of A-I into A-II. This blockade results in a 
decrease in circulating and local levels of A-II, thus inhibiting the effects of A-II. It is important 
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to realize that ACE inhibitors do not antagonize the AT1 receptor and thus do not inhibit the 
unfavourable effects of A-II completely. In addition to this, it needs to be addressed that when 
ACE is inhibited, formation of A-II is restored, at least in part, due to the reactive renin rise that 
occurs when blocking the A-II-induced negative feedback on renin release. A second beneficial 
effect of ACE inhibitors, in contrast to ARBs, is the increase in bradykinin levels by a decrease in 
transformation of bradykinin in inactive peptides (14). The increase in bradykinin levels induced by 
ACE inhibitors leads to the release of nitric oxide and prostaglandins, resulting in vasodilation (15).
Clinical Effects of ACE inhibitors
As indicated above, ACE inhibitors exert their pharmacologic effect through a decrease in produc-
tion of A-II and an increase in bradykinin levels. The clinically most important short-term effect of 
ACE inhibitors is the decrease in blood pressure. In the long term, ACE inhibitor use has antiprolif-
erative effects, resulting in a reduction of vascular and cardiac hypertrophy, which is an important 
aspect in the pathophysiology of chronic hypertension and heart failure. The remodelling effects 
of ACE inhibitors take place at the level of the small blood vessels, the large arteries and the heart 
(16). These beneficial effects of ACE inhibitors are an important reason to administer these agents 
routinely to patients with heart failure. It is generally believed that ACE activity in the heart and 
the blood vessels contributes both to the development and the progression of atherosclerotic 
vascular disease. It has been presumed for years that ACE inhibitors can improve endothelial 
function and stabilize atherosclerotic plaques. Evidence that ACE inhibitors indeed can delay the 
development of atherosclerosis first originated from research in laboratory animals (17). Recently, 
3 large randomized controlled trials have addressed whether patients with chronic ischemic heart 
disease, but withou t heart failure, would benefit from ACE inhibitor therapy (18). The first trial was 
called Heart Outcomes Prevention Evaluation (HOPE) and in this trial ramipril reduced both mortal-
ity and cardiovascular events in coronary artery disease (CAD) patients (19). Second, the European 
Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) 
demonstrated that perindopril significantly lowered the incidence of a combined cardiovascular 
endpoint, consisting of death, myocardial infarction or cardiac arrest (20). Third, the Prevention of 
Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial concluded that trandolapril 
did not influence cardiovascular outcome or mortality (21). The negative results from the PEACE 
trial were most likely due to a lack of statistical power. A meta-analysis of the HOPE, EUROPA and 
PEACE studies by Dagenais et al. (22) assessed cardiovascular outcomes and total mortality in the 
29.805 patients of these 3 trials, randomly assigned an ACE inhibitor or placebo and followed for a 
mean of about 4.5 years. This analysis demonstrated that ACE inhibitors significantly reduced the 
incidences of all-cause mortality (7.8 vs. 8.9%, p = 0.0004), cardiovascular mortality (4.3 vs. 5.2%, 
p = 0.0002), non fatal myocardial infarction (5.3 vs. 6.4%, p = 0.0001), all stroke (2.2 vs. 2.8%, p = 
0.0004), heart failure (2.1 vs. 2.7%, p = 0.0007) and coronary-artery bypass surgery (6.0 vs. 6.9%, 
p = 0.0036) (22). Based on these findings, the authors of the meta-analysis advised to consider the 
use of ACE inhibitors in all patients with atherosclerotic vascular disease.
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ACE inhibitors versus ArBs
ACE inhibitors have been shown to reduce mortality and cardiovascular morbidity among 
patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart 
failure or both. The VALIANT trial compared the effect of the ACE inhibitor captopril versus the 
ARB valsartan in this population of patients and showed that valsartan is as effective as capto-
pril in patients who are at high risk for cardiovascular events after myocardial infarction (23). In 
patients with vascular disease or high-risk diabetes without heart failure, ACE inhibitors reduce 
mortality and morbidity from cardiovascular causes, but the role of ARBs in such patients is 
unknown. The ONTARGET study compared the ACE inhibitor ramipril, the ARB telmisartan and 
the combination of the 2 drugs (24). The investigators concluded that telmisartan was equivalent 
to ramipril in patients with vascular disease or high-risk diabetes. Telmisartan was as effective 
as captopril in reducing the rates of death and other cardiovascular outcomes (including the 
prevention of myocardial infarction). The combination of the two drugs was associated with 
more adverse events without an increase in benefit. 
ACE inhibition – Clinical Applications and guidelines 
It has been suggested that ACE inhibition has the broadest impact of any class of drugs in car-
diovascular medicine (25). The use of ACE inhibitors is beneficial for patients with heart failure, 
left ventricular dysfunction, after myocardial infarction, hypertension, nephropathy, peripheral 
vascular disease, diabetes mellitus and stroke. Current European Society of Cardiology recom-
mendations on the administration of ACE inhibitors in specific patient categories are listed in 
table 2 (26). These recommendations overlap to a large extent with guidelines for secondary 
prevention for patients with coronary vascular disease, as published by the American Heart 
Association/ American College of Cardiology (27). The latter guidelines advice that ACE inhibitors 
should be given to all patients with a left ventricular ejection fraction < 40% and in those with 
hypertension, diabetes mellitus or chronic kidney disease, unless contraindicated (class I-A rec-
ommendation; for an explanation of classes and levels of evidence please see footnote of table 
2). In addition, administration of an ACE inhibitor should be considered in all other patients with 
coronary and other atherosclerotic vascular diseases (class I-B recommendation). Finally, the 
American guidelines state that the use of ACE inhibitors may be considered among lower-risk 
patients with normal left ventricular ejection fraction in whom cardiovascular risk factors are 
well controlled and revascularization has been performed (class IIa-B recommendation). 
Attempts to guide ACE inhibition
Clinical guidelines are helpful tools to standardize medical healthcare. However, it often remains 
difficult in the clinic to predict cardiovascular risk and the response to a certain ACE inhibitor 
in the individual patient. Nowadays, beneficial effects of medications are frequently evalu-
ated in subgroups of patients in large clinical trials. One important research question behind 
these subgroup analyses is whether a possible heterogeneity in treatment effect in patient 
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subgroups could result in a more specified indication of a certain agent, which may enhance 
the cost effectiveness of drug administration. In CAD patients, the heterogeneity in treatment 
effect by ACE inhibition has been extensively investigated. In the EUROPA trial, the beneficial 
effect of perindopril on the primary endpoint was consistent across predefined subgroups of 
patients with and without hypertension, diabetes mellitus or previous myocardial infarction 
(20). In addition, the treatment benefit was independent of (and not affected by) treatment with 
other cardiovascular agents, including statins, platelet inhibitors and _ -blockers. Based on the 
EUROPA study population, Deckers et al. (28) demonstrated that the relative treatment benefit of 
perindopril was independent of baseline risk levels (high, intermediate and low risk) based on 
clinical characteristics. Some investigators have argued that markers of an activated RAAS, such 
as impaired renal function, may be used as a target for ACE inhibition therapy (29). A subgroup 
analysis of the negative PEACE trial indeed showed that there was heterogeneity in the treat-
ment effect of trandolapril with regard to renal insufficiency (30). However, Brugts et al. (31,32) 
recently demonstrated that the treatment benefit of perindopril was consistent in subgroups 
Table 2. ESC Guidelines on administration of ACE inhibitors in specific patient categories
indication specified level
I. Heart failure - Symptomatic heart failure and reduced LVEF I-A
- LVSD after AMI I-A
- Reduced LVEF (40-45%) without symptoms, no previous MI I-A
- Diastolic heart failure IIa-C
IIa. AMI, first 24 h - High risk patients (heart failure, LVD, no reperfusion, large infarcts) I-A
- All patients IIa-A
IIb. Evolving AMI (>24 h), post MI - Clinical heart failure or asymptomatic LVD (LVEF<45%) I-A
- Diabetes mellitus or other high risk patients I-A
III. Hypertension - To control blood pressure I-A
-  Patients with heart failure, systolic LVD, diabetics, previous MI or 
stroke, high coronary disease risk
I-A
IV. Secondary prevention -  High-risk patients (evidence of cardiovascular disease or diabetes 
and one other risk factor)
I-A
V. To prevent sudden cardiac death - Patients with heart failure  I-A
- Patients with previous MI I-A
- Patients with dilated cardiomyopathy I-B
LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; AMI, acute myocardial 
infarction; LVD, left ventricular dysfunction; MI, myocardial infarction. Class I: Evidence and/or general 
agreement that a given procedure/treatment is beneficial, useful and effective. Class II: Conflicting 
evidence about the efficacy of the treatment. Class IIa: Weight of evidence/opinion is in favor of efficacy. 
Level of Evidence A: Data derived from multiple randomised clinical trials or meta-analyses. Level of 
Evidence B: Data derived from a single randomised clinical trial or non-randomised studies. Level of 
Evidence C: Consensus of opinion of the experts and/or small studies.
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of patients with mild to moderate renal insufficiency with stable CAD is rather consistent across 
various subgroups. Until now, based on prior analyses, no adequate way to guide ACE inhibi-
tion has been demonstrated. Therefore, simple clinical characteristics are not useful to select 
those patients who are most likely to benefit from ACE inhibition in CAD. As an alternative way, 
the relatively new field of pharmacogenetics seems promising to reach a more individualized 
way of treatment.
gEnETiCs: An EVolVing fiElD
CAD is a complex, multifactorial disease, influenced by pathophysiologic conditions as well as by 
genetic and environmental factors (33). Genetic differences are supposed to be an explanation for 
the fact that some people, irrespective of lifestyle and common classical cardiovascular risk fac-
tors, are more prone to the development of CAD than others. A large number of researchers are 
currently investigating the most simple and common forms of variation in the human genome. 
These variations are termed single nucleotide polymorphisms (SNPs) and insertion / deletion 
polymorphisms. SNPs represent single base pair substitutions along a DNA sequence of a candi-
date gene. SNPs occur when a single nucleotide (that is, adinine, thymine, cytosine or guanine) 
in the gene is altered. These alterations arise, by definition, in more than 1% of the population. 
Some polymorphisms may play a role in causing diseases, whereas others do not seem to be of 
real significance. Apart from their relation with the genesis and development of diseases, it has 
been hypothesized that SNPs may predict a patient’s response to medicine as well.
rAAs Polymorphisms and CAD 
Polymorphisms have been associated with varying RAAS activity, for example variance in 
plasma ACE levels, indicative for an increased activity of the RAAS (34). The rationale of intensive 
investigation of these polymorphisms was that an enhanced activity of the RAAS, associated 
with these polymorphisms, might subsequently lead to adverse physiologic consequences 
such as an increased cardiovascular risk. The AT1 receptor A1166C and AGT M235T polymor-
phisms have been associated with increased RAAS activity and CAD risk (35-39), although we 
have to take into account that negative results have been published as well (40-43). The most 
comprehensively studied RAAS polymorphism in relationship with CAD is the ACE insertion/
deletion (ACE I/D) polymorphism. This polymorphism is based on the presence (I) or absence 
(D) of a 287-bp Alu repeat sequence within intron 16 of the ACE gene (44). The D allele has 
been associated with increasing plasma and tissue concentrations of ACE (44,45). A number of 
studies have investigated the influence of the ACE I/D polymorphism on the development of 
CAD, resulting in inconsistent results: several research groups have reported an association 
between the D allele and CAD (46-50), whereas others could not confirm this finding (40,51,52). 
In order to interpret these conflicting results more comprehensively, 3 meta-analyses have 
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been performed. First, Samani et al. (53) carried out a meta-analysis of 15 studies containing 
3,394 patients with myocardial infarction and 5,479 control subjects. The mean odds ratio 
(OR) for myocardial infarction for DD versus ID/II genotypes across all studies was 1.26 (95% CI 
1.11–1.38). The relative risk appeared to be even higher in the Japanese population. The second 
meta-analysis analyzed 46 studies with a total number of 32,715 white individuals (54). Five of 
these 46 studies were regarded as large, since they included more than 600 patients. Although 
the overall results from this meta-analysis were positive (pooled OR = 1.21, 95% CI 1.11–1.32, 
for DD vs. ID/II genotypes), the increased risk was only found in small but not in larger studies 
(small vs. large: p = 0.001 for risk of myocardial infarction). In the meta-analysis by Keavney et 
al. (55), 4.629 myocardial infarction patients from the United Kingdom were compared to 5.934 
controls. The ACE DD genotype was found in 29.4% of the myocardial infarction cases and in 
27.6% of the controls (risk ratio of 1.10, 95% CI 1.00–1.21). In addition to these meta-analyses, 
cardiovascular risk associated with the ACE I/D polymorphism was evaluated in the Genetics 
of Hypertension-Associated Treatment (GenHAT) study (56). This study was a trial in 37.939 
American hypertensive patients who were randomized to antihypertensive treatment, that is, 
chlorthalidone, amlodipine, lisinopril or doxazosin. Primary outcome measures used were fatal 
coronary heart disease and/or nonfatal myocardial infarction. In this large trial, the ACE DD 
genotype was not associated with an increased risk of fatal or nonfatal coronary heart disease 
events (relative risk of DD vs. ID and II: 0.99, 95% CI 0.91–1.07). In conclusion, it is currently 
doubted whether the ACE I/D polymorphism is linked to clinical events (57).
PhArmACogEnETiCs of ThE rAAs: TowArDs TAilorED ThErAPy
Pharmacogenetic profiling may enable physicians: (1) to predict the individual risk of disease 
and (2) to predict a patient’s response to drugs. Pharmacogenetics of the RAAS in relationship 
with ACE inhibition is a novel research field and its clinical value still has to be proven. If indeed 
useful, genetic profiling might become a cost-effective tool for routine use in future clinical 
practice. The clinically most relevant studies are those that investigate ACE inhibitor pharma-
cogenetics in relationship to reduction of clinical endpoints. Several studies have investigated 
ACE inhibitor pharmacogenetics using common clinical endpoints of atherosclerotic disease, 
such as myocardial infarction, ischemic stroke or mortality, as a primary outcome measure. The 
polymorphisms that were most extensively investigated in prior studies were the AGT M235T 
polymorphism and, once again, the ACE I/D polymorphism. Regarding these polymorphisms, 
we highlight the largest studies that investigated the modifying effect of genotype on outcome, 
related to the use of an ACE inhibitor. First, Bis et al. (58) investigated the relationship between 
AGT M235T polymorphism and ACE inhibitor therapy. In this study of treated hypertension 
patients from the United States of America, genotyping was performed in survivors of either 
stroke or myocardial infarction (total n = 324). Compared with nonuse, ACE inhibitor use was 
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associated with a lower risk of stroke among AGT TT homozygotes relative to AGT M carriers 
[OR 0.37 (0.14–0.99) vs. 1.4 (0.88–2.4)]. In this study, genotype did not modify the association 
of ACE inhibitor use with risk of myocardial infarction. Unfortunately, the relevance of this 
particular study is limited by its sample size, its retrospective nature and the fact that duration, 
dose and agent choice were not clearly defined. Another study that investigated major clinical 
endpoints was a substudy of the Perindopril Protection against Recurrent Stroke Study (PROG-
RESS) (59) . PROGRESS was a large trial that evaluated the effects of a perindopril-based blood 
pressure-lowering regimen on the risks of major vascular events in patients with a history of 
stroke. In the original study, perindopril provided significant benefit for stroke reduction when 
used in combination with indapamide, but not when used as a single agent (60. The PROGRESS 
substudy investigated the association between ACE I/D polymorphism and blood pressure as 
well as the effects of ACE inhibitor treatment on the risk of stroke, cardiac events and mortal-
ity. The ACE I/D polymorphism was determined in 5.688 patients. All patients had a previous 
ischemic stroke or transient ischemic attack and were enrolled in various countries in Europe, 
Australia and Asia. When evaluating blood pressure response to perindopril use, there was no 
ACE genotype-specific benefit compared with placebo. In addition to this finding, beneficial 
effects of the study treatment were not associated with a specific genotype. The ACE I/D poly-
morphism was also investigated in the Dutch Rotterdam study. This population-based study of 
primarily hypertensive patients (n = 3.365) investigated the association of ACE genotype, ACE 
inhibitor treatment and total and cardiovascular mortality during a mean follow-up of 7.8 years 
(61). Various ACE inhibitor agents were used in this study. ACE inhibitor use was associated with 
increased total mortality in subjects with the DD genotype. The authors explained their find-
ing as a relative resistance to ACE inhibitor therapy in patients with the DD genotype. Finally, 
cardiovascular risk associated with the ACE I/D polymorphism was evaluated in the aforemen-
tioned GenHAT study, which included 37.939 American hypertensive patients (56). In this study, 
the 6-year hazard rate for fatal and nonfatal coronary heart disease in the DD genotype group 
was not different from the ID and II genotype group stratified by type of treatment. 
To summarize, there are only a few large studies that investigated whether the effects of 
ACE inhibition were modified by different RAAS genotypes. Several potential limitations should 
be mentioned when considering the inconsistent results of the aforementioned studies. One 
of the most important limitations is the lack of statistical power to reveal clinically relevant 
differences. One should realize that most studies that have been performed thus far were not 
designed as pharmacogenetics studies. Second, the interpretation of the observed results is 
complicated by the broad variety in specific medication and doses studied. Finally, we have 
to take into account that CAD is likely to be a polygenetic disease state. All pharmacogenetic 
studies on the complicated RAAS have focused on 1 or 2 polymorphisms, with the rare excep-
tion of a few research groups that investigated multiple SNPs (62,63). It seems reasonable to state 
that the likelihood that a single polymorphism accounts for a substantial ACE inhibitor-related 
response is small. Therefore, future pharmacogenetic analyses should ideally be performed in 
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larger studies of ACE inhibitor treatment that focus on multiple polymorphisms in multiple RAAS 
genes. These studies should aim at integrating information by complete haplotype analysis, 
which is a more comprehensive method of genetic profiling. Haplotypes are a combination of 
alleles at different markers along the same chromosome that are inherited as a unit. Although 
each marker can be analyzed independently of the other marker, it is much more informative 
to analyze markers in a region of interest simultaneously which can explore genetic variants 
underlying various human traits. In this way, a more comprehensive in-depth analysis of RAAS 
polymorphisms in relationship to ACE inhibition can be established, which is more likely to 
discover true positive pharmacogenetic associations. In addition, it is important to emphasize 
that when this new approach to guide ACE inhibitor treatment proves to be successful, it will 
need additional validation in prospective trials before it can truly be accepted as guides to 
clinical practice. 
ConClusions
ACE inhibitors belong to a drug class that is frequently administered to patients with cardio-
vascular disease. The beneficial effects of ACE inhibition have been demonstrated in various 
subgroups of patients. It remains difficult to guide ACE inhibition to those patients who will 
benefit most. Subgroup analyses in ACE inhibitor trials could be used as a way to target therapy 
in patients with CAD. However, due to the shown consistency of the beneficial effect of ACE 
inhibition across various subgroups of CAD patients, this approach has not been useful in guid-
ing therapy. Still, it would be of outmost importance in clinical practice to distinguish those 
patients who will have the highest risk of cardiovascular events. This concept could be used to 
decrease the number needed to treat and thus enhance the cost-effectiveness of drug admin-
istration. Pharmacogenetics is regarded as a novel promising way to enable tailored treatment. 
So far, results from pharmacogenetic studies investigating the RAAS are inconclusive. The addi-
tional value of pharmacogenetics of the RAAS has still to be shown. Large pharmacogenetic 
studies in this field, using an adequate methodology, are therefore necessary. 
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ABsTrACT
Purpose of review: Several trials demonstrated that angiotensin-converting enzyme inhibi-
tors reduce the incidence of cardiovascular events during long-term follow-up in high-risk 
and low-risk patients. Clinical treatment guidelines propose that angiotensin-converting 
enzyme inhibitors should be considered in the routine secondary prevention in the broad 
group of coronary artery disease patients. This review discusses several approaches to guide 
angiotensin-converting enzyme-inhibition therapy to more specific groups of patients that are 
most likely to benefit.
recent findings: The beneficial effect of angiotensin-converting enzyme inhibition has been 
shown to be consistent across subgroups in stable coronary artery disease. Still, large inter-
individual variability in blood pressure response is well documented. It should also be realized 
that the absolute treatment effects are modest. The efficiency and cost-effectiveness of this 
prolonged prophylactic treatment would be significantly enhanced if those patients can be 
distinguished who benefit most. Recently, it was suggested that markers of an activated renin–
angiotensin–aldosterone system might be used to guide angiotensin-converting enzyme-
inhibition therapy.
summary: At the start of treatment, clinical characteristics are not sufficient to distinguish 
between patients who will and will not benefit from angiotensin-converting enzyme inhibitors. 
Although pharmacogenetic research in coronary artery disease is still in a premature stage, it 
may be expected to provide a useful tool in optimizing and individualizing the management of 
angiotensin-converting enzyme-inhibitor therapy in coronary artery disease patients. 
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inTroDuCTion
Clinical treatment guidelines recommend the use of angiotensin-converting enzyme (ACE) 
inhibitors as routine secondary prevention for the broad group of coronary artery disease 
(CAD) patients. As the cost-effectiveness of medications is of increasing importance, there is 
a rapidly growing interest in targeting ACE-inhibitor therapy to specific patient groups that 
are most likely to benefit. Subgroup analyses of large ACE-inhibitor trials have shown a strong 
consistency across subgroups. Simple clinical patient characteristics may therefore be insuffi-
cient to guide ACE-inhibition therapy and new approaches that integrate more patient specific 
characteristics are needed. Pharmacogenetic profiling might be a new promising tool to select 
patients for prolonged prophylactic treatment with ACE inhibitors.
TEXT of rEViEw 
The beneficial effect of ACE inhibition on the incidence of cardiovascular events has been 
examined in three large clinical trials (HOPE, PEACE, EUROPA) consisting of patients with stable 
vascular disease without left ventricular systolic dysfunction or heart failure (1-3). HOPE demon-
strated that ramipril reduced the incidence of cardiovascular events during long-term follow-
up in high-risk patients (1). EUROPA demonstrated a significant reduction in the incidence of 
cardiovascular events by perindopril during long-term follow-up in low-risk patients with 
stable CAD (2). In a comparable patient population, PEACE did not show a significant reduction 
in cardiovascular events and all-cause mortality with trandolapril (3). The PEACE investigators 
suggested that the absence of any treatment benefit was related to a lower baseline risk for 
cardiovascular events of their patients as compared with HOPE and EUROPA, in particular, 
because of the high proportion of patients who had previously undergone revascularization 
or were using more concomitant medication. However, subgroup analyses in EUROPA showed 
that the beneficial treatment effect of perindopril was independent of baseline risk levels but 
also of the use of concomitant therapy (beta-blockers, statins, and platelet-inhibitors) (2,4). Thus, 
the absence of a treatment benefit in PEACE is more likely related to the reduced power caused 
by greater crossover and shorter follow-up.
A recent article proposed an alternative explanation for the observed treatment benefit 
differences between PEACE and EUROPA by arguing that ACE inhibitors are most effective in 
patients with an increased cardiovascular risk and an activated rennin–angiotensin–aldoste-
rone system (RAAS) (5). The investigators argued that markers of an activated RAAS, such as 
left ventricular dysfunction, left ventricular hypertrophy (LVH), and renal function as assessed 
by eGFR or urinary albumin excretion, might be used to target ACE-inhibitor therapy in stable 
CAD. This argument was, in part, based on a recent substudy of the PEACE trial showing hetero-
geneity in the treatment effect of trandolapril (6). Trandolapril was effective in reducing mortal-
ity in patients with an eGFR below 60 ml/min per 1.73 m2. The authors state that an impaired 
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renal function could therefore be used to target ACE-inhibitor therapy. Although we share the 
interest in analyses of subgroups to gain insight into the consistency of the treatment effect 
of ACE inhibitors, we are reluctant to draw conclusions from subgroup analyses of negative 
trials. A recent substudy of the EUROPA trial examined whether the cardio protective effects of 
perindopril were indeed modified by renal function (7,8). The authors conclude that the treat-
ment benefit of perindopril remained consistent and was not modified by renal insufficiency. 
According to this analysis, renal insufficiency could not be used to guide ACE-inhibitor therapy 
in stable CAD. 
Consistency of treatment effect of ACE-inhibitors in stable CAD
Several subgroup analyses have shown that the beneficial treatment effect of ACE inhibitors is 
consistent among subgroups of diabetes mellitus, hypertension, and renal insufficiency, and is 
independent of baseline risk (2,4,7-9). Also when the three ACE-inhibitor trials in stable CAD [Heart 
Outcomes Prevention Evaluation (HOPE), EUropean trial on Reduction Of cardiac events with 
Perindopril in stable coronary Artery disease (EUROPA), Prevention of Events with Angiotensin 
Converting Enzyme (PEACE)] were combined, the results show significant reductions in total 
and cardiovascular mortality, recurrent or new nonfatal myocardial infarction, fatal and non-
fatal strokes, heart failure requiring hospitalization, and coronary artery bypass graft (CABG) 
surgery with no significant differences between the studies (9). In our opinion, this consistency 
makes it impossible to guide ACE-inhibitor therapy based on simple clinical characteristics.
from guidelines towards tailored therapy
Currently, ESC and AHA/ACC clinical treatment guidelines recommend to consider the use 
of ACE inhibitors in the routine secondary prevention measures for the broad group of CAD 
patients with, respectively, a class I (level of evidence A) recommendation for ACE-inhibitor 
therapy in CAD patients with coincident indications for ACE inhibition such as hypertension, 
heart failure, left ventricle (LV) dysfunction, prior myocardial infarction (MI) with LV dysfunction 
or diabetes, and a class IIa recommendation of ACE-inhibitor therapy in all patients with angina 
and proven coronary disease (level of evidence B) in angina pectoris without coexisting indica-
tion for ACE-inhibitor treatment (10,11). The anticipated benefit should be weighed against the 
costs and risks of side-effects and the dose and agent used of proven efficacy for this indication. 
The recommendations that are made in treatment guidelines are usually based on clinical 
trials providing consistent evidence for the prescription of a certain drug to a selected group of 
patients. However, a problem clinicians encounter is that the individual patient in the ward or 
outpatient clinic often does not necessarily fit the exact profile (inclusion criteria and exclusion 
criteria) that was used in those trials. Also, large inter-individual variability in the response to 
treatment is well documented for many drugs. These factors may lead to uncertainty over how 
to decide what is best for the individual patient, and explain the inadequate lower adherence 
to guidelines as demonstrated by the findings of the Euro Heart Survey (12). 
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In light of the growing interest in targeting medications to specific subgroups, knowledge 
of the consistency of the treatment effect by ACE inhibitors is highly important. The ACE 
inhibitors comprise some of the most commonly used drugs in stable CAD. The discovery of 
the determinants of treatment effect may lead to a more specified indication, prescription or 
dosage of a certain drug, which will enhance its cost-effectiveness. The number of patients 
needed to treat could be significantly reduced if we targeted therapy to those patients with 
the highest risk, or those with the highest benefit from therapy. Also, patients are likely to differ 
in the needed dosage or type of drug. As discussed earlier, prior subgroup analyses have not 
resulted in adequate means to target ACE-inhibition therapy in stable CAD. As a better method, 
we propose a new strategy to guide ACE-inhibition therapy by integrating patients’ genetic 
information into treatment decisions.
Pharmacogenetics of ACE-inhibition in stable coronary artery disease
The new field of pharmacogenetics involves examining the genetic determinants of patients’ 
responses to drugs; in other words, understanding why some drugs work better for some 
people than others and why some people are more likely than others to experience side-effects. 
In our opinion, pharmacogenetic profiling might be a new way to reach significant advances in 
individualized cardiovascular medicine. A priori, it is expected for several types of factors that 
they play a role in determining the response of a patient to therapy. Genetic factors causing 
differences in drug absorption and metabolic clearance are also relevant; however; there is yet 
a relatively unexplored field. Genetic factors within the pathway that is directly affected by the 
drug, the renin–angiotensin–aldosterone–system, can affect the efficiency of ACE inhibitors. 
With regard to the RAAS genes, several polymorphisms have been shown to contribute to 
the risk of cardiovascular events. Because of this relationship with cardiovascular risk, these 
genetic variants are now also of utmost interest in pharmacogenetic analyses of ACE-inhibitor 
drug response. We will discuss the most extensively studied RAAS genes, the ACE gene and 
the angiotensinogen (AGT) gene, first with regard to cardiovascular risk associations and then 
following the first pharmacogenetic investigations with ACE-inhibitor drug response.
Angiotensin-converting enzyme gene 
ACE generates angiotensin II from angiotensin I and degrades bradykinin. Several studies have 
demonstrated that genetic polymorphisms in the ACE gene influence plasma and tissue ACE 
levels (13,14). Reasonably, ACE gene polymorphisms could therefore also be related to clinical 
outcomes. This has already been investigated extensively, although with inconclusive results. 
The most frequently studied genetic polymorphism for the association with CAD is the ACE 
insertion/deletion genotype, which is based on the presence (I) or absence (D) of a 287-base pair 
Alu repeat sequence within intron 16. In 1992, the first report of a significant association with 
MI for the ACE DD genotype (OR 1.34) was presented (15). This resulted in an enormous boost 
of research, in which many groups reported positive associations, but others did not. The great 
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inconsistency of the results was mainly related to study sample size and ethnicity. In addition, 
the percentage of ACE variability that can be accounted for by the I/D polymorphism turned 
out to be much lower (<20%) than originally described, and ACE I/D polymorphism-related 
differences in angiotensin I–II conversion could not be observed in vivo (16,17). In a recent large 
meta-analysis, the existence of any substantial association with MI could not be confirmed (18). 
The risk ratio of ACE I/D with MI seems to lie in the range of a 10 % increased risk. Another large 
meta-analysis, in 32.715 patients, concluded that the ACE I/D polymorphism affects plasma ACE 
activity but not blood pressure or the risk of MI (19). Smaller studies tended to show a more 
favourable result for the ACE I/D polymorphism (small versus large studies: P for heterogeneity 
<0.001) (19). The contribution of the ACE I/D polymorphism may therefore be much smaller than 
frequently thought and is not likely to be an important causative factor in CAD. 
With regard to the relation with the response to ACE inhibitors, pharmacogenetic knowl-
edge is limited. In hypertensive patients, studies focused mainly on the relation between ACE 
I/D genotype and the response to ACE inhibitors (20-23). Again the smaller studies tended to be 
favourable for an association of the ACE genotype with response to ACE inhibitors. More recent 
larger studies reported no effect of the ACE I/D genotype on the response of ACE inhibitors 
(24,25). Of special interest are two relatively large pharmacogenetic association analyses. The 
GenHAT study consisted of hypertensive patients aged 55 years or over and concluded that ACE 
I/D genotype group (n=7528, lisinopril) was not a predictor of coronary heart disease (CHD), nor 
did it modify the response to antihypertensive treatment (25). The AASK trial (n=342), however, 
showed that the ACE I/D polymorphism predicted the time-course of blood pressure reduction in 
response to ACE inhibition in African–American patients (26). Regrettably, all studies investigated 
the ACE I/D polymorphism only. To date, we have to conclude that, due to inconsistent results, 
we do not know whether there is a relation of the ACE I/D polymorphism with CAD or response 
to ACE inhibitors. At least, the initial enthusiasm has to be tempered. But we also have to realize 
the enormous gap in information, as nearly all studies focused on only one polymorphism in 
the ACE gene, which determines less than 20 % of ACE variability. The ACE I/D polymorphism 
is just one out of several hundred polymorphisms in the ACE gene and many more need to be 
investigated comprehensively before we can generalize these results to the entire ACE gene. 
Many other polymorphisms are expected to be more important based on functionality, location 
in the gene (promoter, exon) or larger effects on plasma ACE levels as compared with the ACE 
I/D polymorphism, which is located in an intronic region of the ACE gene.
Angiotensinogen gene
More promising results were obtained when studying the AGT gene. Polymorphisms in the 
angiotensinogen (AGT) gene, one of the major structural genes in the RAAS pathway, have 
been associated with hypertension (27-31). The AGT single-nucleotide polymorphisms (SNPs) 
M235T (rs699), M174T (rs4762), and A-6G (rs5051) have been associated with increased serum 
AGT levels (28-31). The AGT SNPs have also been associated with BP-related phenotypes within 
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different ethnic groups (29). The most extensively studied polymorphism is the M235T polymor-
phism, a non synonymous SNP with a functional amino acid change (Met-Thr) located in exon 
2 of the AGT gene (32). Of special interest is the PROCAGENE study (n=615), which showed that 
genetic variation of the AGT (M235T polymorphism) contributed significantly to the presence 
of CHD independently of blood pressure profile in a subset of the Spanish population with 
a high prevalence of CHD (33). In multiple logistic regression analysis, the odds ratio for CHD 
associated with 235T was 1.7 (1.1–2.6). The Group Health study (n=1412) used a haplotype 
approach in the AGT gene to assess the risk of MI (34). The authors did find a significant asso-
ciation of AGT haplotypes with the risk of MI; however, results were not statistically significant 
given the number of tests performed. In this study, the haplotype approach was demonstrated 
as a promising tool in pharmacogenetic research. AGT gene polymorphisms have also been 
studied for associations with the response to ACE inhibitors. Two studies with unspecified ACE 
inhibitors found a similar pharmacogenetic association between treatment and AGT M235T 
(although outcomes were different – stroke risk vs. BP lowering, respectively) (35,36). However, in 
studies of AGT M235T with lisinopril and captopril, no pharmacogenetic effect was observed 
(37,38). In a population-based study, Schelleman et al. (40) studied the M235T polymorphism in 
relation to risk of CVD and drug–gene interaction with antihypertensive treatment but no 
strong associations were found. Of special interest is a pharmacogenetic study that originated 
from the Chinese Community-Based Comprehensive Prevention and Control of Hypertension 
project (40). In this substudy, 1447 hypertensive patients from a 3-year benazepril postmarket 
surveillance trial were genotyped for 14 SNPs in the AGT, and AGT-receptor type 1 genes. The 
AGT rs7079 (C/T) SNP (30-untranslated region) polymorphism was significantly associated with 
the response of diastolic blood pressure (BP) to benazepril (diastolic BP response: 7.4 mmHg 
for CC genotype, 8.9 mmHg for CA, and 10.1 mmHg for AA; P<0.001). The authors concluded 
that variants of the AGT gene are associated with BP response to ACE-inhibition therapy. If 
confirmed in other populations, they will be useful for predicting blood pressure response to 
ACE-inhibition treatment.
The enormous open area for the pharmacogenetics of the RAAS polymorphisms and ACE-
inhibitor treatment effects suggests that, although considerable work with ACE inhibitors has 
been done, potentially important pharmacogenetic combinations remain unexplored. Most 
studies were small and therefore limited by statistical power, which explains a large part of 
the inconsistency in the current literature. Also, inconsistent results appear due to method-
ological limitations (e.g., genotyping or phenotyping errors), study design (lack of haplotype 
approach), and differences between study subjects (ethnicity) or applied medications. Regret-
tably, nearly all studies have investigated only one polymorphism, mainly the ACE I/D or the 
M235T polymorphism, in relation to CAD risk or drug response to ACE inhibitors. Combining 
information from multiple SNPs in the RAAS genes, preferably using the haplotype approach, 
will give much more insight in future pharmacogenetic analyses. Haplotypes are a combination 
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of alleles at different markers along the same chromosome that are inherited as a unit (link-
age disequilibrium patterns). If a disease causal SNP is not in linkage disequilibrium with the 
marker / analyzed SNP, association may be missed by single SNP association tests. It is more 
informative to simultaneously analyze markers in a region of interest that identifies genetic 
variants underlying various human traits. In this way, a more comprehensive in-depth analysis 
of RAAS polymorphisms in relation to ACE-inhibitor therapy is performed, which is more likely 
to unravel a pharmacogenetic association. 
ConClusion
The ACE-inhibitors comprise some of the most commonly used drugs in stable CAD. Several 
approaches to target ACE-inhibition therapy to those patients who are most likely to benefit 
have not resulted in adequate ways to guide the prescription of ACE inhibitors. Such ‘tailored 
therapy’ may be achieved through the integration of genetic information of patients. Phar-
macogenetic research of ACE inhibitors in CAD patients is still in a premature stage, but, if it 
were feasible to construct a pharmacogenetic profile related to cardiovascular risk as well as 
to drug response and side effects, it would be the way to help clinicians to target therapy to 
those patients who will benefit most. Until now, pharmacogenetic results have been largely 
inconsistent and we do not know yet whether this new approach will have an impact on clinical 
practice. 
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ABsTrACT
Background: Angiotensin-converting enzyme (ACE) inhibitors reduce clinical symptoms 
and improve outcome in patients with hypertension, heart failure, and stable coronary artery 
disease (CAD) and are among the most frequently used drugs in these patient groups. For 
hypertension, treatment is guided by the level of blood pressure. In the secondary prevention 
setting, there are no means of guiding therapy. Prior attempts to target ACE-inhibitors to those 
patients that are most likely to benefit have not been successful, mainly due to the consistency 
in the treatment effect in clinical subgroups. Still, for prolonged prophylactic treatment with 
ACE-inhibitors it would be best to target treatment to only those patients most likely to benefit, 
which would considerably lower the number needed to treat and increase cost-effectiveness. A 
new approach for such “tailored-therapy” may be to integrate information on the genetic varia-
tion between patients. Until now, pharmacogenetic research of the efficacy of ACE-inhibitor 
therapy in CAD patients is still in a preliminary stage. 
methods: The PERindopril GENEtic association study (PERGENE) is a substudy of the EUROPA 
trial, a randomized double-blind placebo-controlled multicentre clinical trial which demon-
strated a beneficial effect of the ACE-inhibitor perindopril in reducing cardiovascular morbidity 
and mortality in 12.218 patients with stable coronary artery disease (mean follow-up 4.2 years). 
Blood tubes were received from patients at the beginning of the EUROPA trial and buffy coats 
were stored at −40°C at the central core laboratory. Candidate genes were selected in the 
renin–angiotensin-system and bradykinin pathways. Polymorphisms were selected based on 
haplotype tagging principles using the HapMap genome project, Seattle and other up-to-date 
genetic database platforms to comprehensively cover all common genetic variation within 
the genes. Selection also took into consideration the functionality of SNP’s, location within the 
gene (promoter) and existing relevant literature. The main outcome measure of PERGENE is the 
effect of genetic factors on the treatment benefit with ACE-inhibitors. The size of this pharma-
cogenetic substudy allows detection with a statistical power of 98 % to detect a difference in 
hazard ratios (treatment effect) of 20 % between genotypes with minor allele frequency of 0.20 
(two-sided alpha 0.05). 
Conclusion: The PERGENE study is a large cardiovascular pharmacogenetic study aimed to 
assess the feasibility of pharmacogenetic profiling of the treatment effect of ACE-inhibitor use 
with the perspective to individualize treatment in patients with stable coronary artery disease. 
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inTroDuCTion
The efficacy of ACE-inhibitors to improve outcome has been demonstrated by several large 
clinical trials in patients with cardiovascular disease. These include post-myocardial infarction 
(MI) patients, patients with asymptomatic left ventricular systolic dysfunction, heart failure or a 
history of cerebrovascular disease, and stable CAD patients with preserved left ventricular func-
tion (1-7). Currently, the use of ACE inhibitors is recommended in guidelines on the management 
of hypertension, stable CAD, MI, heart failure, and in the prevention of the progression of renal 
insufficiency in diabetes mellitus related kidney disease (8-10).
The ACE-inhibitor perindopril has been extensively studied in several large, controlled tri-
als in a variety of patient groups with different etiologies (7,11-14). Of these, the EUROPA trial 
is noteworthy, as it is the only secondary prevention study with perindopril in a stable CAD 
population. ACE inhibitor research has also led to a better understanding of pathophysiological 
processes and maladaptive responses in the renin–angiotensin aldosterone system (RAAS). In 
particular, several sub-studies of EUROPA (including PERFECT, PERSPECTIVE and PERTINENT), 
have established that ACE inhibitors have additional effects beyond the blood pressure reduc-
tion alone such as the improvement of endothelial function, improvement of the neurohumoral 
balance, and reduction of unfavorable remodeling of the coronary arteries (15-18).
For hypertension, treatment is guided by the level of blood pressure. In the secondary 
prevention setting, there are no means by which we can guide therapy. Many patients need 
to be treated, and absolute benefits are modest. It is not yet possible to predict in advance 
which patients are to benefit most from treatment. Prior attempts to target ACE-inhibitors to 
those patients who are most likely to benefit have not been successful, mainly because of the 
consistency in the treatment effect in clinically relevant subgroups based on simple clinical 
characteristics (19-21). Treating only those patients who are most likely to benefit would consid-
erably lower the number needed to treat and increase cost-effectiveness. 
A new approach to “tailored-therapy” concerns cardiovascular pharmacogenetics which 
examine the genetic determinants of patients’ responses to cardiovascular drugs; in other 
words, understanding why some drugs work better for some patients than others and why 
some patients are more likely to experience serious side-effects than others. Many (if not all) 
aspects of human physiology have genetic determinants and could therefore be subject to 
pharmacogenetic studies. Several factors may be expected to play a dominant role in deter-
mining the response of a patient to therapy. In particular, in the case of ACE inhibition, genetic 
factors within the RAS pathway are likely to affect its pharmacodynamics and clinical efficacy. 
Genetic factors causing differences in drug absorption and metabolic clearance are also rel-
evant. However, until now there are no strong leads to explore this pharmacogenetically since 
there are no metabolic (CYP) genes linked specifically to ACE-inhibitors, although this might 
also be a relevant pathway to investigate in future research. In previous studies, several genetic 
polymorphisms in RAAS genes have been associated with high blood pressure levels or an 
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increased cardiovascular risk (22,23). Nearly all these studies focused at two polymorphisms, the 
ACE I/D polymorphism and the M235T polymorphism in the angiotensinogen gene. Because of 
limited power, due to limited study sample size, results have been inconsistent and the underly-
ing questions not answered adequately. 
With regard to interaction between genetic factors and treatment response, the results are 
scarce. No prior studies have been performed yet with ACE-inhibitors at a large scale neither in a 
randomized setting nor in stable CAD (one of the major indications of ACE-inhibitors). Another 
important limitation of prior research in cardiovascular pharmacogenetics is the investigation 
of one or two polymorphisms within only one gene, thereby ignoring the well documented 
feedback mechanisms within the RAAS and the fact that there are two angiotensin II receptors 
(AT1 and AT2), which have  counteracting effects also in humans. We suggest that a more com-
prehensive coverage of genetic variation in multiple RAAS genes is needed, by using a correct 
haplotype approach. This is achieved by using the latest information on genetic variation and 
linkage disequilibrium patterns in the selection of haplotype-tagging SNP’s. 
The PERGENE study aims at assessing the feasibility of pharmacogenetic profiling of ACE-
inhibitor therapy in patients with stable CAD. We hypothesized that genetic polymorphism in 
the RAAS and kininogen–kallikrein–bradykinin pathways may influence the treatment effect of 
ACE-inhibitors in patients with stable CAD. The PERGENE study is unique in the field of phar-
macogenetic studies because of the large sample size, a randomized and placebo-controlled 
design, and the availability of extensive and accurate phenotypic data. Also, the extensive selec-
tion of tagging SNP’s in multiple genes in both pathways ensures a new and comprehensive 
coverage of common genetic variation in the candidate genes. A detection of heterogeneity in 
the treatment benefit according to genetic determinants may lead to significant advances in 
tailored therapy and personalized medicine. 
mEThoDs
Study population and design
The PERGENE study is a substudy of the EUROPA-trial that will investigate genetic determi-
nants of the treatment effect of ACE-inhibition in all subjects. The study design of the EUROPA 
trial has been described in detail elsewhere (24). In short, the EUROPA-trial was a randomized, 
double-blind, placebo-controlled clinical trial, with 12.218 patients who were randomized after 
a 4-week run-in period. Mean follow-up was 4.2 years. The study recruited men and women 
aged ≥ 18 years without clinical evidence of heart failure and with evidence of coronary artery 
disease documented by either previous MI, percutaneous or surgical coronary revasculariza-
tion or angiographic evidence of ≥ 70% narrowing of ≥ 1major coronary artery. Men were also 
recruited if they had a history of chest pain and a positive exercise test or regional wall motion 
abnormalities during stress echocardiography or nuclear scintigraphy or with transient perfu-
sion defects during scintigraphy perfusion imaging. 
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The EUROPA study comprised a run-in period of 2 weeks during which patients received 
perindopril 4 mg/day, followed by 2 weeks during which patients received perindopril 8 mg/
day provided that the 4 mg/day of perindopril was well tolerated. At the end of the run-in 
period, a double-blind treatment period of at least 36 months started during which patients 
received either perindopril 8 mg/day or placebo. Patients continued in the study until the last 
patient included completed the follow-up period. Following randomization, patients were seen 
at 3, 6 and 12 months and thereafter at six monthly intervals. Written informed consent was 
obtained from all patients for performing genetic association analyses.
Outcome measures 
The main outcome measure of PERGENE is to assess (1) the effect of RAAS and bradykinin poly-
morphisms on the risk reduction of the primary endpoint of EUROPA (cardiovascular mortality, 
non-fatal MI, or successful resuscitated cardiac arrest) by perindopril. Other outcome measures 
are: (2) the effect of RAAS- and bradykinin polymorphisms on the amount of blood pressure 
reduction by perindopril treatment during the run-in period (in which all patient were treated 
with perindopril), (3) the effect of RAAS- and bradykinin polymorphisms on blood pressure, 
(4) the effect of RAAS- and bradykinin polymorphisms on incident cardiovascular risk during 4 
years follow-up, and (5) the effect of RAAS- and bradykinin polymorphisms in relation to intol-
erance of ACE-inhibitors (Table 1). Other relevant hypotheses can be investigated in the future.
Data collection
A logistic procedure and a high-quality program for the creation of a DNA bio-bank were 
established within the EUROPA trial (Figure 1) (25). Our group defined a successful protocol for 
large-scale blood samples collection in a large multicentre clinical trial. Blood sample were sent 
to a central laboratory (TNO Leiden, the Netherlands), registered, labelled and erythrocytes 
were lyzed. Buffy coats were frozen at −40°C in three aliquots. A total of 10.497 blood tubes of 
participants of the EUROPA-trial were received at the central core laboratory for storage. The 
average time between blood collection and processing was 10.1 (SD 8.4) days. The effect of 
transport time in the EUROPA trial was validated and shown to have no major effect on the DNA 
quality and quantity in a selection of 61 blood samples representing a wide range of transport 
Table 1. Outcome measures of the PERGENE study
Endpoint definitions of PErgEnE
- The effect of genetic factors on the treatment effect by perindopril * 
- The effect of genetic factors on blood pressure reduction levels by ACE-inhibition. 
- The effect of genetic factors in relation to baseline hypertension  **
- The effect of genetic factors on incident cardiovascular risk during 4 years of follow-up.
- The effect of genetic factors on side-effects or intolerance during ACE-inhibitor treatment. 
* Defined as the reduction in the primary endpoint of the EUROPA-trial (cardiovascular mortality, non-fatal 
MI, or successfully resuscitated cardiac arrest). ** pre-defined in the EUROPA study protocol as 160 mmHg 
and/or use of antihypertensives.
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times and countries. In all cases, sufficient amounts of DNA could be isolated and obtained 
from all samples; there was no relation with the region of origin, or with varying environmental 
temperatures, and the amount of DNA isolated. The quality and quantity of the DNA was high 
and well suited for performing genetic association studies (25). 
DNA isolation 
DNA was isolated from the stored white blood cells at the Genetic Laboratory of the depart-
ment of Internal Medicine at the Erasmus MC using an automated isolation process (Hamilton 
liquid handler coupled with Magnetic separator for automated DNA extraction). The isolated 
DNA was stored in matrix 2D tubes and normalized and reformatted, using a pipetting robot, 
and dispensed into 384-well PCR plates using a Caliper Sciclone ALH3000 pipetting robot 
(Caliper LS, Mountain View, CA). 
Candidate genes
The candidate genes to be studied are located in the RAAS and bradykinin pathways as pre-
sented in Figure 2. ACE-inhibitors inhibit the angiotensin-converting enzyme, which is a central 
component of the RAAS and genes in this pathway are therefore highly relevant to be studied 
with respect to treatment effect of ACE-inhibitors. Candidate genes are ACE, angiotensinogen 
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Figure 1. 
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figure 1. Flow diagram of PERGENE study design. htSNP= haplotype-tagging SNP
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(AGT) and the angiotensin II receptor type 1 and type 2 gene (AGTR1, AGTR2). Also, several 
new and relatively unexplored genes in this pathway are of interest to investigate pharma-
cogenetically, such as the renin (REN) and aldosterone synthase genes (CYP11b2). Moreover, 
as ACE cleaves bradykinin into inactive peptides, ACE-inhibitors increase bradykinin, which, 
amongst others, results in anti-remodeling, anti-atherosclerotic and anti-thrombotic effects, 
improves endothelial function and is also a strong vasodilator. As such, bradykinin counteracts 
the effect of angiotensin II in many ways. This pathway has not been explored yet with respect 
to pharmacogenetics, but may be very interesting, especially since the blood pressure effect 
and clinical effect of ACE-inhibitors are likely to be caused by bradykinin (26). Relevant genes in 
this pathway are kallikrein (KLK), kininogen (KNG), and bradykinin-receptors (BDKRB 1 and 2), 
and the resultant endothelial nitric oxide synthase genes (eNOS3). This list of candidate genes 
ensures a comprehensive coverage of relevant genes in the RAAS and bradykinin pathways, 
which have not been investigated to this extent in prior studies. 
Selection of single nucleotide polymorphisms (SNPs)
To cover the genetic variation in these candidate genes more comprehensively, the list of selected 
polymorphisms in the candidate genes were selected using the latest genetic information 
Figure 2.  
Selected candidate genes in the renin-angiotensin-aldosteron-system and bradykinin 
pathways. 
 
 
 
 
 
Figure 3. 
Power estimations for PERGENE 
 
 
figure 2. Selected candidate genes in the renin-angiotensin-aldosteron-system and bradykinin pathways. 
Abbreviations: AGT (angiotensinogen), REN (renin), ACE (angiotensin-converting enzyme), AGTR1, 
(angiotensin receptor type 1), AGTR2 (angiotensin receptor type 2), CYP11B (aldosteron synthase), KLK 
(kallikrein), KNG (kininogen), BDKR1 (bradykinin receptor type 1), BDKR2 (bradykinin receptor type 2), 
eNOS3 (nitric oxide synthase).
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from available databases (such as dbSNP: http://www.ncbi.nlm.nih.gov/SNP and Celera http://
www.celeradiscoverysystem.com) and our own research (WAVE dHPLC; sequencing). The final 
selection will also take into account the haplotype block structure of these SNPs by using 
HapMap data (HapMap Release 23a/ Phase II Mar 08/on NCBI B36 assembly/ DbSNP b126), and 
SeattleSNP databases (see: http://hapmap.jst.go.jp/index.html and http://pga.gs.washington.
edu), as well as Ensemble, PARC and OMIM. Tagging SNP’s are representative SNP’s in a region of 
the gene with high linkage disequilibrium, which makes it possible to identify genetic variation 
without genotyping every SNP within the gene and reach a high coverage of common variation 
within the gene with a limited number of tagging SNP’s. Linkage disequilibrium, as provided 
by the HapMap project, is a measure of the non-random association between polymorphisms 
at different loci and it describes a situation in which some combinations of alleles or genetic 
markers occur with a higher or lower frequency in a population than would be expected from a 
random formation of haplotypes from alleles based on their frequencies. We selected tagging 
SNP’s are within the candidate genes using Caucasian subjects as reference population since 
in the EUROPA-trial more than 99 % of the patients were of Caucasian origin. In Haploview, 
we will use a cut-off of minor allele frequency of 5 % and haplotype frequency of 5% with r2 
of 0.80 to select the haplotype tagging SNP’s within the candidate genes and aim to achieve 
more than 90 % coverage of common genetic variation. The selected area of the gene always 
should contain about 2 kb at the 5′ and 3′ ends of the gene to ensure maximum coverage of 
functionally relevant genetic areas. In selecting these haplotype-tagging SNP’s, we prefer to 
use functional SNP’s or SNP’s located in regulatory or promoter regions of the gene. In addition, 
we will add several relevant SNP’s to our list based on prior literature.
Genotyping
We will use a high-throughput genotyping facility including a Caliper Sciclone ALH 3000 pipet-
ting robot (including a TwisterII, and integrated plate sealer, plate reader OD260/ 280)), and 
polymerase-chain-reaction (PCR) machine (ABI 9700, 2×384)), an ABI7900HT Taqman (running 
2 ng gDNA in 2 μL reactions). The most commonly used genotyping techniques are Taqman 
(for one to ten SNP’s) and Sequenom (for five to 40 SNP’s). Allelic discrimination with Taqman 
Genotypes will be determined in genomic DNA with the Taqman allelic discrimination assay 
(Applied Biosystems, Foster City, CA, USA). Assay-by-Design service (http://www.appliedbio-
systems.com) will be used to set up a TaqMan allelic discrimination assay for the selected SNP’s; 
primer designs are readily available at ABI. The PCR mixture includes 1–2 ng genomic DNA 
in a 2-μl volume and the following reagents: probes (200 nM), primers (0.9 μM), 2× Taqman 
PCR master mix (AB gene, or ABI). Reagents are dispensed in a 384-well plate using the Deerac 
Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR cycling reactions will be performed in 
384-well PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster City, CA). These 
consist of initial denaturation for 15 min at 95 °C and 40 cycles with denaturation for 15 s at 95 
°C and annealing and extension for 60 s at 60 °C. Allele specific fluorescence was then analyzed 
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on an ABI Prism 7900HT Sequence Detection System with SDS v 2.1 (Applied Biosystems) and 
results analyzed by the ABI TaqMan 7900HT using the sequence detection system 2.22 soft-
ware (Applied Biosystems). To confirm the accuracy of the genotyping, 5 % randomly selected 
samples and duplicates will be included and genotyped additionally in the same procedure.
Mass-spectrometric genotyping
Polymerase-chain-reaction (PCR) assays and extension primers for these SNP’s are designed 
with the use of MassARRAY software, version 3.0 (Sequenom). The MassARRAY Designer soft-
ware can automatically design both PCR and MassEXTEND primers for multiplexed assays. Mas-
sEXTEND is a primer extension process designed to detect sequence differences at the single 
nucleotide level. The primer is extended, dependent upon the template sequence, resulting in 
an allele-specific difference in mass between extension products. This mass difference allows 
the data analysis software to differentiate between SNP alleles. PCR and extension reactions 
will be performed according to the manufacturer’s instructions, and extension product sizes 
determined by mass spectrometry (Sequenom). The iPLEX Gold assay uses a single termination 
mix and universal reaction conditions for all SNP’s. The SpectroCHIP arrays are placed into the 
MALDI-TOF mass spectrometer and the mass correlating genotype is determined in real time. 
Duplicate test samples (control plates, 5 %) and six water samples per plate (PCR-negative 
controls), of which the technician is unaware, are included in each 96-well plate. The rate of 
concordant results between duplicate samples will be checked. 
Quality control for the genotyping will further involve testing for Hardy–Weinberg equilib-
rium and repeated laboratory analyses in a random group of samples. To ensure high-quality 
output of SNP, eg. if the call rate or clustering was difficult, the SNP can be tested with alternative 
approaches (e.g. Taqman reaction mixtures) or on the other genotyping platform (Sequenom) 
likewise.
Data analysis 
statistical analysis and statistical power 
In the EUROPA study, 9 % of patients (n=1091) had a major cardiovascular event during follow-
up (cardiovascular death, MI, cardiac arrest: 603 (10 %) placebo and 488 (8 %), 20 % relative 
risk reduction (95 % CI 9–29, p=0.0003). A secondary endpoint (total mortality, non-fatal MI, 
hospital admission for UAP, cardiac arrest) occurred in 16 % of patients (n = 1.947). Event 
rates will be compared between treatment groups and the treatment effect will be compared 
between genotype strata (for each gene). Gene–drug interaction for relative risk reductions will 
be assessed using Cox proportional hazards regression analysis. Hardy–Weinberg equilibrium 
of each polymorphism will be tested using Chi-square analysis. All analyses will be based on 
intention to treat. A p-value of 0.05 or less will be deemed significant. 
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Haplotype analysis 
Haplotypes will be inferred with use of the program Haplo. Stats and R. Haplotype alleles pres-
ent in the patient population were inferred by means of the haplo.em function of the program 
Haplo Stats (http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.html), which com-
putes maximum likelihood estimates of haplotype probabilities.
Sample size considerations
The large study size and large number of events (n>1,000) will provide sufficient power for the 
detection of interaction effects. The size of this pharmacogenetic substudy allows detection 
with a power of 98 % to detect a difference in hazard ratios (treatment effect for the primary 
endpoint) of 20 % between genotypes with minor allele frequency of 0.20, based upon ten-
thousand patients (two-sided alpha 0.05). For other genotype distributions, power will be less 
but for most comparisons still above 80%. For a minor allele frequency of 0.10, statistical power 
is 88 % to detect a difference in treatment effect of 20 % with a two-sided alpha 0.05 (Figure 3).
DisCussion
In European countries and in other countries worldwide, millions of patients have coronary 
artery disease, and are at risk of (recurrent) events, particularly cardiovascular death and myo-
cardial infarction. The ACE-inhibitors are among one of the most frequently prescribed drugs 
for secondary prevention in patients with stable coronary artery disease. Still, in the secondary 
prevention setting, there are no means of guiding therapy to those patients who are most 
likely to benefit. Prior attempts to target ACE-inhibitors have not been successful, largely due 
to because of the consistency in the treatment effect in clinical subgroups (19-21). 
Figure 2.  
Selected candidate genes in the renin-angiotensin-aldosteron-system and bradykinin 
pathways. 
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In the EUROPA study, treatment with perindopril in 50 patients for a period of 4 years (200 
patient years) was required to prevent one major cardiovascular event. The efficiency and the 
cost-effectiveness of such prolonged prophylactic treatment would be significantly enhanced 
if patients who do benefit and those who do not benefit from an ACE-inhibitor could be dis-
tinguished prior to the start of treatment. For this purpose, it is important to study possible 
heterogeneities in the treatment effect to assess whether a variation in the treatment effect 
does exist which then can be used to guide ACE-inhibitor therapy to the patients most likely 
to benefit of treatment. There are several arguments that this variation in treatment effect may 
indeed exist. For instance, the activity of ACE and angiotensinogen (plasma levels) have been 
shown to vary widely between patients, also in the response to an ACE-inhibitor (17). Also, a large 
inter-individual variability in blood pressure response to ACE inhibition is well documented. 
Whether the treatment effect on outcome reduction varies in a similar way is unknown. Until 
now subgroup analysis based on clinical characteristics has resulted in consistent treatment 
effects (19-21). Still, relative and absolute risk reductions with ACE inhibitor therapy vary. A larger 
risk reduction is seen in heart failure patients as compared to coronary artery disease patients 
(19). Therefore it is likely that the treatment effect of ACE-inhibitor use on outcome (in CAD 
patients) will also differ, some patients will benefit others will not. 
The integration of genetic information, which is highly specific for each individual patient, 
can be a new way to identify a true heterogeneity in the treatment effect of ACE-inhibitors. A 
pharmacogenetic profile related to drug response can be used to target ACE-inhibitors to those 
patients most likely to benefit of treatment. It has been suggested that the response to drug 
therapy may be influenced by genetic polymorphisms in different ways. Firstly, variations within 
genes of the RAAS and related systems may influence the disease process (atherosclerosis) and 
inherent differences in accessibility to therapeutic agents such as ACE-inhibitors. Secondly, 
pharmacodynamics may be affected by polymorphisms in the genes of all proteins involved in 
the RAAS and related systems, including receptors and signal transduction molecules. Thirdly, 
variations in drug absorption and metabolic clearance may cause inter-individual variation in 
pharmacokinetics. 
Genetic polymorphisms in the ACE and AGT genes have been shown to influence plasma 
levels of these enzymes, mainly M235T and T174M in AGT and ACE I/D in ACE (27). For example 
with the M235T polymorphism, the TT-allele results in higher levels of angiotensinogen. Regard-
ing intermediate endpoints, a series of relatively small studies (34 to 345 patients) reported 
that polymorphisms in the ACE, angiotensinogen and AGTR1 and AGTR2 genes modulated the 
effects of ACE-inhibitors (28). Such interactions were shown for specific alleles in relation with 
blood pressure reduction, regression of left ventricular hypertrophy, diastolic cardiac function 
and restenosis after percutaneous coronary intervention. 
Regarding outcomes, pharmacogenetic data is very scarce. The PROGRESS study, which 
included 5,688 patients with history of stroke, did not show an association of the ACE I/D poly-
morphism and ACE-inhibition on risk reduction of cerebrovascular events (29). The inconsistency 
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in these studies could be explained by the fact that in virtually all association studies only one 
RAAS gene was taken into consideration, thereby ignoring the well-documented feedback 
mechanisms within the RAAS (30). For instance, the elevated angiotensinogen levels which are 
found in Thr235 homozygotes are accompanied by reduced renin levels, so that the angiotensin 
I-generating capacity returns to normal in those with high angiotensinogen concentrations. In 
addition, the two angiotensin II receptors (AT1 and AT2) that exist in humans have counteract-
ing effects (31,32). Thus, future studies should preferably investigate more than one RAAS gene 
(and ideally all genes: renin, angiotensinogen, ACE, AGTR1, AGTR2, aldosterone synthase). 
The DNA samples collected in the EUROPA study offer a unique opportunity to investigate 
the relations between polymorphisms in genes of the RAAS with the treatment benefit of an 
ACE inhibitor on cardiovascular events in a sufficiently large population and in a randomized 
double-blind setting. As mentioned, the available studies of this subject have been of small size, 
not randomized and therefore, reported relationships may have been due to chance findings. 
Furthermore, the majority of studies so far included only one polymorphism or one gene of the 
RAAS. In contrast, the PERGENE study uses a haplotype tagging selection procedure to compre-
hensively cover all common genetic variations (> 90 %) in the relevant genes within the RAAS 
and bradykinin pathways. We will use the latest information from HapMap Genome project, 
SEATTLE and other up to date genetic information platforms as well as sophisticated software 
packages as Haplostats and R for these haplotype analyses. Haplotypes are a combination of 
alleles at different markers along the same chromosome that are inherited as a unit (linkage 
disequilibrium-patterns). The determination of haplotypes is essential for understanding 
genetic variation and the inheritance of complex diseases. An analysis based on haplotypes is 
advantageous over an analysis based on individual SNPs, especially in the presence of multiple 
susceptibility alleles, and when linkage disequilibria between SNPs are weak. With a single SNP 
approach, associations may be missed when the causal SNP is not in linkage disequilibrium 
with the single analyzed SNP. It is more informative to simultaneously analyze multiple markers 
in a region of interest that identifies genetic variants underlying various human traits; also, 
these markers should be selected based on tagging principles and linkage disequilibrium. By 
combining information from multiple SNP’s in the RAAS and bradykinin pathway genes, a more 
efficient and comprehensive in-depth analysis of common genetic variation in relation to ACE-
inhibitor therapy is performed, which is more likely to unravel any important pharmacogenetic 
associations. 
In summary, this project is unique because of its size, design (randomized-setting), accurate 
phenotypic data, complete coverage of two pathways (RAAS and bradykinin), but also because 
of the extensive and comprehensive SNP selection procedure which involves multiple SNP in 
multiple genes of both pathways with integrating information on the haplotype structure of 
RAAS and bradykinin genes. Until now, attempts to target therapy using simple clinical patient 
characteristics have been insufficient to guide ACE-inhibition therapy and it is not yet possible 
to say in advance who to treat or not (19-21). New and improved approaches that integrate more 
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patient-specific characteristics are needed to target ACE-inhibitor therapy. We will investigate 
whether specific genetic polymorphisms in RAAS genes modify the treatment effect of ACE-
inhibitor therapy. Our aim is to develop a pharmacogenetic profile associated with the benefit 
of ACE inhibitor therapy in patients with stable coronary artery disease. If it is possible to con-
struct a pharmacogenetic profile related to treatment benefit, this could lead to a significant 
reduction of the number of patients needed to treat. It should be realized in this regard that 
the absolute treatment effects are only modest (about 2 % absolute risk reduction) in stable 
CAD patients. In the EUROPA trial, 200 patient years of treatment with perindopril 8 mg was 
necessary to prevent one event in the primary endpoint (number needed to treat 50 for 4 years) 
(7,33). A pharmacogenetic profile related to the benefit of perindopril may enable the selection 
of those patients advance of treatment. Likewise, targeting therapy to only those patients 
that are to benefit will considerably increase the cost-effectiveness of treatment. Until now, 
cardiovascular pharmacogenetic research is still in a premature stage but has the potential to 
enhance personalized medicine and tailored-therapy in cardiovascular medicine. 
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ABsTrACT
Aims: The efficacy of angiotensin-converting enzyme (ACE) inhibitors in stable coronary artery 
disease (CAD) may be increased by targeting therapy to those patients most likely to benefit. 
However, these patients cannot be identified by specific clinical characteristics. We investigated 
whether genetic determinants of treatment benefit of ACE-inhibitors exist which could be used 
to tailor-therapy of ACE-inhibitors by pharmacogenetic profiling. 
methods: In 8907 stable CAD patients participating in the randomized placebo-controlled 
EUROPA-trial, we analyzed 52 haplotype-tagging single nucleotide polymorphisms (SNPs) 
in 12 candidate genes within the pharmacodynamic pathway of ACE-inhibitors. The primary 
outcome was the reduction in cardiovascular mortality, non-fatal myocardial infarction and 
resuscitated cardiac arrest during 4.2 years of follow-up. Multivariate Cox regression was per-
formed with multiple-testing corrections using permutation analysis. 
results: In unadjusted analysis, 7 polymorphisms were significantly associated with the treat-
ment benefit of perindopril. After multivariate adjustment for confounders and correction for 
multiple testing three SNPs, located in the angiotensin-II type I receptor and bradykinin type 
I receptor genes, remained significant. The pharmacogenetic profile, combining these 3 SNPs, 
demonstrated a stepwise decrease in treatment benefit of perindopril with increasing number 
of unfavourable alleles (interaction p<0.0001). A pronounced treatment benefit was observed 
in a subgroup of 73.5% of the patients (HR 0.67; 95% CI 0.56-0.79), without any benefit in the 
remaining 26.5% (HR 1.26; 95% CI 0.97-1.67). An interaction effect of similar direction and 
magnitude, though not significant, was observed in a confirmatory analysis of 1051 patients 
with cerebrovascular disease from the PROGRESS-trial. 
Conclusion: The current study identified genetic determinants of treatment benefit of ACE-
inhibitor therapy. Our findings support the emerging concept of individualized-therapy to 
optimize patients’ benefit by pharmacogenetic profiling. 
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inTroDuCTion
ACE-inhibitors improve outcome in patients with stable CAD and are recommended in clinical 
guidelines on secondary prevention of patients with stable CAD (1-6). Accordingly, ACE-inhibitors 
are among the most frequently used drugs in these patients. However, in a relatively low-risk 
population of stable CAD patients, the absolute treatment benefits are modest (2 % reduction 
of cardiovascular death or myocardial infarction at follow-up) and, therefore, the number of 
patients needed to be treated (50 patients treated for 4 years to prevent 1 event in the EUROPA 
trial) remains relatively high (2). 
To optimally treat patients and to develop ways to guide ACE-inhibitor treatment, it is neces-
sary to identify those patients who are most likely to benefit from therapy. In secondary preven-
tion trials, however, the treatment effect was consistent among all clinical subgroups, and no 
intermediate parameter could be identified to assess the efficacy of ACE-inhibitor therapy (1,7-10). 
Also blood pressure, which guides hypertension treatment, did not predict treatment efficacy 
(10). Thus, it is not feasible to base the selection of patients who respond or not respond to treat-
ment upon clinical characteristics. A new approach may be to integrate information on genetic 
variation in patients. This approach could have a large impact on clinical practice by increasing 
the patient’s chances to benefit from specific therapies and by reducing healthcare costs. 
The direct pharmacodynamic pathways affected by ACE-inhibitors are the renin-angiotensin 
aldosterone system (RAAS) which converts angiotensin-I into angiotensin-II, and the kallikrein-
bradykinin (KB) pathway, which degrades bradykinin into inactive peptides (11-13). We hypoth-
esized that genetic variation in these pathways is associated with the treatment benefit of ACE-
inhibitors. The PERGENE substudy of the EUROPA-trial provides the opportunity to evaluate 
this hypothesis, since the EUROPA trial is a large randomized double-blind placebo-controlled 
clinical trial with complete phenotypic data (2,14,15). We applied a haplotype tagging-SNP pro-
cedure in 12 candidate genes to ensure comprehensive coverage of genetic variation in both 
pathways (15), and replicated our findings in another randomized clinical trial with the same 
ACE-inhibitor (PROGRESS) (16). 
mEThoDs
study populations and design
The PERindopril GENEtic association study (PERGENE) is a sub-study of the EUROPA-trial. The 
designs of both studies were previously described in detail (14,15). In short, the EUROPA-trial 
randomized 12.218 stable CAD patients to perindopril (8 mg/day) or placebo. Perindopril 
was associated with a 20% reduction (HR 0.80; 95% CI 0.71-0.91) in the rate of the primary 
endpoint (composite of cardiovascular mortality, non-fatal MI, or resuscitated cardiac arrest) 
during a mean follow-up of 4.2 years (2). The PERGENE study investigates whether common 
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genetic variation modifies the treatment effect of perindopril (15). Written informed consent 
for performing genetic association analyses was obtained from all patients. The confirmation 
study, the PROGRESS-trial, is a randomized, double-blind, placebo-controlled clinical trial of a 
perindopril based-regimen (perindopril 4 mg or perindopril 4 mg + indapamide 2.5 mg) versus 
placebo in 6105 patients with cerebrovascular disease (16). The PROGRESS study demonstrated 
a reduction in stroke in patients receiving perindopril-based therapy (HR 0.72; 95%CI 0.62-0.83). 
In PROGRESS the observed benefits were contingent on indapamide use. 
Data collection
A DNA bio-bank was established within the EUROPA trial for the PERGENE substudy (17). Blood 
samples were received from 10.060 patients and DNA from 9454 patients was successfully 
isolated using an automated isolation process (Hamilton liquid handler coupled with Magnetic 
separator for automated DNA extraction; Nevada, USA). Similarly DNA was isolated from 5.600 
patients participating in PROGRESS at the INSERM laboratory in Paris, of which 1051 samples 
from Caucasian patients using perindopril alone (single therapy) or placebo were used as 
replication cohort.  
Candidate genes and selection of tagging-snPs
Genes that play an important role in pharmacodynamic pathway of ACE-inhibitors, the RAAS and 
KB systems were selected for this analysis (supplement table 1). The candidate genes were: the 
renin (REN), prorenin receptor, angiotensinogen, angiotensin-converting enzyme, angiotensin-
II receptor type 1 (AT1) and 2, aldosteron synthase, endothelial nitric oxide synthase, kininogen, 
kallikrein, and bradykinin type 1 (BK1) and 2 receptor genes. To cover common variation in 
these 12 candidate genes comprehensively, haplotype-tagging SNPs (ht-SNP) were selected 
based on the linkage disequilibrium (LD) structure as provided by the HapMap (http://www.
hapmap.org) and SeattleSNPs (http://pga.mbt.washington.edu) databases (18). Within these 
genes, plus their flanking regions, a total of 52 ht-SNP’s were identified. The haplotype-tagging 
approach was used because within the genes there is a high level of linkage disequilibrium, and 
this approach allowed us to combine minimal genotyping with comprehensive coverage of 
the genetic variation in the genes (19). The selection criteria of the ht-SNPs also included: minor 
allele frequency ≥5%, r2 < 0.80, haplotype frequency ≥ 1% (HapMap Release 23a/Phase II Mar 
08/on NCBI B36 assembly/ DbSNP b126). In the process of selecting tagging SNPs our aim was 
to include, when available, SNPs for which functionality has previously been described, SNPs 
that gave an amino acid change or SNPs that were located in regulatory regions or intron-exon 
boundaries. Further details of this methodology can be found elsewhere (15). In our population, 
several SNPs were in stronger LD than suggested by the HapMap data, and we defined our set 
of tagging-SNPs by excluding one of the SNPs if there was a pairwise r2 >0.95.   
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genotyping
Taqman allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) and Sequenom 
(San Diego, CA, USA) mass-spectrometric genotyping were used to genotype the selected 
SNPs, according to the manufacturer’s protocols. The assays, primers, and probes for these 
assays are readily available from the Assay-by-Design service (www.appliedbio-systems.com) 
or can be requested from Sequenom for all mentioned rs-numbers (supplementary table 1). 
Quality control for the accuracy of genotyping involved testing duplicates from a randomly 
selected group of samples (5%) for concordance between samples (>99%). Individual SNP call 
rates ranged between 95% and 98%. To ensure DNA quality, only patients who were success-
fully genotyped for more than 90% of the 52 SNPs were included in the analyses (n=8907). 
statistical analysis
We tested whether genotypes and allele frequencies were distributed according to Hardy-
Weinberg equilibrium using a χ2 test.  The treatment effect of perindopril was defined as 
the reduction in the event rate of the primary endpoint of the EUROPA-trial (composite of 
cardiovascular mortality, non-fatal MI, and resuscitated cardiac arrest) and compared between 
genotype strata for each SNP (additive model assumption). Genotype-treatment interactions 
were assessed with Cox proportional hazards regression models. Two models were fitted: one 
included genotype, treatment, and treatment * genotype interaction, with adjustments for 
age and gender; the second model additionally included all covariates that were related to 
the incidence of the primary endpoint in the EUROPA trial (7). The results for the full model are 
presented in all analyses, which are concordant with the age/gender model. 
Multiple testing corrections of treatment interaction terms, and estimation of empirical 
p-values, were implemented using Monte Carlo permutation analysis (10,000 permutations) 
on a per gene basis (20). Permutation was chosen as a method of multiple testing correction, 
because, due to the linkage disequilibrium between the SNPs and the fact that the genes are 
located within a common pathway, Bonferoni adjustment would be too conservative. As we 
corrected for the number of tagging-SNPs within each of the 12 candidate genes, the expected 
number of “chance” findings is correctly calculated as 12 * 0.05 = 0.6 SNPs . Permutated p-values 
below 0.05 were considered to be statistically significant. 
Haplotypes were inferred using the estimation-maximization algorithm implemented in 
haplo.stats (21). The associations between the estimated haplotypes and risk of the primary 
endpoint, taking into account the posterior probabilities of the haplotype estimates, were 
assessed with the GLM function in haplo.stats. The haplotype analysis used the same models as 
the Cox analysis. Global p-values for treatment * haplotype interaction were estimated with a 
likelihood ratio test, comparing models with and without the interaction terms. 
A pharmacogenetic profile based on SNPs that modified the treatment effect was con-
structed by counting the number of unfavourable alleles present. Using these risk profile 
categories, both the relative and absolute risk of events were estimated to assess the treatment 
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benefit according to the number of unfavourable alleles. Baseline clinical characteristics and 
intermediate phenotypes, such as blood pressure at baseline were compared between the 
pharmacogenetic profile categories. In an additional analysis, we assessed the relation between 
patients with <3 and with ≥3 unfavourable alleles and the incidence of the primary endpoint 
during 4 years of follow-up using multivariate Cox regression analysis (full model).
All genetic polymorphisms which modified the treatment effect of perindopril (permutated 
p-value <0.10) in the EUROPA-trial were tested on the corresponding endpoint (cardiovascular 
mortality, MI) in the European subjects from the PROGRESS trial. As the treatment effect in 
PROGRESS was contingent on the combination of perindopril with indapamide (duo-therapy), 
we studied 1051 patients who received perindopril alone (as single therapy) or placebo (16). The 
interaction effects on treatment of the 3 individual SNPs were further verified in a combined 
meta-analysis of the two studies. Results from the two studies were combined using an inverse 
variance method in a random effects model (22,23). Additionally, an analysis of treatment effect 
relative to the overall study effect (as a % change in treatment effect according to genotype) 
was performed to study the modification of treatment benefit in both studies. 
All analyses were conducted using R software. Meta-analyses were conducted using RevMan 
5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Analyses are 
based on intention-to-treat principle. In statistical analyses, a p-value of <0.05 (two-sided) was 
considered significant.
rEsulTs
Baseline characteristics of the PERGENE study population were similar to those of the total 
EUROPA trial and are shown in table 1. All genetic variants were in Hardy-Weinberg equilibrium. 
Complete data on follow-up and covariates was obtained for 8746 patients from the EUROPA 
trial. The mean age was 59.9 (9.3) years and 85.7 % were male. Median follow-up was 4.2 years. 
genetic determinants of treatment benefit of perindopril
In the study, 785 events (9.0%) occurred, 342 in patients with perindopril (8.0 %) and 443 in 
patients receiving placebo (10.2%), and the overall treatment effect was HR 0.80 (95% CI 0.68-
0.92). In unadjusted analysis (without adjustment for confounders or correction for multiple test-
ing), 7 SNPs in 4 genes significantly modified the treatment effect of perindopril: AT1 rs275651 
and rs5182; REN rs2887284, rs10900555 and rs11571082; BK1 rs12050217; AGT rs4762 (table 
2). In the multivariate model with correction for multiple testing, 3 SNPs in 2 genes remained 
significant (AT1 rs275651 and rs5182; BK1 rs12050217). In the bradykinin type I (BK1) receptor 
gene; rs12050217 was a strong modifier of the treatment benefit of perindopril. The hazard ratio 
(95% CI) for the reduction in the event rate of the primary endpoint for AA (62.1%) genotypes 
was 0.64 (0.55-0.78), for AG (33.2%) genotypes 1.02 (0.79-1.29) and for GG (4.7%) genotypes 1.10 
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(0.56-2.19), respectively (Table 2). The p-values for interaction were 0.004 (empirical) and 0.012 
(permuted). In the angiotensin-II type I (AT1) receptor gene, rs275651 and rs5182 significantly 
modified the treatment benefit of perindopril, with empirical p-values of 0.008 and 0.011, and 
permutated p-values of 0.049 and 0.054, respectively. No further associations of treatment 
interaction were observed for the other genes (supplementary table 1a and 1b). 
Haplotype analysis confirmed the association between the identified SNPs and treatment 
effect modification observed in single SNP analysis, as presented in supplement tables 2a and 
2b. In both genes, the haplotype carriers of the unfavourable alleles of the identified SNPs 
significantly modified the treatment benefit of perindopril. No association between these indi-
vidual SNPs and the rate of the primary endpoint in either the placebo or perindopril-treated 
group in separate analysis. 
Table 1. Baseline characteristics of the PERGENE study population (n=8907).
Characteristics Total <3 unfavourable 
alleles
≥ 3 unfavourable 
alleles
Age, years 59.9 (9.3)         59.8 (9.3)         60.0 (9.3)
Gender, % female 14.5         14.5         14.5
Hypertension, % 28.5         28.2         29.1
Diabetes, % 12.7         12.9         12.4
Hypercholesterolemia, % 62.8         63.2         62.2
Smoking, % 14.8         14.4         15.4
Body mass index (>30 kg/m2) , % 21.3         21.4         21.3
Symptomatic CAD, % 25.3         25.4         25.3
Family history of CAD, % 27.2         27.3         27.1
Prior myocardial infarction, % 65.0         65.1         65.0
Prior revascularization, % 54.6         54.9         53.8
Prior CVA or PVD, %  8.9          8.7           9.4
Medication use
   Platelet-inhibitors, % 92.2         92.3         92.0
   Beta-blockers, % 63.2         63.2         63.4
   Lipid-lowering agents, % 55.3         55.9         54.4
   Calcium antagonists, % 31.7         31.3         32.5
Total cholesterol, mg/dl 5.4 (1.1)           5.4 (1.0)           5.4 (1.1)
Creatinine clearance, µmol/l 86.5 (25.7)         86.7 (26.0)         86.1 (25.1)
Randomization, perindopril, % 49.9         49.7         50.3
Systolic BP, mmHg 136.9 (15.2)       136.9 (15.3)       136.8 (15.1)
Diastolic BP, mmHg 81.8 (8.1)         81.8 (8.2)         81.8 (8.1)
BP reduction, mmHg* 8.6 / 4.0         8.6 / 4.0        8.6 / 4.0 
Summary statistics for continuous variables are presented as mean (standard deviation (sd)). Categorical 
data are summarized as percentages. * Blood pressure reduction was calculated as the mean difference in 
blood pressure from screening visit 1 to randomization after the 4 week run-in period of the EUROPA-trial 
in which all patients were treated with the ACE-inhibitor perindopril. BP = blood pressure.
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Pharmacogenetic profile of treatment benefit
When we combined the 3 SNPs in a pharmacogenetic profile (composed of rs12050217, rs5182 
and rs275651) the event rate decreased with an increasing number of unfavourable alleles in 
patients allocated placebo (from 12.2% to 8.1%), while the event rate increased in patients 
allocated perindopril (from 6.3% to 10.4%) (figure 1). A stepwise decrease in treatment benefit 
of perindopril was observed with increasing number of unfavourable alleles (p-value for inter-
action <0.0001). As presented in figure 1, treatment benefit was pronounced in patients with 
0, 1 or 2 unfavourable alleles, while absent in patients with ≥3 unfavorable alleles. Integrating 
these findings in a pharmacogenetic profile composed of the 3 SNPs, we identified 73.5% of the 
population with a more pronounced treatment effect (<3 unfavourable alleles; HR 0.67; 95% CI 
0.56-0.79) and 26.5% of the population not benefiting from treatment (≥3 unfavorable alleles; 
HR 1.26; 95% CI 0.97-1.67) as presented in figure 2. 
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Figure 1.  
Pharmacogenetic profile of identified SNPs and the treatment effect of perindopril in stable 
CAD patients from the EUROPA trial.  
 
  figure 1. Pharmacogenetic profile of identified SNPs and the treatment effect of perindopril in stable CAD 
patients from the EUROPA trial. Multivariate Cox proportional hazard regression analysis was adjusted for 
age, gender, systolic BP, total cholesterol, diabetes mellitus, smoking, BMI, creatinine clearance, history 
of MI, history of stroke or peripheral vascular disease, prior revascularization, symptomatic CAD, and 
family history of CAD. 8726 out of 8746 patients have complete genotype data on rs275651, rs5182 and 
rs12050217. Patient with 0-2 (<3) unfavourable alleles experienced a treatment benefit of perindopril 
(called responders) and patients with 3 or more unfavourable alleles experienced no treatment benefit 
of perindopril (non-responders) as reflected in the HR and 95% CI of treatment benefit. P for interaction 
<0.0001. HR= hazard ratio; CI= confidence interval.
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In the overall study population, patients with ≥3 unfavorable alleles had a slightly lower risk 
compared to patients with <3 unfavorable alleles, although this difference was not statistically 
significant: HR 0.88 (95% CI 0.76-1.04). In patients allocated placebo, HR was 0.68 (95% CI 0.53-
0.84) comparing those with ≥3 versus those with <3 unfavorable alleles, in patients allocated 
perindopril HR was 1.18 (95% CI 0.94-1.49), demonstrating the interaction effect. 
No differences in clinical characteristics, including blood pressure, were observed between 
patients with ≥3 and <3 unfavorable alleles (table 1; all p-values = ns).  Furthermore, no dif-
ferences in intermediate phenotypes were observed in terms of blood pressure and blood 
pressure reduction to during the run-in period of the EUROPA-trial (table 1). Thus, the observed 
treatment interaction cannot be explained by clinical differences between the genotypes. 
Confirmation analysis in ProgrEss
In European patients from PROGRESS (n=1051) receiving perindopril as single therapy or pla-
cebo, no benefit of perindopril was apparent in the overall study group: HR 1.19 (95% CI 0.83 
– 1.71). Minor allele frequencies of the 3 SNPs were similar to those in the PERGENE population.
The treatment effects for the individual SNPs are presented in table 3. The estimates of inter-
action effect on treatment in PROGRESS were of similar direction and magnitude as observed in 
the PERGENE study for all 3 individual SNPs (figure 3), although confidence intervals were wide 
Figure 2.  
Pharmacogenetic profile to predict the treatment effect of perindopril in patients with stable 
coronary artery disease. 
 
  
 
 
 
figure 2. Pharmacogenetic profile to predict the treatment effect of perindopril in patients with stable 
coronary artery disease. Multivariate Cox proportional hazard regression analysis. The pharmacogenetic 
profile combined the patients with <3 unfavourable alleles (responders) and patients with ≥3 
unfavourable alleles (non-responders) as one group (based upon the findings of figure 1). The hazard 
ratios were HR 0.67 (95% CI 0.56-0.79) and HR 1.26 (95% CI 0.97-1.67) for responders and non-responders, 
respectively.
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and statistical interaction terms were not significant in the relatively small PROGRESS cohort 
(n=1051; 526 perindopril vs 525 placebo). In a combined analysis of the interaction effects on 
treatment, the initially observed p-values from EUROPA improved by adding the PROGRESS 
data in meta-analysis for each of the 3 individual SNPs. The combined interaction effects were 
Table 3. Treatment effect of perindopril in Caucasian subjects of the PROGRESS trial (n=1051)
gene snP Allele genotype 
frequencies (%)
single therapy (perindopril only)
1/1    1/2     2/2 Common allele Minor allele*
AT1 receptor Rs275651 A>T 66.2  29.6   4.2 1.04 (0.64-1.70) 1.46 (0.70-3.30)
Rs5182 C>T 29.5  50.8  19.7 1.57 (0.68-3.56) 1.03 (0.64-1.67)
BK1 receptor Rs12050217 A>G 62.6  33.5   3.8 0.95 (0.57-1.61) 1.55 (0.78-3.04)
Overall study effect in PROGRESS (n=1051) was HR 1.19 (0.78-1.79), 526 patients allocated perindopril 
and 525 placebo. Treatment effect analyses are adjusted for full model variables. * heterozygous and 
homozygous minor allele groups combined due to low sample size in the homozygous minor allele group.
Figure 3.  
Replication of findings: meta-analysis of treatment interaction effects.  
 
 
 
  
figure 3. Replication of findings: meta-analysis of treatment interaction effects. The interaction effect 
sizes, standard errors and 95% CI were estimated using Cox proportional hazard regression analysis. 
Results from the two studies were combined in meta-analyses using an inverse variance weighted 
method in a random effects model. Heterogeneity tests for the meta-analysis for all three SNPs were 
non-significant (all I2 = 0 for all three SNPs). Meta-analysis of the interaction effects improved the initially 
observed P-values for all 3 SNPs (p-values 0.003; 0.010; 0.003, respectively).
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HR 1.41; 95% CI 1.12-1.78 (p= 0.003) ; HR 0.78; 95% CI 0.65-0.94 (p= 0.010) ; and HR 1.42; 95% CI 
1.13-1.78 (p= 0.003) for rs275651, rs5182 and rs12050217, respectively. In figure 4 the treatment 
effects relative to the overall study (as a % change in treatment benefit) are presented for both 
studies, demonstrating the strong concordance of the effect modification in both independent 
populations. 
DisCussion
The current study demonstrates that the treatment benefit of ACE-inhibitor therapy by 
perindopril is modified by variation in 2 genes in the renin-angiotensin-aldosterone and 
kallikrein-bradykinin systems: the AT1 receptor gene, and the BK1 receptor gene. Based on the 
pharmacogenetic profile, consisting of these variants, both patients with an enhanced treat-
ment benefit (73.5% of the PERGENE population), and patients with a diminished, if not absent, 
treatment effect (26.5% of the PERGENE population) could be identified. A similar interaction 
of this profile with the treatment effect was observed in the replication cohort from PROGRESS. 
The concept of pharmacogenetics to individualize medicine is emerging rapidly and 
clinically highly relevant as it has the potential to revolutionize future clinical practice. Large 
randomized clinical trials that have DNA available, provide the opportunity to study this 
concept of individualized therapy and several successes of this approach have recently been 
Figure 4.  
Relative treatment effects of perindopril in EUROPA and PROGRESS  
(% change in treatment effect) 
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demonstrated for different cardiovascular agents, such as the activation of clopidogrel (24), 
the risk of rhabdomyolysis associated with statin therapy (25), and anti-coagulation therapy by 
warfarin which prescription is already guided by pharmacogenetics (26). Our study is the first 
large-scale pharmacogenetic analysis of patients with stable CAD randomized to ACE-inhibitor 
therapy versus placebo. The proposed pharmacogenetic profile was directly associated with 
the treatment benefit of ACE-inhibitors. This association was independent of baseline clinical 
characteristics and blood pressure, which is in accordance with previous studies in which 
clinical patient characteristics or subgroup analyses did not reveal any treatment heterogeneity 
(1,2,8-10,27).
The genetic basis of the observed interaction with the treatment response of perindopril 
in stable CAD has not yet been investigated comprehensively. Pharmacogenetic data in this 
area are scarce, mainly because only a few large randomized clinical trials with ACE-inhibitors 
have been conducted in these patients, often without systematic collection of DNA. Yet, solid 
conclusions on modification of the treatment effect can only be drawn from such studies. The 
few previous studies on this subject were mostly small, not randomized or lacking a placebo-
control group and, therefore, the reported relations were largely inconclusive (12,15,27,28). 
Virtually all of these studies focused on the ACE insertion/deletion (I/D) polymorphism, and 
two large studies found no association of this polymorphism with treatment response (29,30). 
The GenHAT study was the first to study the concept of pharmacogenetics of the ACE I/D in 
combination with different anti-hypertensive drugs (30). In our study, the optimal proxy (high 
LD; D’ 1.0; r2 0.9) of the ACE I/D polymorphism, rs4343, also was not related with the treatment 
benefit of perindopril (31). Another limitation of the previous studies was that they focussed on 
one single polymorphism. This, however, does not justify the complexity of the RAAS and KB 
system. Comprehensive coverage of all RAAS and KB system genes, with multiple tagging SNPs 
within multiple candidate genes in a common pathway, is necessary to allow truly meaningful 
conclusions. 
In the main analysis of the EUROPA-trial, treatment with perindopril resulted in a relative risk 
reduction of 20% for the primary endpoint, which was consistent across all clinical subgroups 
(7). In contrast, the subgroups based on the proposed genetic profile have a wide range of 
treatment effects, from patients without unfavourable alleles (11.3% of all patients) with a 54% 
reduction in the primary endpoint during follow-up, via patients with one unfavourable allele 
(29.8%) who experienced a 39% relative risk reduction and patients with two unfavourable 
alleles (32.4%) with a 19% relative risk reduction to which is more comparable to the overall 
study effect in these patients. Patients with <3 unfavourable alleles experience a positive 
treatment effect (responders). At the other end of the spectrum, patients with ≥3 unfavourable 
alleles experienced no benefit (26.5%) from perindopril treatment during four years of follow-
up (non-responders). Refraining from treatment with perindopril in this group of patients, 
which were relatively insensitive or resistant to ACE-inhibitor therapy, may considerably reduce 
healthcare cost and increase overall efficacy of the drug.
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Our findings suggest that the genetic variants modifying the treatment effect of perindopril 
are particularly located in the AT1 and BK1 receptor genes. The SNPs in the AT1 receptor were 
located in the promoter (rs275651) and exon (rs5182), the SNP in the BK1 receptor was located 
in an intron. These three SNPs were tagging SNPs and may either be functional themselves or in 
linkage equilibrium with functional SNPs. So far, functionality of these three SNPs is unknown. 
The AT1 receptor does mediate all the well-known effects of angiotensin II, including vaso-
constriction, water and salt retention, aldosterone synthesis and hypertrophy. The role of the 
B1 receptor, on the other hand, is less well established. Bradykinin is a potent vasodilator that 
also induces anti-atherosclerotic and anti-thrombotic effects, which are mediated by bradyki-
nin type II (B2) receptors. Previous studies indicated that the clinical benefit of ACE-inhibitors 
depends, at least in part, on B2 receptor activation 
(32). B1 receptors are weakly expressed under 
physiological conditions, but are strongly induced in response to pathological conditions and/
or RAAS blockade (33,34). Interestingly, it has been suggested that B1 receptors are directly acti-
vated by ACE-inhibitors (thus resulting in an increase in endothelial NO release, for instance in 
the heart (35,36)), by which they contribute to the cardioprotective effects of ACE-inhibitors, but 
this has not been uniformly confirmed by others (37). Therefore, a more likely possibility is that 
the up-regulated B1 receptors are activated by their endogenous ligand during ACE-inhibition. 
Given the hypotensive (38), cardioprotective (33) and cerebro-protective (39) effects of such activa-
tion, as observed in animals, one might speculate that patients with genetic defects in their 
B1 receptor display a diminished response to ACE-inhibition. Clearly, more work is needed to 
support this concept. 
In our study, the combination of ≥3 unfavourable alleles of the 3 SNPs was associated with 
a lower risk of CVD events in placebo patients, while the risk increased in patients receiving 
perindopril independent of clinical characteristics. It may be suggested that the absolute risk 
of events in these patients was very low, preventing any benefit of the addition of an ACE-
inhibitor. However, the absolute risk for cardiovascular death or myocardial infarction in these 
patients was 7.7 % at 4.2 years follow-up. In an earlier analysis of the EUROPA trial a consistent 
treatment benefit was observed in the lower risk tertile (based on assessment of clinical char-
acteristics) with a risk of only 5.3% in the placebo group as well as in the higher risk tertiles (7). 
We observed no significant differences in clinical characteristics and intermediate phenotypes 
(blood pressure and blood-pressure reduction during the run-in period) between patients with 
<3 and with ≥3 unfavourable alleles. The mechanism underlying the association between the 
proposed genetic profile and treatment response is not explained by clinical characteristics 
and is elucidated by the pharmacogenetic basis of drug response. Unfortunately, no serum or 
plasma was available to measure levels of RAAS factors. Future studies will have to be designed 
to allow such mechanistic studies. 
The current study has some limitations that should be noted. The EUROPA-trial consisted 
of predominantly male Caucasian subjects with stable CAD, which were treated with the ACE-
inhibitor perindopril, which limits the generalizability of the results regarding type of patients 
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and type of agent. New pharmacogenetic studies in different patient populations and with dif-
ferent ACE-inhibitors as well as angiotensinogen II receptor blockers are warranted. In EUROPA 
we studied the ACE-inhibitor perindopril at a dose of 8 mg/day. One could argue that patients 
not benefiting from treatment were undertreated; however, 8 mg/day is a relatively high dose, 
and the effect on blood pressure was similar among patients with <3 and with ≥3 unfavourable 
alleles. The generalizability of our results to other ACE-inhibitors is unknown. Although differ-
ences in pharmacological properties do exist between ACE-inhibitors (40), the clinical relevance 
of these differences is uncertain and different ACE-inhibitors consistently improve outcome in 
trials of patients with CAD or heart failure (1). Although we analysed a large group of patients, 
testing of multiple genes and SNPs might result in chance findings. Correction for multiple 
testing and confirmation in other cohorts is, therefore, necessary, which was performed in the 
current analysis. We have chosen to use a gene-based permutation. Another option would have 
been Bonferonni correction, but it is know that this is an overly conservative method because of 
the strength of our a priori study hypothesis and the linkage disequilibrium between the SNPs 
located within genes in a common pathway. Unfortunately, a replication cohort of similar size 
and design as EUROPA is not available and no other randomized placebo controlled trials with 
DNA are available for replication of our findings in patients with stable coronary artery disease. 
For an initial replication of our findings, we had the opportunity to use data of 1051 European 
patients of PROGRESS studying the same ACE-inhibitor, perindopril, albeit in lower dose of 4 
mg. PROGRESS enrolled patients with cerebrovascular disease. Because the treatment benefit 
in PROGRESS was contingent on the combination with indapamide (2,5 mg) (16), we studied 
patients receiving single therapy with perindopril in the European subjects of PROGRESS, 
which ensures comparability with the EUROPA-trial subjects. Although the PROGRESS sample 
was underpowered, a similar direction and magnitude of the pharmacogenetic interaction was 
observed and the combined p-values were effected by adding the PROGRESS data despite 
smaller size and even improved for all 3 SNP’s, which lends additional support to our findings. 
Still, the interaction terms in PROGRESS were not statistically significant which is related to the 
relatively small number of patients (n=1051, 526 perindopril, 525 placebo) as well as statistical 
confront of replicating interaction terms in general. The current study also has several strengths 
to be noted, as it is unique because of its sample size, design (randomization and a placebo 
group), replication cohort (perindopril), prospective follow-up, accurate phenotypic data and 
comprehensive coverage of multiple genes in the pathway of ACE-inhibitors. 
In conclusion, our finding show that three out of four patients had an enhanced benefit of 
ACE-inhibitor therapy (33% reduction of cardiovascular death of myocardial infarction, up to 
54% in patients without any unfavourable alleles) and one out of four patients experienced no, 
or a markedly diminished, benefit of long term perindopril treatment. By developing a pharma-
cogenetic profile related to treatment response, patients can be selected who are most likely to 
benefit from such treatment in advance. When the feasibility of pharmacogenetic profiling of 
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ACE-inhibitor therapy is confirmed, physicians will be able to predict the response to treatment 
(the exciting concept of responders and non-responders) before the start of prescription. Taken 
together, these pharmacogenetic analyses of clinical trials open up a perspective to individu-
alise preventive therapy in patients with stable CAD (24-26) which may avoid unnecessary treat-
ment, and considerably reduce health care costs by the concept of “individualizing therapy” 
based on genetic data. Moreover, the combination of these trials can be used to identify a 
genetic profile for cardiovascular drugs at large. To further explore this concept, we suggest 
that future randomized clinical trials should integrate a pharmacogenetic approach in the trial 
design to optimize patients’ benefit. 
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supplement table 2a. Haplotype analysis of the angiotensin-II type 1 receptor gene for heterogeneity in 
treatment effect. 
rs
27
56
51
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10
93
57
24
rs
93
14
90
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46
81
44
0
rs
51
82
rs
51
86 Frequency (%) Interaction effect size
OR 95% CI Pint Global P
Angiotensin-II
type 1 receptor A A A C T A 24.3 Base -- 0.11
A A A C C C 15.0 1.42 (0.95-2.12) 0.09
A C A C T A 10.4 1.05 (0.66-1.65) 0.85
A A A C C A 8.2 1.22 (0.72-2.07) 0.46
A C A T T A 7.5 0.82 (0.46-1.44) 0.48
T A G C C A 6.6 1.57 (0.93-2.66) 0.92
A C A T C A 5.9 1.55 (0.92-2.61) 0.10
T A G C C C 5.8 1.94 (1.05-3.59) 0.034
T A G C T A 4.8 1.32 (0.71-2.46) 0.37
Multivariate model adjusted for age, gender, systolic blood pressure, diabetes mellitus, smoking, body 
mass index > 30, creatinine clearance, prior MI, prior stroke or peripheral vascular disease, symptomatic 
CAD, and family history of CAD. OR = odds ratio, CI = confidence interval.
supplement table 2b. Haplotype analysis of the bradykinin type I receptor gene for heterogeneity in 
treatment effect. 
rs
49
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Frequency (%) Interaction effect size
OR 95% CI
Pint Global P
Bradykinin 
type 1 receptor G A C G 36.8 Base --- 0.03
G G T G 21.3 1.48 (1.11-1.97)  0.008
G A C A 17.5 1.00 (0.74-1.35) 0.98
G A T G 14.3 0.88 (0.62-1.24) 0.46
C A C G 10.0 1.23 (0.84-1.79) 0.29
Multivariate model adjusted for age, gender, systolic blood pressure, diabetes mellitus, smoking, body 
mass index > 30, creatinine clearance, prior MI, prior stroke or peripheral vascular disease, symptomatic 
CAD, and family history of CAD. The model included a genotype*treatment interaction term. OR = odds 
ratio, CI = confidence interval.
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ABsTrACT
Aims: To investigate whether genetic variation in the renin-angiotensin-aldosterone system 
(RAAS) and kallikrein-bradykinin pathways are related to blood pressure (BP) and BP-response 
to ACE-inhibitor therapy in stable coronary artery disease (CAD) patients. 
methods: In 8907 stable CAD patients from the EUROPA-trial, 52 haplotype-tagging SNP’s in 
12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated 
for association with hypertension (defined as BP≥160/95 mmHg or use of anti-hypertensives) 
and BP-response to ACE-inhibitors, during a 4 week run-in period. All analyses were adjusted 
for age, gender, body mass index and creatinine clearance and further corrected for multiple 
testing. Significant SNPs were verified in the PROGRESS-trial (n=3571). 
results: Hypertension was present in 28.3% of the patients (n=2526); median BP-reduction 
after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angioten-
sinogen (rs5049) and prorenin receptor (rs2968915; rs5981008) genes were significantly related 
to hypertension. A cumulative profile demonstrated a stepwise increase in the prevalence 
of hypertension, mounting to a two-to-three fold increase in both populations (P for trend 
<0.001). In addition, genetic polymorphisms were identified that significantly modified the 
BP-reduction by ACE-inhibitor therapy, however, the observed BP-differences were small and 
did not remain significant after permutation analysis.
Conclusion: This large genetic association study identified genetic determinants of hyperten-
sion in patients with (cardio-)vascular disease. Genetic variation in the RAAS and kallikrein-
bradykinin pathway did not modify the blood pressure response to ACE-inhibitors. 
Genetic determinants of blood pressure 205
inTroDuCTion
Hypertension is a global public health problem, affecting more than 20% of the adult popula-
tion in western societies and one of the leading causes of cardiovascular, cerebrovascular and 
renal disease (1). It is a multifactorial disease for which several important environmental factors 
have been elucidated as well as several genetic factors (1,2). 
The renin-angiotensin-aldosterone system (RAAS) is an important regulator of blood 
pressure (3,4). An activated RAAS leads to excessive production of angiotensin-II, resulting in 
vasoconstriction, increased sodium and water retention and elevated BP. The various genes 
coding for components of the RAAS are likely candidates that may predispose an individual 
to hypertension. Prior genetic research on the RAAS and hypertension has mainly focused 
on the ACE I/D polymorphism and the M235T polymorphism in the angiotensinogen (AGT) 
gene (5-10). However, the investigation of only one or two polymorphisms within a single gene 
ignores the well-documented feedback mechanisms within the RAAS and the presence of two 
angiotensin II receptors (AT1 and AT2) with counteracting effects (4). A further limitation of most 
prior studies is their limited sample size. This probably underlies the many inconsistencies in 
current literature (4-10). 
RAAS activity may determine, at least in part, the response to blockers of this system, i.e., the 
renin inhibitors, the ACE inhibitors and the AT1 receptor antagonists. Clearly, not all patients 
respond equal to RAAS blockade. For instance, patients with high renin levels are likely to 
respond more strongly to renin inhibitors than patients with low renin levels (11,12). Furthermore, 
since ACE degrades bradykinin, the activity of the kallikrein-bradykinin system is also likely to 
contribute to the effect of ACE inhibitors (4). As the levels and functions of these factors are 
influenced by genetic factors, a relationship between genetics and response to ACE inhibitors 
may exist, and could have clinical impact. 
Currently, pharmacogenetic research in randomized clinical trials of ACE-inhibitors for their 
BP-lowering effect is scarce (13). Therefore, we conducted a large-scale pharmacogenetic associa-
tion analysis in patients of the EUROPA trial randomized to the ACE-inhibitor perindopril versus 
placebo (14,15). To ensure comprehensive coverage of genetic variation in the related hormonal 
systems, a haplotype-tagging approach was used to select single nucleotide polymorphisms 
(SNP’s) in multiple RAAS and kallikrein-bradykinin system genes together (15). As hypertension 
is a strong intermediate phenotype of (cardio)-vascular disease, we investigated two issues: 
whether genetic variation in the cascade of RAAS / bradykinin system genes 1) is related to 
the level of blood pressure and  2) determines the BP-response to ACE-inhibitor therapy. In the 
future, such information could be used to tailor ACE-inhibitor therapy, i.e., to select the patient 
that may respond well to ACE-inhibition. 
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study population and design
The PERindopril GENEtic association study (PERGENE) is a sub-study of the EUROPA-trial; the 
designs of both studies were previously described in detail (15,16). In short, the EUROPA-trial ran-
domized 12.218 stable CAD patients to perindopril (8 mg/day) or placebo. During the 4 week 
run-in period, all patients were treated with perindopril after which randomization started. 
Written informed consent was obtained from all patients for performing genetic association 
analyses. Data from the PROGRESS study were used to verify genetic associations observed in 
PERGENE. In brief, the PROGRESS trial is a randomized, double-blind, placebo controlled clinical 
trial of a perindopril based-regimen (perindopril 4 mg / indapamide 2.5 mg) versus placebo in 
patients with cerebrovascular disease. (17) 
Data collection
A DNA bio-bank was established within the EUROPA trial (18). In total, 10060 blood samples 
from EUROPA participants were received at the central laboratory; DNA from 9454 patients was 
successfully isolated using an automated isolation process (Hamilton liquid handler coupled 
with Magnetic separator for automated DNA extraction, Nevada, USA). 
Candidate genes and selection of tagging-SNP’s
Candidate genes were selected from genes in the RAAS and kallikrein-bradykinin systems. The 
list of candidate genes ensured extensive coverage of relevant genetic targets in both pharma-
codynamic pathways affected by ACE-inhibitors (supplementary table 1). We selected the genes 
encoding for renin, the (pro)renin receptor, angiotensinogen, angiotensin-converting enzyme, 
angiotensin-II receptor type 1 and 2, aldosterone synthase, endothelial nitric oxide synthase, 
kininogen, kallikrein, and bradykinin type 1 and 2 receptor. To cover common variation in these 
candidate genes, linkage disequilibrium (LD) structure was estimated in Haploview using the 
data in the HapMap (http://www.hapmap.org) and SeattleSNPs (http://pga.mbt.washington.edu) 
databases (19). SNPs were then selected utilizing an accepted  haplotype-tagging method (20). We 
have applied the following criteria in the initial selection using HapMap: minor allele frequency 
0.05; r2 0.80; haplotype frequency 1% with the aim to cover at least 90% of the common variation 
within all candidate genes (HapMap Release 23a/Phase II Mar 08/on NCBI B36 assembly/ DbSNP 
b126). Functionality, and the location of SNPs in a regulatory or promoter region of the gene, 
was also taken into consideration. Further details of this methodology can be found elsewhere 
(15). Based on our dataset, several SNPs were in stronger LD than suggested by HapMap, and we 
defined our own final set of tagging SNPs by excluding SNPs with pairwise r2 > 0.95. 
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Genotyping
Taqman allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) and Sequenom 
(San Diego, CA, USA) mass-spectrometric genotyping were used to genotype the selected 
SNPs, according to the manufacturer’s protocols. The assays, primers, and probes for these 
assays are readily available from the Assay-by-Design service (www.appliedbio-systems.com) 
or can be requested from Sequenom for all mentioned rs-numbers (supplementary table 1). 
Quality control for the accuracy of genotyping involved testing duplicates from a randomly 
selected group of samples (5%) for concordance between samples (>99%). Individual SNP call 
rates ranged between 95% and 98%. To ensure DNA quality, only patients who were success-
fully genotyped for more than 90% of the 52 SNPs were included in the analyses (n=8907). 
Taqman allelic discrimination assays of the PROGRESS samples (n=3571) were performed in the 
same laboratory using identical methodology. 
statistical analysis
We tested whether genotypes and allele frequencies were distributed according to Hardy-
Weinberg equilibrium (HWE) using a χ2 test.  Hypertension was defined per original study 
protocol of EUROPA as blood pressure ≥160 mmHg systolic or 95 mmHg diastolic or the use 
of anti-hypertensives at baseline (screening visit 1). This will be referred to as “hypertension” 
throughout the manuscript while it refers to stage 2 (moderate-to-severe hypertension) accord-
ing to JCN-7 criteria (21). The association of the polymorphisms and hypertension was analyzed 
using logistic regression analysis adjusted for age, gender, body mass index and creatinine 
clearance (multivariate model). The BP-reduction by ACE-inhibitor therapy was calculated as 
the BP difference measured at randomization (after 4 weeks of treatment with perindopril in 
all patients) minus BP at screening visit 1 (before treatment). BP-reduction was analyzed using 
z-scores adjusted for age and gender. 
By performing 52 tests, 2.6 SNP’s could be significant due to mere chance. However, most 
likely, the SNPs and genes within the RAAS are not completely independent and the actual 
number of chance findings will be lower. In our study, we present uncorrected, empirical 
P-values and in addition, we present multivariate adjusted p-values which were further cor-
rected for multiple testing by Monte Carlo permutation analysis (n = 10,000 permutations) on 
a per gene basis (22). As we corrected for the number of tagging-SNP’s (tests) within each gene, 
the expected number of false positive “chance” findings is calculated as 12 * 0.05 = 0.6 SNP’s in 
our overall study.
Haplotype analyses were performed for all genes. Haplotypes were inferred using the 
estimation-maximization algorithm implemented in haplo.stats (23). The associations between 
the estimated haplotypes and hypertension, taking into account the posterior probabilities of 
the haplotype estimates, were assessed with the GLM function in haplo.stats. Global p-values 
were estimated using haplo.score function. The same models used in the logistic regression 
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analysis were also utilized in the haplotype analysis (adjustment for age, gender, body mass 
index and creatinine clearance).
All genetic polymorphisms significantly associated with hypertension and delta blood 
pressure during the run-in period (permuted p-value <0.05) in PERGENE were tested on the 
corresponding endpoint in the Caucasian subjects (n=3571) of PROGRESS (58.4% of total study 
population). Results from the two studies on hypertension were combined in a meta-analysis 
using the RevMan software v5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2008). As the sample size of the replication cohort was smaller as compared to 
EUROPA, which limits statistical power to reach significance, we tested the SNPs for significance 
in PROGRESS, and additionally, used as confirmation of the initial findings in EUROPA the con-
cordance of the direction and magnitude of the effect for the SNP’s in PROGRESS. As a main 
criteria of confirmation of our initial findings in PERGENE we tested whether the combined 
p-values improved by adding the PROGRESS data (as compared to the initial p-value observed 
in EUROPA), weighted for standard error. 
We tested the cumulative effect of these identified SNPs by counting the number of unfa-
vorable genotypes (associated with hypertension) present. Using this cumulative profile, we 
assessed the prevalence of hypertension according to the number of unfavorable genotypes 
of identified SNPs as a trend in both cohorts. All analyses were conducted using R-software. 
Analyses were based on intention-to-treat principle. A p-value of <0.05 (two-sided) was con-
sidered significant. 
rEsulTs
Baseline characteristics of the study population are presented in table 1. Hypertension was 
present in 28.3% (n=2526) patients of the PERGENE study. Information on SNP’s and genotype 
frequencies is presented in supplementary table 1. All genetic variants were in HWE. 
hypertension
In unadjusted analysis, that was not corrected for multiple testing 11 polymorphisms were sig-
nificantly related to hypertension. In multivariate analysis 9 polymorphisms, and after the cor-
rection for multiple testing by permutation analysis, 7 polymorphisms remained significantly 
associated with an increased prevalence of hypertension in PERGENE (supplementary tables 
1a, 1b). The individual results for these SNP’s, which were located in the ACE (rs4291), angio-
tensinogen (AGT) (rs5049, rs5051, rs699 and rs943580) and (pro)renin-receptor genes (ATP6A2) 
(rs2968915, rs5981008), are presented in table 2. No further associations were observed for the 
other genes (supplementary tables 1a,b).  
Stratified analysis (86.7% males, 14.3% females) according to gender revealed no relevant 
new associations other than presented above. However, the effect of the (pro)renin receptor 
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gene polymorphisms (located on the X-chromosome) was limited to males (rs2968915: males 
OR 1.14 (95% CI 1.05-1.22); females OR 1.01 (95% CI 0.79-1.29) and rs5981008 males OR 1.12 
(95% CI 1.03-1.22); females OR 0.99 (95% CI 0.77-1.27)). 
Haplotype analysis of the ACE, AGT and (pro)renin receptor genes reinforced the associa-
tions between the individual SNP’s and hypertension, as presented in table 3. Carriers of the 
haplotypes containing the unfavorable alleles of the associated SNPs had a higher prevalence 
of hypertension (Global haplotype p-values per gene: ACE = 0.009; AGT = 0.0004; ATP6A2 = 
0.03, respectively). No further associations were observed for the other genes. 
Verification analysis in ProgrEss 
In PROGRESS, hypertension was present in 2197 subjects (61.4 %). All replicated SNP’s were in 
HWE and occurred with similar allele frequencies as compared to PERGENE. The results of the 
7 individual SNPs in PROGRESS are presented in table 4. In the AGT gene, rs5049 replicated 
significantly (OR 1.15 (95% CI 1.00-1.32) P-value 0.04) and in the ATP6A2 gene, rs2968916 
replicated borderline significantly (OR 1.13 (95% CI 0.99-1.30) P-value 0.06) (table 4). The 
meta-analysis of the associations with hypertension from the two populations (PERGENE and 
PROGRESS) improved the initially observed p-values (and narrowed confidence intervals) for 4 
Table 1 Baseline characteristics of the PERGENE study population (n=8907).
Characteristics
Age, years 59.9 (9.3)
Gender, % female 14.5 
Hypertension, % 28.5
Diabetes, % 12.7 
Hypercholesterolemia, % 62.8 
Smoking, % 14.8 
Body mass index, >30 kg/m2 21.3 
Symptomatic CAD, % 25.3 
Family history of CAD, % 27.2 
Prior myocardial infarction, % 65.0 
Prior revascularization, % 29.3 
Prior CVA or PVD, % 29.1 
Medication use
 Platelet-inhibitors, % 92.2 
 Beta-blockers, % 63.2 
 Lipid-lowering agents, % 55.3 
 Calcium antagonists, % 31.7 
Systolic blood pressure, mmHg 136.9 (15.2)
Diastolic blood pressure, mmHg 81.8 (8.2)
Total cholesterol, mg/dl 5.4 (1.1)
Creatinine clearance, umol/l 86.5 (25.7)
Randomization, perindopril, % 49.9 
Summary statistics for continuous variables are presented as mean (standard deviation).
Categorical data are summarized as percentage.
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of the 7 individual SNP’s as presented in table 4 and figure 1. The combined odds ratios were 
OR 1.10 95% CI 1.04-1.17 (p-value 0.001); OR 1.16 95% CI  1.07-1.25 (p-value 0.002); OR 1.13 
95% CI 1.06-1.21 (p-value 0.001); and OR 1.10 95% CI 1.03-1.17 (p-value 0.001), for rs4291, 
rs5049, rs2968915 and rs5981008, respectively. For these 4 SNPs, the risk estimates in PROG-
RESS (n=3571) were in same direction and of similar magnitude as those from PERGENE. The 
remaining, non-replicating 3 SNPs (rs699, rs5051 and rs943580) were all located in the AGT 
gene. Their genotype frequencies were virtually identical (Table 2) and there was high linking 
disequilibrium between these SNPs (r2 >0.85 for all 3 SNP’s). 
Cumulative effect of identified risk markers 
Combining the unfavorable alleles of the 4 SNPs (rs4291; rs5049; rs2968915; rs5981008) 
resulted in a stepwise increase in the prevalence of hypertension in both populations. As 
compared to the reference category (no unfavorable alleles), each additional unfavorable allele 
Table 3. Associations between haplotypes and moderate to severe hypertension
gene Haplotype Frequency Hypertension Pint Global P
OR 95%CI
Angiotensin
Converting Enzyme 1 1 2 1 2 41.1 % Reference --- 0.009
2 2 1 2 1 37.6 % 1.12 (1.04-1.21) 0.002
1 1 1 2 1  8.1 % 0.95 (0.83-1.08) 0.42
1 2 1 1 1  4.9 % 0.89 (0.76-1.05) 0.18
1 1 1 1 2 3.4 % 1.16 (0.97-1.39) 0.11
1 1 2 2 1 1.3 % 0.93 (0.68-1.27) 0.64
1 2 1 1 2  0.7 % 0.90 (0.58-1.38) 0.62
2 2 1 1 2 0.6 % 0.72 (0.44-1.19) 0.40
Angiotensinogen
1 1 1 1 1 2 1 1 30.3 % Reference --- 0.0004
1 1 1 1 1 1 1 1 22.4 % 0.86 (0.79-0.95) 0.002
1 2 2 2 2 1 1 2 12.9 % 1.12 (1.01-1.25) 0.034
2 2 1 2 1 1 1 2 12.1 % 1.11 (0.99-1.24) 0.06
1 2 1 2 2 1 1 2 9.9 % 0.97 (0.86-1.10) 0.62
1 2 1 2 1 1 2 2 7.0 % 0.94 (0.82-1.09) 0.43
1 1 1 1 1 1 1 2     1.0 % 1.01 (0.72-1.61) 0.94
1 2 1 1 1 2 1 1 0.8 % 1.15 (0.79-1.68) 0.46
1 2 1 2 1 1 1 2 0.7 % 1.08 (0.73-1.61) 0.70
1 2 2 2 2 2 1 1 0.7 % 0.61 (0.39-0.97) 0.04
1 1 1 2 2 1 1 2 0.7 % 1.07 (0.71-1.61) 0.73
(Pro)renin receptor
1 1 88.8 % Reference --- 0.028
2 2 8.9 % 1.12 (1.03-1.22) 0.008
2 1 1.6 % 1.14 (0.94-1.37) 0.18
1 2 0.8 % 0.92 (0.68-1.23) 0.55
Logistic regression analysis adjusted for age, gender, body mass index and creatinine clearance. 
Haplotype allele combinations are based upon the order of the SNPs within the gene as presented in 
supplementary table 1 for each gene.
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Table 4 Meta-analyses of identified SNP’s and effect on moderate to severe hypertension
gEnE PErgEnE
(n=8907)
ProgrEss
(n=3571)
Combined meta-
analysis
OR 95% CI P OR 95% CI P OR 95% CI P
ACE
  Rs4291 1.12  (1.05-1.20) 0.002 1.06 (0.96-1.18) 0.286 1.10 (1.04-1.17) 0.0006
AgT
  Rs5049 1.16 (1.05-1.28) 0.004 1.15 (1.00-1.32) 0.045 1.15 (1.06-1.25) 0.0006
  Rs5051 1.11 (1.04-1.19) 0.002 0.98 (0.87-1.08) 0.570 1.04 (0.92-1.19) Ns
  Rs699 1.11 (1.04-1.18) 0.003 0.99 (0.89-1.10) 0.802 1.06 (0.95-1.18) Ns
  Rs943580 1.13 (1.06-1.21) <0.001 0.96 (0.87-1.07) 0.502 1.05 (0.89-1.23) Ns
ATP6A2
  Rs2968915 1.13 (1.04-1.23) 0.002 1.13 (0.99-1.30) 0.062 1.13 (1.05-1.21) 0.0005
  Rs5981008 1.10 (1.02-1.19) 0.019 1.08 (0.94-1.25) 0.289 1.10 (1.02-1.18) 0.009
Logistic regression analysis adjusted for age, gender, body mass index, and creatinine clearance. Meta-
analyses were conducted using the RevMan 5.0.
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Figure 1 
Meta-analysis of identified SNP’s and moderate to severe hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs4291  
Rs5049  
Rs2968915  
Rs5981008 
figure 1 Meta-analysis of identified SNP’s and moderate to severe hypertension. Overall combined 
p-values: rs4291 (ACE) p = 0.0006 ; rs5049 (AGT) p = 0.0006 ; rs2968915 (ATP6A2) p = 0.0005 and 
rs5981008 p = 0.009 after adding the PROGRESS data in meta-analysis.
Genetic determinants of blood pressure 213
was associated with a 7-8% increase in the prevalence of hypertension (OR 95% CI for trend in 
PERGENE 1.08 (1.05-1.12) P<0.01) and in PROGRESS 1.07 (1.02-1.14) P<0.01). The cumulative 
effect of the 4 SNPs is presented in figure 2. Adding the 3 nonsignifant SNPs to this analysis did 
not alter the ORs (1.07 (95% CI 1.02 – 1.11; P<0.01) in PERGENE and 1.05 (95% CI 1.00-1.11; P 
0.03) in PROGRESS). 
Figure 2
Cumulative effects of the identified SNPs on the prevalence of moderate to severe
hypertension 
PERGENE
OR for trend 1.08; 95% CI 1.05-1.12; P<0.01
PROGRESS
OR for trend 1.07; 95% CI 1.02-1.14; P<0.01
figure 2 Cumulative effects of the identified SNPs on the prevalence of moderate to severe hypertension. 
For the complete SNP profile, OR trend was 1.07 (95% CI 1.02 – 1.11; P<0.01) in EUROPA and OR trend 1.05 
(95% CI 1.00-1.11; P 0.03) in PROGRESS. R2 0.95  rs5051 and rs699; r2 rs5051 and rs943580 r2 0.86
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Blood pressure reduction 
In PERGENE, median systolic and diastolic BP reduction during the run-in period was 10 / 4 
mmHg (mean SBP reduction 8.6 (SD 14.6), mean DBP reduction 4.0 (SD 8.6). Several polymor-
phisms significantly modified the BP reduction by ACE-inhibitor therapy, either in terms of sys-
tolic or diastolic BP (table 5a, 5b respectively). However, the differences across genotypes were 
only modest (1-2 mmHg) and did not remain significant after permutation analysis. Haplotype 
analysis revealed no significant results for BP changes (P >0.05, for all genes) and no further 
verification was sought in the PROGRESS. 
DisCussion
The current pharmacogenetic study is the first to comprehensively investigate a large combi-
nation of genes within a common pathway, the renin-angiotensin-aldosterone and kallikrein-
bradykinin systems, with the aim to elucidate candidate genes that determine baseline BP and/
or the BP-response to ACE-inhibitor therapy in two large patient populations: 8907 patients 
with stable coronary artery disease and 3571 patients with cerebrovascular disease (totalling 
12.478 patients). Our approach was meant to overcome the limitations of prior studies related 
to sample size, and the limited number of genetic targets studied within the complex cascade 
of counter-regulatory RAAS hormones. While we found several important genetic determinants 
of hypertension in the direct pharmacodynamic pathway of ACE-inhibitors in both populations, 
Table 5a. Genetic determinants of systolic blood pressure response to ACE-inhibitor therapy. 
gene snP genotype  
   frequencies (%) 1 / 1
Alleles
1 / 2 2 /2 
Empirical 
P-value*
Permuted
P-value
AGTR1 Rs275651 67.4   / 29.4  /  3.3 9.0 10.0 8.5 0.01 0.08
AGTR1 Rs931490 66.6   / 30.0  /  3.4 8.5 10.0 8.0 0.03 0.15
BDKRB1 Rs4905475 81.2   / 17.7  /  1.1 9.0 10.0 10.0 0.03 0.11
BDKRB2 Rs5225 79.5   / 19.1  /  1.4 9.0 10.0 10.0 0.04 0.14
Overall systolic blood pressure reduction by ACE-inhibitor therapy (perindopril) during the 4 weerk run-in 
period was: 10 mmHg. * z-score adjusted for age and gender.
Table 5b. Genetic determinants of diastolic blood pressure response to ACE-inhibitor therapy. 
gene snP genotype     
  frequencies (%) 1 / 1
Alleles
1 / 2 2 /2 
Empirical 
P-value*
Permuted
P-value
AGT Rs5051 30.7  / 49.0  /  20.3 5.0 4.0 2.5 0.03 0.23
AGT Rs699 30.3  / 49.4  /  20.3 5.0 4.0 2.5 0.04 0.28
AGT Rs10864770 86.3  / 13.0  /   0.6 4.0 4.0 0 * 0.02 0.14
AGT Rs943580 30.7  / 49.2  /  20.1 5.0 4.0 2.5 0.05 0.32
AGTR1 Rs931490 66.6  / 30.0  /  3.4 3.5 5.0 4.0 0.03 0.19
Overall diastolic blood pressure reduction by ACE-inhibitor therapy (perindopril) during the 4 week run-in 
period was: 4 mmHg. * z-score adjusted for age and gender.
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which could be combined in an accumulating risk score, we found no genetic determinants of 
BP-response to perindopril therapy. 
The most important genetic determinants of hypertension in our study were: rs4291 in the 
ACE gene (promoter region), rs5049 in the AGT gene (promoter region), and rs2968915 and 
rs5981008 in the (pro)renin receptor gene (exon, and intron, respectively). Polymorphisms 
within the ACE and AGT genes have been described before to be individually associated with 
BP, although several other studies were negative (4-9). In our analysis particularly the promoter 
polymorphisms within the ACE and AGT genes were related to hypertension as opposed to the 
previously described polymorphisms. The promoter region of a gene determines its transcrip-
tional activity. The strong relation between the (pro)renin-receptor gene and hypertension in 
vascular disease patients is a novel genetic target for hypertension research and our study is 
the first to demonstrate the combined effect of the identified SNPs. 
SNP rs4291 in the ACE gene was related to 8 and 28% increases in the prevalence of hyper-
tension in CAD patients with one or both minor allele(s), respectively (P for trend <0.001). The 
rs4291 polymorphisms is not frequently studied, but was an important haplotype tagging SNP 
in our study. The functional consequences of this polymorphism are currently unknown but 
could, due to its location in the promoter region, involve changes in ACE expression. Interest-
ingly, rs4343, which was included in our study as a direct proxy of the ACE I/D polymorphism 
(high LD: D1 1.0; r2 0.9) (24), did not show any association with hypertension. This is most likely 
due to the fact that the effects of the ACE I/D polymorphism on ACE levels are relatively modest 
(25). Such modest effects of one or more ACE SNPs, in combination with a limited sample size, 
might underlie the conflicting results in the literature with regard to the ACE gene (9). In fact, 
although the effect of rs4291 was identical in the PROGRESS trial patients, it did not reach com-
plete significance in that population. Since the PROGRESS population is 2-3 times smaller, this 
may have been a matter of power. Nevertheless, this implies that even the relation of rs4291 
with hypertension in the 8907 patients of PERGENE needs to be interpreted with care. 
The AGT gene appeared to be an important factor in the etiology of hypertension in CAD 
patients, as evidenced by the significant effect of 4 AGT SNPs in PERGENE. Yet, only one of 
these SNPs (rs5049) replicated significantly in PROGRESS. The rs5049 polymorphism is again 
located in the promoter region and associates with the plasma levels of AGT (8). This is a logical 
explanation for its BP effect, assuming at least that the higher AGT levels are not counterbal-
anced by decreased renin levels (24). Two more widely studied polymorphism in the AGT gene, 
rs699 (M235T) and rs5051 has also been associated with plasma AGT and hypertension (4-10). 
Nevertheless, although the PERGENE study supported these observations, the PROGRESS data 
did not. Again, this could be a matter of power. Alternatively, BP regulation in patients with 
cerebrovascular disease may differ from patients with CAD or the promoter region of the AGT 
gene is more important than frequently assumed which is a novel finding. 
Finally, our data suggest a novel association between the (pro)renin receptor gene and BP in 
Caucasians, both in CAD population as in patients with cerebrovascular disease. One previous 
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study in a Japanese population cohort also reported this association, albeit in men only (27). 
The (pro)renin receptor is a recently discovered component of the RAAS (28,29). It binds both 
renin and its inactive precursor, prorenin, and allows the latter to display enzymatic activity 
(30). Prorenin is believed to be particularly important for angiotensin production at tissue sites 
(31), and the stronger effect of renin inhibitors on renal plasma flow as compared to other RAAS 
blockers may relate to their interference with prorenin-dependent tissue angiotensin produc-
tion (32). (Pro)renin receptors downregulate during RAAS blockade (33), and the current study 
now suggests that these receptors affect blood pressure, possibly via the above mechanism. 
Future studies should investigate the functional role of the 2 polymorphisms within the (pro)
renin receptor gene that associate with hypertension.
Unexpectedly, no role for any of the kallikrein-bradykinin system genes was observed, 
suggesting that the contribution of bradykinin to BP regulation (and the BP response to ACE-
inhibition), at least in this population, is modest or absent. This may of course be different in 
other patient groups, e.g. younger patients (34). 
The cumulative effect of the various RAAS gene polymorphisms (Figure 2) is in agreement 
with the concept of an angiotensin-generating cascade involving the (pro)renin receptor, 
angiotensinogen and ACE. Clearly these 3 genetic components are major determinants of the 
activity of the system and our study is the first to demonstrate the cumulative effect of various 
RAAS components by combining the relevant genetic targets within these pathways. 
The second endpoint of our study was the relation between genetic variation in RAAS and 
BP response to ACE-inhibitors. A large inter-individual variability in the BP response to ACE-
inhibitors exists (as reflected in the standard deviations), which could be related to genetic 
differences between patients. Genetic factors that modify the response to ACE-inhibitors could 
potentially be used to target ACE-inhibitors to those patients most likely to benefit of such 
therapy. In fact, we identified several genetic polymorphisms, mainly in the ACE, AGT and 
AT1 receptor genes, that were related to a significantly different BP response to perindopril in 
PERGENE. However, the absolute differences (mmHg) were small and their clinical usefulness 
is therefore probably limited. Also, these SNP’s did not remain significant after correction for 
multiple testing, in contrast to the hypertension results. 
Pharmacogenetic data on the BP-effect of ACE-inhibitors in randomized placebo-controlled 
clinical trials are very scarce. So far, only 2 studies investigated the BP response in relationship 
with the ACE I/D polymorphism and found no association either (13,35). No other genetic studies 
of the BP response to ACE-inhibitor therapy in a large randomized placebo-controlled setting 
exist to our knowledge. Considering our findings, genetic variation in the RAAS and kallikrein-
bradykinin system genes is not likely to determine the large inter-individual differences in BP 
response. Thus, according to the current results, in the future, hypertensive patients are unlikely 
to be selected for BP response to the ACE-inhibitor treatment on the basis of their RAAS and 
kallikrein-bradykinin system genetic profile. In other studies, the level of BP reduction by ACE-
inhibitor therapy was not related to treatment benefit (36).
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Strengths of the current study are the number of patients, design (particularly randomiza-
tion), extensive phenotypic data, and the comprehensive coverage of multiple genes in a 
common pathway. In both populations, the principal genetic influence on hypertension by 
the RAAS is through the ACE, AGT and prorenin genes. The prorenin receptor and its role in 
hypertension is a novel finding in Caucasians. However, several limitations should be noted. 
The study mainly consisted of male patients, predominantly of European Caucasian descent 
(>99%), with stable CAD. These factors may limit the extent to which these findings can be 
generalized, but they also reduce the chance of confounding due to population stratification. 
Accordingly, the statistical power in female subjects is limited. Furthermore, in both studies, 
blood pressure or blood pressure reduction were no primary outcome measures. BP response 
curves in EUROPA was 5 / 2 mmHg and in PROGRESS 5 / 3 mmHg during follow-up (14,17). The 
BP cut-off of 160/95, by study protocol, refers to stage 2 of the JCN-7 criteria for hypertension 
(21). Changing the definition of hypertension retrospectively would have introduced bias, and 
therefore we kept to the original definition. Additionally, multiple testing is an issue due to the 
possibility of chance findings. Correction is, therefore, necessary and we chose for a gene-based 
permutation analysis as we selected our candidate genes in the pharmacodynamic pathways of 
ACE-inhibitors based on our a priori study hypothesis and selected tagging-SNP’s which are not 
entirely independent. Applying more conservative correction (i.e., Bonferroni) would be overly 
conservative due to the strength of the a priori study hypothesis and might lead to a failure to 
notice real existing differences. The initial analysis revealed 11 significant SNPs out of 52 SNPs. 
After multiple testing corrections, we identified 7 significant findings in PERGENE, which was 
much higher than the expected rate of a chance finding. A replication cohort of similar size, 
patients and design as EUROPA does not exist. For replication of our findings of hypertension as 
an intermediate phenotype in patients with cardiovascular disease, we could use data from the 
PROGRESS-trial which studied the same agent in a population of patient with cerebrovascular 
disease. Unfortunately, a replication cohort of healthy individuals was not available which 
would additionally require an even larger population sample to allow a meaningful statistical 
evaluation. We investigated the 3571 Caucasian subjects of PROGRESS, to ensure comparability 
with the EUROPA-trial subjects. Only the rs5049 (AGT) and rs2968915 (ATP6A2) replicated (bor-
derline) significantly, probably related to the lower minor allele frequency and 2-3 times smaller 
sample size of PROGRESS. Nevertheless, a similar direction and magnitude of the interaction 
effect was observed for 4 SNP’s and combined meta-analysis improved the initial p-values for 
the 4 SNPs. The combined profile of the identified SNP’s supports the cumulative effect of vari-
ous combinations of genetic determinants and hypertension in both populations. This strong 
concordance lends additional weight to our findings. 
In conclusion, although genetic variation in the RAAS and kallikrein-bradykinin pathway 
does determine baseline BP, it does not modify the blood pressure response to ACE-inhibitors. 
Future studies should now investigate whether genetic variation, e.g. in pathways beyond the 
above systems, modifies the response to ACE inhibition.
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ABsTrACT 
Angiotensin-converting enzyme (ACE) inhibitors are among the most commonly used drugs 
in stable coronary artery disease (CAD) as these agents have been proven effective in reducing 
the risk of cardiovascular morbidity and mortality. As with other drugs, individual variation in 
treatment benefit is likely. Such heterogeneity could be used to target ACE-inhibitor therapy 
to those patients most likely to benefit of treatment. However, prior attempts to target ACE-
inhibitor therapy to those patients who are most likely to benefit of such prophylactic treatment 
in secondary prevention using clinical characteristics or the level of baseline risk appeared to 
be not appropriate. A new approach of ‘tailored-therapy’ could be to integrate more patient-
specific characteristics such as the genetic information (DNA) of patients. Pharmacogenetic 
research of ACE-inhibitors in coronary artery disease patients is in a formative stage and studies 
are limited. The PERindopril GENEtic association study is a large pharmacogenetic sub-study 
of the randomized placebo-controlled EUROPA-trial, aimed to assess the feasibility of pharma-
cogenetic profiling of ACE-inhibitor therapy by perindopril. This review summarizes the recent 
findings of the PERGENE-study and pharmacogenetic research of the treatment benefit of 
perindopril in stable coronary artery disease. 
Tailored-therapy by pharmacogenetics 229
AngioTEnsin-ConVErTing EnZymE inhiBiTors
ACE-inhibitors competitively block the conversion of angiotensin-I (AT-1) into angiotensin-II (AT-
II). This blockade results in a decrease in circulating and local levels of AT-II, thereby inhibiting 
the main effects of AT-II: arteriolar vasoconstriction and water and salt retention. ACE-inhibitors 
do not antagonize the AT-1 receptor and thus do not inhibit the unfavorable effects of AT-II 
completely. Furthermore, the formation of AT-II is restored, at least partially, due to the reactive 
rise in rise that occurs when the renin release is blocked by the A-II-induced negative feedback. 
A second beneficial effect of ACE-inhibitors, and a main difference with angiotensin-receptor 
antagonists, is the increase in bradykinin levels by a decrease in transformation of bradykinin in 
inactive peptides (1,2). The increase in bradykinin levels induced by ACE inhibitors leads to the 
release of nitric oxide and prostaglandins, with vasodilative effects on vessel walls (2,3). 
The efficacy of ACE-inhibitors has been demonstrated by several large clinical trials in patients 
at high-risk of cardiovascular disease, including those with left ventricular ejection fraction of 
<40% after myocardial infarction (MI), heart failure or a history of cerebrovascular accidents, 
and those with a lower risk of cardiovascular events, in particular patients with stable coronary 
artery disease without overt heart failure (4-10). Nowadays, the use of ACE inhibitors is recom-
mended in guidelines on the management of hypertension, stable CAD, MI, heart failure, and 
in the prevention of the progression of renal insufficiency in diabetes mellitus related kidney 
disease (11-13). In particular ACE-inhibitors are recommended as secondary prevention for the 
broad group of patients with known CAD (11). This review is primarily focused at patients with 
stable CAD and the ACE-inhibitor perindopril as studied in the EURopean trial On reduction of 
cardiac events with Perindopril in patients with stable coronary Artery disease (EUROPA) (10,14). 
ThE EuroPA TriAl
The EUROPA trial studied the ACE-inhibitor perindopril in a population with stable coronary 
artery disease without heart failure (10). In EUROPA, 12218 patients were randomly assigned 
perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The primary endpoint 
was cardiovascular mortality, myocardial infarction, or cardiac arrest. Mean age of patients was 
60 years and 85% were male, 92% were taking platelet inhibitors, 62% beta-blockers, and 58% 
statins. During a mean follow-up of 4.2 years, perindopril was associated with a 20 % relative 
reduction in the primary endpoint, from 9.9% to 8.0%, (HR 0.80; 95% CI 0.71-0.91; 8% vs 10%). 
These benefits were consistent in all clinical subgroups, across several secondary endpoints and 
independent of baseline blood pressure and use of concomitant medication. Perindopril was 
safe and well tolerated. To prevent one major cardiovascular event, 50 patients with stable CAD 
need to be treated for a period of 4.2 years (10). Several sub-studies of EUROPA have established 
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that ACE inhibitors have additional effects by improving endothelial function, neurohumoral 
balance, and reducing of unfavorable remodeling of the coronary arteries (15-18).
Prior ATTEmPTs To guiDE ACE-inhiBiTor ThErAPy To ThosE PATiEnTs 
mosT likEly To BEnEfiT
Several analyses have been performed to test the consistency of the treatment benefit ACE-
inhibitors among patient subgroups based on clinical characteristics (19- 23). Heterogeneity in 
the clinical treatment effect of ACE-inhibitors could be used to guide ACE-inhibitor therapy 
to those patients most likely to benefit of such therapy. Tailored ACE-inhibitor therapy will 
improve patients’ benefit, and reduce unnecessary health care costs and side effects. Using the 
EUROPA trial data, a risk model based on baseline clinical characteristics was developed (20). The 
treatment benefit of perindopril was consistent across different risk categories and therefore 
not modified by the level baseline risk (figure 1). Renal insufficiency is an important risk factor 
for developing cardiovascular disease (21). To study whether patient with normal renal func-
tion and impaired real function experienced a different treatment benefit, a subgroup analysis 
was performed within the EUROPA-trial. This analysis showed that treatment benefit was not 
modified by renal insufficiency (22). In a recent meta-analysis of the EUROPA, PROGRESS and 
ADVANCE trials, investigating the same ACE-inhibitor perindopril, we demonstrated a consis-
tent treatment effect of ACE-inhibitor based regimens independent of clinical characteristics or 
baseline blood pressure levels (23). Hence, no heterogeneity of treatment benefit was observed 
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Figure 1
Consistency of the treatment benefit of perindopril in the EUROPA trial 
according to a risk models based on clinical characteristics.  
Figure 2.
Treatment effect modifying SNPs in PERGENE
figure 1 Consistency of the treatment benefit of perindopril in the EUROPA trial according to a risk 
models based on clinical characteristics. Adapted from Deckers JW, Goedhart D, Simoons ML, et al. 
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. 
Eur Heart J. 2006;27(7):796-801 with permission. P-value for interaction between treatment benefit and 
risk tertile is non-significant.
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according to clinical characteristics. It appeared to be no feasible to guide ACE-inhibitor 
therapy in patients with stable CAD to specific subgroups that are most likely to benefit of such 
prolonged prophylactic treatment based on simple clinical characteristics. 
PhArmACogEnETiC APProACh of inDiViDuAliZing ACE-inhiBiTor 
ThErAPy
As simple clinical patient characteristics are inadequate to tailor ACE-inhibition therapy, new 
approaches that integrate more patient-specific characteristics should be considered, such as 
pharmacogenetic profiling of the drug response. The new field of cardiovascular pharmaco-
genetics involves examining the genetic determinants of patients’ responses to drugs and is 
expanding rapidly. Pharmacogenetics is aimed to understand why some drugs work better for 
some people than others and why some people are more likely than others to experience side-
effects. Indeed, pharmacogenetic profiling might be a new way to reach significant advances in 
individualized cardiovascular medicine. A priori, it is expected for several types of factors that 
they play a role in determining the response of a patient to therapy. Genetic factors causing 
differences in drug absorption and metabolic clearance are highly relevant; however; this is yet 
a relatively unexplored field for ACE-inhibitors. Genetic factors within the direct pharmacody-
namic pathway that is affected by the ACE-inhibitors, the renin–angiotensin–aldosteron–sys-
tem (RAAS) and bradykinin pathways are likely to affect the clinical efficacy of ACE inhibitors. 
In recent years, several genetic polymorphisms in RAAS genes have been associated with high 
blood pressure levels or an increased cardiovascular risk (3,24,25). Nearly all prior studies focused 
at two polymorphisms, the angiotensin-converting enzyme (ACE) I/D polymorphism and the 
M235T polymorphism in the angiotensinogen (AGT) gene. Because of limited study sample 
size and power, results have been inconsistent and these important topics have not yet been 
answered convincingly. With regard to interaction between genetic variation and ACE-inhibitor 
treatment response, the results are scarce as clinical data is lacking. No prior research with ACE-
inhibitors in stable CAD has been performed at large-scale nor in a randomized trial setting. 
It has been suggested that the response to drug therapy may be influenced by genetic poly-
morphisms in different ways. Firstly, pharmacodynamics may be affected by polymorphisms 
in the genes of all proteins involved in the RAAS and related systems, including receptors and 
signal transduction molecules. Secondly, variations in drug absorption and metabolic clear-
ance may cause inter-individual variation in pharmacokinetics. Thirdly, variations within genes 
of the RAAS and related systems may influence atherosclerosis (underlying disease process) 
and inherent differences in the susceptibility to therapeutic agents such as ACE inhibitors. 
The concept of pharmacogenetic research to individualize medicine is emerging rapidly and 
is clinically highly relevant. Several successes of this approach have recently been demonstrated 
for different cardiovascular agents, such as the activation of clopidogrel (26,27) and the risk of 
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rhabdomyolysis associated with statin therapy (28). Current pharmacogenetic data is often 
obtained from observational cohort studies or cross sectional data. Large randomized clinical 
trials with available DNA offer a unique opportunity to study this concept of tailored-therapy 
and truly test the feasibility of pharmacogenetic profiling of treatment benefit. The objective is 
to construct a genetic profile which enables the doctor to predict the patient’s benefit of treat-
ment in advance. Additionally, pharmacogenetics will teach us more in the individual response 
mechanism to medications. 
CurrEnT liTErATurE 
Three studies have performed a pharmacogenetic analysis of ACE-inhibitors or a treatment 
regimen containing ACE-inhibitors (29-31), two of them only studied the ACE I/D polymorphism 
and found no associations (29,30), one study examined for relevant genetic targets within the 
RAAS and found some interesting results (31):
The Genetics of Hypertension-Associated Treatment (GenHAT) Study first assessed the con-
cept of pharmacogenetics of anti-hypertensive drugs (29).  The investigators used a double-blind, 
active-controlled randomized trial of antihypertensive treatment that included hypertensives 
>55 years of age with at least 1 risk factor for cardiovascular disease. The ACE insertion/deletion 
genotype was determined in 37939 participants randomized to chlorthalidone, amlodipine, 
lisinopril, or doxazosin treatments and followed up for 4 to 8 years. Primary outcomes included 
fatal coronary heart disease (CHD) and/or nonfatal myocardial infarction. Fatal and nonfatal 
CHD occurred in 3096 individuals during follow-up. The hazard rates for fatal and nonfatal 
CHD were similar across antihypertensive treatments. The ACE I/D genotype group was not 
associated with fatal and nonfatal CHD (relative risk of DD versus ID and II, 0.99; 95% CI, 0.91 
to 1.07). The 6-year hazard rate for fatal and nonfatal CHD in the DD genotype group was not 
statistically different from the ID and II genotype group by type of treatment. Therefore, the 
authors concluded that the ACE I/D genotype group was not a predictor of CHD, nor did it 
modify the response to antihypertensive treatment. The ACE I/D polymorphism is not a useful 
marker to predict antihypertensive treatment response (29). Unfortunately, the authors did not 
study other relevant candidate genes or multiple genetic polymorphisms within the complex 
RAAS system. 
In PROGRESS (30), the insertion/deletion (I/D) polymorphism of the ACE genotype was stud-
ied for the effect of a perindopril-based blood pressure-lowering regimen on macro vascular 
events, dementia, and cognitive decline among hypertensive and nonhypertensive patients 
with a history of cerebrovascular disease. There were no associations between ACE genotypes 
and cerebrovascular disease history or cardiovascular risk factors, including baseline blood 
pressure. The ACE genotype was not associated with the long-term risks of stroke, cardiac 
events, mortality, dementia, or cognitive decline; neither did the ACE genotype predict the 
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blood pressure reduction associated with the use of the ACE inhibitor perindopril. Similarly, 
there was no evidence that the ACE genotype modified the relative benefits of ACE inhibitor-
based therapy over placebo. The ACE genotype is not useful for predicting either the risk of 
disease or the benefits of perindopril-based blood pressure-lowering treatment (30).  
Within the Chinese Community-Based Comprehensive Prevention and Control of Hyperten-
sion project, investigators studied the genetic contribution to the variation in blood pressure 
(BP) response to ACE-inhibitors (31). Fourteen single-nucleotide polymorphisms (SNPs) in the 
angiotensinogen (AGT), angiotensin receptor 1 (AGTR1), and angiotensin receptor 2 (AGTR2) 
genes were evaluated for their association with BP response to ACEI in 1447 Chinese patients 
with hypertension in a 2-stage design from a 3-year benazepril postmarket surveillance. The 
AGT rs7079 (C/T) SNP (3’-untranslated region) was significantly associated with the response of 
diastolic BP to benazepril (diastolic BP response: 7.4 mm Hg for subjects with the CC genotype, 
8.9 mm Hg for CA, and 10.1 mm Hg for AA; P<0.001). Although there was no association of 
individual SNPs in the AGTR1 gene, there was a graded response between common haplotypes 
and systolic BP reduction. The total variations in response to ACEI therapy that were explained 
by the AGT SNP and AGTR1 haplotype groups were 13% for systolic and 9% to 9.6% for diastolic 
BP, respectively. These findings are useful in future studies, providing genetic markers to predict 
the hypertensive response to ACE-inhibitor therapy (31). An important limitation of prior studies 
is the investigation of one or two polymorphisms within one candidate gene, thereby ignoring 
the well documented feedback mechanisms within the RAAS but also the fact that there are 
two angiotensin II receptors (AT1 and AT2), which have counteracting effects. Additionally, the 
ACE I/D polymorphisms is not a reflection of the entire renin-angiotensin system. We suggest 
that a more comprehensive coverage of genetic variation in multiple RAAS genes is needed, by 
using a haplotype approach to study common variation within relevant candidate genes. Com-
bining information from multiple SNPs in the RAAS genes, will result in a more comprehensive 
in-depth analysis of RAAS and BK system genes in relation to ACE-inhibitor treatment benefit, 
which is more likely to unravel any existing pharmacogenetic association.
ThE PErgEnE sTuDy
The PERindopril GENEtic association study (PERGENE) is a pharmacogenetic substudy within 
the main EUROPA trial (32). PERGENE aims at assessing the feasibility of pharmacogenetic 
profiling of treatment benefit of ACE-inhibitors in patients with stable CAD. We hypothesized 
that genetic polymorphism in the RAAS and kininogen–kallikrein–bradykinin pathways may 
influence the treatment benefit of ACE-inhibitors in patients with stable CAD. Polymorphisms 
were selected based on haplotype tagging SNP’s using the HapMap genome project to 
comprehensively cover all genetic variation within genes; additional selection was based on 
functionality, location within the gene (promoter) or relevant literature. The PERGENE study 
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is unique in the field of pharmacogenetic studies because of the large sample size, a random-
ized and placebo-controlled design, and the availability of extensive and accurate phenotypic 
data. Also, the extensive selection of 52 tagging SNP’s in 12 candidate genes in both pathways 
ensures a new and comprehensive coverage of common genetic variation in the candidate 
genes. The main outcome measure of PERGENE was the interaction between genetic factors 
and treatment effect of ACE-inhibitors during follow-up. The size of this pharmacogenetic 
substudy allows detection with a statistical power of 98% to detect a difference in hazard ratios 
(treatment effect) of 20% between genotypes with minor allele frequency of 0.20 (two-sided 
alpha 0.05). More details on the study design, SNP selection procedure and statistical analysis 
can be found elsewhere (32).
Clinical treatment effect of ACE-inhibitors
An analysis of heterogeneity in clinical effectiveness of perindopril according to genetic 
variation in RAAS was further performed in PERGENE (33). The EUROPA-trial provides a unique 
opportunity to evaluate this hypothesis, since it is a large randomized double-blind placebo-
controlled clinical trial with complete phenotypic data (2,13). We studied whether genetic poly-
morphisms in the renin-angiotensin-aldosterone and kallikrein-bradykinin systems modify the 
treatment benefit of the ACE-inhibitor perindopril. The main EUROPA-trial randomized 12,218 
stable CAD patients to perindopril (8 mg/day) or placebo and perindopril was associated with 
a 20% reduction (HR 0.80; 95% CI 0.71-0.91) in the event rate of the primary endpoint (com-
posite of cardiovascular mortality, non-fatal MI, or resuscitated cardiac arrest) during a mean 
follow-up of 4.2 years (2). Event rates were 9.9% with placebo and 8.0% in patients receiving 
perindopril. In 8907 stable CAD patients from this trial, we analyzed 12 genes within the two 
pharmacodynamic pathways affected by ACE-inhibitors, using 52 haplotype-tagging SNPs. The 
primary outcome was the reduction in cardiovascular mortality, non-fatal myocardial infarction 
and resuscitated cardiac arrest during 4.2 years of follow-up. Cox regression was performed 
with multiple-testing corrections by permutation analysis.
In unadjusted analysis, 7 SNPs in 4 genes were associated with the treatment effect of 
perindopril. In multivariate permutation analysis, 3 of these SNPs, located in the angiotensin-
II type I receptor and bradykinin type I receptor genes, significantly modified the treatment 
benefit of perindopril. In the bradykinin type I (BK1) receptor gene; rs12050217 was a strong 
modifier of the treatment benefit of perindopril. The hazard ratio (95% CI) for the reduction in 
the event rate of the primary endpoint for AA (62.1%) genotypes was 0.64 (0.55-0.78), for AG 
(33.2%) genotypes 1.02 (0.79-1.29) and for GG (4.7%) genotypes 1.10 (0.56-2.19). The p-values 
for interaction were 0.004 (empirical) and 0.012 (permutated) (33). In the angiotensin-II type I 
(AT1) receptor gene, rs275651 and rs5182 significantly modified the treatment benefit of perin-
dopril in a similar way, with empirical p-values of 0.008 and 0.011, and permutated p-values of 
0.049 and 0.054, respectively (figure 2). No further associations of treatment interaction were 
observed for the other genes (33). 
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A pharmacogenetic profile, combining the unfavorable alleles of these 3 SNPs, demonstrated 
a stepwise decrease in treatment benefit of perindopril with increasing number of unfavorable 
alleles (interaction p<0.0001). The treatment benefit was concentrated in 73.5% of the patients 
(responders, HR 0.67; 95% CI 0.56-0.79) and absent in 26.5% of the patients (non-responders, 
HR 1.26; 95% CI 0.97-1.67) (figure 3) (33). An interaction effect of similar direction and magnitude 
was observed in a confirmatory analysis of 1051 patients with cerebrovascular disease from 
the PROGRESS-trial. This unique pharmacogenetic analysis identified genetic determinants for 
the treatment benefit of ACE-inhibitor therapy by perindopril in patients with stable CAD for 
the first time. Haplotype analysis confirmed the association between the identified SNPs and 
treatment effect modification. In both genes, the haplotype carriers of the unfavorable alleles 
of the identified SNPs significantly modified the treatment effect of perindopril (33). 
The PERGENE study demonstrates that the treatment benefit of ACE-inhibitor therapy 
by perindopril is modified by genetic variation in the renin-angiotensin-aldosterone and 
kallikrein-bradykinin systems (33). Based on the aggregated pharmacogenetic profile, both 
patients with a higher treatment benefit (responders, 73.5%), and patients with a diminished 
treatment effect (non-responders, 26.5%), could be identified (34) (figure 4). For the first time, a 
group with significantly different treatment effect could be identified within the EUROPA trial 
based upon pharmacogenetic data. Non-responding patients demonstrate a relative resistance 
or unresponsiveness to ACE-inhibitors. 
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Figure 1
Consistency of the treatment benefit of perindopril in the EUROPA trial 
according to a risk models based on clinical characteristics.  
Figure 2.
Treatment effect modifying SNPs in PERGENE
figure 2 Treatment effect modifying SNPs in PERGENE 1/1 = homozygous common allele, 1/2 = 
heterozygous, 2/2 = homozygous common allele. Percentages correspond to the number of patients 
within each group according to genotype. The x-axis corresponds to the hazard ratio and 95% CI 
estimates and Y-axis to genotype category.
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In the patients which were identified as responders and non-responders with pharmacoge-
netic profiling, no differences in clinical characteristics were observed between responders 
and non-responders in PERGENE (table 1) (33).  Responders and non-responders were of similar 
age (mean age 60 vs 60), gender (% of males, 85 vs 85) and cardiovascular risk factors were 
evenly distributed between patients (diabetes 12% vs 12%, hypertension 29% vs 28% prior 
MI 65% vs 66%). Thus, the observed treatment interaction cannot be explained by clinical dif-
ferences between the genotypes. This is in line with the article by Deckers et al. (20) which also 
demonstrated that the level of baseline risk, calculated with a risk score of clinical baseline 
characteristics, did not modify the treatment benefit of perindopril in patients with stable CAD. 
We also studied whether the observed differences in treatment benefit could be explained 
by a difference in the baseline level of blood pressure between responders and non-responders. 
The level of blood pressure at baseline was identical between responders and non-responders 
(137/82 mmHg) and did not modify the treatment effect of perindopril. This is in line with the 
article by Brugts et al. (23) which analyzed thirty-thousand patients with vascular disease treated 
with ACE-inhibitors and demonstrated that the level of baseline blood pressure did not modify 
the treatment benefit of ACE-inhibitor therapy. We further studied the level of blood pressure 
reduction by ACE-inhibitor therapy (perindopril) during the run-in period of four weeks of the 
Figure 3. 
Treatment effect according to the pharmacogenetic profile categories
figure 3 Treatment effect according to the pharmacogenetic profile categories responders = <3 
unfavorable alleles, non-responders ≥ 3 unfavorable alleles.
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EUROPA trial. Responders and non-responders demonstrated a similar BP reduction during 
these four weeks on ACE-inhibitor therapy. A similar results was observed in the analysis by 
Brugts et al. (23) which demonstrated the independence of the treatment effect of ACE-inhibitors 
in terms of the level of blood pressure reduction during run-in period. We observed no differ-
ences in intermediate phenotypes such as blood pressure and blood pressure reduction which 
suggests a direct genetic effect which results in a resistance to ACE-inhibitors in patients 3 or 
more unfavourable alleles of the SNPs located in the AT1 and BK1 receptor. Thus, the observed 
treatment interaction cannot be explained by clinical differences between the genotypes. To 
strengthen our results,  the BPLTCC consortium studied the blood pressure dependent and 
independent effects of ACE-inhibitors in 146838 patients and confirmed that blood pressure 
beneficial effects up and above the blood pressure reduction are present (14). As perindopril 
is one of the most competent ACE-I with highest tissue ACE penetrance, blood pressure inde-
pendent effects are likely as demonstrated in several substudies of the EUROPA trial (23). Several 
Table 1. Baseline characteristics according to pharmacogenetic profile category. 
(%) Responders Non-responders p-value 
Age, years 60 60 ns
Gender, male 85 85 ns
Diabetes Mellitus 12 12 ns
Hypertension 29 28 ns
Current smoking 15 16 ns
Prior MI 65 66 ns
Prior revascularization 55 54 ns
Blood pressure, mmHg 137/82 137/82 ns
BP-reduction, run-in period 9/4 9/4 ns 
Legend: responders = <3 unfavorable alleles, non-responders ≥ 3 unfavorable alleles.
Figure 3. 
Treatment effect according to the pharmacogenetic profile categories
figure 4 Heterogeneity in treatment benefit by pharmacogenetic profiling identifies responders  and 
non-responders to ACE-inhibitor therapy.
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sub-studies of EUROPA (PERFECT, PERSPECTIVE and PERTINENT), have studied the additional 
effects of ACE-inhibitors and have established that ACE inhibitors have additional effects 
beyond the blood pressure reduction alone such as the improvement of endothelial function, 
improvement of the neurohumoral balance, and reduction of unfavorable remodeling of the 
coronary arteries (15-18).
Absolute risk of events 
In our pharmacogenetic analysis of treatment benefit, the combination of ≥3 unfavourable 
alleles of the 3 SNPs located in AT1 and BK1 receptor genes was associated with a decreased 
risk of cardiac events in patient receiving placebo, while the risk increased in patients receiv-
ing perindopril which is independent of clinical characteristics. It may be suggested that the 
absolute risk of events in these patients was already low (stable CAD is a relatively low-risk 
group, in which one can argue whom to treat now), preventing any benefit of the addition of 
an ACE-inhibitor. However, the absolute risk for cardiovascular death or myocardial infarction 
in these patients was 7.7 % at four years follow-up. In a previous analysis of the EUROPA trial 
a consistent treatment benefit was observed in the lower risk tertile (based on assessment of 
clinical characteristics) with a risk of only 5.3 % in the patients treated with placebo as well as 
in the higher risk tertiles (7).
PoTEnTiAl mEChAnism
Our findings suggest that the genetic variants modifying the clinical treatment effect of perin-
dopril are particularly located in the AT1 and BK1 receptors. The SNPs in the AT1 receptor were 
located in the promoter (rs275651) and exon (rs5182), the SNP in the BK1 receptor was located 
in an intron, all three were important tagging SNPs within the candidate gene (33). Functionality 
of these SNPs is yet unknown but under extensive investigation. The AT1 receptor is well-
known and mediates all the well-known effects of angiotensin II, including vasoconstriction, 
water and salt retention, aldosterone synthesis and hypertrophy, and thus its appearance in 
this analysis is not particularly surprising. The role of the BK1 receptor, on the other hand, is less 
well established but recent reports increase the current interest in this receptor. Bradykinin is a 
potent vasodilator that also induces anti-atherosclerotic and anti-thrombotic effects, which are 
mediated by bradykinin type II receptors. Previous studies indicated that the clinical benefit of 
ACE-inhibitors depends, at least in part, on BK2 receptor activation (34). In the past year, more 
data is emerging on the effect of the BK1 receptor, which effects are less well known. BK1 recep-
tors are weakly expressed under physiological conditions, but are strongly induced in response 
to pathological conditions and/or RAAS blockading agents (35,36). Recent reports indicate that 
BK1  receptor deficiency predisposes to atherosclerosis (37) and kinins and the BK1 receptor 
plays an important deleterious role in this process (38). Interestingly, it has been suggested that 
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BK1 receptors are directly activated by ACE-inhibitors (thus resulting in an increase in endo-
thelial NO release, for instance in the cardiac tissue (38,39,40)), by which they do contribute to the 
cardioprotective beneficial effects of ACE-inhibitors, but this has not been uniformly confirmed 
by others (41). Therefore, a more likely possibility is that the up-regulated BK1 receptors (under 
pathologic conditions) are activated by their endogenous ligand during ACE-inhibition. Such 
activation results in the hypotensive (42), cardioprotective (34) and cerebroprotective (43) effects 
of kinins, as observed in animals, and one could speculate that patients with genetic defects in 
their BK1 receptor display a diminished response or relative resistance to ACE-inhibitors with 
regard to kinins. Indeed, in our study we observed that especially patients with the minor allele 
variants of the BK1 receptor were relatively insensitive or resistant to the beneficial effect of the 
ACE-inhibitor perindopril. In patients with the genetic defect in the BK1 receptor, one could 
speculate that the kinins can not have their beneficial effects by BK1 receptor activation (up-
regulated during ACE-inhibition) and in such way do not benefit from treatment. Likewise, the 
patients without these genetic defects in the BK1 receptor have a much more pronounced effect 
as the activation of the BK1 receptor is not negatively affected. Clearly, more work is needed to 
support this interesting concept for which we have set up an additional basic research project. 
The lack of a blood pressure mediated effect of the pharmacogenetic profile by 3 identified 
SNPs in the treatment effect analysis suggests a different pathway of clinical effect. In the clini-
cal subgroups analyses, the treatment effect was also independent of baseline blood pressure 
as well as blood pressure reduction which supports our findings. As blood pressure indepen-
dent effects of ACE-inhibitors is often proposed for the BK pathway (14). In our analyses, indeed 
the responding and non-responding patients did not differ in clinical characteristics, baseline 
blood pressure or BP reduction level by ACE-inhibitor therapy while a clear heterogeneity was 
observed in the reduction in the event rate of the primary endpoint during follow-up related to 
the BK1  receptor. The blood pressure lowering effect must be important for the clinical effect, 
but it might be speculated that the presumed additional effects beyond lowering blood pres-
sure alone which is frequently debated, might me more related to the BK system. Our findings 
do support that discussion, as it might be speculated that the genetic defects in the BK1 recep-
tor alter the anti-atherosclerotic properties of ACE-inhibitor treatment effect which might be an 
important cornerstone of the treatment benefit besides blood pressure lowering. 
CliniCAl imPliCATions
The PERGENE study demonstrated that RAAS and BK polymorphisms modified the response to 
the ACE-inhibitor perindopril in patient with stable CAD. We demonstrated a relative resistance 
to ACE-inhibitors in patients with unfavorable alleles of the AT1 receptor and BK1 receptor 
genes. Based on the PERGENE findings, three out of four patients with stable CAD (participating 
in EUROPA) had an enhanced benefit of ACE-inhibitor therapy (responders, 33% reduction of 
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cardiovascular death of myocardial infarction, up to 54% in patients without any unfavorable 
alleles), and one out of four patients experienced a markedly diminished benefit of treatment 
with perindopril (non-responders). 
In the overall study, 50 patients needed to be treated for four years to prevent one cardiovas-
cular event. The relative risk reduction in the primary endpoint was 20% (HR 0.80; 95% CI 0.71-
0.91) and absolute risk reduction 2%. In our pharmacogenetic profile categories of patients 
with respectively <3 and ≥ 3 unfavorable alleles, relative risk reduction were respectively 
33% (HR 0.67; 95% CI 0.56-0.79) and +26% (HR 1.26; 95% CI 0.97-1.67). Refraining from treat-
ment with perindopril in this group of patients may considerably reduce healthcare cost and 
increase overall efficacy of the drug. In the fictive scenario that one would only patient with <3 
unfavourable alleles were treated, which compromises 76.5% of the population, the absolute 
risk would be reduced from 11.1 % in placebo to 7.5 % in perindopril patients. Likewise, the 
number needed to treat would decrease from 50 to 32 (figure 5). Considering the millions of 
patients treated with ACE-inhibitors this reduction has huge clinical implications and fictively 
demonstrates the potential of pharmacogenetic profiling of drug response. 
fEAsiBiliTy of PhArmACogEnETiC Profiling of ACE-inhiBiTors
The PERGENE study is one of the first pharmacogenetic analyses within a randomized clinical 
trial (assessing one agent), and one of the first demonstrating results for ACE-inhibitors. The 
concept of pharmacogenetic should be investigated further and replicated in similar patient 
populations but also at patients at higher risk of events as stable CAD patients are at relatively 
low risk of CVD events. When the feasibility of pharmacogenetic profiling of ACE-inhibitor 
therapy is confirmed in other studies, pharmacogenetic analyses of clinical trials truly open 
up a perspective to individualize preventive therapy in patients with cardiovascular disease. 
Figure 5.  
Numbers needed to treat according to the pharmacogenetic profile
 
figure 5 Numbers needed to treat according to the pharmacogenetic profile
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Physicians will be able to predict the response to treatment (responders and non-responders) 
in advance, before starting prescription. Considering the findings of the PERGENE study, further 
replication must be sought in other cohorts. Additionally, other relevant genetic targets need 
to be investigated such as genes involved in the metabolism of ACE-inhibitors, fe CYP450 genes 
(pharmacokinetics). However, until now no specific genetic targets for ACE-inhibitor metabo-
lism have been demonstrated. Ultimately, one would wish to perform a genome wide scan 
on the PERGENE data to elucidate further relevant pharmacogenetic targets throughout the 
genome related to the treatment benefit of ACE-inhibitors. 
A similar approach could be used for other cardiovascular drugs such as statins to optimize 
patients’ benefits as a strong consistency in the treatment benefit has been demonstrated as 
well (44). The combination of these cardiovascular drug trials could be used to develop a phar-
macogenetic profile for cardiovascular drugs in general. We advocate that future large scale 
randomized clinical trials should also integrate a pharmacogenetic analysis in their trial design 
to prospectively test treatment efficacy in a similar way as usually done with clinical risk factor 
assessment of trial patients. “Individualized therapy” by pharmacogenetic profiling will avoid 
unnecessary treatment of non-responding patients and considerably reduce health care costs. 
ConClusion
The PERGENE study demonstrated the feasibility of pharmacogenetic profiling of treatment 
benefit of ACE-inhibitors in patients with stable CAD. Unfavorable alleles of genetic variants in 
the AT1 and BK1 receptor genes identified patients with a relative resistance to ACE-inhibitors. 
Patients without the unfavourable alleles experienced a much more pronounced treatment 
benefit as compared to the overall study results and treatment should not be withheld in these 
patients. 
Executive summary 
•	 ACE-inhibitors reduce cardiovascular risk in patients with stable CAD
•	 Assessing the consistency of treatment benefit is crucial for the efficacy and cost-effective 
prescription of ACE-inhibitors
•	 The treatment benefit of ACE-inhibitors is not modified by clinical characteristics. Thus 
guiding ACE-inhibitor therapy appeared not feasible using clinical characteristics.
•	 The PERGENE study is a pharmacogenetic analysis of treatment benefit of ACE-inhibitors in 
a large randomized placebo controlled clinical trial of patients with stable CAD
•	 The PERGENE study demonstrated that genetic variation in the AT1 and BK1 receptor modi-
fied the treatment benefit of the ACE-inhibitor perindopril
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•	 The constructed pharmacogenetic profile identified 73.5 % of the patients with treatment 
benefit – responders- and 26.5 % of the patients with a diminished treatment benefit – non-
responders-
•	 Pharmacogenetic profiling will optimize patients benefit of treatment and reduce unneces-
sary treatment of patient and reduce health care costs
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ABsTrACT
objectives: To investigate whether statins reduce all cause mortality and major coronary and 
cerebrovascular events  in people without established cardiovascular disease but with cardio-
vascular risk factors, and whether these effects are similar in men and women, in young and 
older (>65 years) people, and in people with diabetes mellitus.
methods: Meta-analysis of randomised trials. Data sources Cochrane controlled trials register, 
Embase, and Medline. Two independent investigators identified studies on the clinical effects 
of statins compared with a placebo or control group and with follow-up of at least one year, at 
least 80% or more participants without established cardiovascular disease, and outcome data 
on mortality and major cardiovascular disease events. Heterogeneity was assessed using the 
Q and I2 statistics. Publication bias was assessed by visual examination of funnel plots and the 
Egger regression test.   
results: Ten trials enrolled a total of 70388 people, of whom 23681 (34%) were women and 
16078 (23%) had diabetes mellitus. Mean follow-up was 4.1 years. Treatment with statins sig-
nificantly reduced the risk of all cause mortality (odds ratio 0.88, 95% confidence interval 0.81 
to 0.96), major coronary events (OR 0.70, 95% CI 0.61 to0.81), and major cerebrovascular events 
(OR 0.81, 95% CI 0.71 to 0.93). No evidence of an increased risk of cancer was observed. There 
was no significant heterogeneity of the treatment effect in clinical subgroups.
Conclusion: In patients without established cardiovascular disease but with cardiovascular risk 
factors, statin use was associated with significantly improved survival and large reductions in 
the risk of major cardiovascular events.
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inTroDuCTion
Cardiovascular disease is the leading cause of death and disability in the Western world and 
contributes substantially to healthcare budgets (1). Several clinical trials and meta-analyses 
have shown the beneficial effects of lipid lowering treatment using hydroxylmethyl glutaryl 
coenzyme A reductase inhibitors (statins) in reducing mortality and cardiovascular morbidity 
in patients with established cardiovascular disease (2-6). Statins therefore have a place in the 
secondary prevention of cardiovascular disease (7-10).
The use of statins in patients without established cardiovascular disease (that is, primary 
prevention) and at relatively low risk has important public health implications. To date research 
has provided ambiguous answers. In addition, the reliability of treatment in older people (>65 
years), women, and those with diabetes mellitus is uncertain, mainly because of a lack of data 
or inconsistent findings within these clinically defined groups (11,12). Most meta-analyses have 
been carried out on published tabular data and failed to provide consistent answers on treat-
ment effect in these subgroups (13,14). We carried out a meta-analysis of randomised trials that 
focused on primary prevention to determine whether statins reduce all cause mortality and 
the incidence of major coronary and cerebrovascular events in people without established 
cardiovascular disease but with cardiovascular risk factors. We also assessed whether these 
effects differed by sex, age, and the presence of diabetes.
mEThoDs
We followed the quality of reporting of meta-analysis guidelines (15). We searched the Cochrane 
Central Register of Controlled Trials, Medline (1990-November 2008), Embase (1980-November 
2008), DARE, and the ACP Journal Club for randomised clinical trials that compared statins with 
a control group in people without established cardiovascular disease but with cardiovascular 
risk factors. We identified relevant studies using the MeSH terms “HMG-CoA reductase inhibi-
tor”, “atorvastatin”, “simvastatin”, “pravastatin”, “fluvastatin”, “rosuvastatin”, or “lovastatin”, and 
“cardiovascular disease”, “coronary heart disease”, “cerebrovascular disease”, or “myocardial 
infarction”, and “cholesterol”, “LDL” [low density lipoprotein], “HDL” [high density lipoprotein], 
or “triglycerides”, and primary prevention restricted to randomised controlled trials or meta-
analyses. In addition we examined the reference lists and related links of retrieved articles in 
PubMed to detect studies potentially eligible for inclusion.
study selection
We included studies if they were randomised trials of statins compared with controls (placebo, 
active control, or usual care), had a mean follow-up of at least one year, reported on mortality 
or cardiovascular disease events as primary outcomes, and included at least 80% of people 
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without established cardiovascular disease or reported data separately on a sole primary pre-
vention group and provided specific numbers for patients and events in that group. Eight 
studies were excluded that primarily investigated statin related non-clinical and intermediate 
surrogate end points such as changes in the thickness of the carotid intima media and lipid 
levels that collectively contributed fewer than 50 clinical events (16-23). We also excluded one 
study in patients with renal transplants because of the specific nature of that population,(24) 
and three studies with design problems, fewer than 20 events overall, and insufficient follow-up 
(25-27). Our study therefore focused on people without established cardiovascular disease but 
with cardiovascular risk factors. 
Validity assessment
Our search identified 1230 studies, of which 10 fulfilled our inclusion criteria.w1-w10 Figure 1 sum-
marizes the results of the search. We evaluated suitable trials for concealment of treatment alloca-
tion, performance of the analysis according to the intention to treat principle, and completeness 
of follow-up. The Jadad scale was used to score study quality (range 0-5, higher scores indicating 
better quality) (28). Study quality was sufficient (≥4) for all included randomised clinical trials. 
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Figure 1.  
Flow diagram of included trials 
  figure 1. Flow diagram of included trials. Odds ratios (95% confidence intervals) for all cause mortality, 
major coronary events, major cerebrovascular events, and incidence of cancer. Mortality risk based on 
mean follow-up of 4.1 years, with data from nine trials, and 67476 patients free of cardiovascular disease 
(no data available from HPS diabetic armw5. Risk of coronary events based on mean follow-up of 4.9 years, 
with data from eight trials, and 50681 patients free of cardiovascular disease (no data available from 
ASPENw3 and JUPITERw1). Risk of cerebrovascular events based on mean follow-up of 4.1 years, with data 
from nine trials, and 67476 patients free of cardiovascular disease (no data available from HPS diabetic 
arm). Risk of cancer based on mean follow-up of 3.9 years, with data from six trials, and 52027 patients 
free of cardiovascular disease (no data available from HPS, ASCOT,w10 PROSPER,w6 and ASPEN). See 
footnote to table 1 for full titles of studies. *Measures of heterogeneity.
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Data abstraction
From each study two investigators separately extracted information on trial characteristics, 
patient data, outcome measures, and study quality using a standardized protocol and report-
ing document. Disagreements were resolved by consensus. 
subgroup analysis
We searched the papers for data on clinically defined subgroups. The Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)w7 presented data on our 
prespecified subgroups. The other studies did not publish results stratified by age (<65 or >65 
years), sex, or diabetes. To obtain data for these stratified groups we sent an electronic sheet 
with data fields to the principal investigators of these studies, requesting the number of events 
and number of patients in the treatment and placebo groups. We obtained data on subgroups 
for five trials.w1-w3 w6 w8 Subgroup analyses were therefore done in six studies. w1-w3 w6 w7 Not all 
end points were recorded in these studies. 
End points 
The primary end point of our meta-analysis was all cause mortality. Secondary end points were 
the composite of major coronary events defined as death from coronary heart disease and 
non-fatal myocardial infarction, and the composite of major cerebrovascular events defined 
as fatal and non-fatal stroke. We also assessed death from coronary heart disease, non-fatal 
myocardial infarction, revascularisations (percutaneous coronary intervention or coronary 
artery bypass graft), and cancer (fatal and non-fatal). The clinical outcomes evaluated in the 
subgroup analysis (data should be reported in two or more studies) were all cause mortality, 
major coronary events, major cerebrovascular events, and cancer.
Quantitative data synthesis
For each trial we calculated the summary odds ratios and 95% confidence intervals for the 
clinical outcomes. We pooled studies using both fixed effect and random effects models (29). 
A random effects model makes the assumption that individual studies are estimating different 
treatment effects. Our conclusions were drawn from the results of the random effects model. 
We were unable to exclude a small proportion of secondary prevention patients from the West 
of Scotland Coronary Prevention Study (1069/6595; WOSCOPS),w9 ALLHAT (1470/10355),w7 
and the Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm (1906/ 10305; ASCOT-
LLA),w10 and these therefore constitute about 6% of our study population (4445/70388) (30, w7 
w9). In a separate analysis we verified whether our results remained consistent after exclusion 
of these studies. We also investigated whether our results differed when we used the original 
study results from ASCOT without extended follow-up (30, w10).
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We assessed the results for heterogeneity in the main analysis and subgroup analysis by 
examining the forest plots and then calculating a Q statistic, which we compared with a χ² 
distribution, and the I2 index (31). The Q test indicates the statistical significance of the homoge-
neity hypothesis and the I2 index measures the extent of the heterogeneity. We considered the 
results for heterogeneity to be significant at P<0.10 (two sided). Publication bias was assessed 
for the main end points by visually examining for funnel plot asymmetry and quantified by 
using the Egger regression test to calculate two tailed P values (32).
rEsulTs
Table 1 shows the characteristics of the 10 included studies w1-w10. In total, 70388 participants 
were randomised, of whom 35138 were allocated to statin therapy and 35250 to control. The 
number of participants in the trials ranged from 1905 to 17802. The mean age was 63 years 
(range 55.3 to 75.0), and the mean follow-up was 4.1 years (range 1.9 to 5.3). Thirty four per cent 
of participants were women and 23% had diabetes. The mean baseline low density lipoprotein 
cholesterol level was 3.63 mmol/l. The mean reduction in levels of total cholesterol was 17.1%, 
low density lipoprotein cholesterol was 25.6%, and triglyceride was 9.3%. High density lipopro-
tein cholesterol increased by a mean 3.3%. 
mortality, coronary events, and cerebrovascular events
During a mean follow-up of 4.1 years 5.7% (1925/33793) of participants died in the control 
group compared with 5.1% (1725/33683) in the statin group. Statin therapy was therefore 
associated with a 12% risk reduction in all cause mortality compared with the control (odds 
ratio 0.88, 95% confidence interval 0.81 to 0.96; figure 2 and table 2). The annual rate for all 
cause mortality with placebo in our study was 1.4% (figure 2). Overall, 5.4% (1266/23946) of 
participants in the control group had a major coronary event compared with 4.1% (966/23 
823) in the statin group, a 30% risk reduction (odds ratio 0.70, 95% confidence interval 0.61 
to 0.81). The annual rate for major coronary events with placebo in our study was 1.1% (figure 
2). Overall, 2.3% (767/33793) of participants in the control group had a major cerebrovascular 
event compared with 1.9% (627/33683) in the statin group, a 19% risk reduction (OR 0.81, 95% 
CI 0.71 to 0.93). The annual rate for major cerebrovascular events with placebo in our study was 
0.6% (figure 2). The annual rate for coronary heart disease mortality with placebo in our study 
was 0.3%, for non-fatal myocardial infarction it was 0.6%, for revascularization it was 0.6%, and 
for incidence of cancer it was 1.2%. The association between statin therapy and risk of cancer 
was not significant (OR 0.97, 95% CI 0.89 to 1.05; figure 2 and table 2). Table 2 also shows the 
summary odds ratios for other end points. The outcome of the analyses was not influenced by 
removal of the three trials that enrolled 4445 patients (6%) with a previous cardiovascular event 
(all cause mortality OR 0.87, 95% CI 0.78 to 0.97). Also, using only the first reported data from 
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ASCOT-LLA instead of the extended follow-up data that were published later did not influence 
the result of the analyses (OR 0.88, 95% CI 0.81 to 0.97) w10. When the only study (Justification 
for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; JUPITER)w1 
that found a significant effect on mortality was removed from the analysis, the reduction in 
mortality in the other nine trials remained significant (OR 0.89, 95% CI 0.81 to 0.97). No funnel 
plot asymmetry was visualised for the main end points, and P values using the Egger regression 
test were greater than 0.10 for all the major end points (all cause mortality: intercept −0.8, 95% 
CI -3.1 to 1.5; P value 0.42). 
subgroup analyses 
No heterogeneity in treatment effect was observed for end points in men and women and for 
age (≤65 and >65 years) or diabetic status (figure 3).
Figure 2.  
Odds ratios (95% CI) for all cause mortality, major coronary events, major cerebrovascular 
events, and incidence of cancer. 
 
 
figure 2. Odds ratios (95% CI) for all cause mortality, major coronary events, major cerebrovascular 
events, and incidence of cancer. NR = not reported. See footnote to table 1 for full titles of studies. *Data 
from  Thavendiranathan et al.(14).Fixed effect and random effect models in meta-analysis gave identical 
results, making important statistical heterogeneity unlikely. †No data in primary prevention group 
(n=3239).w6 ‡Significant heterogeneity; however, a positive trend of statin therapy is observed in all trials, 
only of different magnitude (no neutral or negative trials).
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DisCussion
The current meta-analysis totaled 70388 participants without established cardiovascular 
disease but with cardiovascular risk factors who were randomized to statin therapy or control. 
Statin therapy was associated with a significant risk reduction in all cause mortality of 12%, in 
major coronary events of 30%, and in major cerebrovascular events of 19%. Moreover, statin 
use was not associated with an increased risk of cancer. These results are in line with those 
previously published on the effects of statins in secondary prevention.
Our meta-analysis differs from earlier analyses in several ways(13,14). We were able to include 
several recently published studies targeted at primary prevention that enrolled a large number 
of women and people with diabetes.w1-w3 For example, the Management of Elevated Cho-
lesterol in the Primary Prevention Group of Adult Japanese trial (MEGA)w2 comprised a large 
number of women (68%, 5356/7832), and we were able to obtain subgroup data. Additionally, 
the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-
Dependent Diabetes Mellitus study (ASPEN)w3 was carried out in a large group of people with 
type 2 diabetes (n=1905) who did not have established cardiovascular disease. 
We also included data from the recently published JUPITER trial,w1 totaling 17802 partici-
pants with no apparent vascular disease, low density lipoprotein cholesterol levels less than 3.4 
Table 2. Treatment Effects of Statin Therapy (OR; 95% CI)
Clinical trial All-cause mortality major Coronary 
Events
major 
Cerebrovascular 
Events
fatal or nonfatal 
Cancer
WOSCOPS 0.78 (0.60 to 1.01) 0.68 (0.56 to 0.83) 0.90 (0.60 to 1.34) 1.09 (0.84 to 1.43)
AFCAPS 1.04 (0.76 to 1.43) 0.61 (0.45 to 0.83)   0.82 (0.40 to 1.67)† 0.97 (0.81 to 1.16)
PROSPER  0.98 (0.79 to 1.21)† 0.90 (0.70 to 1.15) 1.03 (0.72 to 1.47) NR*
ALLHAT-LLT 0.99 (0.88 to 1.11) 0.90 (0.78 to 1.04) 0.90 (0.75 to 1.09) 1.03 (0.89 to 1.19)
ASCOT-LLA 0.85 (0.73 to 0.97) 0.64 (0.52 to 0.78) 0.77 (0.63 to 0.95) NR
HPS NR  0.57 (0.41 to 0.79)† NR NR
CARDS 0.72 (0.51 to 1.02) 0.65 (0.44 to 0.97) 0.52 (0.31 to 0.90) 0.65 (0.37 to 1.16)
ASPEN 1.06 (0.69 to 1.64) NR 0.92 (0.54 to 1.56) NR 
MEGA 0.71 (0.50 to 1.00) 0.55 (0.33 to 0.91) 0.83 (0.57 to 1.20) 0.97 (0.75 to 1.25)
JUPITER 0.80 (0.66 to 0.96) NR 0.51 (0.34 to 0.78) 0.89 (0.77 to 1.04)
Combined:
 - Fixed effects 0.90 (0.84 to 0.96) 0.74 (0.68 to 0.81) 0.82 (0.74 to 0.91) 0.97 (0.89 to 1.05)
 - Random effect 0.88 (0.81 to 0.96) 0.70 (0.61 to 0.81) 0.81 (0.71 to 0.93) 0.97 (0.89 to 1.05)
heterogeneity:
 - Q-statistic
 - I-square index
0.20
Low (27 %)
0.02‡
Moderate (60 %)
0.23
Low (24 %)
0.61
Low (0 %)
Data are reported as odds ratios (95% confidence interval). NR=trial did not report data. *No data 
of PROSPER presented on malignancies in the primary prevention group (N=3239)33 †Data from 
Thavendiranathan et al.14  The fixed effect and random effect models in our study gave almost identical 
results, which makes it unlikely, that there is important statistical heterogeneity. ‡ significant heterogeneity, 
however in all trials a positive trend of statin therapy is observed (no neutral or negative trials).
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mmol/l, and increased levels of high sensitivity C reactive protein (>2.0 mg/l).w1 As our study 
is based on such large numbers, this meta-analysis, including the subgroups, has significant 
statistical power. Previously, only the JUPITER trial showed improved survival associated with 
statin use in high risk participants, but it is clear from the current analysis that a mortality ben-
efit is a shared characteristic of long term statin use in people without previous cardiovascular 
Figure 3.  
Odds ratios (95% CI) for clinically defined subgroups of sex, age, and diabetes for 
end points of all cause mortality, major coronary events, major cerebrovascular 
events, and cancer. 
  
 
  
 
 
  
 
 
figure 3. Odds ratios (95% CI) for clinically defined subgroups of sex, age, and diabetes for end points of 
all cause mortality, major coronary events, major cerebrovascular events, and cancer. Odds ratios (95% 
CI) for clinically defined subgroups of sex, age, and diabetes for end points of all cause mortality, major 
coronary events, major cerebrovascular events, and cancer. Subgroup data are obtained from AFCAPS,w8 
PROSPER,w6 ASPEN,w3 MEGA,w2 and JUPITERw1, and for mortality and coronary events from ALLHAT-LLT.w7 
We had complete mortality data from all six trials for sex; for age, no data from PROSPER on age<65; for 
diabetes, no data from ASPEN and AFCAPS on participants without diabetes, and no data from AFCAPS 
and JUPITER on participants with diabetes. For cardiovascular events, studies included in subgroup 
analysis were same as for mortality, except no data from AFCAPS for age groups. For cerebrovascular 
disease, no data from AFCAPS and ALLHAT for all subgroups; also no data from PROSPER on age <65, 
from ASPEN for participants without diabetes, and from JUPITER for participants with diabetes. For cancer 
no subgroup data were obtained from ALLHAT; also no data for age <65 from PROSPER, for participants 
without diabetes from AFCAPS and ASPEN, and for participants with diabetes from JUPITER and AFCAPS. 
See footnote to table 1 for full titles of studies.
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disease. The currently observed benefit, a 12% risk reduction in mortality, may even be an 
underestimation of the true effect because subsequent death after a morbid cardiovascular 
event was not always considered in individual trials. 
The numbers and duration of follow-up of our study allow for relatively strong inferences 
on risk of cancer with long term statin use. We found no evidence for an increased risk of can-
cer, fatal or non-fatal. One of the trials (Prospective Study of Pravastatin in the Elderly at Risk; 
PROSPER)w6 did report an increased risk of cancer with use of statins among men and women 
older than 70. Although our results show that statins do not seem to increase the risk of can-
cer, longer follow-up would be helpful to determine whether new cancer events could occur 
with time. This is especially critical when statins are used in primary prevention. Follow-up of 
patients in WOSCOPS for 10 years did not show higher rates of malignancies (34,35). Concerns 
might remain about the higher risk of cancer in elderly patients (70-82 years) as in PROSPERw6 
and further follow-up studies in such patients are required. Although this meta-analysis cannot 
fully remove that uncertainty, it confirms that the risk of cancer is not increased in middle aged 
patients. Tolerance to statins is also important to tackle in primary prevention. Side effects such 
as an increase in creatine kinase levels and myopathy have been reported relatively frequently, 
but rhabdomyolysis and hepatotoxicity are rare(5). Lastly, by contacting principal investigators 
of each trial we were able to obtain data on clinically defined subgroups. This allowed us to 
draw meaningful inferences on treatment effects in large numbers of women, older people, 
and people with diabetes. Although there is little reason to suspect different treatment effects 
between such groups from a pathophysiological standpoint, it is reassuring that no significant 
treatment heterogeneity was found between the sexes, in elderly and young people, and 
between people with and without diabetes. 
limitations of the study
Some limitations of our study need to be mentioned. Firstly, we included three trials in the 
analyses that had recruited a small proportion of patients (about 6%) with clinical cardiovas-
cular disease (30, w7, w9) Exclusion of these trials did not affect the outcome of our analyses. 
Secondly, the dose and type of statin differed between included trials. Depending on the 
statin and the dose, some treatment regimens may be more effective in lowering lipid levels. 
However, according to guidelines from the Adult Treatment Panel III, the statins included in 
our meta-analysis at their respective doses have similar clinical efficacy (8). Thirdly, the included 
trials represented participants with a clinically heterogeneous level of risk (although statistical 
heterogeneity was low). The benefit observed in the pooled estimate of treatment effect could 
be of different magnitude depending on the level of risk. However, exclusion of the studies 
with a small proportion of patients at higher risk did not influence the outcome of the analysis 
because our subgroup analysis indicated no heterogeneity in clinically defined groups such as 
elderly participants or those with diabetes mellitus who are at relatively higher risk. Such a risk 
dependent effect seems unlikely.
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Clinical implications
Our meta-analysis shows that the relative risk reduction from long term statin use in a primary 
care setting is comparable to that observed in secondary prevention. Our findings confirm the 
results of JUPITERw1 regarding the beneficial effect of statins on survival across a broader range 
of patients (n=70388) at different levels of risk, and show that there is no significant differ-
ence in treatment benefit across a range of clinically defined groups (men and women, elderly 
people, and those with diabetes). Although our study population comprised participants 
without established cardiovascular disease, the pooled risk was high. The overall annual mor-
tality was in the range of 1.4%, and fatal as well as non-fatal cardiac and cerebrovascular events 
occurred at an annual rate of about 1.1% and 0.6%, respectively. This is not too different from 
the event rates reported in trials of patients at relatively low risk in secondary prevention - for 
example, the European trial on reduction of cardiac events with perindopril in stable coronary 
artery disease and the Prevention of Events with Angiotensin-Converting Enzyme inhibition 
trial (PEACE) (36,37). Statin based secondary prevention is considered mandatory in participants 
in PEACE. Still, the absolute overall treatment benefit observed in the current study population 
would certainly be less than 1%, and significant numbers of participants would need to be 
treated to prevent one event. From the currently pooled data it is not possible to exactly define 
one group of people who would benefit most from long term statin use. From current risk scor-
ing systems, as well from current data, it is obvious that older men (>65 years) with risk factors, 
or older women with diabetes and risk factors, constitute the highest risk group. In view of the 
large treatment effects described here, it is likely that a considerable number of such people 
would benefit from long term statin use at reasonable costs. The correct identification of such 
people remains a challenge and, in addition to the assessment on the future cardiovascular risk 
based on standard cardiovascular risk factors, auxiliary diagnostic or prognostic assessments 
to improve risk prediction could be useful to identify these men and women more accurately. 
Given the favourable effects of long term statin treatment it would be wrong to deny these 
benefits to people at increased risk for cardiovascular disease.
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The objective of this thesis was to study the feasibility of tailored ACE-inhibitor therapy with 
the aim to individualize treatment of patients with stable coronary artery disease. Most studies 
described in this thesis, were conducted within the EUROPA-trial, a randomized double-blind 
placebo controlled clinical trial studying the effect of the ACE-inhibitor perindopril versus pla-
cebo in 12.218 patients with stable CAD during 4 years of follow-up (1). In the present chapter, 
methodological considerations with regard to the studies described in this thesis are described 
and the main findings of this thesis are placed in a broader context. Also, the potential implica-
tions for future clinical practice of physicians are discussed. Finally, directions for future research 
are discussed.  
mEThoDologiCAl ConsiDErATions
Methodological considerations pertaining to the separate studies have been described in the 
specific chapters. Here, general methodological considerations will be discussed with regard to 
the presented genetic association studies. 
genetic association studies 
In genetic association studies, candidate genes in relevant pathways can be selected, and the 
association between variation in these genes and disease occurrence or effect of the drug 
(reduction in disease occurrence) investigated. Genes may be selected on the basis of assumed 
relation in the pathofysiology of the disease with genetic variants, such as single nucleotide 
polymorphisms (SNPs). SNPs may be selected because of their functional implications or loca-
tion in the gene. On the other hand, genetic variants may be selected because they “tag” gene 
haplotypes. A haplotype is a set of tagging SNPs on a single chromatid that are statistically 
associated and tend to inherit together. It is thought that the identification of the alleles of a 
haplotype block can unambiguously identify all other polymorphic sites within its region. As 
such, the haplotype-approach is important to discover the genetics behind common diseases. 
In this thesis, we selected the renin-angiotensin and kallikrein-bradykinin system genes as 
candidate genes as they are the primary targets affected by ACE-inhibitors (pharmacodynam-
ics) (2). We combined the two described approaches of selecting the SNPs by functional role 
and haplotype tagging. To ensure a comprehensive coverage of the common genetic variation 
in these candidate genes, we used a haplotype tagging-SNP approach with multiple tagging 
SNP’s to reach a minimum coverage of at least 90% of the common genetic variation in the 
candidate gene (2). In choosing the tagging-SNPs, we preferred functional SNPs or SNPs located 
in coding or promoter (transcriptional activity) regions of the gene. In addition, we enriched 
our set of SNPs with SNPs of interest due to prior literature. One of the most frequently studied 
polymorphisms in the RAAS is the ACE I/D, located in an intronic region of the ACE gene, with 
only minor effects on ACE plasma levels (3-6). As it is very laborious SNPs to genotype (286 bp 
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insertion / deletion) using polymerase chain reactions, we used a direct proxy in the ACE gene: 
rs4343 which is reported with high LD (D’ 1.0; r2 0.9) with the ACE I/D (3,4). In total, we studied 12 
candidate genes and 52 tagging-SNPs (2). The current study is one of the most comprehensive 
analyses of the RAAS and BK pathways ever performed in genetic association studies. 
Important to note here is that we only studied the two direct pharmacodynamic pathways 
of ACE-inhibitors: the renin-angiotensin system and kallikrein-bradykinin system (2,7,8). ACE-
inhibitors inhibit the ACE activity which reduces the activation of AT-2 from AT-1 and increases 
the degradation of BK. There are other candidate genes to study, most importantly the genes 
involved in the metabolism of ACE-inhibitors for example genes encoding the CYP450 enzymes. 
However, the exact targets to study are yet unknown and no relevant metabolic candidate 
genes could be included. This is a field for ongoing research. 
Plasma-levels
Genetic variants in the RAAS may also influence plasma levels of the hormones involved. For 
example, it is known that genetic polymorphisms in coding regions of the AGT gene influence 
the levels of AGT in the human body (7,8). The M235T polymorphism (rs699) located in exon 5 of 
the AGT gene influences the plasma levels of AGT (7-9). In genetic association studies it is very 
important to have a biologically plausible mechanism for your findings. Investigation of such 
variants may provide solutions for problems encountered with causal inference. If the blood 
levels truly increases risk of disease, then carriage of the genetic variant that exposes individu-
als to an elevation of the blood levels should confer an increased risk of disease proportional to 
the difference in the marker attributable to the genetic variant. Considering our project, plasma 
levels of angiotensinogen, angiotensin-converting enzyme, renin, and aldosteron, would have 
been needed to make remarks on the potential mechanisms of our findings. Unfortunately, as 
these genetic polymorphisms are rare with about 4-5% homozygous minor allele patients, one 
would need plasma levels of several hundreds or even thousands of patients to make mean-
ingful inferences. To date, plasma levels of RAAS hormones together with genetic information 
is only available in limited numbers of fifty to hundred patients which makes it inevitably 
underpowered. Performing the assays needed for angiotensinogen are expensive and labor 
intensive. As we found associations in bradykinin receptors, plasma levels of bradykinin would 
be very interesting, however, no laboratories have these levels in high quantities available. 
This is a shortcoming of our genetic findings, however, it does open new ways of research and 
advocates to study the mechanism of action of ACE-inhibitors more intensively, including levels 
of bradykinin, angiotensinogen, ACE, and AT-II. 
Causality
Genetic association studies in general may have several other shortcomings. An association 
found between a single variant and a disease outcome may have been caused by linkage 
General Discussion 271
disequilibrium with another genetic variant. A more comprehensive approach is obtained by 
constructing gene haplotypes that capture the common genetic variation across a gene, as 
described above. In our study, we found genetic variants in the AT1 and BK1 receptor modifying 
treatment benefit of perindopril (10). Both AT1 receptor gene polymorphisms were located in 
an influential region of the gene, respectively in the promoter and exon. A functional or causal 
mechanism is plausible. The polymorphism located in the BK1 receptor was located in an intronic 
region of the gene, and the above mentioned scenario could apply for this SNP (10) but additional 
research is needed to study the functional role of the BK1 receptor. Several recent studies report 
a influential role of this receptor in the cascade of the RAAS and cardiovascular risk. 
sample size
Furthermore, large sample sizes are needed to provide enough power to detect the effect 
(albeit small) of a genetic variant on disease with a multifactorial origin. Such diseases are 
thought to result from variation in a large spectrum of genes with small individual effects, the 
same probably applies for studying the effect of treatments. As demonstrated in chapter 10, 
the PERGENE study due to the large size and large number of events we had sufficient power 
for the detection of interaction effects (2). The size of this pharmacogenetic sub study allows 
detection with a power of 98% to detect a difference in hazard ratios (treatment effect for the 
primary endpoint) of 20% between genotypes with minor allele frequency of 0.20, based upon 
ten-thousand patients (two-sided alpha 0.05). For other genotype distributions, power will be 
less but for most comparisons still above 80%. For a minor allele frequency of 0.10, statistical 
power is 88% to detect a difference in treatment effect of 20% with a two-sided alpha 0.05 (2). 
multiple testing
Multiple testing is an important issue due to the possibility of chance findings in genetic 
association studies. Correction is therefore necessary. There are several approaches to correct 
for multiple testing, which are all vividly debated. A clear distinction needs to be made here 
between genome-wide scans and candidate-genes approaches. In a genome-wide scan, half a 
million of detectors of SNP’s are placed on a chip and tested on the DNA of the patients, rigorous 
multiple testing correction is necessary due to the large number of tests and SNP are entirely 
independent of each other. Therefore, p-values of exponent 10-15 are often needed to reach 
significance in these studies after Bonferonni correction (0.05 divided by the number of test 
performed is significance level to be reached). In a candidate gene approach, genes and SNPs 
are manually selected based upon a strong prior study hypothesis. SNP’s are selected by tagging 
principle, functionality or location in the gene. In our study, we selected candidate genes in the 
two pharmacodynamic pathways of ACE-inhibitors by study hypothesis and we selected, manu-
ally, the 52 tagging SNPs needed in these genes, which are therefore not entirely independent as 
SNP’s are taggers and located within one common pathway (2,10). To correct for multiple testing, 
we have chosen for a gene-based permutation analysis. Applying more extensive correction (ie. 
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Bonferonni or permutations for 52 tests) would be overly conservative due to the strength of the 
a priori study hypothesis and may fail to notice real existing differences.
reproducibility
Finally, reproducibility or replication of the results of genetic association studies is important. 
Considering the exclusivity of our pharmacogenetic analysis in a randomized clinical trial 
studying one single drug treatment, no suitable replication cohort of similar size and design 
does exist. Still, as demonstrated in chapter 11, even with low sample size, the same trend in 
the direction and magnitude of the interaction effects was observed as compared with the 
findings in the EUROPA-trial which reassures the validity and consistency of our findings. With 
replication of your findings, the issue of multiple testing vanishes. Still, as mentioned, finding a 
suitable replication cohort is one of the major limitations of this project as clearly the data are 
unique and no other randomized clinical trial with access to DNA in patients with stable CAD 
was available. For an initial replication of our findings, we had the opportunity to use data of 
1051 Caucasian patients of PROGRESS studying the same ACE-inhibitor, perindopril, albeit in 
lower dose of 4 mg (10,11). The small sample size results in an underpowered statistical analysis 
and actual replication of interaction terms would be impossible just to the small number of 
patients, still a verification of a similar direction of the interaction effect can be made in such 
small replication studies. PROGRESS enrolled patients with cerebrovascular disease. Because 
the treatment benefit in PROGRESS was contingent on the combination with indapamide (2,5 
mg), we studied patients receiving single therapy with perindopril in the European subjects 
of PROGRESS, which ensures comparability with the EUROPA-trial subjects (10,11). Additional 
replication needs to be sought in different trials with different ACE-inhibitors, to test the gener-
alizability to other patient groups and other ACE-inhibitors as well.  
mAin finDings 
In the current thesis, we demonstrate that guiding ACE-inhibitor therapy was not feasible using 
clinical characteristics of patients (12-15). Furthermore, the treatment benefit of perindopril based 
regimens in a combined analysis of EUROPA, ADVANCE and PROGRESS trials was not modified 
by baseline risk factors, blood pressure or the blood pressure reduction during run-in period (15). 
Still, heterogeneity in treatment effect of ACE-inhibitors is likely as there is a large inter-individual 
variability in response to ACE-inhibitors. As a new approach, we tested whether genetic varia-
tion in the direct pharmacodynamic pathway of ACE-inhibitors, the renin-angiotensin system 
and kallikrein-bradykinin pathway, modified the treatment benefit of ACE-inhibitors. 
The current study demonstrates that the treatment benefit of ACE-inhibitor therapy by per-
indopril is modified by variation in 2 candidate genes: the AT1 receptor gene, and the BK1 
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receptor gene (10). Based on the pharmacogenetic profile, consisting of these variants, both 
patients with an enhanced treatment benefit (73.5% of the PERGENE population), and patients 
with a diminished, if not absent, treatment effect (26.5% of the PERGENE population) could be 
identified. A similar interaction of this profile with the treatment effect was observed in the 
replication cohort from PROGRESS. The proposed pharmacogenetic profile was directly associ-
ated with the treatment benefit of ACE-inhibitors. This association was independent of baseline 
clinical characteristics and blood pressure, which is in accordance with previous studies in 
which clinical patient characteristics or subgroup analyses that did not reveal any treatment 
heterogeneity (10).
In the main analysis of the EUROPA-trial, treatment with perindopril resulted in a relative risk 
reduction of 20% for the primary endpoint, which was consistent across all clinical subgroups 
(1). In contrast, the subgroups based on the proposed genetic profile have a wide range of treat-
ment effects (10), from patients without unfavourable alleles (11.3% of all patients) with a 54% 
reduction in the primary endpoint during follow-up, via patients with one unfavourable allele 
(29.8%) who experienced a 39% relative risk reduction and patients with two unfavourable 
alleles (32.4%) with a 19% relative risk reduction, which is more comparable to the overall study 
effect. At the other end of the spectrum, patients with ≥3 unfavourable alleles experienced no 
benefit (26.5%) from perindopril treatment during 4 years of follow-up. Refraining from treat-
ment with perindopril in these patients may considerably reduce healthcare cost and increase 
the overall efficacy of the drug. 
In essence, we have found several genetic determinants related to the treatment benefit 
of ACE-inhibitors. The aggregated pharmacogenetic profile predicted the response to ACE-
inhibitors as it identified responders and non-responders. The current study demonstrates 
the feasibility of pharmacogenetic profiling of ACE-inhibitor therapy in patients with coronary 
artery disease.
PAThoPhysiology AnD mEChAnism
Our findings suggest that the genetic variants modifying the treatment effect of perindopril 
are particularly located in the AT1 and BK1 receptor genes. The SNPs in the AT1 receptor were 
located in the promoter (rs275651) and exon (rs5182), the SNP (rs12050217) in the BK1 receptor 
was located in an intron. These three SNPs were tagging SNPs and may either be functional 
themselves or in linkage equilibrium with important functional SNPs. So far, functionality of 
these three SNPs is unknown. The AT1 receptor does mediate all the well-known effects of 
angiotensin II, including vasoconstriction, water and salt retention, aldosterone synthesis 
and hypertrophy (7). The role of the B1 receptor, on the other hand, is less well established. 
Bradykinin is a potent vasodilator that also induces anti-atherosclerotic and anti-thrombotic 
effects, which are mediated by bradykinin type II (B2) receptors 
(7). Previous studies indicated 
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that the clinical benefit of ACE-inhibitors depends, at least in part, on B2 receptor activation 
(17). 
B1 receptors are weakly expressed under physiological conditions, but are strongly induced in 
response to pathological conditions and/or RAAS blockade (18,19). Interestingly, it has been sug-
gested that B1 receptors are directly activated by ACE-inhibitors (thus resulting in an increase in 
endothelial NO release, for instance in the heart, by which they contribute to the cardioprotec-
tive effects of ACE-inhibitors (20,21,22), but this has not been uniformly confirmed by others (23). 
Therefore, a more likely possibility is that the up-regulated B1 receptors are activated by their 
endogenous ligand during ACE-inhibition. Given the hypotensive (24), cardioprotective (18) and 
cerebro-protective (25) effects of such activation, as observed in animals, one might speculate 
that patients with genetic defects in their B1 receptor display a diminished response to ACE-
inhibition. Clearly, more work is needed to support this concept. 
CliniCAl imPliCATions
Our finding show that three out of four patients had an enhanced benefit of ACE-inhibitor 
therapy (33% reduction of cardiovascular death of myocardial infarction, up to 54% in patients 
without any unfavourable alleles) and one out of four patients experienced no, or a markedly 
diminished, benefit of long term perindopril treatment. By developing a pharmacogenetic 
profile related to treatment response, patients can be selected who are most likely to benefit 
from such treatment in advance. When the feasibility of pharmacogenetic profiling of ACE-
inhibitor therapy is confirmed, physicians will be able to predict the response to treatment (the 
exciting concept of responders and non-responders) before the start of prescription. Taken 
together, these pharmacogenetic analyses of clinical trials open up a perspective to individual-
ize preventive therapy in patients with stable CAD, which may avoid unnecessary treatment, 
and considerably reduce health care costs by the concept of “individualizing therapy” based on 
genetic data. Moreover, the combination of these trials can be used to identify a genetic profile 
for cardiovascular drugs at large. As our results demonstrate the feasibility of pharmacogenetic 
profiling, we advocate that the current pharmacogenetics approach should be integrated in 
future randomized clinical trials designs as standard procedure to optimize patients’ benefit.
DirECTions of ongoing AnD fuTurE PhArmACogEnETiC rEsEArCh
“Getting the right drug to the right patient”
Through pharmacogenetics, medical science reclaims the art of individual medicine, which 
serves as the gateway to understanding heterogeneity among individuals in drug response. 
Pharmacogenetics teaches that different patients respond differently to medications. In the 
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current clinical trial arenas of therapeutic drug response optimization and individualization 
strategies, pharmacogenetic testing is used with an ever increasing frequency and is defin-
ing a new frontier in diagnostic and therapeutic patient approaches. Correlation between 
clinical and genetic heterogeneity allows for optimization of therapeutic strategies, while we 
keep developing new technologies, such as DNA arrays and advanced bioinformatics, in the 
quest for the Holy Grail, which is “tailoring drug therapies to individual patients”. Ultimately, 
pharmacogenetics will also help in the development of new drugs targeted at critical signalling 
pathways in disease pathogenesis allowing for both treatment and prevention. 
Pharmacogenetic research is emerging rapidly and is expected to revolutionize clinical prac-
tice in the next decennia. At this moment, successes are presented for several cardiovascular 
drugs for example clopidogrel. Pharmacogenetic determinants of the response of patients 
to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug as well 
as the clinical efficacy of clopidogrel, especially the genetic variants of genes modulating 
clopidogrel absorption (ABCB1), metabolic activation (CYP3A5 and CYP2C19), and biologic 
activity (P2RY12) are under extensive investigation (26,27). Also pharmacogenetics proves to be 
important in dosing of coumarin derivates such as warfarin by which the incidence of major 
hemorrhage can be significantly reduced (28,29). Clopidogrel and warfarin are just two of many 
successful (upcoming) examples of pharmacogenetics. 
Within the PERGENE study, we will focus on further replication of the main findings in other 
randomized clinical trials, which studied different patient populations or a different ACE-
inhibitor. Another important issue to investigate is the pathophysiological mechanism behind 
the current findings addressing the functional role of the genetic variants and the role of the 
bradykinin type I receptor within cardiovascular disease with respect to drug interaction. A new 
research project has been set up to investigate the functional role of the BK-1 and AT-1 recep-
tor genetic variants and correlate them with plasma levels. Furthermore, genetic research in 
the metabolic enzyme genes responsible for the absorption and degradation of ACE-inhibitor 
metabolites is necessary, for example the various CYP450 enzymes. However, no exact target 
genes have been discovered at the moment. Ultimately, we hope that the current findings will 
provide opportunities to test the genetic determinants of treatment effect genome-wide. A 
large-scale genome wide scan of patients across both randomized treatment arms may further 
reveal relevant genetic targets related to the treatment benefit of ACE-inhibitors.  
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Worldwide, millions of patients with stable coronary artery disease are treated with ACE-inhib-
itors according to the recommendations of international treatment guidelines on secondary 
prevention based on the results of large clinical trials. In the EUROPA-trial, treatment with the 
ACE-inhibitor perindopril at 8 mg / day was associated with 20% risk reduction in the event rate 
of cardiovascular mortality, MI or resuscitated cardiac arrest as compared to placebo during 
four years of follow-up. Also, in other patient categories ACE-inhibitors have proven clinical 
benefits. These studies were the basis for recommendations on ACE-inhibitors in the treatment 
guidelines for secondary prevention in patients with cardiovascular disease. 
Still, in a relatively low-risk group of stable CAD patients, the absolute risk reduction with 
perindopril was 2% and 50 patients needed to be treated to prevent one cardiovascular event 
(200 patient years). To improve the clinical efficacy of ACE-inhibitors, several attempts have been 
made to target ACE-inhibitors only to those patients most likely to benefit of such prolonged 
prophylactic treatment. As the results of clinical trials are based on a selected patient group 
(inclusion and exclusion criteria) and results may not apply to all patients studied. However, 
treatment guidelines are based on these studies, which in general do not always perfectly 
reflect the patient in front of your desk as a physician. One should consider that the treatment 
effect will differ between patients. To optimally treat patients, one would rather know whom 
to treat rather than to treat everyone. Elucidating an existing heterogeneity in the treatment 
effect of ACE-inhibitors will be crucial if one would wish to target ACE-inhibitors to those who 
will benefit (responders versus non-responders). In this thesis, we examined the consistency in 
treatment benefit of ACE-inhibitor therapy in patients with stable coronary artery disease. Most 
of the studies have been performed in the EUROPA-trial, a randomized placebo-controlled 
clinical trial comparing perindopril versus placebo in patients with stable coronary artery dis-
ease. We assessed the consistency of the treatment effect of ACE-inhibitor therapy according 
to clinical characteristics and genetic factors with the aim to detect a possible heterogeneity 
which could be used to target ACE-inhibitors to those patients most likely to benefit and test 
the feasibility of pharmacogenetic profiling. 
Part i focuses on the established role of ACE-inhibitors in the treatment of cardiovascular 
disease patients. Especially, extensive evidence has been gathered with the ACE-inhibitor, 
perindopril, which properties will be described in detail (chapter 2), as well as an overview 
of other ACE-inhibitor trials in different patient categories (chapter 3). Part ii focuses on the 
identification of risk factors which could be involved in a heterogeneity in the treatment benefit 
of ACE-inhibitors. Renal insufficiency has been identified as an important cardiovascular risk 
factor of in relatively health subjects (chapter 4) as well as in patients with cardiovascular 
disease (chapter 5). Renal insufficiency could therefore be an important modifier of treatment 
effect of ACE-inhibitors considering pharmacokinetics (renal clearance) as well as patients’ 
increased cardiovascular risk. However, in our analysis in the EUROPA-trial, renal insufficiency 
did not modify the treatment effect of perindopril (chapter 6). In part iii, we describe a 
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combined analysis of the EUROPA, ADVANCE and PROGRESS-trials with 30.000 vascular disease 
patients which could not identify a heterogeneity in the treatment effect according to clinical 
characteristics including blood pressure (chapter 7). From part II and III, we conclude that no 
heterogeneity in the treatment effect of ACE-inhibitors in stable CAD patients can been eluci-
dated using simple clinical characteristics. More advanced approaches are therefore necessary. 
In part iV, we discuss these new steps needed to guide ACE-inhibitor therapy. A new approach 
could be to integrate more patient-specific characteristics, such as the genetic information 
(DNA) of patients (chapter 8), especially the pharmacodynamic pathway of ACE-inhibitors – 
the renin-angiotensin-aldosterone-system – is expected to be involved in the inter-individual 
variability in the response to ACE-inhibitors (chapter 9). In part V, we present the design and 
rationale of the PERindopril GENEtic association study (PERGENE), the largest pharmacogenetic 
study of ACE-inhibitors and one of the first randomized clinical trials presenting genetic data 
with regard to treatment effect analyses (chapter 10). The aim of the research project was to 
develop a pharmacogenetic profile related to the treatment effect of ACE-inhibitor therapy 
predicting patients’ response to such prolonged prophylactic treatment. Indeed, several 
genetic factors were related to the treatment benefit of perindopril (chapter 11). These genetic 
variants were located in the AT1-receptor and BK1-receptor. A pharmacogenetic profile com-
bining the unfavorable alleles of these genetic variants demonstrated a stepwise decrease in 
the treatment benefit of perindopril. Patients with no or little genetic variants in these recep-
tors experienced a more pronounced treatment benefit of perindopril (responders, 73.5%). 
In contrast, patients with 3 or more of the unfavorable alleles did not benefit of treatment at 
all, in other words, no risk reduction of perindopril treatment during follow-up occurred in 
these patients which were relatively resistant to perindopril (non-responders, 26.5%). These 
findings were verified in the PROGRESS-trial. This new concept of “tailored-therapy” by pharma-
cogenetic profiling can reduce unnecessary treatment of non-responding patients and reduce 
health care costs. The selected candidate genes were also related to blood pressure and blood 
pressure reduction by perindopril (chapter 12). However, the differences in blood pressure 
reduction were so small that they count not explain the difference in clinical risk reduction, but 
feed the discussion for BP-independent effects of ACE-inhibitors. The current findings support 
more extensive research in the mechanism of action of ACE-inhibitors. Finally, in part Vi, the 
clinical implications of our findings and “the feasibility of tailored therapy of ACE-inhibitors” will 
be discussed in chapter 13. 
In overview, this thesis presents a new concept of individualizing drug prescriptions. The 
concept of pharmacogenetics can be generalized to other frequently used drugs in cardiology 
such as beta-blockers, calcium-antagonists, platelet-inhibitors. For one of the most frequently 
prescribed drugs, statins, the current concept of individualizing therapy is clinically highly 
relevant (Part Vii, chapter 14). As chapter 14 demonstrates the strong consistency of the 
treatment benefit of statins independent of several clinical characteristics, one could again 
argue that a comparable pharmacogenetic approach would be useful. We advocate that the 
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pharmacogenetic concept will be integrated in the design of all emerging randomized clinical 
trials to optimize patients’ benefits. In the general discussion (Part Viii, chapter 15), method-
ological considerations with regard to the studies described in this thesis are mentioned and 
the main findings of this thesis are placed in a broader context. Finally, directions for on-going 
research and future research are discussed.  

samenvatting

Samenvatting 287
Miljoenen patiënten met stabiel coronair lijden worden behandeld met ACE-remmers volgens 
de internationale richtlijnen. In de EUROPA-trial was de behandeling met de ACE-remmer per-
indopril (8mg/dag) geassocieerd met een daling van 20% in het optreden van cardiovasculaire 
events (cardiovasculaire sterfte, myocard infarct, of hartstilstand) ten opzichte van placebo 
tijdens vier jaren van follow-up. Ook in andere patiënten populaties hebben ACE-remmers een 
bewezen gunstig effect. Dit heeft geleid tot de aanbeveling ACE-remmers voor te schrijven ter 
secundaire preventie van hart- en vaatziekten in alle internationale richtlijnen. ACE-remmers 
spelen een belangrijke rol in de dagelijkse behandeling van vele patiënten in de cardiologie. 
Aangezien de absolute daling van het risico op events door perindopril 2% was en er 200 
patienten behandeld moeten worden gedurende 4 jaren om 1 event te voorkomen, zijn er 
verscheidene pogingen ondernomen om ACE-remmers te richten op alleen die patiënten die 
er baat bij hebben. Subgroep analyses, o.a. in de EUROPA trial, hebben de heterogeniteit van 
het behandeleffect onderzocht maar niet aangetoond. Geen van de klinische kenmerken die 
onderzocht werden, zoals hoge bloeddruk of het hebben van suikerziekte, bleek van waarde in 
het gericht voorschrijven van ACE-remmers. Het behandeleffect is consistent in patiënten met 
stabiel coronair lijden en dus niet afhankelijk van klinische factoren. Om patiënten optimaal te 
behandelen, is het van belang vooraf te weten wie er meeste baat hebben bij het medicijn. De 
ontdekking van een mogelijke heterogeniteit in het behandeleffect blijft derhalve cruciaal (wie 
wel of niet op het medicijn reageren). Dit staat in direct contrast met het medicijn aan iedereen 
voor te schrijven. Een nieuwe aanpak zou kunnen zijn om meer patiëntspecifieke informatie te 
gebruiken: de genetica of pharmacogenetica. Pharmacogenetica is een nieuw onderzoeksveld 
gericht op het ontdekken van genetische factoren gerelateerd aan de response op een medicijn 
of de bijwerkingen van het medicijn. Wanneer de response op ACE-remmers verschilt op basis 
van genetische verschillen tussen mensen, kan dat een handvat zijn om een genetisch profiel 
te ontwikkelen dat de respons op deze behandeling voorspelt. Idealiter voorspelt dit wie wel 
reageert en wie niet reageert op het medicijn. Een pharmacogenetisch profiel gerelateerd aan 
behandeleffect kan het onnodig behandelen van patiënten reduceren en de kosten van de 
gezondheidszorg drukken. 
In dit proefschrift hebben we deze aspecten van het gericht voorschrijven van ACE-remmers 
in verscheidene facetten bestudeerd. De meeste studies zijn verricht in de EUROPA-trial, een 
gerandomiseerde placebo-gecontroleerde studie naar het behandeleffect van perindopril 
versus placebo in patiënten met stabiel coronair lijden. Vanuit het bloed van deze deelnemers, 
werd genetische informatie van deze patiënten gedestileerd en het verband met de response 
op de ACE-remmer perindopril onderzocht. 
Deel i is gericht op de rol van ACE-remmers in de cardiologie, vooral de ACE-remmer in 
kwestie, perindopril, wordt hierin uitvoerig beschreven in verschillende patiënten groepen 
(hoofdstuk 2), evenals een overzicht van de verscheidene andere ACE-remmers trials 
(hoofdstuk 3). Deel ii is gericht op de zoektocht naar klinische factoren die de response op 
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ACE-remmers voorspellen. Nierinsufficientie is een belangrijke risicofactor voor het optreden 
van hartinfarcten of cardiovasculaire sterfte in relatief gezonde mensen (hoofdstuk 4) maar 
zeker ook in hart- en vaatziekten patiënten (hoofdstuk 5). Nierinsufficientie, kan derhalve 
een belangrijke factor zijn om patiënten te identificeren die meer of minder baat hebben bij 
ACE-remmer behandeling. In onze analyse binnen de EUROPA trial bleek nierinsufficiëntie 
echter niet het behandeleffect te modificeren richten (hoofdstuk 6). Risicofactoren zoals 
diabetes, hypertensie, of het hebben van eerder myocard infarct bleken in een analyse binnen 
de EUROPA, ADVANCE en PROGRESS-trial niet gerelateerd aan het behandeleffect van ACE-
remmers (deel iii, hoofdstuk 7). Uit Part II en III kunnen we concluderen dat klinische kenmer-
ken niet gebruikt kunnen worden om te voorspellen wie baat heeft van het medicijn of niet, 
om de effectiviteit van het medicijn te vergroten zou men dit wel willen. In deel iV bestuderen 
we de nieuwe stappen die nodig zijn om dit te bereiken. Een nieuwe aanpak hierin kan zijn om 
patiënt-specifiekere gegevens te gebruiken, het DNA van patiënten (hoofdstuk 8 en 9). In deel 
V wordt het design en rationale voor het opzetten van een grote genetische studie binnen de 
EUROPA trial besproken (hoofdstuk 10). De hypothese van deze studie was dat er bepaalde 
genetische factoren, met name in het direct pharmacodynamische pathway van ACE-remmers, 
een effect hebben op de werking van het medicijn. Inderdaad bleken er genetische factoren 
in het renine-angiotensine-aldosteron systeem en kallikrein-bradykinin systeem te bestaan die 
het behandeleffect van perindopril beïnvloeden (hoofdstuk 11). Drie afwijkingen in het DNA 
van patiënten bleken gerelateerd aan het behandel effect. Een gecombineerd risico profiel van 
deze 3 afwijkingen liet een stapsgewijze afname van het behandeleffect met perindopril zien. 
Patienten zonder deze genetische afwijkingen lieten een zeer uitgesproken behandeleffect 
zien (responders, 73.5%). Echter, mensen met 3 of meer van de genetische varianten bleken 
geen enkel behandeleffect van de behandeling met perindopril (non-responders, 26.5%) 
gedurende de 4 jaren van follow-up te ondervinden. Deze bevindingen werden geverifeerd 
in de PROGRESS trial. Dit ontwikkelde pharmacogenetisch profiel identificeert responders en 
non-responders, en kan zo het aantal onnodig behandelde patiënten en de kosten voor de 
gezondheidszorg reduceren. De genetische factoren in het renine-angiotensine en kallikrein-
bradykinin systeem bleken ook gerelateerd aan de bloeddruk van patiënten en de bloeddruk 
daling op behandeling met ACE-remmers (hoofdstuk 12). Echter, de verschillen in deze bloed-
druk daling waren zo klein dat dit geen klinische effecten had. Tevens staat het werkingsme-
chanisme van ACE-remmers, hetzij bloeddruk afhankelijk of bloeddruk onafhankelijk effecten 
ter discussie, iets wat versterkt wordt door deze genetische bevindingen. Deze resultaten spo-
ren aan tot nader onderzoek in het exacte werkingsmechanisme van ACE-remmers. Tenslotte 
worden in deel Vi de klinische implicaties van onze bevindingen besproken: “the feasibility of 
tailored-therapy of ACE-inhibitors” hoofdstuk 13). 
Dit proefschrift beschrijft een nieuw concept van tailored-therapy van ACE-remmers 
door middel van genetische informatie van patiënten. Dit concept valt te generaliseren naar 
andere medicijnen binnen de cardiologie zoals de beta-blockers, calcium antagonisten en 
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plaatjesremmers, maar zeker ook de cholesterolverlagers (statines) verdienen een dergelijk 
aanpak om het juiste medicijn bij de juiste patiënt te krijgen. Statines zijn een van de meest 
voorgeschreven medicijnen in de cardiologie en tonen net als de ACE-remmers ook een 
grote consistentie in het behandeleffect (deel Vii, hoofdstuk 14). Te overwegen valt of een 
dergelijke pharmacogenetische aanpak standaard procedure dient te worden in de opzet van 
nieuwe gerandomiseerde klinische trials. In de algemene discussie (deel Viii, hoofdstuk 15) 
worden de methodologische overwegingen met betrekking tot de studies in dit proefschrift 
beschreven. Ook worden de belangrijkste bevindingen in perspectief geplaatst van de huidige 
inzichten en worden de klinische implicaties voor de toekomst van de dagelijkse praktijk van 
een dokter besproken. Tenslotte worden de richtpunten van verder onderzoek besproken.
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Graag wil ik op deze plaats iedereen bedanken die heeft bijgedragen aan de totstandkoming 
van dit proefschrift, met op de eerste plaats de patiënten die bereid waren deel te nemen aan 
de EUROPA-trial en de vele controles die daarmee gepaard gingen gedurende vier jaren van 
studie, en de artsen betrokken bij de studie in de verschillende centra in Europa. Een aantal 
mensen wil ik persoonlijk bedanken voor hun bijdrage:
Mijn promotoren, Prof. dr. maarten l. simoons en Prof. dr. Eric Boersma. Geachte Prof. 
dr. Simoons, bedankt dat u mij de kans heeft gegeven om mijn promotieonderzoek in deze 
bijzondere setting te verrichten, en dat u mij de gelegenheid heeft gegeven vrij en zelfstandig 
te werken aan verschillende projecten. Uw bijdrage aan dit proefschrift is essentieel en de basis 
voor het merendeel van de inhoud. Ik heb veel geleerd van uw inzicht, kennis, kritische blik, en 
ervaring zowel op klinisch gebied als wetenschappelijk. Al in een vroeg stadium gaf u mij het 
vertrouwen om een-op-een met de projectleiders van andere trials te communiceren, mijns 
inziens is dat van onschatbare waarde voor een toekomstig arts-onderzoeker. Tevens waardeer 
ik uw persoonlijke betrokkenheid bij dit onderwerp, “tailored-therapy”, wat naar ik hoop een 
succesvolle nieuwe onderzoekslijn wordt binnen het Thoraxcentrum waar nog vele nieuwe 
mogelijkheden liggen. Naast uw betrokkenheid als promotor, wil ik u ook danken voor het 
in mij gestelde vertrouwen door mij toe te laten tot de opleiding Cardiologie. Geachte Prof. 
dr. Boersma, beste Eric, bedankt voor jouw begeleiding en betrokkenheid bij mijn promotie 
onderzoek en alle zaken rondom een promotie-traject waarin ik altijd op jou kon rekenen. Het 
gaf rust om te weten dat jij binnen het PERGENE project betrokken was. Ook jouw bijdrage aan 
dit proefschrift was essentieel. Ik heb het scala aan statistische analyses die we samen hebben 
gedaan, en de vele nuttige gesprekken enorm gewaardeerd. Daarin konden we behoorlijk in 
de diepte gaan, wat leuk en leerzaam was. Het was bijzonder om altijd bij jou binnen te kunnen 
lopen en weer met nieuwe ideeën of aangescherpte analyses terug te komen. Bedankt voor 
jouw snelle bereikbaarheid voor commentaar en aanvullingen op mijn artikelen. Tevens waar-
deer ik jouw betrokkenheid bij toekomstig onderzoek wat veel vertrouwen geeft. Op een of 
andere manier denk ik dat onze wegen nogmaals zullen kruisen waarop ik mij nu al verheug. De 
combinatie met wetenschappelijk onderzoek zal een vast onderdeel blijven van mijn beroep. 
Mijn beste promotoren, ik ben trots op het resultaat wat nu voor u ligt!
Mijn co-promotor, Dr. de maat, wil ik hartelijk danken voor alle betrokkenheid en begeleiding 
van mijn onderzoeksperiode. De begeleiding bij de tagging-SNP bepalingen en haplotypen 
aanpak bij de start van het onderzoek was essentieel. Ook jouw hulp bij de verzameling en 
verwerking van de bloed samples bij TNO en de verfrissende inbreng in de groep gezien jouw 
achtergrond in de biochemie verdient een speciaal dankwoord. Daarnaast waardeerde ik jouw 
snelle bereikbaarheid en respons bij de bijbehorende papers.
Prof. dr. Danser, Prof. dr. stricker en Prof. dr. Bernardi, wil ik bedanken voor hun bereid-
heid zitting te nemen in de kleine commissie en inhoudelijke beoordeling van het proefschrift. 
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Prof. dr. Danser, een bijzonder dankwoord gaat uit naar uw rol en betrokkenheid. De stukken 
die wij samen hebben geschreven over het renin-angiotensin-system gaven de nodige ver-
dieping in dit complexe systeem. De bevindingen in de bradykinine receptoren en prorenine 
receptoren bieden nieuwe inzichten in de betrokkenheid van deze vasoactieve stoffen in het 
cardiovasculaire systeem. De leden van de grote commissie, Prof. dr. uitterlinden en Prof. dr. 
Doevendans wil bedanken voor hun bereidheid zitting te nemen en aanwezig te zijn bij de 
promotie voor de inhoudelijke verdediging van het proefschrift. 
Dr. isaacs, a special word of thanks I want to devote to your participation in my research proj-
ect. Your statistical experience and great passion for the genetic analyses of the permutation 
model were fundamental for the genetic papers. 
Dear executive board members of the EUROPA-trial, Prof.dr. fox, Prof.dr. ferrari, Prof.dr. Ber-
trand and Prof.dr. remme. It was a great honor to work so close with you on several projects 
in the EUROPA-trial and the PERGENE study. It was a great pleasure to meet each of you during 
the Schiphol meetings and the staff meetings in Paris about PERGENE or at ESC scientific ses-
sions. Your experience in the field and personal comments to most of my manuscripts were 
very constructive, improved the quality of my work and enhanced my personal development 
as a researcher. It was a privilege to work with this distinctive team of professors, all former or 
current ESC presidents, which is truly a unique opportunity to learn from the experts in clinical 
trial management.
Dear Prof. dr. Chalmers and Prof. dr. mac mahon, thank you for your comments on my manu-
script and kindly providing me the individual data of the PROGRESS and ADVANCE-trials. Your 
cooperation was essential in many of my manuscripts, and it was a privilege to work with the 
experts in clinical trial management, thank you!
Beste Dr. Deckers en Dr. van Domburg, u beiden wil ik bedanken voor de vele kansen die ik 
kreeg tot presentatie van mijn onderzoeks-resultaten bij de COEUR of journal clubs maar zeker 
ook onze gezamenlijke interesse in (primaire) preventie die wij delen wat ons bracht tot een 
artikel in de BMJ over het gebruik van statines in relatief gezonde mensen. Jullie betrokkenheid 
hierin was essentieel. Dear Prof. dr. ridker, I would like to thank you for your participation in 
our research project on statins in primary prevention and sharing the JUPITER-trial data and 
commenting on our analysis, which was a great pleasure to work with you. I look forward to the 
ongoing collaboration projects.
Prof. Dr. serruys, u wil ik bedanken voor de twee studies die ik heb mogen doen met PCI 
patiënten binnen de EXCITE trial, waar tevens een belangrijke interesse van mij ligt.
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Mijn kamergenoten, Corstiaan den uil, Amber otten, Tuncay yetgin, harm feringa, radosav 
Vidakovic, Jan-Peter van kuijck, en willem flu, bedankt voor de leuke discussies, prettige 
samenwerking en vooral de gezellige tijd die wij samen hebben beleefd. Op het Genetisch 
Laboratorium: beste saskia & michael, wat een ongelooflijke tijd hebben wij doorgemaakt. 
met de tienduizend bloedbuisjes welke wij zelf moesten labelen, pipetteren, schrapen, uitpla-
ten, genotyperen, ..er leek geen eind aan te komen en toch, zie hier het resultaat waar ook jullie 
een belangrijke rol in hebben gespeeld. Een dikke pluim voor jullie, om een zulk groot project 
af te ronden!
Mijn paranimphen, Corstiaan den uil, en meindert Crop. Beste Corstiaan, samen doorliepen 
wij ons promotie onderzoek, en stonden elkaar bij in alle facetten van een promotie-onderzoek, 
bedankt daarvoor! We hebben veel voor elkaar kunnen betekenen, en elkaar gestimuleerd 
er helemaal voor te gaan in het onderzoek en geen enkele mogelijkheid onbenut te laten. 
Onze vriendschap zetten we nu voort, wederom als directe collega’s, in het Albert Schweitzer 
ziekenhuis! Beste Meindert (en Sietse), graag spreek ik jullie samen aan, helaas kan er maar 1 
paranimph zijn, maar dat zul je altijd zien bij tweelingen. Jullie vriendschap, de manier waarop 
wij van de geneeskunde studie konden genieten en de passie ontwikkelden om altijd het 
maximale uit jezelf en de mogelijkheden binnen de studie te halen is iets om trots op te zijn. 
En wat hebben we een hoop mooie dingen samen meegemaakt (Boston!). Kijkend naar de 
toekomst zal dat ongetwijfeld zo blijven. Het vlammetje voor wetenschappelijk onderzoek 
brandde bij mij al vroeg in de studie, Meindert, wat leuk om jou nu zo bedreven bezig te zien in 
onderzoek! Veel succes met jouw eigen proefschrift. Beste reinier, sinds de middelbare school 
zijn we al vrienden. Jouw spontane maar rationele aanpak, zowel qua carrière als privé, en je 
doorzettings-vermogen heb ik altijd bewonderd en van geleerd. Ik ben erg blij dat wij samen 
op een dergelijke manier het Erasmiaans hebben doorgemaakt. Al zit je nu ver weg in Stuttgart, 
goede vriendschap blijft altijd! Meindert, Sietse, Meelan, Lisette, Corstiaan en Reinier, ik ben blij 
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young investigator Award ACC 
58th Annual Scientific Session 2009, clinical cardiology council 
American College of Cardiology, Orlando, United States of America
European society of Cardiology
State of the Art lecture “The new fronitier of hypertension trials”
Best abstract, ESC 2009, Barcelona, Spain
nederlandse Verening voor Cardiologie
Onderzoeksprijs “General Cardiology” 2009, Amsterdam.
Zon mw Agiko Cardiologie persoonsgebonden stipendium (voorjaarsronde 2006)
Dr stiggelbout  persoonsgebonden subsidie Nederlandse Hartstichting 
nEVEnfunCTiEs
[2002 – 2005] KNMG Studenten-Platform, Domus Medica, Utrecht
[2002 – 2003] Faculteitsraad  Erasmus Universiteit Faculteit Geneeskunde
[2003 – 2004] Studentenraad Erasmus Universiteit Faculteit Geneeskunde
[2003 – 2004] Commissie Onderwijs&Onderzoek Erasmus MC
[2000 – 2004] Onderwijsraad MORE Erasmus MC
[2004 – 2006] Jaarvertegenwoordiging collegejaar 1-4
[2004 – 2006] Co-raad Erasmus MC (Commissie ECG & Echo. cursussen)
[2002 – 2006] Hart- en Vaatziekten groep Afd. Epidemiologie Erasmus MC)
ACTiViTEiTEn
 -  European Society of Cardiology Working Group on Cardiovascular Drug Therapy.
 - Young CardioVascular Clinical Trialists’ Initiative (global CVCT forum).
 - Editorial Board World Journal of Cardiology.
rEfErEnTiEs
- Prof. Dr. A. Hofman, Wetenschappelijk Directeur NIHES.
- Prof. Dr. M.L. Simoons, afdelingshoofd Cardiologie, thoraxcentrum.
- Prof. Dr. E. Boersma, hoofd Cardiovasculaire Epidemiologie Thoraxcentrum.
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followed Courses 
summer and winter Programmes Erasmus mC
Principles of Research in Medicine and Epidemiology  2002
Introduction to Data-Analysis    2003
Clinical Decision Analysis     2002
Regression Analysis     2003
Methods of Clinical Research    2002
Topics in Meta-Analysis     2004
Pharmaco-epidemiology     2002
Survival Analysis      2003
Decision Making in Medicine I    2002
Topics in evidence-based medicine    2002
Epidemiology and Public Health    2002
Study design for Scientific Medicine    2004
Core curriculum msc. Clinical Epidemiology 
Study design      2002
Data-Analysis      2003
Discussion Meetings Research Proposals   2003
skills courses
Medical Writing      2004
Computer Facilities     2002
Working with SPSS for windows    2004
How to publish in medicine     2004
Advanced courses, Erasmus mC
Analysis of time-varying Exposures    2004
Introduction to Clinical Research    2004
Decision Making in Medicine II    2004
Advanced Courses, university of utrecht
Clinic trials and Drug Risk Assessment    2004
international courses and programmes
Cambridge university, Cambridge (United Kingdom)  2003
“Cardiovascular Disease Epidemiology” module   (Prof. K. Khaw)
harvard medical school and school of Public heath  2004
Boston, Massachusetts (United States of America)
“Management in Health Care Organizations”   (grade: A)
“Clinical Epidemiology”     (grade: A)
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PhD PorTfolio summAry
summary of PhD training and teaching activities
Name PhD student: J.J.Brugts
Erasmus MC Department: Cardiology
Research School: C.O.E.U.R.
PhD period: 2006-2009
Promotor(s):  Prof. dr. Maarten Simoons 
Prof. dr. Eric Boersma
1. PhD training
year workload
(hours/ECTs)
general academic skills 
- Biomedical English Writing and Communication
- Research Integrity, Statistical software (SPSS,SAS)
2004
2004
1.5
1.5
research skills
-  Master of Science in Clinical Epidemiology (NIHES)
-  Statistics (multiple statistics and advanced statistics 
courses)
- Methodology (study design, randomized trials)
2002-2006
2002-2006
2002-2006
30
10
10
in-depth courses (e.g. research school, medical Training)
-  COEUR courses on heart failure, clinical epidemiology, 
cardiovascular imaging (CT, MRI, echocardiography), 
interventional cardiology, cardiovascular pharmacology, 
hypertension research.
-  Cardiovascular epidemiology module, Cambridge Uni-
versity, Cambridge, United Kingdom.
-  Management courses in Health Care Organization, Har-
vard Medical School, Boston, United States of America.
2006-2009
2004-2005
2004-2005
7.5
1.5
4.5
oral presentations
-  6x Oral Communication ESC, AHA or ACC scientific sessions
-  3x COEUR research seminar presenter (hypertension 
research and pharmacogenetics)
-  4x Stafpresentaties cardiologie en interne geneeskunde
2006-2009
2006-2009
2006-2009
4.8
1.6
6.0
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-  3x presenter Vascular Medicine & Cardiology Update 
(ESC), Dutch Heart Foundation congress (NHS), Dutch 
Society of Cardiology congress (NVCC)
2008-2009 2.4
international conferences
-  European Society of Cardiology, American College of Car-
diology, American Heart Association scientific sessions 
-  Human Genome Variation, Human Genome, Pharma-
cogenomics congresses 
2006-2009
2006-2009
12
4.5
seminars and workshops
-  COEUR research seminars, courses Molecular Medicine 
research school
2006-2009 2.5
2. Teaching activities
lecturing:
-   Keuzeonderwijs begeleiding van 8 tweedejaars-
studenten (3 weken)
-  Keuzeonderzoek begeleiding van 1 zesdejaars-student  
(6 maanden)
2007-2008
2008-2009
2.4
3.0
